



# Summary Tables by Region, Health Area, Country and Product

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Region**  
**1/2017 - 8/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
West and Central Africa	17,593	-	-	-	3,413,809	3,513	808,034	44,167	1,402	306	-	47,262
East Africa	39,035	10	-	-	3,492,951	2,647	923,820	15,673	513	1,583	-	18,620
Southern Africa	92,599	16	-	2	1,647,805	706	327,976	9,814	396	1,375	-	12,491
Americas	1,952	14	-	648	432,835	46	91,895	-	112	-	-	781
Asia and Eastern Europe	5,932	-	50	2,825	4,348,810	982	1,143,258	309	538	-	-	4,569
<b>Total</b>	<b>157,111</b>	<b>40</b>	<b>50</b>	<b>3,475</b>	<b>13,336,209</b>	<b>7,893</b>	<b>3,294,983</b>	<b>69,963</b>	<b>2,961</b>	<b>3,265</b>	<b>-</b>	<b>83,723</b>

\* Using USAID CYP conversion factors

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Region**  
**Period: 8**  
**Year: 2017**

	DALY 8/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>2,860,812</b>	<b>22,892,850</b>	<b>18,461,726</b>	<b>(19%)</b>		<b>29,529,513</b>	<b>63%</b>
<b>West and Central Africa</b>	<b>955,895</b>	<b>10,746,396</b>	<b>6,483,899</b>	<b>(40%)</b>	<b>100 %</b>	<b>10,124,875</b>	<b>64%</b>
Family Planning	249,989	1,826,904	1,830,270	0%	28%	2,434,357	75%
HIV & STIs	86,608	1,046,552	703,687	(33)%	11%	1,434,900	49%
Malaria	592,610	7,664,987	3,721,531	(51)%	57%	5,926,969	63%
Maternal, Newborn, and Child Health	14,849	105,605	152,678	45%	2%	149,686	102%
Non-communicable diseases	5	397	160	(60)%	0%	326	49%
Nutrition	-	-	-	0%	0%	-	0%
Safe Abortion	11,594	89,532	70,124	(22)%	1%	174,275	40%
Tuberculosis	-	9,109	-	(100)%	0%	-	0%
WASH	239	3,312	5,450	65%	0%	4,364	125%
<b>East Africa</b>	<b>643,451</b>	<b>5,592,230</b>	<b>4,814,179</b>	<b>(14%)</b>	<b>100 %</b>	<b>8,579,902</b>	<b>56%</b>
Family Planning	149,763	1,326,621	1,719,135	30%	36%	2,436,560	71%
HIV & STIs	240,959	2,533,993	1,584,065	(37)%	33%	3,150,257	50%
Malaria	231,975	1,555,409	1,278,479	(18)%	27%	1,760,498	73%
Maternal, Newborn, and Child Health	18,664	128,883	184,584	43%	4%	866,929	21%
Non-communicable diseases	37	517	274	(47)%	0%	894	31%
Nutrition	-	-	20,370	0%	0%	-	0%
Safe Abortion	451	27,394	14,327	(48)%	0%	344,144	4%
Tuberculosis	-	29	-	(100)%	0%	-	0%
WASH	1,602	19,384	12,945	(33)%	0%	20,620	63%
<b>Southern Africa</b>	<b>1,068,040</b>	<b>5,469,693</b>	<b>5,622,262</b>	<b>3%</b>	<b>100 %</b>	<b>8,054,990</b>	<b>70%</b>
Family Planning	97,942	427,421	448,181	5%	8%	819,499	55%
HIV & STIs	828,023	4,416,739	4,208,664	(5)%	75%	6,106,101	69%
Malaria	129,378	508,218	774,214	52%	14%	921,962	84%
Maternal, Newborn, and Child Health	10,504	97,568	124,233	27%	2%	165,421	75%
Non-communicable diseases	15	233	180	(23)%	0%	159	113%
Nutrition	-	-	-	0%	0%	-	0%
Safe Abortion	1,451	-	47,316	0%	1%	3,049	1,552%
Tuberculosis	37	192	197	3%	0%	166	119%
WASH	688	19,322	19,276	0%	0%	38,634	50%
<b>Americas</b>	<b>32,915</b>	<b>94,705</b>	<b>171,354</b>	<b>81%</b>	<b>100 %</b>	<b>219,289</b>	<b>78%</b>
Family Planning	5,352	26,670	32,243	21%	19%	53,376	60%
HIV & STIs	13,203	59,228	91,970	55%	54%	114,251	80%
Malaria	-	-	-	0%	0%	2,258	0%
Maternal, Newborn, and Child Health	-	8,657	10,288	19%	6%	14,123	73%
Non-communicable diseases	6	-	6	0%	0%	-	0%
Nutrition	19	81	114	41%	0%	183	62%
Safe Abortion	124	69	325	371%	0%	870	37%
Tuberculosis	14,212	-	36,409	0%	21%	34,228	106%
<b>Asia and Eastern Europe</b>	<b>160,511</b>	<b>989,825</b>	<b>1,370,033</b>	<b>38%</b>	<b>100 %</b>	<b>2,550,456</b>	<b>54%</b>
Family Planning	89,762	568,658	860,082	51%	63%	1,357,188	63%
HIV & STIs	33,731	181,656	283,972	56%	21%	632,895	45%
Malaria	4,538	43,821	28,583	(35)%	2%	262,011	11%
Maternal, Newborn, and Child Health	2,417	80,421	12,526	(84)%	1%	49,398	25%
Non-communicable diseases	-	387	183	(53)%	0%	-	0%
Nutrition	29	-	50	0%	0%	-	0%
Safe Abortion	6,579	26,889	48,371	80%	4%	90,136	54%
Tuberculosis	21,451	87,941	120,024	36%	9%	145,648	82%
WASH	2,003	51	16,242	31,649%	1%	13,180	123%

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Health Area**  
**Period: 8**  
**Year: 2017**

	DALY 8/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>2,860,812</b>	<b>22,892,850</b>	<b>18,461,726</b>	<b>(19)%</b>		<b>29,529,513</b>	<b>63%</b>
<b>Family Planning</b>	<b>592,808</b>	<b>4,176,274</b>	<b>4,889,910</b>	<b>17%</b>	<b>100%</b>	<b>7,100,980</b>	<b>69 %</b>
West and Central Africa	249,989	1,826,904	1,830,270	0%	37 %	2,434,357	75%
East Africa	149,763	1,326,621	1,719,135	30%	35 %	2,436,560	71%
Southern Africa	97,942	427,421	448,181	5%	9 %	819,499	55%
Americas	5,352	26,670	32,243	21%	1 %	53,376	60%
Asia and Eastern Europe	89,762	568,658	860,082	51%	18 %	1,357,188	63%
<b>HIV &amp; STIs</b>	<b>1,202,525</b>	<b>8,238,168</b>	<b>6,872,359</b>	<b>(17)%</b>	<b>100%</b>	<b>11,438,404</b>	<b>60 %</b>
West and Central Africa	86,608	1,046,552	703,687	(33)%	10 %	1,434,900	49%
East Africa	240,959	2,533,993	1,584,065	(37)%	23 %	3,150,257	50%
Southern Africa	828,023	4,416,739	4,208,664	(5)%	61 %	6,106,101	69%
Americas	13,203	59,228	91,970	55%	1 %	114,251	80%
Asia and Eastern Europe	33,731	181,656	283,972	56%	4 %	632,895	45%
<b>Malaria</b>	<b>958,503</b>	<b>9,772,434</b>	<b>5,802,807</b>	<b>(41)%</b>	<b>100%</b>	<b>8,873,698</b>	<b>65 %</b>
West and Central Africa	592,610	7,664,987	3,721,531	(51)%	64 %	5,926,969	63%
East Africa	231,975	1,555,409	1,278,479	(18)%	22 %	1,760,498	73%
Southern Africa	129,378	508,218	774,214	52%	13 %	921,962	84%
Americas	-	-	-	0%	0 %	2,258	0%
Asia and Eastern Europe	4,538	43,821	28,583	(35)%	0 %	262,011	11%
<b>Maternal, Newborn, and Child Health</b>	<b>46,434</b>	<b>421,135</b>	<b>484,309</b>	<b>15%</b>	<b>100%</b>	<b>1,245,556</b>	<b>39 %</b>
West and Central Africa	14,849	105,605	152,678	45%	32 %	149,686	102%
East Africa	18,664	128,883	184,584	43%	38 %	866,929	21%
Southern Africa	10,504	97,568	124,233	27%	26 %	165,421	75%
Americas	-	8,657	10,288	19%	2 %	14,123	73%
Asia and Eastern Europe	2,417	80,421	12,526	(84)%	3 %	49,398	25%
<b>Non-communicable diseases</b>	<b>63</b>	<b>1,535</b>	<b>802</b>	<b>(48)%</b>	<b>100%</b>	<b>1,378</b>	<b>58 %</b>
West and Central Africa	5	397	160	(60)%	20 %	326	49%
East Africa	37	517	274	(47)%	34 %	894	31%
Southern Africa	15	233	180	(23)%	22 %	159	113%
Americas	6	-	6	0%	1 %	-	0%
Asia and Eastern Europe	-	387	183	(53)%	23 %	-	0%
<b>Nutrition</b>	<b>48</b>	<b>81</b>	<b>20,534</b>	<b>25,379%</b>	<b>100%</b>	<b>183</b>	<b>11,212 %</b>
West and Central Africa	-	-	-	0%	0 %	-	0%
East Africa	-	-	20,370	0%	99 %	-	0%
Southern Africa	-	-	-	0%	0 %	-	0%
Americas	19	81	114	41%	1 %	183	62%
Asia and Eastern Europe	29	-	50	0%	0 %	-	0%
<b>Safe Abortion</b>	<b>20,199</b>	<b>143,883</b>	<b>180,463</b>	<b>25%</b>	<b>100%</b>	<b>612,473</b>	<b>29 %</b>
West and Central Africa	11,594	89,532	70,124	(22)%	39 %	174,275	40%
East Africa	451	27,394	14,327	(48)%	8 %	344,144	4%
Southern Africa	1,451	-	47,316	0%	26 %	3,049	1,552%
Americas	124	69	325	371%	0 %	870	37%
Asia and Eastern Europe	6,579	26,889	48,371	80%	27 %	90,136	54%
<b>Tuberculosis</b>	<b>35,700</b>	<b>97,271</b>	<b>156,629</b>	<b>61%</b>	<b>100%</b>	<b>180,042</b>	<b>87 %</b>
West and Central Africa	-	9,109	-	(100)%	0 %	-	0%
East Africa	-	29	-	(100)%	0 %	-	0%
Southern Africa	37	192	197	3%	0 %	166	119%

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Health Area**  
**Period: 8**  
**Year: 2017**

	DALY 8/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Americas	14,212	-	36,409	0%	23 %	34,228	106%
Asia and Eastern Europe	21,451	87,941	120,024	36%	77 %	145,648	82%
<b>WASH</b>	<b>4,532</b>	<b>42,069</b>	<b>53,913</b>	<b>28%</b>	<b>100%</b>	<b>76,798</b>	<b>70 %</b>
West and Central Africa	239	3,312	5,450	65%	10 %	4,364	125%
East Africa	1,602	19,384	12,945	(33)%	24 %	20,620	63%
Southern Africa	688	19,322	19,276	0%	36 %	38,634	50%
Asia and Eastern Europe	2,003	51	16,242	31,649%	30 %	13,180	123%

POPULATION SERVICES INTERNATIONAL  
 Monthly DALY Report by Country  
 Period: 8  
 Year: 2017

	DALY 8/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>2,860,812</b>	<b>22,892,850</b>	<b>18,461,726</b>	<b>(19%)</b>		<b>29,529,513</b>	<b>63%</b>
<b>West and Central Africa</b>	<b>955,895</b>	<b>10,746,396</b>	<b>6,483,899</b>	<b>(40%)</b>		<b>10,124,875</b>	<b>64%</b>
<b>Benin</b>	<b>16,744</b>	<b>166,045</b>	<b>132,723</b>	<b>(20)%</b>	100%	<b>252,456</b>	<b>53%</b>
Family Planning	12,313	123,690	100,588	(19)%	76%	185,959	54 %
HIV & STIs	1,373	12,099	10,594	(12)%	8%	21,795	49 %
Malaria	127	2,265	461	(80)%	0%	1,027	45 %
Maternal, Newborn, and Child Health	1,498	24,942	11,651	(53)%	9%	33,276	35 %
Non-communicable diseases	2	37	16	(57)%	0%	-	0 %
Safe Abortion	1,323	2,444	8,857	262%	7%	9,355	95 %
WASH	108	568	556	(2)%	0%	1,044	53 %
<b>Cameroon</b>	<b>38,316</b>	<b>315,997</b>	<b>205,557</b>	<b>(35)%</b>	100%	<b>343,441</b>	<b>60%</b>
Family Planning	20,058	160,891	123,626	(23)%	60%	200,367	62 %
HIV & STIs	7,419	100,043	36,298	(64)%	18%	59,219	61 %
Malaria	1,289	9,635	5,918	(39)%	3%	15,650	38 %
Maternal, Newborn, and Child Health	8,460	38,920	30,444	(22)%	15%	46,603	65 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	1,091	6,503	9,261	42%	5%	21,593	43 %
WASH	-	4	10	130%	0%	10	99 %
<b>Congo-Kinshasa</b>	<b>105,995</b>	<b>3,814,625</b>	<b>1,368,033</b>	<b>(64)%</b>	100%	<b>4,764,972</b>	<b>29%</b>
Family Planning	69,780	149,747	387,654	159%	28%	288,193	135 %
HIV & STIs	13,348	7,871	29,371	273%	2%	14,133	208 %
Malaria	19,785	3,654,606	894,292	(76)%	65%	4,452,382	20 %
Maternal, Newborn, and Child Health	3,077	801	56,594	6,966%	4%	10,012	565 %
WASH	6	1,600	121	(92)%	0%	252	48 %
<b>Cote d'Ivoire</b>	<b>306</b>	<b>2,189</b>	<b>1,931</b>	<b>(12)%</b>	100%	<b>1,263</b>	<b>153%</b>
Family Planning	132	990	866	(12)%	45%	537	161 %
HIV & STIs	174	1,199	1,065	(11)%	55%	726	147 %
<b>Ghana</b>	<b>9,970</b>	<b>-</b>	<b>139,853</b>	<b>- %</b>	100%	<b>72,274</b>	<b>194%</b>
Family Planning	9,969	-	136,801	0%	98%	65,356	209 %
HIV & STIs	1	-	3,052	0%	2%	6,836	45 %
WASH	-	-	-	0%	0%	82	0 %
<b>Guinea</b>	<b>12,435</b>	<b>56,067</b>	<b>80,788</b>	<b>44 %</b>	100%	<b>146,993</b>	<b>55%</b>
Family Planning	9,906	22,444	42,014	87%	52%	117,224	36 %
HIV & STIs	2,529	1,756	10,683	508%	13%	29,768	36 %
Maternal, Newborn, and Child Health	-	22,526	25,030	11%	31%	-	0 %
Tuberculosis	-	9,109	-	(100)%	0%	-	0 %
WASH	-	233	3,062	1,215%	4%	-	0 %
<b>Liberia</b>	<b>815</b>	<b>3,847</b>	<b>4,426</b>	<b>15 %</b>	100%	<b>9,880</b>	<b>45%</b>
Family Planning	286	1,368	1,499	10%	34%	3,417	44 %
HIV & STIs	512	2,449	2,686	10%	61%	6,271	43 %
WASH	18	30	241	715%	5%	193	125 %
<b>Mali</b>	<b>585,253</b>	<b>1,474,177</b>	<b>1,808,143</b>	<b>23 %</b>	100%	<b>1,673,132</b>	<b>108%</b>
Family Planning	14,912	165,102	112,186	(32)%	6%	224,782	50 %
HIV & STIs	-	1,068	-	(100)%	0%	570	0 %
Malaria	569,922	1,307,358	1,691,390	29%	94%	1,443,891	117 %
Non-communicable diseases	3	151	70	(53)%	0%	326	22 %
Safe Abortion	386	497	3,530	610%	0%	2,384	148 %
WASH	29	-	966	0%	0%	1,180	82 %

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 8

Year: 2017

	DALY 8/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>Niger</b>	<b>4,025</b>	<b>3,857</b>	<b>25,826</b>	<b>570 %</b>	100%	<b>11,647</b>	<b>222%</b>
Family Planning	4,023	2,691	17,223	540%	67%	10,160	170 %
HIV & STIs	2	1,166	299	(74)%	1%	1,252	24 %
Safe Abortion	-	-	8,303	0%	32%	234	3,546 %
<b>Nigeria</b>	<b>175,950</b>	<b>4,866,992</b>	<b>2,698,648</b>	<b>(45)%</b>	100%	<b>2,755,660</b>	<b>98%</b>
Family Planning	104,749	1,185,929	901,221	(24)%	33%	1,309,753	69 %
HIV & STIs	59,369	895,715	598,604	(33)%	22%	1,240,068	48 %
Malaria	1,157	2,685,882	1,129,135	(58)%	42%	3,814	29,606 %
Maternal, Newborn, and Child Health	1,814	18,416	28,959	57%	1%	59,795	48 %
Non-communicable diseases	-	209	74	(65)%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	8,794	80,087	40,172	(50)%	1%	140,709	29 %
WASH	67	754	483	(36)%	0%	1,522	32 %
<b>Senegal</b>	<b>6,086</b>	<b>42,600</b>	<b>17,972</b>	<b>(58)%</b>	100%	<b>93,157</b>	<b>19%</b>
Family Planning	3,861	14,052	6,591	(53)%	37%	28,611	23 %
HIV & STIs	1,882	23,185	11,036	(52)%	61%	54,261	20 %
Malaria	331	5,240	335	(94)%	2%	10,205	3 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	11	123	11	(91)%	0%	81	14 %
<b>East Africa</b>	<b>643,451</b>	<b>5,592,230</b>	<b>4,814,179</b>	<b>(14)%</b>		<b>8,579,902</b>	<b>56%</b>
<b>Burundi</b>	<b>13,677</b>	<b>81,939</b>	<b>87,640</b>	<b>7 %</b>	100%	<b>162,466</b>	<b>54%</b>
Family Planning	1,844	18,370	14,566	(21)%	17%	28,897	50 %
HIV & STIs	2,549	33,909	21,670	(36)%	25%	36,855	59 %
Malaria	9,274	29,608	51,193	73%	58%	96,590	53 %
Safe Abortion	10	52	211	307%	0%	125	169 %
<b>Ethiopia</b>	<b>3,673</b>	<b>112,679</b>	<b>69,866</b>	<b>(38)%</b>	100%	<b>205,237</b>	<b>34%</b>
Family Planning	464	23,767	14,156	(40)%	20%	43,686	32 %
HIV & STIs	2,454	81,905	50,979	(38)%	73%	151,973	34 %
Tuberculosis	-	29	-	(100)%	0%	-	0 %
WASH	755	6,977	4,731	(32)%	7%	9,577	49 %
<b>Kenya</b>	<b>149,478</b>	<b>1,233,303</b>	<b>897,495</b>	<b>(27)%</b>	100%	<b>2,393,098</b>	<b>38%</b>
Family Planning	24,392	440,205	241,290	(45)%	27%	895,469	27 %
HIV & STIs	120,659	748,083	586,726	(22)%	65%	1,385,441	42 %
Malaria	108	41,061	43,424	6%	5%	80,480	54 %
Maternal, Newborn, and Child Health	3,804	217	22,148	10,093%	2%	26,033	85 %
Non-communicable diseases	6	249	84	(66)%	0%	93	91 %
WASH	508	3,487	3,824	10%	0%	5,584	68 %
<b>Malawi</b>	<b>129,308</b>	<b>548,549</b>	<b>784,677</b>	<b>43 %</b>	100%	<b>918,685</b>	<b>85%</b>
Family Planning	38,283	110,142	305,441	177%	39%	265,964	115 %
HIV & STIs	90,779	372,284	466,854	25%	59%	646,971	72 %
Malaria	220	59,050	11,597	(80)%	1%	4,573	254 %
Maternal, Newborn, and Child Health	-	6,241	-	(100)%	0%	-	0 %
WASH	25	832	785	(6)%	0%	1,178	67 %
<b>Rwanda</b>	<b>14,734</b>	<b>195,263</b>	<b>109,910</b>	<b>(44)%</b>	100%	<b>219,295</b>	<b>50%</b>
Family Planning	2,530	34,836	19,927	(43)%	18%	36,565	54 %
HIV & STIs	12,184	160,200	89,754	(44)%	82%	182,180	49 %
WASH	20	227	229	1%	0%	551	42 %
<b>Somaliland</b>	<b>8,792</b>	<b>13,999</b>	<b>21,537</b>	<b>54 %</b>	100%	<b>32,618</b>	<b>66%</b>

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Country**  
**Period: 8**  
**Year: 2017**

	DALY 8/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Family Planning	40	1,169	641	(45)%	3%	1,953	33 %
Maternal, Newborn, and Child Health	8,505	11,915	19,218	61%	89%	28,939	66 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	247	915	1,678	83%	8%	1,726	97 %
<b>South Sudan</b>	<b>227,189</b>	<b>1,388,456</b>	<b>1,292,978</b>	<b>(7)%</b>	100%	<b>2,218,619</b>	<b>58%</b>
Malaria	221,842	1,294,939	1,138,286	(12)%	88%	1,418,762	80 %
Maternal, Newborn, and Child Health	5,347	93,439	134,322	44%	10%	799,857	17 %
Nutrition	-	-	20,370	0%	2%	-	0 %
WASH	-	79	-	(100)%	0%	-	0 %
<b>Tanzania</b>	<b>38,442</b>	<b>1,262,455</b>	<b>794,038</b>	<b>(37)%</b>	100%	<b>1,346,068</b>	<b>59%</b>
Family Planning	25,640	429,476	490,092	14%	62%	613,291	80 %
HIV & STIs	11,837	713,403	255,666	(64)%	32%	590,393	43 %
Malaria	531	88,220	33,237	(62)%	4%	114,927	29 %
Maternal, Newborn, and Child Health	3	-	772	0%	0%	-	0 %
Non-communicable diseases	7	124	60	(52)%	0%	90	67 %
Safe Abortion	400	27,105	13,856	(49)%	2%	26,850	52 %
WASH	24	4,128	356	(91)%	0%	517	69 %
<b>Uganda</b>	<b>58,159</b>	<b>755,587</b>	<b>756,038</b>	<b>- %</b>	100%	<b>1,083,816</b>	<b>70%</b>
Family Planning	56,569	268,656	633,022	136%	84%	550,735	115 %
HIV & STIs	497	424,210	112,417	(73)%	15%	156,444	72 %
Malaria	-	42,531	742	(98)%	0%	45,166	2 %
Maternal, Newborn, and Child Health	1,005	17,071	8,124	(52)%	1%	12,101	67 %
Non-communicable diseases	24	145	130	(10)%	0%	712	18 %
Safe Abortion	42	237	260	10%	0%	317,170	0 %
WASH	22	2,738	1,343	(51)%	0%	1,488	90 %
<b>Southern Africa</b>	<b>1,068,040</b>	<b>5,469,693</b>	<b>5,622,262</b>	<b>3%</b>		<b>8,054,990</b>	<b>70%</b>
<b>Angola</b>	<b>122,434</b>	<b>297,854</b>	<b>654,128</b>	<b>120 %</b>	100%	<b>534,115</b>	<b>122%</b>
Family Planning	903	16,302	20,989	29%	3%	37,672	56 %
HIV & STIs	1,076	23,586	6,364	(73)%	1%	19,464	33 %
Malaria	119,003	255,307	577,575	126%	88%	468,546	123 %
Safe Abortion	1,425	-	46,896	0%	7%	3,049	1,538 %
WASH	27	2,658	2,304	(13)%	0%	5,384	43 %
<b>Botswana</b>	<b>1,626</b>	<b>10,973</b>	<b>13,189</b>	<b>20 %</b>	100%	<b>16,170</b>	<b>82%</b>
Family Planning	114	769	924	20%	7%	1,133	82 %
HIV & STIs	1,513	10,204	12,266	20%	93%	15,038	82 %
<b>Lesotho</b>	<b>17,782</b>	<b>415,487</b>	<b>167,978</b>	<b>(60)%</b>	100%	<b>430,778</b>	<b>39%</b>
Family Planning	1,151	23,030	10,624	(54)%	6%	33,308	32 %
HIV & STIs	16,615	392,457	157,265	(60)%	94%	397,470	40 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	16	-	89	0%	0%	-	0 %
<b>Madagascar</b>	<b>38,464</b>	<b>554,763</b>	<b>553,288</b>	<b>- %</b>	100%	<b>863,919</b>	<b>64%</b>
Family Planning	17,572	175,665	189,719	8%	34%	188,883	100 %
HIV & STIs	952	27,881	55,590	99%	10%	71,032	78 %
Malaria	8,964	244,556	175,415	(28)%	32%	418,610	42 %
Maternal, Newborn, and Child Health	10,504	97,568	124,233	27%	22%	165,421	75 %
Non-communicable diseases	2	-	21	0%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	26	-	421	0%	0%	-	0 %
WASH	443	9,093	7,889	(13)%	1%	19,974	39 %



POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 8

Year: 2017

	DALY 8/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>Mozambique</b>	<b>52,182</b>	<b>136,141</b>	<b>287,847</b>	<b>111 %</b>	100%	<b>562,319</b>	<b>51%</b>
Family Planning	19,010	43,097	80,349	86%	28%	270,265	30 %
HIV & STIs	31,729	82,971	178,997	116%	62%	269,827	66 %
Malaria	1,411	5,449	21,224	290%	7%	13,281	160 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	32	4,625	7,278	57%	3%	8,947	81 %
<b>Namibia</b>	<b>-</b>	<b>23,414</b>	<b>3,320</b>	<b>(86)%</b>	100%	-	<b>-%</b>
Family Planning	-	1,861	266	(86)%	8%	-	0 %
HIV & STIs	-	21,539	3,055	(86)%	92%	-	0 %
Tuberculosis	-	14	-	(100)%	0%	-	0 %
<b>South Africa</b>	<b>476,141</b>	<b>2,006,277</b>	<b>1,550,696</b>	<b>(23)%</b>	100%	<b>2,468,398</b>	<b>63%</b>
Family Planning	18,833	81,228	54,747	(33)%	4%	89,925	61 %
HIV & STIs	457,308	1,925,049	1,495,949	(22)%	96%	2,378,473	63 %
<b>Swaziland</b>	<b>82,799</b>	<b>478,379</b>	<b>523,981</b>	<b>10 %</b>	100%	<b>696,535</b>	<b>75%</b>
Family Planning	3,496	21,099	23,363	11%	4%	30,805	76 %
HIV & STIs	79,303	457,280	500,618	9%	96%	665,730	75 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Zambia</b>	<b>73,945</b>	<b>463,228</b>	<b>688,163</b>	<b>49 %</b>	100%	<b>752,675</b>	<b>91%</b>
Family Planning	33,833	5,428	39,597	630%	6%	117,895	34 %
HIV & STIs	39,927	455,558	647,541	42%	94%	631,328	103 %
WASH	186	2,242	1,025	(54)%	0%	3,451	30 %
<b>Zimbabwe</b>	<b>202,666</b>	<b>1,083,178</b>	<b>1,179,670</b>	<b>9 %</b>	100%	<b>1,730,081</b>	<b>68%</b>
Family Planning	3,030	58,943	27,604	(53)%	2%	49,613	56 %
HIV & STIs	199,601	1,020,214	1,151,020	13%	98%	1,657,739	69 %
Malaria	-	2,907	-	(100)%	0%	21,525	0 %
Non-communicable diseases	13	233	158	(32)%	0%	159	100 %
Tuberculosis	21	177	108	(39)%	0%	166	65 %
WASH	-	704	779	11%	0%	879	89 %
<b>Americas</b>	<b>32,915</b>	<b>94,705</b>	<b>171,354</b>	<b>81%</b>		<b>219,289</b>	<b>78%</b>
<b>Belize</b>	<b>-</b>	<b>43</b>	<b>-</b>	<b>(100)%</b>	0%	-	<b>-%</b>
Family Planning	-	1	-	(100)%	0%	-	0 %
HIV & STIs	-	42	-	(100)%	0%	-	0 %
<b>Caribbean</b>	<b>8</b>	<b>35</b>	<b>26</b>	<b>(26)%</b>	100%	-	<b>-%</b>
Family Planning	2	6	4	(25)%	17%	-	0 %
HIV & STIs	7	29	22	(26)%	83%	-	0 %
<b>Costa Rica</b>	<b>182</b>	<b>1,094</b>	<b>1,251</b>	<b>14 %</b>	100%	<b>1,607</b>	<b>78%</b>
Family Planning	12	72	83	14%	7%	106	78 %
HIV & STIs	170	1,022	1,169	14%	93%	1,501	78 %
<b>Dominican Republic</b>	<b>1,818</b>	<b>10,794</b>	<b>13,607</b>	<b>26 %</b>	100%	<b>15,810</b>	<b>86%</b>
Family Planning	401	2,378	3,015	27%	22%	3,483	87 %
HIV & STIs	1,417	8,416	10,592	26%	78%	12,327	86 %
<b>El Salvador</b>	<b>383</b>	<b>14,268</b>	<b>5,153</b>	<b>(64)%</b>	100%	<b>7,913</b>	<b>65%</b>
Family Planning	168	2,525	1,524	(40)%	30%	3,004	51 %
HIV & STIs	214	11,728	3,607	(69)%	70%	4,772	76 %
Maternal, Newborn, and Child Health	-	-	2	0%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Country**  
**Period: 8**  
**Year: 2017**

	DALY 8/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Safe Abortion	1	15	21	39%	0%	136	15 %
<b>Guatemala</b>	<b>4,320</b>	<b>22,047</b>	<b>25,711</b>	<b>17 %</b>	<b>100%</b>	<b>31,762</b>	<b>81%</b>
Family Planning	3,116	12,694	15,728	24%	61%	14,766	107 %
HIV & STIs	1,106	9,212	9,738	6%	38%	16,567	59 %
Maternal, Newborn, and Child Health	-	92	2	(98)%	0%	-	0 %
Safe Abortion	98	49	243	397%	1%	428	57 %
<b>Haiti</b>	<b>20,438</b>	<b>8,719</b>	<b>86,810</b>	<b>896 %</b>	<b>100%</b>	<b>94,734</b>	<b>92%</b>
Family Planning	456	154	3,851	2,401%	4%	17,271	22 %
HIV & STIs	5,765	-	36,260	0%	42%	26,854	135 %
Malaria	-	-	-	0%	0%	2,258	0 %
Maternal, Newborn, and Child Health	-	8,565	10,285	20%	12%	14,123	73 %
Non-communicable diseases	6	-	6	0%	0%	-	0 %
Tuberculosis	14,212	-	36,409	0%	42%	34,228	106 %
<b>Honduras</b>	<b>1,907</b>	<b>11,245</b>	<b>12,239</b>	<b>9 %</b>	<b>100%</b>	<b>17,859</b>	<b>69%</b>
Family Planning	140	818	898	10%	7%	1,306	69 %
HIV & STIs	1,768	10,427	11,341	9%	93%	16,553	69 %
<b>Nicaragua</b>	<b>1,640</b>	<b>8,817</b>	<b>9,303</b>	<b>6 %</b>	<b>100%</b>	<b>15,056</b>	<b>62%</b>
Family Planning	547	4,099	3,479	(15)%	37%	6,711	52 %
HIV & STIs	1,068	4,713	5,763	22%	62%	8,040	72 %
Safe Abortion	25	5	61	1,132%	1%	305	20 %
<b>Panama</b>	<b>294</b>	<b>4,257</b>	<b>3,373</b>	<b>(21)%</b>	<b>100%</b>	<b>7,586</b>	<b>44%</b>
Family Planning	39	566	448	(21)%	13%	1,008	44 %
HIV & STIs	255	3,691	2,925	(21)%	87%	6,578	44 %
<b>Paraguay</b>	<b>1,924</b>	<b>13,385</b>	<b>13,879</b>	<b>4 %</b>	<b>100%</b>	<b>26,963</b>	<b>51%</b>
Family Planning	471	3,357	3,212	(4)%	23%	5,721	56 %
HIV & STIs	1,433	9,947	10,553	6%	76%	21,059	50 %
Nutrition	19	81	114	41%	1%	183	62 %
<b>Asia and Eastern Europe</b>	<b>160,511</b>	<b>989,825</b>	<b>1,370,033</b>	<b>38%</b>		<b>2,550,456</b>	<b>54%</b>
<b>Cambodia</b>	<b>16,801</b>	<b>123,194</b>	<b>123,911</b>	<b>1 %</b>	<b>100%</b>	<b>194,931</b>	<b>64%</b>
Family Planning	8,626	58,287	61,853	6%	50%	90,297	68 %
HIV & STIs	5,692	46,058	45,352	(2)%	37%	77,864	58 %
Malaria	882	4,132	2,345	(43)%	2%	5,732	41 %
Maternal, Newborn, and Child Health	64	1,659	715	(57)%	1%	1,426	50 %
Safe Abortion	1,537	13,058	13,646	5%	11%	19,613	70 %
<b>India</b>	<b>23,705</b>	<b>131,907</b>	<b>118,985</b>	<b>(10)%</b>	<b>100%</b>	<b>338,455</b>	<b>35%</b>
Family Planning	15,985	80,917	90,814	12%	76%	276,022	33 %
HIV & STIs	-	34,787	(2)	(100)%	0%	-	0 %
Maternal, Newborn, and Child Health	-	9,047	(237)	(103)%	0%	-	0 %
Non-communicable diseases	-	381	182	(52)%	0%	-	0 %
Safe Abortion	-	6,776	(117)	(102)%	0%	-	0 %
Tuberculosis	5,738	-	12,150	0%	10%	49,533	25 %
WASH	1,983	-	16,195	0%	14%	12,899	126 %
<b>India LLC</b>	<b>34,251</b>	<b>-</b>	<b>260,173</b>	<b>- %</b>	<b>100%</b>	<b>785,882</b>	<b>33%</b>
Family Planning	15,288	-	113,369	0%	44%	332,087	34 %
HIV & STIs	14,804	-	114,717	0%	44%	359,969	32 %
Maternal, Newborn, and Child Health	416	-	5,129	0%	2%	37,493	14 %
Safe Abortion	3,743	-	26,958	0%	10%	56,332	48 %

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Country**  
**Period: 8**  
**Year: 2017**

	DALY 8/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>Kazakhstan</b>	<b>23</b>	-	<b>345</b>	<b>80,631 %</b>	100%	<b>665</b>	<b>52%</b>
Family Planning	-	-	3	0%	1%	62	4 %
HIV & STIs	23	-	342	79,985%	99%	603	57 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Kyrgyzstan</b>	<b>27</b>	<b>4</b>	<b>505</b>	<b>12,833 %</b>	100%	<b>621</b>	<b>81%</b>
HIV & STIs	27	4	505	12,833%	100%	621	81 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Laos</b>	<b>2,602</b>	<b>7,878</b>	<b>14,968</b>	<b>90 %</b>	100%	<b>21,241</b>	<b>70%</b>
Family Planning	1,958	7,120	12,309	73%	82%	15,211	81 %
HIV & STIs	269	-	1,172	0%	8%	3,257	36 %
Malaria	-	-	-	0%	0%	-	0 %
Safe Abortion	330	703	1,320	88%	9%	2,709	49 %
Tuberculosis	46	55	168	204%	1%	65	260 %
<b>Myanmar</b>	<b>27,070</b>	<b>253,577</b>	<b>196,473</b>	<b>(23)%</b>	100%	<b>305,116</b>	<b>64%</b>
Family Planning	5,085	24,347	35,399	45%	18%	57,757	61 %
HIV & STIs	7,768	57,697	71,616	24%	36%	106,567	67 %
Malaria	3,655	38,904	26,235	(33)%	13%	37,680	70 %
Maternal, Newborn, and Child Health	1,937	69,653	6,794	(90)%	3%	9,975	68 %
Non-communicable diseases	-	6	-	(95)%	0%	-	0 %
Nutrition	29	-	50	0%	0%	-	0 %
Tuberculosis	8,578	62,949	56,359	(10)%	29%	93,110	61 %
WASH	16	22	19	(13)%	0%	27	72 %
<b>Nepal</b>	<b>5,218</b>	<b>13,247</b>	<b>22,271</b>	<b>68 %</b>	100%	<b>30,235</b>	<b>74%</b>
Family Planning	4,374	6,798	15,416	127%	69%	17,486	88 %
HIV & STIs	-	93	1,183	1,172%	5%	1,267	93 %
Safe Abortion	844	6,352	5,672	(11)%	25%	11,481	49 %
WASH	-	4	-	(100)%	0%	-	0 %
<b>Pakistan</b>	<b>48,524</b>	<b>440,653</b>	<b>600,130</b>	<b>36 %</b>	100%	<b>591,047</b>	<b>102%</b>
Family Planning	38,426	390,395	529,948	36%	88%	566,770	94 %
HIV & STIs	2,884	25,302	17,942	(29)%	3%	24,276	74 %
Safe Abortion	125	-	892	0%	0%	-	0 %
Tuberculosis	7,089	24,937	51,348	106%	9%	-	0 %
WASH	-	19	-	(100)%	0%	-	0 %
<b>Papua New Guinea</b>	<b>16</b>	<b>3,112</b>	<b>2,457</b>	<b>(21)%</b>	100%	<b>221,572</b>	<b>1%</b>
Family Planning	6	795	816	3%	33%	886	92 %
HIV & STIs	10	1,469	1,514	3%	62%	1,660	91 %
Malaria	-	786	-	(100)%	0%	218,518	0 %
Maternal, Newborn, and Child Health	-	62	125	102%	5%	504	25 %
WASH	-	-	1	949%	0%	4	30 %
<b>Tajikistan</b>	<b>1,292</b>	-	<b>11,419</b>	<b>- %</b>	100%	<b>28,120</b>	<b>41%</b>
Family Planning	-	-	120	0%	1%	173	70 %
HIV & STIs	1,292	-	11,299	0%	99%	27,947	40 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Viet Nam</b>	<b>981</b>	<b>16,252</b>	<b>18,396</b>	<b>13 %</b>	100%	<b>32,573</b>	<b>56%</b>
Family Planning	15	-	34	0%	0%	438	8 %
HIV & STIs	961	16,246	18,332	13%	100%	28,864	64 %
Malaria	1	-	3	0%	0%	81	4 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 8

Year: 2017

	DALY 8/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Tuberculosis	-	-	-	0%	0%	2,940	0 %
WASH	4	6	27	349%	0%	250	11 %

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Product

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Acute Malnutrition Screening_CU</b>	200	84	676	-	-	-%	-	676	-
West and Central Africa	200	84	676	-	-	-%	-	676	-
<b>Antiretroviral Treatment</b>	-	-	-	-	-	-%	-	18,119	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	18,119	-
<b>Antiretroviral Treatment (Currentl</b>	47,896	47,668	321,095	128,032	-	-%	12,235	333,330	56,002
East Africa	1,752	3,308	25,605	6,986	-	-%	5,564	31,169	5,186
Southern Africa	9,481	8,816	66,150	76,596	-	-%	5,010	71,160	11,753
Americas	32,432	31,786	202,191	8,000	-	-%	-	202,191	34,320
Asia and Eastern Europe	4,231	3,757	27,149	36,450	-	-%	1,661	28,810	4,743
<b>Antiretroviral Treatment (Newly E</b>	2,054	1,952	14,680	2,100	-	-%	7,226	21,906	-
East Africa	214	315	2,202	-	-	-%	901	3,103	-
Southern Africa	1,015	935	7,336	-	-	-%	5,283	12,619	-
Americas	533	431	3,140	-	-	-%	-	3,140	-
Asia and Eastern Europe	292	272	2,002	2,100	-	-%	1,042	3,044	-
<b>Antiretroviral Treatment (Tablet)</b>	-	-	-	-	-	-%	-	97,980	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	97,980	-
<b>ARV Prophylaxis 28 wks (Mother</b>	-	-	-	-	-	-%	-	382	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	382	-
<b>ARV Prophylaxis 28 wks (Mother</b>	-	-	-	-	-	-%	-	359	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	359	-
<b>Basic Care Package</b>	-	-	400	-	42,574,842	(100)%	52,637,120	176,452,481	-
East Africa	-	-	400	-	42,574,842	(100)%	52,637,120	176,034,156	-
Southern Africa	-	-	-	-	-	-%	-	418,325	-
<b>CD4 Tests Provided to HIV+ Clie</b>	1,946	1,557	12,535	-	-	-%	1,193	13,728	-
West and Central Africa	471	101	837	-	-	-%	297	1,134	-
East Africa	-	81	485	-	-	-%	-	485	-
Southern Africa	1,475	1,375	11,100	-	-	-%	778	11,878	-
Americas	-	-	113	-	-	-%	118	231	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Cervical Cancer-HPV DNA and Re</b>	-	4	11	-	-	-%	-	11	3
Southern Africa	-	4	11	-	-	-%	-	11	3
<b>Cervical Cancer-HPV DNA and Re</b>	-	3	9	-	-	-%	-	9	2
Southern Africa	-	3	9	-	-	-%	-	9	2
<b>Cervical Cancer-Pap and Cryothe</b>	-	-	-	-	-	-%	-	35	-
Americas	-	-	-	-	-	-%	-	35	-
<b>Cervical Cancer-Pap and Refer to</b>	-	-	1	-	1	-%	1	2	-
Southern Africa	-	-	1	-	1	-%	1	2	-
<b>Cervical Cancer-Pap and Refer to</b>	-	-	-	-	7	(100)%	7	9	-
Southern Africa	-	-	-	-	7	(100)%	7	9	-
<b>Cervical Cancer-Pap Smear Scree</b>	-	-	479	-	4,373	(89)%	6,309	7,029	-
West and Central Africa	-	-	-	-	1,450	(100)%	1,450	1,450	-
East Africa	-	-	173	-	-	-%	-	173	-
Southern Africa	-	-	2	-	116	(98)%	116	118	-
Americas	-	-	-	-	-	-%	-	241	-
Asia and Eastern Europe	-	-	304	-	2,807	(89)%	4,743	5,047	-
<b>Cervical Cancer-VIA and Conizati</b>	14	14	145	185	-	-%	10	155	41
Southern Africa	14	14	145	185	-	-%	10	155	41
<b>Cervical Cancer-VIA and Cryothe</b>	230	220	2,357	3,542	5,333	(56)%	9,025	18,224	672
West and Central Africa	15	25	542	719	1,402	(61)%	2,406	3,557	160
East Africa	110	153	906	2,545	1,889	(52)%	2,707	6,410	274
Southern Africa	36	42	420	278	623	(33)%	1,194	4,107	118
Americas	69	-	69	-	-	-%	-	137	6
Asia and Eastern Europe	-	-	420	-	1,419	(70)%	2,718	4,013	115
<b>Cervical Cancer-VIA and Refer to</b>	6	5	105	-	15	600%	65	401	14
Southern Africa	6	5	26	-	15	73%	17	274	4
Asia and Eastern Europe	-	-	79	-	-	-%	48	127	11
<b>Cervical Cancer-VIA and Refer to</b>	-	3	69	200	361	(81)%	402	1,958	10

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	-	3	69	200	361	(81)%	402	1,958	10
<b>Cervical Cancer-VIA and Refer to</b>	-	-	435	102	33	1,218%	479	2,045	59
West and Central Africa	-	-	-	-	-	-%	-	546	-
East Africa	-	-	-	102	-	-%	-	19	-
Southern Africa	-	-	16	-	33	(52)%	33	615	2
Asia and Eastern Europe	-	-	419	-	-	-%	446	865	57
<b>Cervical Cancer-VIA/VILI Screenir</b>	17,577	17,603	137,512	-	244,046	(44)%	443,880	745,381	-
West and Central Africa	5,858	5,076	47,409	-	55,661	(15)%	90,919	183,882	-
East Africa	10,054	11,182	72,313	-	115,545	(37)%	228,181	389,424	-
Southern Africa	1,321	1,334	11,849	-	19,564	(39)%	26,740	63,330	-
Americas	337	-	337	-	-	-%	-	1,416	-
Asia and Eastern Europe	7	11	5,604	-	53,276	(89)%	98,040	107,329	-
<b>Chlorhexidine</b>	9,460	9,303	116,686	293,741	30,370	284%	293,776	470,387	10,762
West and Central Africa	4,600	5,000	91,806	200,000	-	-%	46,000	137,806	9,237
East Africa	320	913	4,069	40,000	-	-%	6,682	10,751	254
Southern Africa	4,540	3,390	20,811	53,741	30,370	(31)%	241,094	321,830	1,271
<b>Clean Delivery Kit</b>	1,241	5,802	34,920	15,000	34,040	3%	58,792	1,693,106	2,974
West and Central Africa	665	2,908	9,390	15,000	3,700	154%	4,400	234,500	1,189
East Africa	576	2,894	25,530	-	29,940	(15)%	53,992	460,473	1,785
Asia and Eastern Europe	-	-	-	-	400	(100)%	400	998,133	-
<b>Condom</b>	53,810,813	47,492,521	375,085,814	748,578,078	440,352,192	(15)%	706,462,137	20,723,411,400	3,596,510
West and Central Africa	17,062,406	9,889,635	87,024,326	163,145,833	115,030,581	(24)%	166,460,451	5,516,765,515	877,116
East Africa	7,348,712	7,456,372	70,711,411	147,400,070	115,381,382	(39)%	168,952,588	2,665,450,796	1,214,617
Southern Africa	6,852,210	8,429,697	52,780,973	99,975,773	68,887,107	(23)%	100,081,646	2,388,836,295	1,080,752
Americas	3,446,679	3,663,971	28,252,185	44,696,925	25,297,506	12%	38,832,417	1,177,356,573	63,239
Other Africa	-	-	-	-	-	-%	-	14,310,880	-
Asia and Eastern Europe	19,100,806	18,052,846	136,316,919	293,359,477	115,755,616	18%	232,135,035	8,960,691,341	360,786
<b>Condom Provided</b>	-	-	-	-	3,017,450	(100)%	3,659,226	18,930,351	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
West and Central Africa	-	-	-	-	45,516	(100)%	55,399	83,854	-
East Africa	-	-	-	-	2,221,951	(100)%	2,231,548	17,065,364	-
Southern Africa	-	-	-	-	564,112	(100)%	842,352	1,079,341	-
Americas	-	-	-	-	154,684	(100)%	466,816	616,702	-
Asia and Eastern Europe	-	-	-	-	31,187	(100)%	63,111	85,090	-
<b>Counseling &amp; Tx for Moderate Ac</b>	-	-	155,155	-	-	-%	-	155,155	-
West and Central Africa	-	-	8	-	-	-%	-	8	-
East Africa	-	-	155,147	-	-	-%	-	155,147	-
<b>Deworming Tablets</b>	-	-	-	-	-	-%	-	1,095,308	-
East Africa	-	-	-	-	-	-%	-	978,174	-
Southern Africa	-	-	-	-	-	-%	-	117,134	-
<b>Diarrhea Treatment Kit</b>	94,932	141,866	1,389,913	1,651,226	1,688,662	(18)%	2,396,570	18,741,116	88,134
West and Central Africa	76,281	79,878	1,008,202	1,012,000	914,504	10%	1,301,535	8,914,423	68,851
East Africa	14,800	14,210	113,978	188,671	122,291	(7)%	176,147	1,280,118	12,217
Southern Africa	568	40,968	211,810	318,195	390,524	(46)%	479,996	2,083,234	5,348
Americas	-	-	-	40,000	-	-%	-	-	-
Asia and Eastern Europe	3,283	6,809	55,923	92,360	261,343	(79)%	438,892	6,463,341	1,718
<b>Diarrhea Treatment Kit Provided</b>	1,491	2,043	16,527	-	-	-%	24,604	41,131	615
West and Central Africa	-	-	-	-	-	-%	2,400	2,400	-
East Africa	1,109	1,541	12,442	-	-	-%	17,338	29,780	501
Southern Africa	382	502	4,085	-	-	-%	4,866	8,951	115
<b>Early Infant Male Circumcision</b>	-	-	-	-	2	(100)%	5	4,886	-
Southern Africa	-	-	-	-	2	(100)%	5	4,886	-
<b>Emergency Contraception</b>	305,261	375,679	2,784,240	4,511,652	3,205,242	(13)%	4,760,176	39,659,472	20,833
West and Central Africa	158,599	174,228	1,204,966	2,055,000	1,201,050	-%	1,808,411	14,261,435	14,387
East Africa	879	4,474	120,196	154,000	51,280	134%	73,906	1,569,478	993
Southern Africa	(67)	3,002	57,471	181,900	133,895	(57)%	208,155	1,071,347	295
Americas	27,952	49,800	200,559	336,500	202,576	(1)%	308,976	4,064,106	277



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Asia and Eastern Europe	117,898	144,174	1,201,048	1,784,252	1,616,441	(26)%	2,360,728	18,693,106	4,881
<b>Emergency Contraception Provid</b>	<b>782</b>	<b>1,243</b>	<b>8,969</b>	<b>2,170</b>	<b>7,439</b>	<b>21%</b>	<b>11,214</b>	<b>32,548</b>	<b>48</b>
West and Central Africa	7	18	203	-	161	26%	201	725	2
East Africa	74	182	1,175	2,000	18	6,428%	246	1,477	9
Southern Africa	77	101	752	170	1,215	(38)%	1,660	2,803	6
Americas	-	1	5	-	2	150%	6	93	-
Asia and Eastern Europe	624	940	6,834	-	6,043	13%	9,101	27,450	30
<b>Expanded Clean Delivery Kit</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>25,000</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>-</b>	<b>-</b>
East Africa	-	-	-	25,000	-	-%	-	-	-
<b>Expanded Clean Delivery Kit (+Cf</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>14,000</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>-</b>	<b>-</b>
East Africa	-	-	-	14,000	-	-%	-	-	-
<b>Family Planning Counseling</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>5,312</b>	<b>(100)%</b>	<b>42,161</b>	<b>42,190</b>	<b>-</b>
West and Central Africa	-	-	-	-	337	(100)%	20,577	20,606	-
East Africa	-	-	-	-	1,285	(100)%	17,574	17,574	-
Southern Africa	-	-	-	-	-	-%	223	223	-
Americas	-	-	-	-	3,690	(100)%	3,787	3,787	-
<b>Fecal Sludge Management (Hous</b>	<b>191</b>	<b>34</b>	<b>524</b>	<b>670</b>	<b>-</b>	<b>-%</b>	<b>921</b>	<b>1,445</b>	<b>-</b>
Asia and Eastern Europe	191	34	524	670	-	-%	921	1,445	-
<b>Fecal Sludge Management (Liters</b>	<b>927,200</b>	<b>147,333</b>	<b>2,425,200</b>	<b>1,571,000</b>	<b>-</b>	<b>-%</b>	<b>3,021,000</b>	<b>5,446,200</b>	<b>134</b>
Asia and Eastern Europe	927,200	147,333	2,425,200	1,571,000	-	-%	3,021,000	5,446,200	134
<b>Female Condom</b>	<b>125,606</b>	<b>166,948</b>	<b>1,197,464</b>	<b>1,538,252</b>	<b>8,152,967</b>	<b>(85)%</b>	<b>6,171,177</b>	<b>83,815,621</b>	<b>17,703</b>
West and Central Africa	51,900	59,741	273,579	224,568	1,965,644	(86)%	2,318,144	25,641,533	1,721
East Africa	4,266	29,433	378,746	140,000	1,019,952	(63)%	1,099,340	11,206,082	3,726
Southern Africa	64,100	67,206	470,854	1,020,724	5,089,146	(91)%	2,644,759	39,792,100	11,925
Americas	-	-	-	-	-	-%	-	3,751,762	-
Asia and Eastern Europe	5,340	10,567	74,285	152,960	78,225	(5)%	108,934	3,424,144	331
<b>Female Condom Provided</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>71,140</b>	<b>(100)%</b>	<b>83,044</b>	<b>112,394</b>	<b>-</b>
West and Central Africa	-	-	-	-	1,492	(100)%	2,591	3,027	-

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Product

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	-	-	-	-	-	-%	-	9,654	-
Southern Africa	-	-	-	-	69,647	(100)%	80,452	99,712	-
Americas	-	-	-	-	1	(100)%	1	1	-
<b>Fever Cases Attended</b>	<b>192,554</b>	<b>93,042</b>	<b>1,011,203</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>3,637,532</b>	<b>4,648,735</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	2,927,861	2,927,861	-
East Africa	-	-	664	-	-	-%	26,315	26,979	-
Southern Africa	3,136	3,680	297,176	-	-	-%	24,338	321,514	-
Americas	-	1,466	31,104	-	-	-%	1,187	32,291	-
Asia and Eastern Europe	189,418	87,897	682,259	-	-	-%	657,831	1,340,090	-
<b>Fever Cases Tested with Microsc</b>	<b>90</b>	<b>5,456</b>	<b>97,451</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>261,944</b>	<b>359,395</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	247,772	247,772	-
East Africa	-	-	121	-	-	-%	7,353	7,474	-
Southern Africa	90	764	3,946	-	-	-%	1,885	5,831	-
Americas	-	4,692	93,384	-	-	-%	4,934	98,318	-
<b>Fever Cases Tested with RDTs</b>	<b>192,193</b>	<b>112,633</b>	<b>1,378,113</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>3,355,756</b>	<b>4,733,869</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	2,634,426	2,634,426	-
East Africa	-	-	543	-	-	-%	18,608	19,151	-
Southern Africa	2,794	3,361	277,478	-	-	-%	20,935	298,413	-
Americas	-	21,376	417,852	-	-	-%	23,956	441,808	-
Asia and Eastern Europe	189,399	87,897	682,240	-	-	-%	657,831	1,340,071	-
<b>Free Condom</b>	<b>27,867,779</b>	<b>14,008,489</b>	<b>119,117,027</b>	<b>210,301,145</b>	<b>148,470,712</b>	<b>(20)%</b>	<b>220,640,510</b>	<b>2,352,989,229</b>	<b>1,931,435</b>
West and Central Africa	5,149,317	4,980,643	31,390,773	62,124,626	19,252,960	63%	32,825,359	201,980,764	173,373
East Africa	2,724,793	5,246,009	30,769,424	57,032,717	49,082,918	(37)%	85,946,047	656,607,372	460,406
Southern Africa	19,555,232	3,463,425	54,457,691	78,425,768	72,906,193	(25)%	93,108,576	1,383,412,155	1,292,221
Americas	438,437	271,040	1,762,793	7,684,000	7,186,951	(75)%	8,079,494	63,774,305	2,991
Asia and Eastern Europe	-	47,372	736,346	5,034,034	41,690	1,666%	681,034	47,214,633	2,444
<b>Free Female Condom</b>	<b>643,693</b>	<b>331,947</b>	<b>1,968,836</b>	<b>4,018,234</b>	<b>1,191,548</b>	<b>65%</b>	<b>1,354,037</b>	<b>15,162,490</b>	<b>17,508</b>
West and Central Africa	230,463	143,551	884,944	1,564,945	400,422	121%	431,422	3,475,633	3,025

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	307,030	149,162	791,522	1,419,000	82,090	864%	107,658	3,582,252	8,474
Southern Africa	106,200	39,233	288,370	1,000,289	561,458	(49)%	626,979	7,670,022	6,005
Americas	-	-	-	-	147,578	(100)%	167,978	258,270	-
Asia and Eastern Europe	-	-	4,000	34,000	-	-%	20,000	176,313	5
<b>HAART (Mother and Baby)</b>	-	-	-	-	-	-%	-	256	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	256	-
<b>HAART (Mother Only)</b>	-	-	-	-	-	-%	-	239	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	239	-
<b>HIV Testing Services</b>	220,327	209,100	1,560,047	1,978,892	1,103,167	41%	2,028,322	20,312,297	71,847
West and Central Africa	14,762	10,879	82,787	65,753	84,840	(2)%	201,781	3,706,182	524
East Africa	35,059	33,905	283,367	332,377	312,186	(9)%	450,690	2,924,616	8,700
Southern Africa	137,336	131,708	941,117	1,299,724	649,030	45%	950,683	12,290,796	61,228
Americas	22,787	22,229	180,853	167,485	12,813	1,311%	355,059	774,420	1,289
Asia and Eastern Europe	10,383	10,379	71,923	113,553	44,298	62%	70,109	616,283	106
<b>Hypertension Diagnosis</b>	5,539	430	12,861	-	-	-%	31,408	44,269	-
East Africa	-	-	5,790	-	-	-%	31,404	37,194	-
Southern Africa	699	20	850	-	-	-%	4	854	-
Asia and Eastern Europe	4,840	410	6,221	-	-	-%	-	6,221	-
<b>Hypertension Screening</b>	27,860	17,243	361,888	-	-	-%	142,939	504,827	-
East Africa	-	-	57,107	-	-	-%	129,978	187,085	-
Southern Africa	20,412	16,279	294,273	-	-	-%	12,961	307,234	-
Asia and Eastern Europe	7,448	963	10,508	-	-	-%	-	10,508	-
<b>Hypertension Controlled Condition</b>	3,699	412	8,577	-	-	-%	25,845	34,422	-
East Africa	-	-	3,495	-	-	-%	25,842	29,337	-
Southern Africa	12	6	48	-	-	-%	3	51	-
Asia and Eastern Europe	3,687	406	5,034	-	-	-%	-	5,034	-
<b>Implant 3</b>	(7,671)	9,161	93,131	356,915	157,072	(41)%	153,491	774,611	123,982
West and Central Africa	(1,207)	2,666	15,029	7,550	7,153	110%	9,011	15,334	24,937

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	(6,743)	5,696	70,084	331,101	149,959	(53)%	143,202	725,031	95,754
Southern Africa	80	20	(671)	6,814	(1,574)	-%	(1,712)	832	(651)
Americas	(19)	663	1,915	450	166	1,054%	333	2,547	1,913
Asia and Eastern Europe	218	115	6,774	11,000	1,368	395%	2,657	30,867	2,028
<b>Implant 3 Insertion</b>	<b>30,998</b>	<b>22,294</b>	<b>175,704</b>	<b>49,442</b>	<b>64,808</b>	<b>171%</b>	<b>165,326</b>	<b>502,510</b>	<b>298,863</b>
West and Central Africa	5,417	873	24,660	20,002	7,969	209%	20,727	56,535	51,274
East Africa	23,492	19,420	135,837	21,248	46,515	192%	127,841	379,683	235,890
Southern Africa	975	918	7,285	1,151	7,334	(1)%	11,806	45,864	7,998
Americas	151	28	410	311	586	(30)%	797	5,059	216
Asia and Eastern Europe	963	1,054	7,512	6,730	2,404	212%	4,155	15,369	3,486
<b>Implant 4</b>	<b>142</b>	<b>240</b>	<b>1,659</b>	<b>51</b>	<b>2,563</b>	<b>(35)%</b>	<b>3,419</b>	<b>31,632</b>	<b>3,890</b>
East Africa	-	-	-	-	-	-%	(369)	(369)	-
Southern Africa	142	240	1,659	51	2,563	(35)%	3,788	32,701	3,890
Asia and Eastern Europe	-	-	-	-	-	-%	-	(700)	-
<b>Implant 4 Insertion</b>	<b>-</b>	<b>3</b>	<b>27</b>	<b>169</b>	<b>172</b>	<b>(84)%</b>	<b>1,789</b>	<b>10,169</b>	<b>39</b>
West and Central Africa	-	2	7	-	-	-%	-	7	11
East Africa	-	-	-	-	-	-%	1,460	1,460	-
Southern Africa	-	1	20	169	172	(88)%	329	3,360	28
Asia and Eastern Europe	-	-	-	-	-	-%	-	5,342	-
<b>Implant 5</b>	<b>893</b>	<b>12,266</b>	<b>53,505</b>	<b>268,613</b>	<b>80,933</b>	<b>(34)%</b>	<b>109,688</b>	<b>509,669</b>	<b>139,953</b>
West and Central Africa	5,275	8,379	41,010	84,157	18,078	127%	29,265	230,186	108,356
East Africa	(5,118)	4,052	15,893	180,121	65,575	(76)%	63,837	161,811	42,914
Southern Africa	(167)	(491)	(5,740)	527	(4,900)	-%	(4,356)	36,457	(13,207)
Americas	532	(69)	(651)	558	(42)	-%	(333)	12,781	(392)
Asia and Eastern Europe	371	395	2,993	3,250	2,222	35%	21,275	68,434	2,283
<b>Implant 5 Insertion</b>	<b>34,277</b>	<b>23,924</b>	<b>204,825</b>	<b>147,439</b>	<b>147,254</b>	<b>39%</b>	<b>251,846</b>	<b>1,485,562</b>	<b>527,230</b>
West and Central Africa	8,827	9,422	87,912	41,399	77,682	13%	106,632	598,491	264,257
East Africa	12,592	10,655	81,735	38,768	42,571	92%	104,800	522,685	187,901

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	12,117	2,688	27,679	62,375	21,870	27%	32,406	302,457	70,929
Americas	504	796	4,984	2,372	2,949	69%	4,862	31,369	2,389
Asia and Eastern Europe	237	362	2,515	2,525	2,182	15%	3,146	30,560	1,755
<b>Infant Fortified Food</b>	-	-	-	-	-	-%	-	91,859	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	91,859	-
<b>Injectable 1</b>	5,972	11,033	78,305	133,742	77,915	1%	116,015	3,491,908	1,128
West and Central Africa	-	-	-	-	-	-%	-	224,928	-
Americas	2,622	3,166	22,157	54,269	23,126	(4)%	30,791	362,884	160
Asia and Eastern Europe	3,350	7,868	56,148	79,473	54,789	2%	85,224	2,904,096	968
<b>Injectable 1 Provided</b>	5,159	7,299	45,779	142	26,811	71%	41,833	118,347	667
Southern Africa	276	123	770	100	-	-%	135	905	28
Americas	2,725	4,282	19,965	42	7,300	173%	11,222	37,242	160
Asia and Eastern Europe	2,158	2,894	25,044	-	19,511	28%	30,476	80,200	479
<b>Injectable 2</b>	85,068	124,882	907,976	1,270,556	1,224,325	(26)%	1,838,773	22,747,517	75,517
West and Central Africa	70,226	101,327	692,604	1,045,150	1,021,879	(32)%	1,538,928	15,856,363	68,088
Americas	-	-	-	-	(7)	-%	(7)	22	-
Asia and Eastern Europe	14,842	23,555	215,372	225,406	202,453	6%	299,852	6,891,132	7,429
<b>Injectable 2 Provided</b>	8,482	3,579	34,055	538	26,593	28%	40,856	105,988	1,708
West and Central Africa	1,347	966	8,257	-	6,900	20%	10,433	18,690	582
Southern Africa	4,859	52	5,111	538	381	1,241%	686	5,797	434
Americas	318	762	4,479	-	5,125	(13)%	6,869	19,162	72
Asia and Eastern Europe	1,958	1,799	16,208	-	14,187	14%	22,868	62,339	621
<b>Injectable 3</b>	524,776	829,143	6,726,883	7,199,351	4,285,800	57%	6,510,929	86,157,016	566,380
West and Central Africa	257,101	211,944	2,599,135	2,252,284	1,177,895	121%	1,814,801	27,748,631	253,121
East Africa	48,734	309,940	1,891,867	1,894,283	547,087	246%	857,441	15,112,381	193,817
Southern Africa	84,760	147,663	1,106,452	1,138,166	1,472,965	(25)%	2,240,708	19,270,208	77,438
Americas	-	1	-	57,500	(410)	-%	(414)	3,366,886	-
Asia and Eastern Europe	134,181	159,596	1,129,429	1,857,118	1,088,263	4%	1,598,393	20,658,910	42,004

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Injectable 3 Provided</b>	123,551	90,396	686,677	386,273	178,060	286%	365,694	1,282,558	59,682
West and Central Africa	15,751	4,615	38,859	27,082	12,262	217%	16,028	68,318	5,627
East Africa	17,628	17,299	131,361	155,758	34,200	284%	62,588	226,117	13,579
Southern Africa	60,467	25,371	215,945	193,875	86,301	150%	210,309	561,178	25,024
Americas	1,893	8,724	45,812	58	21,957	109%	37,200	111,605	1,102
Asia and Eastern Europe	27,812	34,388	254,700	9,500	23,340	991%	39,569	315,340	14,350
<b>IPTp2</b>	771	635	21,207	1,009,317	10,564	101%	177,461	227,662	1,210
West and Central Africa	-	3	54	836,961	-	-%	-	54	3
East Africa	760	630	4,625	-	10,564	(56)%	19,006	52,625	228
Southern Africa	11	2	16,528	172,356	-	-%	158,455	174,983	979
<b>Iron Folic Acid Tablet</b>	1,540	6,007	23,160	-	-	-%	9,088	48,266,218	-
West and Central Africa	1,540	6,007	23,160	-	-	-%	14,500	37,660	-
Asia and Eastern Europe	-	-	-	-	-	-%	(5,412)	48,228,558	-
<b>IRS (# of household)</b>	-	-	-	721,863	-	-%	-	-	-
Southern Africa	-	-	-	721,863	-	-%	-	-	-
<b>ITN</b>	-	-	-	-	-	-%	-	19,397,605	-
West and Central Africa	-	-	-	-	-	-%	-	891,146	-
East Africa	-	-	-	-	-	-%	-	17,134,604	-
Southern Africa	-	-	-	-	-	-%	-	1,341,567	-
Americas	-	-	-	-	-	-%	-	30,288	-
<b>IUD 10</b>	1,488	20,379	168,897	249,325	229,110	(26)%	275,556	2,585,109	342,183
West and Central Africa	1,652	6,475	39,463	95,321	78,130	(49)%	112,075	1,608,599	134,994
East Africa	(10,217)	1,082	19,633	(17,071)	39,584	(50)%	(6,010)	265,570	64,974
Southern Africa	(2,461)	1,699	1,964	14,334	(1,012)	-%	3,605	27,833	6,784
Americas	1,922	66	2,145	2,183	6,991	(69)%	4,625	205,345	1,688
Asia and Eastern Europe	10,592	11,057	105,692	154,558	105,417	-%	161,261	477,762	133,743
<b>IUD 10 Insertion</b>	54,879	50,939	382,525	411,678	193,299	98%	404,855	2,434,645	996,243
West and Central Africa	12,382	9,870	81,328	57,282	75,886	7%	117,595	622,896	319,517

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	25,858	23,811	161,691	242,836	67,033	141%	195,352	949,796	489,512
Southern Africa	5,024	1,979	18,422	48,331	14,563	26%	25,159	278,867	46,484
Americas	1,901	1,711	13,312	25,173	9,766	36%	18,956	180,568	7,411
Asia and Eastern Europe	9,714	13,569	107,772	38,056	26,051	314%	47,793	402,518	133,319
<b>IUD 5</b>	<b>6,984</b>	<b>9,279</b>	<b>120,790</b>	<b>399,277</b>	<b>21,258</b>	<b>468%</b>	<b>35,316</b>	<b>4,252,181</b>	<b>103,060</b>
West and Central Africa	-	-	-	-	-	-%	-	3,726	-
East Africa	(31)	8	(154)	-	595	(126)%	477	13,970	(343)
Southern Africa	-	-	-	-	-	-%	-	937	-
Americas	46	29	208	50	351	(41)%	587	795	72
Asia and Eastern Europe	6,969	9,242	120,736	399,227	20,312	494%	34,252	4,232,753	103,331
<b>IUD 5 Insertion</b>	<b>16,887</b>	<b>11,864</b>	<b>121,866</b>	<b>950</b>	<b>136,852</b>	<b>(11)%</b>	<b>203,272</b>	<b>987,859</b>	<b>124,565</b>
West and Central Africa	-	-	-	-	-	-%	-	45	-
East Africa	31	72	395	-	469	(16)%	691	28,138	979
Southern Africa	-	3	8	150	216	(96)%	241	3,170	20
Americas	-	-	1	800	40	(98)%	154	155	-
Asia and Eastern Europe	16,856	11,790	121,462	-	136,127	(11)%	202,186	956,351	123,566
<b>IUS 5</b>	<b>89</b>	<b>141</b>	<b>475</b>	<b>3,500</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>475</b>	<b>880</b>
Southern Africa	89	141	475	-	-	-%	-	475	880
Asia and Eastern Europe	-	-	-	3,500	-	-%	-	-	-
<b>IUS 5 Insertion</b>	<b>55</b>	<b>106</b>	<b>412</b>	<b>500</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>412</b>	<b>1,112</b>
West and Central Africa	44	85	300	-	-	-%	-	300	949
Southern Africa	11	21	112	500	-	-%	-	112	163
<b>LifeStraw</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>15,965</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	-	645	-
East Africa	-	-	-	-	-	-%	-	15,320	-
<b>LLIN</b>	<b>1,269,832</b>	<b>1,805,596</b>	<b>11,324,115</b>	<b>25,051,409</b>	<b>21,046,531</b>	<b>(46)%</b>	<b>42,829,969</b>	<b>313,877,579</b>	<b>2,101,415</b>
West and Central Africa	304,681	178,114	2,520,723	12,347,682	13,062,726	(81)%	30,675,129	143,193,056	980,658
East Africa	117,759	588,078	4,053,960	7,978,360	6,306,523	(36)%	9,344,931	91,811,164	479,542

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	841,630	1,036,201	4,734,061	4,334,567	1,677,282	182%	2,787,629	69,663,231	640,023
Americas	-	-	-	375,000	-	-%	-	3,396,535	-
Other Africa	-	-	-	-	-	-%	-	22,408	-
Asia and Eastern Europe	5,762	3,203	15,371	15,800	-	-%	22,280	5,791,185	1,192
<b>LLIN (Hammock net)</b>	-	-	-	550	-	-%	-	-	-
Asia and Eastern Europe	-	-	-	550	-	-%	-	-	-
<b>Lubricant</b>	2,344,557	936,293	7,761,205	-	2,304,425	237%	3,223,877	69,274,244	-
West and Central Africa	1,855,385	595,245	4,901,697	-	211,553	2,217%	349,026	7,257,659	-
East Africa	86,849	71,815	709,528	-	363,760	95%	538,215	2,207,240	-
Southern Africa	230,280	80,005	830,929	-	428,673	94%	621,962	5,146,311	-
Americas	105,017	116,465	743,124	-	798,157	(7)%	1,002,585	7,174,597	-
Asia and Eastern Europe	67,026	72,763	575,927	-	502,282	15%	712,089	47,488,437	-
<b>Malaria PPT (ACT)</b>	1,676,260	1,250,285	10,538,964	9,875,035	13,809,573	(24)%	17,642,023	122,853,071	3,697,894
West and Central Africa	929,094	989,308	7,345,160	4,289,752	9,892,612	(26)%	12,109,484	83,124,107	2,740,869
East Africa	720,066	188,082	2,593,373	3,117,784	2,778,730	(7)%	4,074,406	27,109,598	798,691
Southern Africa	8,405	58,008	418,981	1,237,169	825,675	(49)%	991,622	7,337,301	133,212
Asia and Eastern Europe	18,695	14,887	181,450	1,230,330	312,556	(42)%	466,511	5,282,065	25,122
<b>Malaria PPT (Non-ACT)</b>	103	187	1,180	11,344	5,036	(77)%	3,078	13,896,248	165
West and Central Africa	-	-	-	-	-	-%	-	5,009,188	-
Southern Africa	-	-	-	-	-	-%	-	8,462,175	-
Americas	-	-	-	11,000	-	-%	-	318,740	-
Asia and Eastern Europe	103	187	1,180	344	5,036	(77)%	3,078	106,145	165
<b>Malaria RDK</b>	1,042,477	465,791	5,867,443	12,669,578	10,033,840	(42)%	12,864,534	43,966,924	-
West and Central Africa	39,407	170,726	1,647,188	7,528,315	6,666,195	(75)%	8,902,668	18,587,299	-
East Africa	821,225	123,208	1,234,250	1,881,088	1,580,269	(22)%	1,596,819	5,429,168	-
Southern Africa	25,375	34,825	2,053,301	1,873,659	1,079,210	90%	1,133,756	10,108,426	-
Americas	-	-	-	-	-	-%	-	190	-
Asia and Eastern Europe	156,470	137,031	932,704	1,386,516	708,166	32%	1,231,291	9,841,841	-



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Male Circumcision (HIV-Positive)</b>	-	-	-	-	2,681	(100)%	3,526	10,836	-
East Africa	-	-	-	-	220	(100)%	287	614	-
Southern Africa	-	-	-	-	2,461	(100)%	3,239	10,222	-
<b>Manual Vacuum Aspiration for PA</b>	3,510	2,597	26,973	2,994	4,879	453%	46,635	73,679	2,779
West and Central Africa	491	246	2,302	1,909	881	161%	7,369	9,742	1,136
East Africa	189	173	1,377	250	862	60%	1,253	2,630	268
Southern Africa	70	146	1,273	55	-	-%	1,457	2,730	381
Americas	327	522	4,630	780	3,136	48%	5,421	10,051	103
Asia and Eastern Europe	2,433	1,509	17,391	-	-	-%	31,135	48,526	892
<b>Manual Vacuum Aspiration for SA</b>	-	-	-	-	-	-%	-	3,249	-
West and Central Africa	-	-	-	-	-	-%	-	-	-
East Africa	-	-	-	-	-	-%	-	-	-
Southern Africa	-	-	-	-	-	-%	-	-	-
Americas	-	-	-	-	-	-%	-	-	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	3,249	-
<b>Medical Abortion</b>	66,483	68,711	506,641	979,436	293,956	72%	390,819	3,449,200	45,721
West and Central Africa	(28)	-	(28)	-	-	-%	(105)	(133)	(10)
East Africa	(13)	14	28	25,000	-	-%	-	28	9
Southern Africa	-	-	-	-	-	-%	-	10,451	-
Asia and Eastern Europe	66,524	68,697	506,641	954,436	293,956	72%	390,924	3,438,854	45,723
<b>Medical Abortion Provided</b>	622	794	5,385	-	-	-%	105	5,490	533
West and Central Africa	28	-	28	-	-	-%	105	133	11
East Africa	67	62	252	-	-	-%	-	252	86
Asia and Eastern Europe	527	732	5,105	-	-	-%	-	5,105	436
<b>Micronutrient Powder</b>	1,307,505	1,983,124	10,633,198	6,672,570	2,013,980	428%	4,607,780	36,171,758	-
West and Central Africa	104,760	130,777	824,261	1,713,790	-	-%	85,400	909,661	-
East Africa	-	-	-	100,000	3,500	(100)%	3,500	1,238,055	-
Southern Africa	793,920	607,240	5,160,430	4,858,780	1,990,020	159%	4,024,990	16,955,740	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	-	-	-	-	20,460	(100)%	395,910	3,365,323	-
Asia and Eastern Europe	408,825	1,245,107	4,648,507	-	-	-%	97,980	13,702,979	-
<b>Misoprostol for PAC (Oral)</b>	<b>104,312</b>	<b>111,648</b>	<b>877,208</b>	<b>1,931,906</b>	<b>1,228,690</b>	<b>(29)%</b>	<b>2,011,632</b>	<b>6,837,889</b>	<b>80,969</b>
West and Central Africa	60,715	84,966	403,126	906,686	430,508	(6)%	626,258	2,055,099	66,262
East Africa	10,436	14,464	382,018	750,300	757,252	(50)%	1,265,369	4,409,811	13,595
Southern Africa	(537)	(755)	(4,002)	-	-	-%	(6,537)	(10,539)	(359)
Americas	14,698	640	20,066	118,920	430	4,567%	2,042	37,618	151
Asia and Eastern Europe	19,000	12,333	76,000	156,000	40,500	88%	124,500	345,900	1,320
<b>Misoprostol for PAC (oral) Provid</b>	<b>3,696</b>	<b>4,215</b>	<b>30,813</b>	<b>10,720</b>	<b>-</b>	<b>-%</b>	<b>9,129</b>	<b>39,942</b>	<b>3,482</b>
West and Central Africa	1,893	1,732	14,931	10,120	-	-%	2,427	17,358	2,725
East Africa	372	339	2,832	-	-	-%	129	2,961	288
Southern Africa	537	755	4,002	-	-	-%	6,537	10,539	399
Americas	894	1,389	9,048	600	-	-%	36	9,084	70
<b>Misoprostol for PAC (Sublingual)</b>	<b>7,072</b>	<b>75,190</b>	<b>232,860</b>	<b>2,495,200</b>	<b>88</b>	<b>264,514%</b>	<b>6,156</b>	<b>239,016</b>	<b>46,961</b>
East Africa	4	7	244	2,480,200	88	177%	156	400	65
Southern Africa	7,068	75,183	232,616	15,000	-	-%	6,000	238,616	46,896
<b>Misoprostol for PAC (sublingual)</b>	<b>8</b>	<b>3</b>	<b>56</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>56</b>	<b>17</b>
East Africa	8	3	56	-	-	-%	-	56	17
<b>Misoprostol for PPH</b>	<b>277,460</b>	<b>314,033</b>	<b>1,909,640</b>	<b>330,000</b>	<b>1,235,300</b>	<b>55%</b>	<b>1,714,080</b>	<b>8,135,498</b>	<b>6,618</b>
West and Central Africa	-	-	-	300,000	-	-%	-	373,010	-
East Africa	277,460	314,033	1,908,760	30,000	1,184,600	61%	1,634,400	6,871,499	6,616
Southern Africa	-	-	-	-	-	-%	-	684,608	-
Americas	-	-	880	-	50,700	(98)%	79,680	184,166	2
Asia and Eastern Europe	-	-	-	-	-	-%	-	22,215	-
<b>Multivitamin</b>	<b>375,060</b>	<b>385,897</b>	<b>1,745,300</b>	<b>2,476,080</b>	<b>1,089,570</b>	<b>60%</b>	<b>1,789,770</b>	<b>95,047,389</b>	<b>164</b>
West and Central Africa	-	-	-	-	-	-%	-	15,761,378	-
Southern Africa	-	-	-	-	-	-%	-	12,270,645	-
Americas	252,780	356,840	1,535,850	2,476,080	1,089,570	41%	1,789,770	53,295,871	114

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Asia and Eastern Europe	122,280	29,057	209,450	-	-	-%	-	13,719,495	50
<b>Naloxone</b>	-	669	2,066	5,892	-	-%	-	64,236	2,819
Asia and Eastern Europe	-	669	2,066	5,892	-	-%	-	64,236	2,819
<b>Needle &amp; Syringe</b>	310,900	478,533	4,041,411	6,082,749	2,455,605	65%	4,903,605	23,679,059	32,608
Americas	-	-	-	-	-	-%	-	1,540,000	-
Asia and Eastern Europe	310,900	478,533	4,041,411	6,082,749	2,455,605	65%	4,903,605	22,139,059	32,608
<b>NVP</b>	-	-	-	-	-	-%	-	11,442	-
East Africa	-	-	-	-	-	-%	-	235	-
Southern Africa	-	-	-	-	-	-%	-	11,057	-
Americas	-	-	-	-	-	-%	-	150	-
<b>OCs</b>	3,321,870	2,872,688	22,821,885	38,762,595	17,216,176	33%	30,011,035	598,624,778	454,799
West and Central Africa	1,205,181	786,591	6,102,254	11,612,236	6,252,665	(2)%	9,528,389	165,499,736	209,417
East Africa	387,974	611,927	4,720,538	6,170,698	3,908,435	21%	7,878,628	75,067,029	120,236
Southern Africa	339,442	323,125	2,382,256	2,721,504	1,574,862	51%	2,583,428	71,054,438	45,884
Americas	87,790	118,413	563,524	1,100,620	619,419	(9)%	901,873	35,415,956	2,641
Asia and Eastern Europe	1,301,483	1,032,633	9,053,313	17,157,537	4,860,795	86%	9,118,717	251,587,619	76,620
<b>OCs Provided</b>	124,175	133,191	963,653	457,682	498,165	93%	764,724	2,338,122	21,662
West and Central Africa	20,495	12,710	86,552	15,000	17,602	392%	28,690	139,679	3,567
East Africa	5,276	8,524	50,392	39,344	46,278	9%	58,379	138,649	1,529
Southern Africa	46,441	35,055	287,447	379,864	370,633	(22)%	573,214	1,340,052	8,467
Americas	1,128	4,140	18,095	40	8,036	125%	12,463	48,215	119
Asia and Eastern Europe	50,835	72,762	521,167	23,434	55,616	837%	91,978	671,527	7,979
<b>ORS</b>	119,512	216,372	1,462,314	3,789,196	1,681,736	(13)%	1,692,324	436,047,462	46,129
West and Central Africa	-	77,666	500,903	1,965	56,224	791%	70,974	64,412,787	19,524
East Africa	23,656	40,625	177,288	1,086,611	637,787	(72)%	752,366	24,191,151	5,570
Southern Africa	-	-	-	-	-	-%	-	1,999,000	-
Americas	-	-	300,000	330,000	249,840	20%	300,000	10,047,338	10,285
Other Africa	-	-	-	-	-	-%	-	6,127,779	-

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Asia and Eastern Europe	95,856	98,081	484,123	2,370,620	737,885	(34)%	568,984	329,269,407	10,750
<b>ORS Provided</b>	306	330	123,250	-	-	-%	5,546	128,796	4,452
East Africa	306	330	123,250	-	-	-%	5,546	128,796	4,452
<b>Pneumonia PPT</b>	51,150	78,607	411,689	1,390,257	493,681	(17)%	827,943	6,075,655	191,557
West and Central Africa	11,690	3,933	38,130	60,000	53,935	(29)%	57,518	831,045	26,121
East Africa	11,660	25,889	53,379	910,330	93,773	(43)%	266,190	2,203,086	47,936
Southern Africa	27,800	48,785	320,180	419,927	233,947	37%	376,369	1,507,278	117,500
Asia and Eastern Europe	-	-	-	-	112,026	(100)%	127,866	1,534,246	-
<b>Pneumonia PPT Provided</b>	1,295	1,694	95,764	-	-	-%	22,354	118,118	87,358
West and Central Africa	-	-	-	-	-	-%	2,500	2,500	-
East Africa	1,295	1,694	95,764	-	-	-%	19,854	115,618	87,358
<b>Positive RDTs</b>	11,719	1,589	142,873	-	-	-%	2,068,034	2,210,907	-
West and Central Africa	-	-	-	-	-	-%	2,047,931	2,047,931	-
East Africa	-	-	110	-	-	-%	3,656	3,766	-
Southern Africa	287	489	100,317	-	-	-%	2,177	102,494	-
Americas	-	150	25,283	-	-	-%	1,069	26,352	-
Asia and Eastern Europe	11,432	950	17,163	-	-	-%	13,201	30,364	-
<b>Positive RDTs Given First Line Tr</b>	10,699	923	15,726	-	-	-%	2,062,102	2,077,828	-
West and Central Africa	-	-	-	-	-	-%	2,047,743	2,047,743	-
East Africa	-	-	110	-	-	-%	3,489	3,599	-
Asia and Eastern Europe	10,699	923	15,616	-	-	-%	10,870	26,486	-
<b>Pregnancy Test</b>	-	-	-	-	-	-%	-	930,449	-
West and Central Africa	-	-	-	-	-	-%	-	5,685	-
Americas	-	-	-	-	-	-%	-	129,873	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	794,891	-
<b>PrEP</b>	198	273	1,870	19,960	-	-%	403	2,273	61
Southern Africa	198	273	1,870	19,960	-	-%	403	2,273	61
<b>PUR</b>	5,824,163	9,827,544	57,762,772	54,971,647	51,740,691	12%	73,371,542	544,861,561	2,183

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
West and Central Africa	72,720	171,600	1,316,406	4,792,000	1,315,564	-%	5,988,604	45,176,051	120
East Africa	5,071,376	9,640,422	55,645,568	49,069,647	49,145,464	13%	65,302,222	414,692,638	2,043
Southern Africa	-	-	-	-	-	-%	-	4,694,784	-
Americas	-	-	-	-	-	-%	-	21,231,358	-
Asia and Eastern Europe	680,067	15,522	800,798	1,110,000	1,279,663	(37)%	2,080,716	59,066,730	19
<b>QAACts Provided after Confirma</b>	<b>9,862</b>	<b>483</b>	<b>13,089</b>	<b>10,513</b>	<b>-</b>	<b>-%</b>	<b>2,046,155</b>	<b>2,059,244</b>	<b>1,892</b>
West and Central Africa	-	-	-	-	-	-%	2,034,979	2,034,979	-
East Africa	-	-	110	-	-	-%	3,815	3,925	18
Asia and Eastern Europe	9,862	483	12,979	10,513	-	-%	7,361	20,340	1,874
<b>Referral to Advanced Cervical Cai</b>	<b>3</b>	<b>7</b>	<b>42</b>	<b>85</b>	<b>113</b>	<b>(63)%</b>	<b>142</b>	<b>385</b>	<b>-</b>
Southern Africa	3	7	42	85	113	(63)%	142	385	-
<b>Referral to CD4/Clinical Staging</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>11,794</b>	<b>8,207</b>	<b>(100)%</b>	<b>10,820</b>	<b>34,138</b>	<b>-</b>
West and Central Africa	-	-	-	553	-	-%	-	18	-
East Africa	-	-	-	2,043	1,601	(100)%	2,210	3,364	-
Southern Africa	-	-	-	9,198	6,606	(100)%	8,610	30,613	-
Americas	-	-	-	-	-	-%	-	143	-
<b>Referral to Clinical Staging</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,919</b>	<b>(100)%</b>	<b>2,986</b>	<b>18,909</b>	<b>-</b>
East Africa	-	-	-	-	101	(100)%	107	1,893	-
Southern Africa	-	-	-	-	2,818	(100)%	2,879	17,016	-
<b>Referral to Diabetes Management</b>	<b>1</b>	<b>-</b>	<b>1</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>1</b>	<b>-</b>
Southern Africa	1	-	1	-	-	-%	-	1	-
<b>Referral to Early Infant Male Circu</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>28</b>	<b>(100)%</b>	<b>36</b>	<b>94</b>	<b>-</b>
Southern Africa	-	-	-	-	28	(100)%	36	94	-
<b>Referral to Emergency Contracep</b>	<b>-</b>	<b>-</b>	<b>5</b>	<b>-</b>	<b>31</b>	<b>(84)%</b>	<b>43</b>	<b>141</b>	<b>-</b>
East Africa	-	-	5	-	25	(80)%	37	133	-
Southern Africa	-	-	-	-	6	(100)%	6	8	-
<b>Referral to HIV Testing Services</b>	<b>2,864</b>	<b>3,523</b>	<b>26,598</b>	<b>183,580</b>	<b>25,940</b>	<b>3%</b>	<b>36,096</b>	<b>267,894</b>	<b>548</b>
West and Central Africa	-	-	-	60,035	5,401	(100)%	5,682	66,105	-

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	1,167	2,095	11,734	113,410	10,716	9%	12,052	129,779	31
Southern Africa	1,688	1,368	9,664	7,200	5,053	91%	7,911	36,347	510
Americas	-	-	-	-	24	(100)%	27	577	-
Asia and Eastern Europe	9	60	5,200	2,935	4,746	10%	10,424	35,086	8
<b>Referral to Hypertension Manager</b>	<b>34</b>	<b>137</b>	<b>456</b>	<b>50</b>	<b>-</b>	<b>-%</b>	<b>27</b>	<b>483</b>	<b>-</b>
Southern Africa	34	137	456	50	-	-%	27	483	-
<b>Referral to Implant 3 Insertion</b>	<b>-</b>	<b>2</b>	<b>22</b>	<b>8,500</b>	<b>311</b>	<b>(93)%</b>	<b>1,223</b>	<b>16,105</b>	<b>16</b>
West and Central Africa	-	-	-	-	-	-%	-	4,343	-
East Africa	-	1	19	8,500	311	(94)%	586	7,940	15
Southern Africa	-	1	3	-	-	-%	1	1,510	2
Americas	-	-	-	-	-	-%	-	974	-
Asia and Eastern Europe	-	-	-	-	-	-%	636	1,338	-
<b>Referral to Implant 5 Insertion</b>	<b>16</b>	<b>34</b>	<b>214</b>	<b>1,520</b>	<b>217</b>	<b>(1)%</b>	<b>1,831</b>	<b>19,436</b>	<b>140</b>
West and Central Africa	-	16	49	-	-	-%	-	12,990	63
East Africa	-	-	23	1,500	153	(85)%	1,717	3,702	26
Southern Africa	-	2	5	20	-	-%	-	1,753	4
Americas	-	-	-	-	-	-%	-	260	-
Asia and Eastern Europe	16	16	137	-	64	114%	114	731	48
<b>Referral to Implant Insertion (dura</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>89</b>	<b>-</b>
East Africa	-	-	-	-	-	-%	-	89	-
<b>Referral to Injectable (duration un</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>773</b>	<b>-</b>
Southern Africa	-	-	-	-	-	-%	-	110	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	663	-
<b>Referral to Injectable 1</b>	<b>43</b>	<b>30</b>	<b>143</b>	<b>100</b>	<b>16</b>	<b>794%</b>	<b>32</b>	<b>175</b>	<b>3</b>
Southern Africa	43	30	143	100	16	794%	32	175	3
<b>Referral to Injectable 2</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>200</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>1</b>	<b>-</b>
Southern Africa	-	-	-	200	-	-%	-	1	-
<b>Referral to Injectable 3</b>	<b>94</b>	<b>74</b>	<b>462</b>	<b>15,848</b>	<b>1,293</b>	<b>(64)%</b>	<b>13,305</b>	<b>22,290</b>	<b>23</b>

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
West and Central Africa	-	16	49	-	-	-%	-	49	3
East Africa	-	2	39	10,000	1,120	(97)%	12,012	13,715	2
Southern Africa	91	49	297	370	-	-%	45	1,074	16
Asia and Eastern Europe	3	7	77	5,478	173	(55)%	1,248	7,452	1
<b>Referral to IUD 10 Insertion</b>	<b>22</b>	<b>142</b>	<b>707</b>	<b>67,034</b>	<b>701</b>	<b>1%</b>	<b>2,382</b>	<b>132,331</b>	<b>720</b>
West and Central Africa	-	116	348	-	-	-%	22	21,151	550
East Africa	-	-	-	11,200	34	(100)%	343	24,155	-
Southern Africa	-	2	33	-	6	450%	7	14,755	30
Americas	-	-	-	-	-	-%	-	52,430	-
Asia and Eastern Europe	22	24	326	55,834	661	(51)%	2,010	19,840	140
<b>Referral to IUD 5 Insertion</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>30</b>	<b>9</b>	<b>(100)%</b>	<b>9</b>	<b>498</b>	<b>-</b>
East Africa	-	-	-	-	9	(100)%	9	49	-
Southern Africa	-	-	-	30	-	-%	-	9	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	440	-
<b>Referral to IUD Insertion (duration</b>	<b>-</b>	<b>2</b>	<b>5</b>	<b>-</b>	<b>2</b>	<b>150%</b>	<b>2</b>	<b>16</b>	<b>3</b>
East Africa	-	-	-	-	-	-%	-	9	-
Southern Africa	-	2	5	-	2	150%	2	7	3
<b>Referral to IUS 3 Insertion</b>	<b>-</b>	<b>9</b>	<b>26</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>26</b>	<b>13</b>
Southern Africa	-	9	26	-	-	-%	-	26	13
<b>Referral to Linkage to HIV Care</b>	<b>1,726</b>	<b>1,922</b>	<b>14,912</b>	<b>17,241</b>	<b>-</b>	<b>-%</b>	<b>4,072</b>	<b>18,984</b>	<b>9,210</b>
West and Central Africa	-	-	-	460	-	-%	281	281	-
East Africa	369	275	1,360	-	-	-%	-	1,360	691
Southern Africa	1,251	1,501	12,096	15,609	-	-%	2,624	14,720	7,201
Americas	-	-	-	-	-	-%	333	333	-
Asia and Eastern Europe	106	146	1,456	1,172	-	-%	834	2,290	1,318
<b>Referral to Manual Vacuum Aspir:</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>46</b>	<b>46</b>	<b>-</b>
Asia and Eastern Europe	-	-	-	-	-	-%	46	46	-
<b>Referral to Medication Abortion</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>24</b>	<b>24</b>	<b>-</b>

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Asia and Eastern Europe	-	-	-	-	-	-%	24	24	-
<b>Referral to OCs</b>	127	49	405	1,830	355	14%	3,408	8,968	5
West and Central Africa	-	4	11	-	-	-%	-	11	-
East Africa	-	-	7	1,500	287	(98)%	2,049	2,725	-
Southern Africa	125	40	322	330	1	32,100%	79	1,248	5
Asia and Eastern Europe	2	6	65	-	67	(3)%	1,280	4,984	-
<b>Referral to Opioid Treatment</b>	49	14	154	-	-	-%	136	290	-
Asia and Eastern Europe	49	14	154	-	-	-%	136	290	-
<b>Referral to PAC Service (unknowr</b>	-	-	-	-	-	-%	488	488	-
Asia and Eastern Europe	-	-	-	-	-	-%	488	488	-
<b>Referral to Pre-Exposure Prophyl:</b>	10	8	122	-	-	-%	-	122	2
Southern Africa	10	8	122	-	-	-%	-	122	2
<b>Referral to STI Diagnosis (lab con</b>	-	-	332	-	-	-%	-	332	-
East Africa	-	-	332	-	-	-%	-	332	-
<b>Referral to STI Screening (syndro</b>	1,141	2,248	12,410	338	-	-%	8	12,418	-
East Africa	1,135	2,238	12,340	-	-	-%	-	12,340	-
Southern Africa	6	10	70	338	-	-%	8	78	-
<b>Referral to STI Treatment (unknov</b>	3	7	47	142,281	935	(95)%	957	8,884	-
East Africa	-	-	1	142,281	5	(80)%	5	916	-
Southern Africa	3	7	46	-	930	(95)%	952	5,638	-
Americas	-	-	-	-	-	-%	-	4	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	2,326	-
<b>Referral to TB Diagnosis</b>	611	158	2,879	19,794	-	-%	1,446	30,189	-
East Africa	-	19	414	-	-	-%	-	8,112	-
Southern Africa	31	22	170	6,750	-	-%	11	7,633	-
Asia and Eastern Europe	580	117	2,295	13,044	-	-%	1,435	14,444	-
<b>Referral to TB DOTS (completion</b>	262	9	719	9,502	293	145%	773	1,776	1,205
Southern Africa	-	-	1	-	-	-%	2	17	1



POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Product

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Asia and Eastern Europe	262	9	718	9,502	293	145%	771	1,759	1,204
<b>Referral to TB DOTS (completion)</b>	<b>584</b>	<b>108</b>	<b>2,027</b>	<b>7,096</b>	<b>337</b>	<b>501%</b>	<b>1,778</b>	<b>7,546</b>	<b>2,888</b>
East Africa	-	-	-	-	26	(100)%	26	1,617	-
Southern Africa	31	30	179	300	311	(42)%	484	2,632	99
Asia and Eastern Europe	553	78	1,848	6,796	-	-%	1,268	3,297	2,789
<b>Referral to TB Screening</b>	<b>12,670</b>	<b>2,621</b>	<b>63,295</b>	<b>12,177</b>	<b>-</b>	<b>-%</b>	<b>35,695</b>	<b>98,990</b>	<b>-</b>
East Africa	1,554	1,246	10,662	-	-	-%	-	10,662	-
Southern Africa	335	168	9,052	-	-	-%	434	9,486	-
Asia and Eastern Europe	10,781	1,206	43,581	12,177	-	-%	35,261	78,842	-
<b>Referral to Treatment for Cerviciti</b>	<b>7</b>	<b>9</b>	<b>34</b>	<b>-</b>	<b>4</b>	<b>750%</b>	<b>4</b>	<b>60</b>	<b>2</b>
East Africa	-	-	-	-	-	-%	-	3	-
Southern Africa	7	9	34	-	4	750%	4	57	2
<b>Referral to Treatment for Genital I</b>	<b>3</b>	<b>-</b>	<b>3</b>	<b>5</b>	<b>-</b>	<b>-%</b>	<b>3</b>	<b>9</b>	<b>-</b>
East Africa	-	-	-	-	-	-%	-	3	-
Southern Africa	3	-	3	5	-	-%	3	6	-
<b>Referral to Treatment for Inguinal</b>	<b>-</b>	<b>-</b>	<b>28</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>133</b>	<b>-</b>
East Africa	-	-	28	-	-	-%	-	133	-
<b>Referral to Treatment for Lower A</b>	<b>-</b>	<b>2</b>	<b>34</b>	<b>-</b>	<b>13</b>	<b>162%</b>	<b>13</b>	<b>130</b>	<b>-</b>
East Africa	-	1	30	-	5	500%	5	103	-
Southern Africa	-	1	4	-	8	(50)%	8	27	-
<b>Referral to Treatment for Urethral</b>	<b>6</b>	<b>8</b>	<b>103</b>	<b>-</b>	<b>26</b>	<b>296%</b>	<b>32</b>	<b>2,574</b>	<b>1</b>
East Africa	6	7	102	-	-	-%	-	2,517	1
Southern Africa	-	-	1	-	26	(96)%	32	57	-
<b>Referral to Treatment for Vaginitis</b>	<b>22</b>	<b>22</b>	<b>167</b>	<b>5</b>	<b>139</b>	<b>20%</b>	<b>143</b>	<b>7,217</b>	<b>2</b>
East Africa	22	22	167	-	136	23%	136	7,205	2
Southern Africa	-	-	-	5	3	(100)%	7	12	-
<b>Referral to Tubal Ligation</b>	<b>-</b>	<b>-</b>	<b>1</b>	<b>-</b>	<b>3</b>	<b>(67)%</b>	<b>3</b>	<b>65</b>	<b>2</b>
East Africa	-	-	-	-	3	(100)%	3	3	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	-	-	1	-	-	-%	-	1	2
Asia and Eastern Europe	-	-	-	-	-	-%	-	61	-
<b>Referral to Tx for Nonherpetic Ge</b>	<b>9</b>	<b>8</b>	<b>64</b>	<b>-</b>	<b>32</b>	<b>100%</b>	<b>35</b>	<b>1,073</b>	<b>7</b>
East Africa	2	2	39	-	22	77%	22	1,026	3
Southern Africa	7	6	25	-	10	150%	13	47	4
<b>Referral to Tx for Urethral Discha</b>	<b>3</b>	<b>12</b>	<b>98</b>	<b>-</b>	<b>198</b>	<b>(51)%</b>	<b>222</b>	<b>2,418</b>	<b>9</b>
East Africa	-	-	-	-	66	(100)%	66	1,921	-
Southern Africa	3	12	98	-	132	(26)%	156	497	9
<b>Referral to Vasectomy</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>2</b>	<b>-</b>
Southern Africa	-	-	-	3	-	-%	-	2	-
<b>Referral to Voluntary Medical Mal</b>	<b>19</b>	<b>34</b>	<b>355</b>	<b>2,249</b>	<b>3,564</b>	<b>(90)%</b>	<b>3,891</b>	<b>20,481</b>	<b>1,627</b>
East Africa	-	-	-	-	42	(100)%	42	42	-
Southern Africa	19	34	355	2,249	3,522	(90)%	3,849	20,439	1,627
<b>Retreatment</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>46,984,114</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	-	1,638,283	-
East Africa	-	-	-	-	-	-%	-	40,242,797	-
Southern Africa	-	-	-	-	-	-%	-	543,345	-
Americas	-	-	-	-	-	-%	-	111,568	-
Other Africa	-	-	-	-	-	-%	-	26,407	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	4,421,714	-
<b>Retreatment IconMaxx</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>4,873,846</b>	<b>-</b>
East Africa	-	-	-	-	-	-%	-	2,297,300	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	2,576,546	-
<b>Retreatment KO123</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>9,124,110</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	-	4,082	-
East Africa	-	-	-	-	-	-%	-	8,813,436	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	306,592	-
<b>Retreatment KO123 net</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>10,259,477</b>	<b>-</b>

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	-	-	-	-	-	-%	-	10,259,477	-
<b>Safe Injection Kit</b>	-	-	-	-	-	-%	-	5	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	5	-
<b>Safe Water Solution</b>	445,779	619,192	5,585,687	10,138,837	5,933,345	(6)%	9,075,837	155,641,296	27,724
West and Central Africa	12,600	14,042	730,356	200,000	143,431	409%	160,999	13,257,107	3,779
East Africa	318,819	225,027	2,132,752	4,239,239	2,700,117	(21)%	4,616,248	62,902,089	7,608
Southern Africa	114,360	380,123	2,722,579	5,699,598	3,082,824	(12)%	4,291,617	72,853,615	16,336
Americas	-	-	-	-	-	-%	-	449,298	-
Asia and Eastern Europe	-	-	-	-	6,973	(100)%	6,973	6,179,187	-
<b>SD NVP w/o Baby ARV Prophylax</b>	-	-	-	-	-	-%	-	271	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	271	-
<b>SD NVP with Baby ARV Prophyla:</b>	-	-	-	-	-	-%	-	235	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	235	-
<b>SDM (Cycle Beads)</b>	1,938	8,372	30,953	35,563	24,476	26%	31,571	609,327	27,388
West and Central Africa	888	2,490	11,074	18,256	14,484	(24)%	20,227	370,096	13,926
East Africa	-	-	-	-	5	(100)%	5	8,591	-
Southern Africa	1,050	5,882	19,879	17,307	9,989	99%	11,341	228,146	13,462
Americas	-	-	-	-	(2)	-%	(2)	(2)	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	2,496	-
<b>SDM (Cycle Beads) Provided</b>	316	507	4,773	-	2,257	111%	5,027	11,562	5,660
West and Central Africa	211	307	3,193	-	2,224	44%	2,812	6,877	4,477
East Africa	-	-	-	-	-	-%	-	134	-
Southern Africa	105	199	1,568	-	10	15,580%	2,176	4,433	1,180
Americas	-	1	12	-	23	(48)%	39	118	3
<b>Skilled Birth Attendance</b>	6,173	4,327	35,852	16,237	11,662	207%	28,307	98,435	15,656
West and Central Africa	2,443	1,893	17,175	-	-	-%	-	17,175	-
East Africa	3,730	2,434	18,677	16,237	11,662	60%	28,307	81,260	15,656
<b>STI Kit</b>	-	-	-	-	-	-%	-	691,263	-

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
West and Central Africa	-	-	-	-	-	-%	-	1,796	-
East Africa	-	-	-	-	-	-%	-	438,695	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	250,772	-
<b>STI Kit (Non-Ulcerative)</b>	<b>91</b>	<b>1,000</b>	<b>4,400</b>	<b>9,311</b>	<b>59,123</b>	<b>(93)%</b>	<b>62,324</b>	<b>4,010,321</b>	<b>343</b>
West and Central Africa	-	-	-	-	-	-%	-	7,704	-
East Africa	-	923	3,840	9,070	16,259	(76)%	18,139	853,782	243
Southern Africa	91	77	560	241	428	31%	797	2,058,126	100
Asia and Eastern Europe	-	-	-	-	42,436	(100)%	43,388	1,090,709	-
<b>STI Kit (Ulcerative)</b>	<b>21</b>	<b>244</b>	<b>794</b>	<b>1,305</b>	<b>5,803</b>	<b>(86)%</b>	<b>7,179</b>	<b>1,854,256</b>	<b>173</b>
West and Central Africa	-	-	-	-	-	-%	-	480	-
East Africa	-	230	690	1,121	2,788	(75)%	3,373	72,218	132
Southern Africa	21	14	104	184	51	104%	127	1,721,085	40
Asia and Eastern Europe	-	-	-	-	2,964	(100)%	3,679	60,473	-
<b>STI Screening</b>	<b>37,852</b>	<b>41,443</b>	<b>299,151</b>	<b>3,000</b>	<b>327,057</b>	<b>(9)%</b>	<b>443,197</b>	<b>900,610</b>	<b>-</b>
West and Central Africa	624	521	4,278	-	4,952	(14)%	19,906	27,876	-
East Africa	7,661	8,877	75,155	3,000	110,179	(32)%	153,790	365,983	-
Southern Africa	6,018	8,540	55,920	-	32,626	71%	47,096	117,272	-
Americas	20,724	20,767	141,460	-	179,161	(21)%	222,184	366,337	-
Asia and Eastern Europe	2,825	2,739	22,338	-	139	15,971%	221	23,142	-
<b>TB Diagnosis</b>	<b>13,058</b>	<b>5,311</b>	<b>53,419</b>	<b>-</b>	<b>27,955</b>	<b>91%</b>	<b>62,507</b>	<b>140,623</b>	<b>-</b>
West and Central Africa	-	-	-	-	6,186	(100)%	10,219	10,219	-
East Africa	-	-	-	-	-	-%	-	615	-
Southern Africa	75	43	326	-	205	59%	336	1,061	-
Americas	3,121	986	9,484	-	-	-%	11,406	20,890	-
Asia and Eastern Europe	9,862	4,283	43,609	-	21,564	102%	40,546	107,838	-
<b>TB DOTS</b>	<b>8,486</b>	<b>3,932</b>	<b>33,635</b>	<b>32,517</b>	<b>19,210</b>	<b>75%</b>	<b>39,561</b>	<b>311,470</b>	<b>152,537</b>
West and Central Africa	-	-	-	-	3,668	(100)%	5,763	5,763	-
Southern Africa	5	3	17	-	11	55%	11	59	98

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	4,152	1,125	10,637	10,000	-	-%	9,997	20,634	36,409
Asia and Eastern Europe	4,329	2,803	22,981	22,517	15,531	48%	23,790	285,014	116,030
<b>TB Screening</b>	<b>62,184</b>	<b>46,000</b>	<b>429,194</b>	<b>-</b>	<b>342,785</b>	<b>25%</b>	<b>556,967</b>	<b>1,507,255</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	7,139	7,139	-
East Africa	5,443	7,747	65,262	-	107,292	(39)%	143,594	416,871	-
Southern Africa	25,729	24,584	211,849	-	198,943	6%	284,453	744,653	-
Americas	4,008	1,312	11,507	-	-	-%	12,026	23,533	-
Asia and Eastern Europe	27,004	12,358	140,576	-	36,550	285%	109,755	315,059	-
<b>Toilets Constructed</b>	<b>106</b>	<b>432</b>	<b>16,371</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>16,371</b>	<b>-</b>
West and Central Africa	106	432	3,569	-	-	-%	-	3,569	-
Asia and Eastern Europe	-	-	12,802	-	-	-%	-	12,802	-
<b>Toilets Sold</b>	<b>15,568</b>	<b>7,771</b>	<b>127,130</b>	<b>108,137</b>	<b>-</b>	<b>-%</b>	<b>75,880</b>	<b>203,010</b>	<b>17,043</b>
West and Central Africa	106	432	3,564	3,000	-	-%	2,598	6,162	955
Asia and Eastern Europe	15,462	7,339	123,566	105,137	-	-%	73,282	196,848	16,088
<b>Treatment for Cervicitis</b>	<b>14</b>	<b>25</b>	<b>265</b>	<b>120</b>	<b>-</b>	<b>-%</b>	<b>20</b>	<b>285</b>	<b>24</b>
East Africa	-	1	9	-	-	-%	-	9	-
Southern Africa	14	24	256	120	-	-%	20	276	24
<b>Treatment for Genital Herpes</b>	<b>24</b>	<b>2</b>	<b>63</b>	<b>312</b>	<b>-</b>	<b>-%</b>	<b>7</b>	<b>70</b>	<b>2</b>
East Africa	19	1	22	300	-	-%	2	24	1
Southern Africa	5	1	41	12	-	-%	5	46	2
<b>Treatment for Inguinal Bubo</b>	<b>12</b>	<b>7</b>	<b>85</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>8</b>	<b>93</b>	<b>-</b>
East Africa	4	1	15	-	-	-%	-	15	-
Southern Africa	8	6	70	-	-	-%	8	78	-
<b>Treatment for Lower Abdominal P</b>	<b>189</b>	<b>163</b>	<b>1,239</b>	<b>430</b>	<b>-</b>	<b>-%</b>	<b>106</b>	<b>1,345</b>	<b>-</b>
East Africa	79	51	303	400	-	-%	4	307	-
Southern Africa	110	111	936	30	-	-%	102	1,038	-
<b>Treatment for Nonherpetic Genita</b>	<b>838</b>	<b>899</b>	<b>6,462</b>	<b>450</b>	<b>-</b>	<b>-%</b>	<b>1,466</b>	<b>7,928</b>	<b>1,075</b>
East Africa	91	104	560	300	-	-%	14	574	83

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	184	197	1,579	150	-	-%	162	1,741	271
Americas	563	597	4,323	-	-	-%	1,290	5,613	721
<b>Treatment for Pre-Eclampsia (with</b>	<b>6</b>	<b>4</b>	<b>62</b>	<b>39</b>	<b>-</b>	<b>-%</b>	<b>28</b>	<b>90</b>	<b>42</b>
East Africa	6	4	62	39	-	-%	28	90	42
<b>Treatment for Severe Acute Malnutrition</b>	<b>-</b>	<b>-</b>	<b>16,206</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>25,444</b>	<b>41,650</b>	<b>20,370</b>
West and Central Africa	-	-	4	-	-	-%	-	4	-
East Africa	-	-	16,202	-	-	-%	25,444	41,646	20,370
<b>Treatment for Urethral Discharge</b>	<b>724</b>	<b>790</b>	<b>6,263</b>	<b>772</b>	<b>-</b>	<b>-%</b>	<b>698</b>	<b>6,961</b>	<b>83</b>
West and Central Africa	-	-	-	-	-	-%	116	116	-
East Africa	145	181	886	700	-	-%	1	887	11
Southern Africa	579	609	5,377	72	-	-%	581	5,958	73
<b>Treatment for Urethral Discharge</b>	<b>228</b>	<b>236</b>	<b>1,655</b>	<b>1,240</b>	<b>-</b>	<b>-%</b>	<b>224</b>	<b>1,879</b>	<b>165</b>
West and Central Africa	-	-	-	-	-	-%	138	138	-
East Africa	175	163	917	900	-	-%	2	919	29
Southern Africa	53	72	738	340	-	-%	84	822	136
<b>Treatment for Vaginitis</b>	<b>623</b>	<b>736</b>	<b>6,025</b>	<b>5</b>	<b>-</b>	<b>-%</b>	<b>671</b>	<b>6,696</b>	<b>171</b>
East Africa	73	135	748	-	-	-%	67	815	15
Southern Africa	550	602	5,277	5	-	-%	604	5,881	156
<b>Tubal Ligation</b>	<b>4,725</b>	<b>2,555</b>	<b>31,629</b>	<b>72,802</b>	<b>13,948</b>	<b>127%</b>	<b>24,786</b>	<b>286,551</b>	<b>129,755</b>
West and Central Africa	-	1	12	-	-	-%	-	12	86
East Africa	1,830	1,239	8,677	5,500	1,968	341%	4,523	13,739	51,014
Southern Africa	121	2	160	-	-	-%	-	160	899
Americas	296	411	2,305	-	1,164	98%	1,982	12,915	3,611
Asia and Eastern Europe	2,478	901	20,475	67,302	10,816	89%	18,281	259,725	74,146
<b>Type 2 Diabetes Diagnosis</b>	<b>43</b>	<b>1</b>	<b>47</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>47</b>	<b>-</b>
Southern Africa	43	1	47	-	-	-%	-	47	-
<b>Type 2 Diabetes Screening</b>	<b>937</b>	<b>770</b>	<b>4,518</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>4,518</b>	<b>-</b>
Southern Africa	937	770	4,518	-	-	-%	-	4,518	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Type 2 Diabetes_ Controlled Cond</b>	1	1	6	-	-	-%	-	6	-
Southern Africa	1	1	6	-	-	-%	-	6	-
<b>Vasectomy</b>	333	80	1,683	2,112	1,008	67%	1,886	3,828	6,123
West and Central Africa	-	-	1	-	-	-%	-	1	7
East Africa	-	-	7	-	1	600%	2	11	43
Southern Africa	28	-	28	-	-	-%	-	28	182
Americas	54	22	133	-	12	1,008%	14	404	212
Asia and Eastern Europe	251	58	1,514	2,112	995	52%	1,870	3,384	5,678
<b>Vivax Treatment after Confirmati</b>	207	192	1,399	3,443	-	-%	3,796	5,195	230
Asia and Eastern Europe	207	192	1,399	3,443	-	-%	3,796	5,195	230
<b>Voluntary Medical Male Circumcis</b>	49,367	41,261	292,778	385,679	197,377	48%	279,911	1,937,711	1,987,681
East Africa	12,866	2,364	28,298	68,253	25,821	10%	30,631	120,294	102,004
Southern Africa	36,501	38,897	264,480	317,426	171,556	54%	249,280	1,817,417	1,885,677
<b>Water Treatment Tablets</b>	3,420,747	6,194,401	38,866,264	62,058,922	71,167,933	(45)%	92,147,698	763,287,175	6,830
West and Central Africa	1,018,087	494,218	4,439,162	14,097,521	15,089,393	(71)%	23,980,058	174,402,763	596
East Africa	1,120,440	3,774,870	20,666,790	23,405,999	43,868,140	(53)%	47,341,850	393,655,902	3,294
Southern Africa	1,277,920	1,923,580	13,745,312	24,505,402	11,967,470	15%	20,557,660	179,646,820	2,940
Americas	-	-	-	-	-	-%	-	4,918,000	-
Asia and Eastern Europe	4,300	1,733	15,000	50,000	242,930	(94)%	268,130	10,663,690	1
<b>Woman Condom</b>	4,656	3,416	20,016	81,624	6,912	190%	9,600	29,616	374
Southern Africa	4,656	3,416	20,016	81,624	6,912	190%	9,600	29,616	374
<b>Zika Prevention Kit</b>	-	14	105	-	-	-%	112,890	112,995	2
Americas	-	14	105	-	-	-%	112,890	112,995	2
<b>Zinc</b>	22,157	412,973	2,269,002	356,167	68,914	3,193%	98,094	6,409,043	29,609
West and Central Africa	7,024	395,250	2,096,155	34,685	31,972	6,456%	42,892	2,730,899	27,756
East Africa	15,133	17,723	164,357	312,992	36,692	348%	53,910	2,243,493	1,794
Asia and Eastern Europe	-	-	8,490	8,490	250	3,296%	1,292	1,434,651	58
<b>Zinc Provided</b>	-	-	33,075	-	-	-%	-	33,075	401

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

**Period: 8**

**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	-	-	33,075	-	-	-%	-	33,075	401





# West & Central Africa

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 8/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
West and Central Africa	17,593	-	-	-	3,413,809	3,513	808,034	44,167	1,402	306	-	47,262
Benin	261	-	-	-	203,567	160	59,727	6	142	-	-	307
Cameroon	858	-	-	-	221,831	230	62,456	71	50	306	-	594
Congo-Kinshasa	666	-	-	-	640,261	705	163,249	10,570	638	-	-	11,207
Cote d'Ivoire	27	-	-	-	3,343	2	476	-	-	-	-	-
Ghana	75	-	-	-	496,543	254	111,549	-	-	-	-	-
Guinea	269	-	-	-	127,175	87	18,173	-	329	-	-	329
Liberia	57	-	-	-	5,849	4	838	-	3	-	-	3
Mali	-	-	-	-	126,286	166	42,038	20,338	21	-	-	20,423
Niger	7	-	-	-	20,784	23	6,561	-	-	-	-	150
Nigeria	15,078	-	-	-	1,542,187	1,875	338,314	13,178	220	-	-	14,244
Senegal	295	-	-	-	25,982	10	4,653	4	-	-	-	4

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 8  
 Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>West and Central Africa - All</b>									<b>703,687</b>	<b>5,780,212</b>	<b>6,483,899</b>
Acute Malnutrition Screen	200	84	676	-	-	-%	-	676	-	-	-
CD4 Tests Provided to HIV	471	101	837	-	-	-%	297	1,134	-	-	-
Cervical Cancer-Pap Sme:	-	-	-	-	1,450	(100)%	1,450	1,450	-	-	-
Cervical Cancer-VIA and C	15	25	542	719	1,402	(61)%	2,406	3,557	-	160	160
Cervical Cancer-VIA/VILI §	5,858	5,076	47,409	-	55,661	(15)%	90,919	174,528	-	-	-
Chlorhexidine	4,600	5,000	91,806	200,000	-	-%	46,000	137,806	-	9,237	9,237
Clean Delivery Kit	665	2,908	9,390	15,000	3,700	154%	4,400	53,140	-	1,189	1,189
Condom	17,062,406	9,889,635	87,024,326	163,145,833	115,057,108	(24)%	166,491,204	3,941,730,758	617,418	259,698	877,116
Condom Provided	-	-	-	-	45,516	(100)%	55,399	83,854	-	-	-
Counseling & Tx for Mode	-	-	8	-	-	-%	-	8	-	-	-
Diarrhea Treatment Kit	76,281	79,878	1,008,202	1,012,000	914,504	10%	1,303,935	8,100,740	-	68,851	68,851
Diarrhea Treatment Kit Pri	-	-	-	-	-	-%	2,400	2,400	-	-	-
Emergency Contraception	158,599	174,228	1,204,966	2,055,000	1,201,050	-%	1,808,411	13,259,512	-	14,387	14,387
Emergency Contraception	7	18	203	-	161	26%	201	725	-	2	2
Family Planning Counseli	-	-	-	-	337	(100)%	20,577	20,606	-	-	-
Female Condom	51,900	59,741	273,579	224,568	1,965,955	(86)%	2,318,459	22,458,250	1,163	557	1,721
Female Condom Provided	-	-	-	-	1,492	(100)%	2,591	3,027	-	-	-
Fever Cases Attended	-	-	-	-	-	-%	2,927,861	2,927,861	-	-	-
Fever Cases Tested with I	-	-	-	-	-	-%	247,772	247,772	-	-	-
Fever Cases Tested with F	-	-	-	-	-	-%	2,634,426	2,634,426	-	-	-
Free Condom	5,149,317	4,980,643	31,390,773	62,124,626	19,252,960	63%	32,825,359	169,668,901	83,477	89,896	173,373

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Female Condom	230,463	143,551	884,944	1,564,945	400,422	121%	431,422	2,660,830	1,105	1,920	3,025
HIV Testing Services	14,762	10,879	82,787	65,753	84,840	(2)%	201,781	3,081,180	524	-	524
Implant 3	(1,207)	2,666	15,029	7,550	7,353	104%	9,211	23,952	-	24,937	24,937
Implant 3 Insertion	5,417	873	24,660	20,002	7,969	209%	20,727	48,873	-	51,274	51,274
Implant 4 Insertion	-	2	7	-	-	-%	-	7	-	11	11
Implant 5	5,275	8,379	41,010	84,157	20,966	96%	32,153	302,033	-	108,356	108,356
Implant 5 Insertion	8,827	9,422	87,912	41,399	77,682	13%	106,632	534,893	-	264,257	264,257
Injectable 2	70,226	101,327	692,604	1,045,150	1,021,879	(32)%	1,538,928	15,856,363	-	68,088	68,088
Injectable 2 Provided	1,347	966	8,257	-	6,900	20%	10,433	18,690	-	582	582
Injectable 3	257,101	211,944	2,599,135	2,252,284	1,179,055	120%	1,815,961	25,342,399	-	253,121	253,121
Injectable 3 Provided	15,751	4,615	38,859	27,082	12,262	217%	16,028	68,318	-	5,627	5,627
IPTp2	-	3	54	836,961	-	-%	-	54	-	3	3
Iron Folic Acid Tablet	1,540	6,007	23,160	-	-	-%	14,500	37,660	-	-	-
IUD 10	1,652	6,475	39,463	95,321	82,023	(52)%	115,968	1,696,970	-	134,994	134,994
IUD 10 Insertion	12,382	9,870	81,328	57,282	75,886	7%	117,595	608,656	-	319,517	319,517
IUS 5 Insertion	44	85	300	-	-	-%	-	300	-	949	949
LLIN	304,681	178,114	2,520,723	12,347,682	13,062,726	(81)%	30,675,129	108,630,430	-	980,658	980,658
Lubricant	1,855,385	595,245	4,901,697	-	211,553	2,217%	349,026	6,781,848	-	-	-
Malaria PPT (ACT)	929,094	989,308	7,345,160	4,289,752	9,892,612	(26)%	14,144,463	62,805,061	-	2,740,869	2,740,869
Malaria RDK	39,407	170,726	1,647,188	7,528,315	6,666,195	(75)%	8,902,668	16,816,774	-	-	-
Manual Vacuum Aspiratio	491	246	2,302	1,909	881	161%	7,369	9,742	-	1,136	1,136
Medical Abortion	(28)	-	(28)	-	-	-%	-	(28)	-	(10)	(10)

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Medical Abortion Provider	28	-	28	-	-	-%	105	133	-	11	11
Micronutrient Powder	104,760	130,777	824,261	1,713,790	-	-%	85,400	909,661	-	-	-
Misoprostol for PAC (Oral	60,715	84,966	403,126	906,686	430,508	(6)%	626,258	2,055,099	-	66,262	66,262
Misoprostol for PAC (oral)	1,893	1,732	14,931	10,120	-	-%	2,427	17,358	-	2,725	2,725
Misoprostol for PPH	-	-	-	300,000	-	-%	-	349,630	-	-	-
OCs	1,205,181	786,591	6,102,254	11,612,236	6,252,665	(2)%	9,528,389	68,620,043	-	209,417	209,417
OCs Provided	20,495	12,710	86,552	15,000	17,602	392%	28,690	139,679	-	3,567	3,567
ORS	-	77,666	500,903	1,965	56,224	791%	70,974	4,059,917	-	19,524	19,524
Pneumonia PPT	11,690	3,933	38,130	60,000	53,935	(29)%	60,018	428,308	-	26,121	26,121
Pneumonia PPT Provided	-	-	-	-	-	-%	2,500	2,500	-	-	-
Positive RDTs	-	-	-	-	-	-%	2,047,931	2,047,931	-	-	-
Positive RDTs Given First	-	-	-	-	-	-%	2,047,743	2,047,743	-	-	-
PUR	72,720	171,600	1,316,406	4,792,000	1,315,564	-%	5,988,604	20,185,172	-	120	120
QAACs Provided after Ct	-	-	-	-	-	-%	2,034,979	2,034,979	-	-	-
Referral to CD4/Clinical St	-	-	-	553	-	-%	-	18	-	-	-
Referral to HIV Testing Se	-	-	-	60,035	5,401	(100)%	5,682	7,471	-	-	-
Referral to Implant 5 Inser	-	16	49	-	-	-%	-	3,581	-	63	63
Referral to Injectable 3	-	16	49	-	-	-%	-	49	-	3	3
Referral to IUD 10 Insertio	-	116	348	-	-	-%	22	6,046	-	550	550
Referral to Linkage to HIV	-	-	-	460	-	-%	281	281	-	-	-
Referral to OCs	-	4	11	-	-	-%	-	11	-	-	-
Safe Water Solution	12,600	14,042	730,356	200,000	143,431	409%	160,999	12,849,140	-	3,779	3,779

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>SDM (Cycle Beads)</b>	<b>888</b>	<b>2,490</b>	<b>11,074</b>	<b>18,256</b>	<b>14,484</b>	<b>(24)%</b>	<b>20,227</b>	<b>327,347</b>	-	<b>13,926</b>	<b>13,926</b>
<b>SDM (Cycle Beads) Provic</b>	<b>211</b>	<b>307</b>	<b>3,193</b>	-	<b>2,224</b>	<b>44%</b>	<b>2,812</b>	<b>6,877</b>	-	<b>4,477</b>	<b>4,477</b>
<b>Skilled Birth Attendance</b>	<b>2,443</b>	<b>1,893</b>	<b>17,175</b>	-	-	<b>-%</b>	-	<b>17,175</b>	-	-	-
<b>STI Screening</b>	<b>624</b>	<b>521</b>	<b>4,278</b>	-	<b>4,952</b>	<b>(14)%</b>	<b>19,906</b>	<b>27,876</b>	-	-	-
<b>TB Diagnosis</b>	-	-	-	-	<b>6,186</b>	<b>(100)%</b>	<b>10,219</b>	<b>10,219</b>	-	-	-
<b>TB DOTS</b>	-	-	-	-	<b>3,668</b>	<b>(100)%</b>	<b>5,763</b>	<b>5,763</b>	-	-	-
<b>TB Screening</b>	-	-	-	-	-	<b>-%</b>	<b>7,139</b>	<b>7,139</b>	-	-	-
<b>Toilets Constructed</b>	<b>106</b>	<b>432</b>	<b>3,569</b>	-	-	<b>-%</b>	-	<b>3,569</b>	-	-	-
<b>Toilets Sold</b>	<b>106</b>	<b>432</b>	<b>3,564</b>	<b>3,000</b>	-	<b>-%</b>	<b>2,598</b>	<b>6,162</b>	-	<b>955</b>	<b>955</b>
<b>Treatment for Severe Acu</b>	-	-	<b>4</b>	-	-	<b>-%</b>	-	<b>4</b>	-	-	-
<b>Treatment for Urethral Dis</b>	-	-	-	-	-	<b>-%</b>	<b>116</b>	<b>116</b>	-	-	-
<b>Treatment for Urethral Dis</b>	-	-	-	-	-	<b>-%</b>	<b>138</b>	<b>138</b>	-	-	-
<b>Tubal Ligation</b>	-	<b>1</b>	<b>12</b>	-	-	<b>-%</b>	-	<b>12</b>	-	<b>86</b>	<b>86</b>
<b>Vasectomy</b>	-	-	<b>1</b>	-	-	<b>-%</b>	-	<b>1</b>	-	<b>7</b>	<b>7</b>
<b>Water Treatment Tablets</b>	<b>1,018,087</b>	<b>494,218</b>	<b>4,439,162</b>	<b>14,097,521</b>	<b>15,089,393</b>	<b>(71)%</b>	<b>23,980,058</b>	<b>165,474,313</b>	-	<b>596</b>	<b>596</b>
<b>Zinc</b>	<b>7,024</b>	<b>395,250</b>	<b>2,096,155</b>	<b>34,685</b>	<b>31,972</b>	<b>6,456%</b>	<b>42,892</b>	<b>2,351,109</b>	-	<b>27,756</b>	<b>27,756</b>

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>West and Central Africa - All</b>										<b>703,687</b>	<b>5,780,212</b>	<b>6,483,899</b>
<b>Benin</b>										<b>10,594</b>	<b>122,129</b>	<b>132,723</b>
Cervical Cancer-VIA and Cryotherapy	8	5	54	-	127		(57)%	155	285	-	16	16
Cervical Cancer-VIA and Cryotherapy	8	5	54	-	127	2/13	(57)%	155	285	-	16	16
Cervical Cancer-VIA/VILI Screening	3,355	2,394	24,094	-	30,549		(21)%	41,466	78,706	-	-	-
Cervical Cancer-VIA/VILI Screening	3,355	2,394	24,094	-	30,549		(21)%	41,466	78,706	-	-	-
Condom	508,480	548,867	3,985,056	9,000,000	4,795,397		(17)%	6,861,921	69,321,872	9,565	8,044	17,609
PSI Condom Distributed Provided	-	-	-	-	(23,880)		-%	(28,048)	(49,532)	-	-	-
Kool	90,760	152,101	1,105,844	2,000,000	1,235,396	2/10	(10)%	1,872,356	15,967,531	2,654	2,232	4,887
Prudence Plus	417,720	396,765	2,879,212	7,000,000	3,583,881	1/08	(20)%	5,017,613	53,403,873	6,911	5,812	12,723
Condom Provided	-	-	-	-	23,948		(100)%	28,116	49,600	-	-	-
PSI Condom Provided	-	-	-	-	23,880		(100)%	28,048	49,532	-	-	-
Non-PSI Condom Provided	-	-	-	-	68		(100)%	68	68	-	-	-
Diarrhea Treatment Kit	15,757	14,254	122,549	350,000	262,339		(53)%	450,468	2,919,912	-	11,651	11,651
Orasel Zinc DTK	15,757	14,254	122,549	350,000	262,339	4/08	(53)%	450,468	2,919,912	-	11,651	11,651
Family Planning Counseling	-	-	-	-	-		0%	19,918	19,918	-	-	-
Family Planning Counseling	-	-	-	-	-		-%	19,918	19,918	-	-	-
Female Condom	12,960	4,602	50,188	5,000	3,297		1422%	21,399	155,166	120	78	198
Cupid	-	-	13,917	-	1,783	3/14	681%	5,698	23,646	33	22	55
Femidom	12,960	4,602	36,271	5,000	1,514	6/08	2,296%	15,701	131,520	87	56	143
Free Condom	33,604	35,292	248,244	-	86,958		185%	247,097	1,144,195	596	501	1,097
No Logo	33,604	35,292	248,244	-	86,958	1/12	185%	247,097	1,144,195	596	501	1,097
HIV Testing Services	7,658	7,464	59,035	34,058	58,251		1%	83,163	562,282	312	-	312
VCT Concordant Couple (HIV-Negative)	-	-	-	-	18	1/10	(100)%	30	8,527	-	-	-
VCT Individual (HIV-Negative)	7,572	7,407	58,399	34,058	57,549	1/10	1%	82,139	547,397	309	-	309

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Positive)	86	57	636	-	684	1/10	(7)%	994	6,358	3	-	3
Implant 5	585	821	7,221	20,501	326		2115%	437	34,564	-	14,159	14,159
PSI Implant 5 Distributed Inserted (	(1,045)	(539)	(5,109)	(19,499)	(22,916)		-%	(31,168)	(120,330)	-	(10,018)	(10,018)
Implant 5 (insertion)	1,630	1,360	12,330	-	23,242	12/09	(47)%	31,605	67,688	-	24,178	24,178
Jadelle	-	-	-	40,000	-	9/09	-%	-	87,206	-	-	-
Implant 5 Insertion	2,095	1,775	18,214	19,499	23,597		(23)%	31,849	134,116	-	39,684	39,684
PSI Implant 5 Inserted	1,045	539	5,109	19,499	22,916		(78)%	31,168	120,330	-	11,131	11,131
Non-PSI Implant 5 Inserted	1,050	1,236	13,105	-	681		1,824%	681	13,786	-	28,553	28,553
Injectable 2	5,726	5,061	33,498	45,150	21,653		55%	30,602	224,563	-	2,124	2,124
PSI Injectable 2 Distributed Provide	(814)	(537)	(4,418)	-	(6,264)		-%	(9,797)	(14,215)	-	(280)	(280)
Noristerat	6,540	5,598	37,916	45,150	27,917	1/12	36%	40,399	238,778	-	2,404	2,404
Injectable 2 Provided	1,347	966	8,257	-	6,900		20%	10,433	18,690	-	582	582
PSI Injectable 2 Provided	814	537	4,418	-	6,264		(29)%	9,797	14,215	-	311	311
Non-PSI Injectable 2 Provided	533	429	3,839	-	636		504%	636	4,475	-	270	270
Injectable 3	-	-	-	-	(1,160)		0%	(1,160)	(6,968)	-	-	-
PSI Injectable 3 Distributed Provide	-	-	-	-	(1,160)		-%	(1,160)	(6,968)	-	-	-
Injectable 3 Provided	-	-	-	-	1,160		(100)%	1,160	6,968	-	-	-
PSI Injectable 3 Provided	-	-	-	-	1,160		(100)%	1,160	6,968	-	-	-
IUD 10	(687)	28	569	13,000	8,540		(93)%	9,115	42,965	-	1,379	1,379
PSI IUD 10 Distributed Inserted (1)	(1,559)	(922)	(8,332)	(16,000)	(12,754)		-%	(19,392)	(86,391)	-	(20,198)	(20,198)
IUD (insertion)	812	713	3,630	-	-	12/09	-%	-	4,340	-	8,800	8,800
IUD Copper-T TCU 380A	60	237	5,271	29,000	21,294	9/09	(75)%	28,507	125,016	-	12,778	12,778
IUD 10 Insertion	1,827	1,184	10,854	16,000	12,911		(16)%	19,549	89,082	-	29,236	29,236
PSI IUD 10 Inserted	1,559	922	8,332	16,000	12,754		(35)%	19,392	86,391	-	22,443	22,443
Non-PSI IUD 10 Inserted	268	262	2,522	-	157		1,506%	157	2,691	-	6,793	6,793

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>LLIN</b>	<b>962</b>	<b>684</b>	<b>3,497</b>	<b>7,800</b>	<b>17,197</b>		<b>(80)%</b>	<b>18,304</b>	<b>750,188</b>	-	<b>461</b>	<b>461</b>
Moustiquaires Peace Corps	-	-	-	-	<b>10,000</b>	3/13	(100)%	<b>10,000</b>	<b>20,000</b>	-	-	-
Super Moustiquaire Longue Durée	<b>922</b>	<b>607</b>	<b>3,123</b>	<b>7,800</b>	<b>5,316</b>	5/06	(41)%	<b>6,209</b>	<b>724,050</b>	-	<b>411</b>	<b>411</b>
SuperMoustiquaire (blanche 1 place	<b>40</b>	<b>75</b>	<b>359</b>	-	<b>1,195</b>	9/15	(70)%	<b>1,404</b>	<b>3,153</b>	-	<b>47</b>	<b>47</b>
SuperMoustiquaire (blanche 3 place	-	<b>2</b>	<b>15</b>	-	<b>686</b>	9/15	(98)%	<b>691</b>	<b>2,985</b>	-	<b>2</b>	<b>2</b>
<b>Lubricant</b>	<b>44,336</b>	<b>32,192</b>	<b>211,952</b>	-	-		<b>0%</b>	<b>106,260</b>	<b>318,212</b>	-	-	-
Gel Lubricant 5 mL	<b>44,336</b>	<b>32,192</b>	<b>211,952</b>	-	-	12/16	-%	<b>106,260</b>	<b>318,212</b>	-	-	-
<b>Manual Vacuum Aspiration for PAC</b>	<b>84</b>	<b>20</b>	<b>478</b>	-	-		<b>0%</b>	<b>689</b>	<b>1,167</b>	-	<b>149</b>	<b>149</b>
MVA for PAC	<b>84</b>	<b>20</b>	<b>478</b>	-	-	10/16	-%	<b>689</b>	<b>1,167</b>	-	<b>149</b>	<b>149</b>
<b>Medical Abortion</b>	-	-	-	-	-		<b>0%</b>	<b>(105)</b>	<b>(105)</b>	-	-	-
PSI Medical Abortion Distributed Pr	-	-	-	-	-		-%	<b>(105)</b>	<b>(105)</b>	-	-	-
<b>Medical Abortion Provided</b>	-	-	-	-	-		<b>0%</b>	<b>105</b>	<b>105</b>	-	-	-
PSI Medical Abortion Provided	-	-	-	-	-		-%	<b>105</b>	<b>105</b>	-	-	-
<b>Misoprostol for PAC (Oral)</b>	<b>13,705</b>	<b>14,828</b>	<b>92,280</b>	<b>100,000</b>	<b>26,128</b>		<b>253%</b>	<b>113,461</b>	<b>375,629</b>	-	<b>8,633</b>	<b>8,633</b>
PSI Misoprostol for PAC Oral Dist F	<b>(135)</b>	<b>(39)</b>	<b>(720)</b>	-	-		-%	<b>(111)</b>	<b>(831)</b>	-	<b>(67)</b>	<b>(67)</b>
Misoprostol for PAC (oral)	<b>13,840</b>	<b>14,867</b>	<b>93,000</b>	<b>100,000</b>	<b>26,128</b>	1/13	256%	<b>113,572</b>	<b>376,460</b>	-	<b>8,700</b>	<b>8,700</b>
<b>Misoprostol for PAC (oral) Provided</b>	<b>141</b>	<b>39</b>	<b>726</b>	-	-		<b>0%</b>	<b>111</b>	<b>837</b>	-	<b>75</b>	<b>75</b>
PSI Misoprostol for PAC (oral) Prov	<b>135</b>	<b>39</b>	<b>720</b>	-	-		-%	<b>111</b>	<b>831</b>	-	<b>75</b>	<b>75</b>
Non-PSI Misoprostol for PAC (oral) I	<b>6</b>	-	<b>6</b>	-	-		-%	-	<b>6</b>	-	<b>1</b>	<b>1</b>
<b>OCs</b>	<b>57,871</b>	<b>7,211</b>	<b>154,483</b>	<b>208,635</b>	<b>144,997</b>		<b>7%</b>	<b>209,829</b>	<b>1,010,568</b>	-	<b>3,978</b>	<b>3,978</b>
PSI OCs Distributed Provided	<b>(419)</b>	<b>(280)</b>	<b>(2,216)</b>	-	<b>(2,275)</b>		-%	<b>(3,299)</b>	<b>(24,170)</b>	-	<b>(57)</b>	<b>(57)</b>
Laafia Pilule	<b>58,290</b>	<b>7,491</b>	<b>156,699</b>	<b>208,635</b>	<b>147,272</b>	6/12	6%	<b>213,125</b>	<b>1,034,735</b>	-	<b>4,035</b>	<b>4,035</b>
Microgynon	-	-	-	-	-	9/15	-%	<b>3</b>	<b>3</b>	-	-	-
<b>OCs Provided</b>	<b>518</b>	<b>370</b>	<b>2,944</b>	-	<b>2,349</b>		<b>25%</b>	<b>3,373</b>	<b>24,972</b>	-	<b>84</b>	<b>84</b>
PSI OCs Provided	<b>419</b>	<b>280</b>	<b>2,216</b>	-	<b>2,275</b>		(3)%	<b>3,299</b>	<b>24,170</b>	-	<b>63</b>	<b>63</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI OCs Provided	99	90	728	-	74		884%	74	802	-	21	21
SDM (Cycle Beads)	281	99	745	2,500	597		25%	3,196	35,118	-	672	672
PSI SDM (Cycle Beads) Distributed	(15)	(8)	(65)	-	(35)		-%	(48)	(143)	-	(59)	(59)
CycleBeads	296	107	810	2,500	632	12/04	28%	3,244	35,261	-	731	731
SDM (Cycle Beads) Provided	15	9	67	-	35		91%	48	145	-	67	67
PSI SDM (Cycle Beads) Provided	15	8	65	-	35		86%	48	143	-	65	65
Non-PSI SDM (Cycle Beads) Provid	-	1	2	-	-		-%	-	2	-	2	2
Skilled Birth Attendance	2,443	1,893	17,175	-	-		0%	-	17,175	-	-	-
Skilled Birth Attendance	2,443	1,893	17,175	-	-		-%	-	17,175	-	-	-
STI Screening	583	443	4,003	-	4,952		(19)%	6,499	14,194	-	-	-
STI Screening	583	443	4,003	-	4,952		(19)%	6,499	14,194	-	-	-
Toilets Constructed	-	-	5	-	-		0%	-	5	-	-	-
Toilet Type 1	-	-	5	-	-		-%	-	5	-	-	-
Treatment for Urethral Discharge (Mer	-	-	-	-	-		0%	116	116	-	-	-
Treatment for Urethral Discharge (M	-	-	-	-	-		-%	116	116	-	-	-
Treatment for Urethral Discharge (Wor	-	-	-	-	-		0%	138	138	-	-	-
Treatment for Urethral Discharge (W	-	-	-	-	-		-%	138	138	-	-	-
Water Treatment Tablets	784,500	480,433	4,028,400	7,560,000	4,116,250		(2)%	7,464,550	62,599,870	-	556	556
Aquatab	784,500	480,433	4,028,400	7,560,000	4,116,250	1/08	(2)%	7,464,550	62,599,870	-	556	556
<b>Cameroon</b>										36,298	169,259	205,557
CD4 Tests Provided to HIV+ Clients	295	-	295	-	-		0%	297	592	-	-	-
CD4 Tests Provided to HIV+ Clients	295	-	295	-	-		-%	297	592	-	-	-
Condom	1,015,200	495,275	5,025,074	8,250,000	12,845,577		(61)%	20,438,811	188,451,404	35,562	11,951	47,514
Lovers Plus	-	(3,852)	(139,356)	-	1,644,516	1/15	(108)%	2,169,288	3,230,280	(986)	(331)	(1,318)
Préservatif Masculin Aromatisé UNF	-	643	1,930	50,000	-	12/15	-%	144	2,074	14	5	18

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Préservatif Masculin UNFPA	-	10,084	59,824	1,200,000	20,652	12/15	190%	61,016	120,840	423	142	566
Prudence Plus	-	(720)	(2,160)	-	2,718	8/06	(179)%	2,718	141,672,845	(15)	(5)	(20)
Prudence Plus Nouveau	1,015,200	489,120	5,104,836	7,000,000	11,177,691	1/15	(54)%	18,205,645	43,425,365	36,127	12,141	48,268
Diarrhea Treatment Kit	6,304	8,374	69,024	87,000	-		0%	16,065	730,886	-	3,972	3,972
PSI Diarrhea Treatment Kit Distribu	-	-	-	-	-		-%	(2,400)	(2,400)	-	-	-
Orasel Zinc	6,304	8,374	69,024	87,000	-	10/09	-%	18,465	733,286	-	3,972	3,972
Diarrhea Treatment Kit Provided	-	-	-	-	-		0%	2,400	2,400	-	-	-
PSI Diarrhea Treatment Kit Provide	-	-	-	-	-		-%	2,400	2,400	-	-	-
Emergency Contraception	1,481	2,142	16,869	15,000	6,071		178%	10,842	27,711	-	151	151
PSI Emergency Contraception Distr	-	-	(33)	-	(57)		-%	(65)	(98)	-	-	-
Norlevo	1,481	2,142	16,902	15,000	6,128	11/15	176%	10,907	27,809	-	152	152
Emergency Contraception Provided	-	1	34	-	57		(40)%	65	99	-	-	-
PSI Emergency Contraception Prov	-	-	33	-	57		(42)%	65	98	-	-	-
Non-PSI Emergency Contraception I	-	-	1	-	-		-%	-	1	-	-	-
Female Condom	3,410	18,009	63,966	19,568	1,271,162		(95)%	1,531,414	8,051,412	453	117	570
Préservatif Féminin CUPID	-	698	2,195	10,000	355,673	7/14	(99)%	488,548	613,865	16	4	20
Préservatif Féminins UNFPA	3,410	311	9,771	-	419,538	3/15	(98)%	504,712	794,387	69	18	87
Protectiv	-	-	-	6,437	-	11/02	-%	-	4,184,561	-	-	-
Protectiv Plus	-	-	1,000	-	1,880	4/14	(47)%	19,116	958,157	7	2	9
Securite Plus Female Condom	-	17,000	51,000	3,131	494,071	11/13	(90)%	519,038	1,500,442	361	93	454
Fever Cases Attended	-	-	-	-	-		0%	12,764	12,764	-	-	-
Fever Cases Attended	-	-	-	-	-		-%	12,764	12,764	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	-		0%	13,416	13,416	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	-		-%	13,416	13,416	-	-	-
Free Condom	21,201	300	30,925	-	-		0%	735,220	766,145	219	74	292

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Generic MC	21,201	300	30,925	-	-	11/16	-%	735,220	766,145	219	74	292
Free Female Condom	1,500	-	1,500	-	-		0%	1,000	2,500	11	3	13
Generic FC	1,500	-	1,500	-	-	1/08	-%	1,000	2,500	11	3	13
HIV Testing Services	2,142	-	2,291	10,035	5,985		(62)%	11,896	60,790	53	-	53
VCT Individual (HIV-Negative)	1,740	-	1,881	9,523	5,747	1/10	(67)%	11,335	57,100	44	-	44
VCT Individual (HIV-Positive)	402	-	410	512	238	1/10	72%	561	3,690	10	-	10
Implant 3	(1,207)	1,836	10,639	6,612	4,734		125%	9,165	19,804	-	16,695	16,695
PSI Implant 3 Distributed Inserted (	(3,589)	-	(4,371)	(8,388)	(2,847)	3/16	-%	(4,594)	(8,965)	-	(6,859)	(6,859)
Implanon NXT	2,382	1,836	15,010	15,000	7,581	12/15	98%	13,759	28,769	-	23,554	23,554
Implant 3 Insertion	3,589	1	4,374	8,388	2,847		54%	4,594	8,968	-	7,626	7,626
PSI Implant 3 Inserted	3,589	-	4,371	8,388	2,847	3/16	54%	4,594	8,965	-	7,621	7,621
Non-PSI Implant 3 Inserted	-	1	3	-	-		-%	-	3	-	5	5
Implant 5	(756)	572	2,654	5,000	7,145		(63)%	8,625	3,896	-	6,119	6,119
PSI Implant 5 Distributed Inserted (	(1,486)	(151)	(3,226)	-	(1,514)		-%	(3,134)	(27,409)	-	(7,437)	(7,437)
Jadelle UNFPA	730	723	5,880	5,000	8,659	3/15	(32)%	11,759	31,305	-	13,556	13,556
Implant 5 Insertion	1,486	180	3,374	-	1,537		120%	3,170	28,299	-	8,643	8,643
PSI Implant 5 Inserted	1,486	151	3,226	-	1,514		113%	3,134	27,409	-	8,264	8,264
Non-PSI Implant 5 Inserted	-	29	148	-	23		543%	36	890	-	379	379
Injectable 3	(9,780)	6,191	31,192	172,568	30,004		4%	52,057	131,269	-	3,495	3,495
PSI Injectable 3 Distributed Provid	(12,948)	(152)	(14,566)	(26,082)	(3,200)		-%	(4,794)	(19,360)	-	(1,632)	(1,632)
Depo-Provera UNFPA	1,775	3,473	17,119	37,650	33,204	3/15	(48)%	42,529	107,668	-	1,918	1,918
Equilibre	1,393	2,870	28,639	161,000	-	5/16	-%	14,322	42,961	-	3,209	3,209
Injectable 3 Provided	12,948	236	14,817	26,082	3,200		363%	4,794	19,611	-	1,845	1,845
PSI Injectable 3 Provided	12,948	152	14,566	26,082	3,200		355%	4,794	19,360	-	1,814	1,814
Non-PSI Injectable 3 Provided	-	84	251	-	-		-%	-	251	-	31	31

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 10	499	3,338	13,594	21,118	25,376		(46)%	29,990	93,361	-	38,685	38,685
PSI IUD 10 Distributed Inserted (1)	(2,351)	(531)	(7,409)	(17,882)	(5,528)		-%	(11,279)	(63,718)	-	(21,084)	(21,084)
DIU UNFPA	-	217	1,250	-	13,843	3/15	(91)%	17,643	22,693	-	3,557	3,557
IUD	2,400	2,758	15,225	-	8,250	9/09	85%	12,250	118,482	-	43,326	43,326
IUD Copper T 380A	450	894	4,528	39,000	8,811	2/16	(49)%	11,376	15,904	-	12,886	12,886
IUD 10 Insertion	2,351	566	7,518	17,882	5,528		36%	11,303	64,457	-	23,771	23,771
PSI IUD 10 Inserted	2,351	531	7,409	17,882	5,528		34%	11,279	63,718	-	23,427	23,427
Non-PSI IUD 10 Inserted	-	35	109	-	-		-%	24	739	-	345	345
LLIN	703	2,016	12,348	40,000	22,172		(44)%	39,178	7,987,471	-	2,699	2,699
Super Moustiquaire	703	2,003	12,308	40,000	22,172	1/09	(44)%	39,178	7,987,431	-	2,690	2,690
Super Moustiquaire Interceptor	-	13	40	-	-	10/15	-%	-	40	-	9	9
Lubricant	405	161	6,330	-	5,996		6%	11,891	18,541	-	-	-
Lubricant 60 mL bottle	405	95	1,080	-	5,996	12/15	(82)%	7,266	8,666	-	-	-
Water-based Lubricant, 4 mL sachet	-	67	5,250	-	-	12/16	-%	4,625	9,875	-	-	-
Malaria PPT (ACT)	4,108	1,017	11,653	25,000	17,334		(33)%	29,363	83,215	-	3,219	3,219
ACT 1 (ASAQ 25 / 67.5 mg, 3 tablet)	-	-	-	1,000	2,800	2/15	(100)%	5,100	5,100	-	-	-
ACT 2 (ASAQ 50 / 135.5 mg, 3 table	2,007	700	6,557	15,000	6,800	2/15	(4)%	15,000	51,631	-	1,812	1,812
ACT 3 (ASAQ 100 / 270 mg, 3 table	1,022	142	2,372	4,500	3,364	2/15	(29)%	4,493	13,365	-	655	655
ACT 4 (ASAQ 100 / 270 mg, 6 table	1,079	175	2,724	4,500	4,370	2/15	(38)%	4,770	13,119	-	753	753
Malaria RDK	6,657	1,200	15,857	25,000	26,328		(40)%	25,569	191,134	-	-	-
Malaria Ag Pf/Pan_PA	6,657	1,200	15,857	25,000	26,328	12/12	(40)%	25,569	191,134	-	-	-
Manual Vacuum Aspiration for PAC	197	-	197	314	-		0%	-	197	-	68	68
MVA for PAC	197	-	197	314	-		-%	-	197	-	68	68
Medical Abortion	(28)	-	(28)	-	-		0%	-	(28)	-	(10)	(10)
PSI Medical Abortion Distributed Pr	(28)	-	(28)	-	-		-%	-	(28)	-	(10)	(10)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Medical Abortion Provided	28	-	28	-	-		0%	-	28	-	11	11
PSI Medical Abortion Provided	28	-	28	-	-		-%	-	28	-	11	11
Micronutrient Powder	104,760	130,777	824,261	1,713,790	-		0%	85,400	909,661	-	-	-
Super Bebe	104,760	130,777	824,261	1,713,790	-	9/16	-%	85,400	909,661	-	-	-
Misoprostol for PAC (Oral)	9,510	12,560	88,510	205,380	62,880		41%	107,297	456,684	-	9,154	9,154
PSI Misoprostol for PAC Oral Dist F	(330)	-	(330)	(2,120)	-		-%	(1,383)	(1,713)	-	(34)	(34)
Misoprostol for PAC (oral)	9,840	12,560	88,840	207,500	62,880	1/13	41%	108,680	458,397	-	9,188	9,188
Misoprostol for PAC (oral) Provided	330	-	330	2,120	-		0%	1,383	1,713	-	38	38
PSI Misoprostol for PAC (oral) Prov	330	-	330	2,120	-		-%	1,383	1,713	-	38	38
OCs	49,114	7,502	115,155	159,000	54,495		111%	88,610	645,866	-	3,494	3,494
PSI OCs Distributed Provided	(8,401)	(31)	(10,071)	-	(1,493)		-%	(2,500)	(12,571)	-	(306)	(306)
Microgynon Ed Fe	1,440	3,990	21,750	15,000	55,988	7/14	(61)%	67,958	456,873	-	660	660
Novelle Duo	56,075	3,543	103,476	144,000	-	1/08	-%	23,152	201,564	-	3,140	3,140
OCs Provided	8,401	44	10,108	-	1,493		577%	2,567	12,675	-	341	341
PSI OCs Provided	8,401	31	10,071	-	1,493		575%	2,500	12,571	-	340	340
Non-PSI OCs Provided	-	12	37	-	-		-%	67	104	-	1	1
ORS	-	-	450	1,965	56,224		(99)%	70,974	3,559,464	-	13	13
Orasel	-	-	450	1,965	56,224	9/98	(99)%	70,974	3,559,464	-	13	13
Pneumonia PPT	11,690	3,933	38,130	60,000	53,935		(29)%	57,518	425,808	-	26,121	26,121
PSI Pneumonia PPT Distributed Pr	-	-	-	-	-		-%	(2,500)	(2,500)	-	-	-
Amoxicillin 500mg x 15's -- Children	11,690	3,933	38,130	2,400	52,606	1/13	(28)%	57,600	279,792	-	26,121	26,121
Amoxicillin 500mg x 7's - Children 2-	-	-	-	57,600	1,329	1/13	(100)%	2,418	148,516	-	-	-
Pneumonia PPT Provided	-	-	-	-	-		0%	2,500	2,500	-	-	-
PSI Pneumonia PPT Provided	-	-	-	-	-		-%	2,500	2,500	-	-	-
Positive RDTs	-	-	-	-	-		0%	12,952	12,952	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Positive RDTs	-	-	-	-	-		-%	12,952	12,952	-	-	-
Positive RDTs Given First Line Treatm	-	-	-	-	-		0%	12,764	12,764	-	-	-
Positive RDTs Given First Line Trea	-	-	-	-	-		-%	12,764	12,764	-	-	-
Referral to HIV Testing Services	-	-	-	10,035	-		0%	281	1,285	-	-	-
Referral to HIV Testing & Counselin	-	-	-	10,035	-	12/13	-%	281	1,285	-	-	-
Referral to Implant 5 Insertion	-	16	49	-	-		0%	-	3,581	-	63	63
Referral to Implant 5 Insertion	-	16	49	-	-	12/14	-%	-	3,581	-	63	63
Referral to Injectable 3	-	16	49	-	-		0%	-	49	-	3	3
Referral to Injectable 3	-	16	49	-	-		-%	-	49	-	3	3
Referral to IUD 10 Insertion	-	116	348	-	-		0%	-	6,024	-	550	550
Referral to IUD 10 Insertion	-	116	348	-	-	12/14	-%	-	6,024	-	550	550
Referral to Linkage to HIV Care	-	-	-	460	-		0%	281	281	-	-	-
Referral to Linkage to HIV Care	-	-	-	460	-		-%	281	281	-	-	-
Referral to OCs	-	4	11	-	-		0%	-	11	-	-	-
Referral to OCs	-	4	11	-	-		-%	-	11	-	-	-
Water Treatment Tablets	3,337	7,384	75,770	76,791	32,999		130%	76,459	152,229	-	10	10
Aquatabs 67 mg (20 L)	3,337	7,384	75,770	76,791	32,999	12/15	130%	76,459	152,229	-	10	10
Zinc	7,024	2,483	26,755	34,685	31,972		(16)%	42,892	281,709	-	338	338
Zinc	7,024	2,483	26,755	34,685	31,972	7/09	(16)%	42,892	281,709	-	338	338
<b>Congo-Kinshasa</b>										29,371	1,338,662	1,368,033
Condom	8,217,622	1,141,296	12,265,510	9,000,000	851,457		1341%	5,295,269	501,779,510	16,545	34,910	51,454
PSI Condom Distributed Provided	-	-	-	-	(2,647)		-%	(2,705)	(6,043)	-	-	-
Prudence	87,480	71,361	539,571	9,000,000	571,944	11/87	(6)%	4,679,032	473,482,243	728	1,536	2,264
Prudence Sensuel	8,130,142	1,069,935	11,725,939	-	282,160	12/12	4,056%	618,942	28,303,310	15,817	33,374	49,191
Condom Provided	-	-	-	-	16,984		(100)%	17,042	23,943	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Condom Provided	-	-	-	-	2,647		(100)%	2,705	6,043	-	-	-
Non-PSI Condom Provided	-	-	-	-	14,337		(100)%	14,337	17,900	-	-	-
Diarrhea Treatment Kit	38,420	24,063	120,669	125,000	10,000		1107%	20,537	537,871	-	9,665	9,665
ORA-ZINC	38,420	24,063	120,669	125,000	10,000	11/13	1,107%	20,537	537,871	-	9,665	9,665
Emergency Contraception	2,366	4,790	25,723	40,000	11		233745%	7,209	52,756	-	276	276
PSI Emergency Contraception Distr	(2)	(14)	(76)	-	(65)		-%	(67)	(395)	-	(1)	(1)
Norlevo	2,368	4,804	25,799	40,000	76	10/14	33,846%	7,276	53,151	-	277	277
Emergency Contraception Provided	7	18	169	-	104		63%	136	626	-	2	2
PSI Emergency Contraception Prov	2	14	76	-	65		17%	67	395	-	1	1
Non-PSI Emergency Contraception I	5	4	93	-	39		138%	69	231	-	1	1
Female Condom	21,706	28,682	107,875	-	250,359		(57)%	309,955	7,739,170	146	236	382
PSI Female Condom Distributed Pr	-	-	-	-	(311)		-%	(315)	(374)	-	-	-
Prudence Femme	21,706	28,682	107,875	-	250,670	8/04	(57)%	310,270	7,739,544	146	236	382
Female Condom Provided	-	-	-	-	1,492		(100)%	2,591	3,027	-	-	-
PSI Female Condom Provided	-	-	-	-	311		(100)%	315	374	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	1,181		(100)%	2,276	2,653	-	-	-
Fever Cases Attended	-	-	-	-	-		0%	2,915,097	2,915,097	-	-	-
Fever Cases Attended	-	-	-	-	-		-%	2,915,097	2,915,097	-	-	-
Fever Cases Tested with Microscopy	-	-	-	-	-		0%	247,772	247,772	-	-	-
Fever Cases Tested with Microscopy	-	-	-	-	-		-%	247,772	247,772	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	-		0%	2,621,010	2,621,010	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	-		-%	2,621,010	2,621,010	-	-	-
Free Condom	1,503,000	1,581,134	8,697,982	859,750	4,323,000		101%	5,115,000	41,467,867	11,732	24,756	36,488
Generic MC	1,503,000	1,581,134	8,697,982	859,750	4,323,000	3/09	101%	5,115,000	41,467,867	11,732	24,756	36,488
Free Female Condom	153,000	122,319	703,157	617,960	390,000		80%	420,000	2,426,757	948	1,539	2,488

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Generic FC	153,000	122,319	703,157	617,960	390,000	3/09	80%	420,000	2,426,757	948	1,539	2,488
Implant 3	-	830	4,390	938	2,419		81%	(154)	3,948	-	8,243	8,243
PSI Implant 3 Distributed Inserted (	-	-	(21)	-	(4,521)		-%	(14,530)	(14,839)	-	(39)	(39)
Implanon	-	830	4,411	938	6,940	6/16	(36)%	14,376	18,787	-	8,282	8,282
Implant 3 Insertion	-	-	14,530	-	4,521		221%	14,530	29,348	-	30,313	30,313
PSI Implant 3 Inserted	-	-	21	-	4,521		(100)%	14,530	14,839	-	44	44
Non-PSI Implant 3 Inserted	-	-	14,509	-	-		-%	-	14,509	-	30,269	30,269
Implant 5	5,136	5,985	24,645	46,656	2,565		861%	3,351	37,991	-	67,975	67,975
PSI Implant 5 Distributed Inserted (	(727)	(2,821)	(20,587)	-	(16,865)		-%	(18,068)	(92,303)	-	(56,783)	(56,783)
Jadelle	5,863	8,806	45,232	46,656	19,430	9/09	133%	21,419	130,294	-	124,758	124,758
Implant 5 Insertion	844	2,929	32,875	-	17,371		89%	19,994	110,263	-	100,750	100,750
PSI Implant 5 Inserted	727	2,821	20,587	-	16,865		22%	18,068	92,303	-	63,092	63,092
Non-PSI Implant 5 Inserted	117	108	12,288	-	506		2,328%	1,926	17,960	-	37,658	37,658
Injectable 3	85,529	73,224	319,798	422,467	77,531		312%	126,833	2,135,993	-	42,885	42,885
PSI Injectable 3 Distributed Provide	(779)	(1,207)	(10,174)	-	(6,648)		-%	(7,886)	(24,174)	-	(1,364)	(1,364)
Confiance Depo-Provera	29,986	53,263	200,578	272,467	79,181	9/03	153%	129,721	2,025,773	-	26,897	26,897
Sayana Press	56,322	21,168	129,394	150,000	4,998	10/15	2,489%	4,998	134,394	-	17,352	17,352
Injectable 3 Provided	801	1,274	11,073	-	7,110		56%	8,514	25,931	-	1,650	1,650
PSI Injectable 3 Provided	779	1,207	10,174	-	6,648		53%	7,886	24,174	-	1,516	1,516
Non-PSI Injectable 3 Provided	22	68	899	-	462		95%	628	1,757	-	134	134
IPTp2	-	-	-	836,961	-		0%	-	-	-	-	-
IPTp2	-	-	-	836,961	-		-%	-	-	-	-	-
IUD 10	1,060	496	4,694	5,203	2,437		93%	2,590	32,950	-	15,978	15,978
PSI IUD 10 Distributed Inserted (1)	(68)	(146)	(1,450)	-	(1,823)		-%	(2,334)	(10,210)	-	(4,936)	(4,936)
Confiance	1,128	642	6,144	5,203	4,260	9/03	44%	4,924	43,160	-	20,914	20,914

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 10 Insertion	73	150	3,391	-	1,837		85%	2,538	12,515	-	12,825	12,825
PSI IUD 10 Inserted	68	146	1,450	-	1,823		(20)%	2,334	10,210	-	5,484	5,484
Non-PSI IUD 10 Inserted	5	4	1,941	-	14		13,764%	204	2,305	-	7,341	7,341
LLIN	58	9,100	322,734	8,769,882	7,774,265		(96)%	22,968,572	67,448,548	-	117,929	117,929
Dawa Plus Large Rectangular Mosc	-	-	-	8,037,600	-	11/15	-%	7,782,222	8,666,468	-	-	-
Dawa Plus Rectangular Mosquito Net	-	-	-	-	5,056,192	11/15	(100)%	11,733,728	13,740,547	-	-	-
Olyset 160X180X150 cm	-	-	-	-	-	7/14	-%	13,803	3,680,169	-	-	-
PermaNet	58	9,100	322,734	-	941,464	9/06	(66)%	1,662,210	37,576,462	-	117,929	117,929
Yorkool Rectangular Mosquito Net	-	-	-	732,282	1,776,609	11/15	(100)%	1,776,609	3,784,902	-	-	-
Lubricant	6,000	13,450	65,399	-	-		0%	-	84,799	-	-	-
Personal Lubricant 4.5 g	6,000	13,450	65,399	-	-	7/13	-%	-	84,799	-	-	-
Malaria PPT (ACT)	65,897	150,478	2,588,611	3,944,752	2,713,542		(5)%	2,805,565	13,890,866	-	776,362	776,362
PSI QAACts Distributed Provided	-	-	-	-	-		-%	(2,034,979)	(2,034,979)	-	-	-
ACT 1 (2 to 11 months)	8,391	21,259	233,191	3,944,752	378,458	4/11	(38)%	445,352	1,408,497	-	69,937	69,937
ACT 2 (1 to 5 years)	5,329	38,686	666,144	-	845,732	4/11	(21)%	1,210,730	5,104,758	-	199,786	199,786
ACT 3 (6 to 13 years)	900	29,962	710,188	-	688,165	12/13	3%	1,268,434	4,159,280	-	212,996	212,996
ACT 4 (over 13 years)	51,277	60,571	979,088	-	801,187	12/13	22%	1,916,028	5,253,310	-	293,643	293,643
Malaria RDK	32,750	92,458	1,323,225	7,503,315	2,753,892		(52)%	3,773,657	9,882,769	-	-	-
SD Bioline	32,750	92,458	1,323,225	7,503,315	2,753,892	12/13	(52)%	3,773,657	9,882,769	-	-	-
OCs	232,108	156,424	761,571	1,273,200	641,374		19%	739,882	5,119,224	-	27,653	27,653
PSI OCs Distributed Provided	(3,148)	(5,461)	(30,100)	-	(8,229)		-%	(9,528)	(44,848)	-	(1,093)	(1,093)
Combination 3	195,009	139,866	670,476	1,102,500	649,603	11/11	3%	749,410	5,042,877	-	24,345	24,345
Microgynon	-	683	3,189	-	-	8/16	-%	-	3,189	-	116	116
Microlut	40,247	21,337	118,006	170,700	-	2/17	-%	-	118,006	-	4,285	4,285
OCs Provided	3,264	5,537	32,027	-	9,311		244%	10,744	48,311	-	1,292	1,292

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI OCs Provided	3,148	5,461	30,100	-	8,229		266%	9,528	44,848	-	1,214	1,214
Non-PSI OCs Provided	116	76	1,927	-	1,082		78%	1,216	3,463	-	78	78
ORS	-	77,666	500,453	-	-		0%	-	500,453	-	19,511	19,511
ORS	-	77,666	500,453	-	-	10/16	-%	-	500,453	-	19,511	19,511
Positive RDTs	-	-	-	-	-		0%	2,034,979	2,034,979	-	-	-
Positive RDTs	-	-	-	-	-		-%	2,034,979	2,034,979	-	-	-
Positive RDTs Given First Line Treatm	-	-	-	-	-		0%	2,034,979	2,034,979	-	-	-
Positive RDTs Given First Line Trea	-	-	-	-	-		-%	2,034,979	2,034,979	-	-	-
PUR	62,400	160,400	1,230,480	1,292,000	542,284		127%	929,884	4,415,561	-	113	113
P&G Purifiant	-	-	-	-	26,204	12/13	(100)%	26,204	907,200	-	-	-
P&G Purifiant Water	62,400	160,400	1,230,480	1,292,000	516,080	3/14	138%	903,680	3,508,361	-	113	113
QAACs Provided after Confirmatory I	-	-	-	-	-		0%	2,034,979	2,034,979	-	-	-
PSI QAACs Provided after Confirm	-	-	-	-	-		-%	2,034,979	2,034,979	-	-	-
SDM (Cycle Beads)	507	2,224	9,423	5,756	4,587		105%	4,731	91,182	-	11,964	11,964
PSI SDM (Cycle Beads) Distributed	(169)	(283)	(2,737)	-	(2,048)		-%	(2,561)	(6,089)	-	(3,475)	(3,475)
CycleBeads	676	2,507	12,160	5,756	6,635	9/04	83%	7,292	97,271	-	15,439	15,439
SDM (Cycle Beads) Provided	196	298	3,124	-	2,188		43%	2,763	6,722	-	4,407	4,407
PSI SDM (Cycle Beads) Provided	169	283	2,737	-	2,048		34%	2,561	6,089	-	3,861	3,861
Non-PSI SDM (Cycle Beads) Provid	27	15	387	-	140		176%	202	633	-	546	546
Water Treatment Tablets	-	-	43,942	725,000	8,433,084		(99)%	13,584,989	53,594,478	-	8	8
Aquatab	-	-	43,942	725,000	8,433,084	7/08	(99)%	13,584,989	53,594,478	-	8	8
Zinc	-	392,767	2,069,400	-	-		0%	-	2,069,400	-	27,418	27,418
Zinc Sulfate 20 mg	-	392,767	2,069,400	-	-	10/16	-%	-	2,069,400	-	27,418	27,418
<b>Cote d'Ivoire</b>										1,065	866	1,931
CD4 Tests Provided to HIV+ Clients	176	101	542	-	-		0%	-	542	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
CD4 Tests Provided to HIV+ Clients	176	101	542	-	-		-%	-	542	-	-	-
Free Condom	60,920	60,615	389,526	238,320	447,458		(13)%	469,778	5,203,277	941	847	1,788
Free Distribution	60,920	60,615	389,526	238,320	447,458	1/08	(13)%	469,778	5,203,277	941	847	1,788
Free Female Condom	-	1,333	11,627	11,000	10,272		13%	10,272	62,763	28	19	48
Female Condom Free	-	1,333	11,627	11,000	10,272	8/12	13%	10,272	62,763	28	19	48
HIV Testing Services	3,684	1,935	13,275	17,260	10,209		30%	11,043	109,383	95	-	95
VCT Individual (HIV-Negative)	3,515	1,802	12,499	16,569	10,015	1/10	25%	10,827	104,199	90	-	90
VCT Individual (HIV-Positive)	169	133	776	691	194	1/10	300%	216	5,184	6	-	6
Lubricant	-	3,694	14,884	-	28,568		(48)%	28,568	72,531	-	-	-
Gel Lubricant 4.5 g	-	3,694	14,884	-	28,568	9/12	(48)%	28,568	72,531	-	-	-
Referral to CD4/Clinical Staging	-	-	-	553	-		0%	-	18	-	-	-
Referral to CD4/Clinical Staging	-	-	-	553	-		-%	-	18	-	-	-
Referral to HIV Testing Services	-	-	-	-	5,401		(100)%	5,401	6,185	-	-	-
Referral to HIV Testing & Counseling	-	-	-	-	5,401		(100)%	5,401	6,185	-	-	-
<b>Ghana</b>										3,052	136,801	139,853
Condom	300	2,827	702,096	1,572,430	-		0%	73,612	775,708	3,052	1,028	4,080
Protector	300	2,827	702,096	1,572,430	-		-%	73,612	775,708	3,052	1,028	4,080
Injectable 3	70,600	71,562	1,610,687	427,249	-		0%	4,771	1,615,458	-	111,111	111,111
Famplan	70,600	71,562	1,610,687	427,249	-		-%	4,771	1,615,458	-	111,111	111,111
OCs	272,940	157,340	1,320,300	1,797,801	-		0%	174,665	1,494,965	-	24,661	24,661
Secure	272,940	157,340	1,320,300	1,797,801	-		-%	174,665	1,494,965	-	24,661	24,661
Water Treatment Tablets	-	-	-	1,761,730	-		0%	-	-	-	-	-
Aquatabs 67 mg (20 L)	-	-	-	1,761,730	-	7/17	-%	-	-	-	-	-
<b>Guinea</b>										10,683	70,105	80,788
Condom	-	-	-	-	2,511,165		(100)%	1,562,745	48,130,314	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Prudence Plus	-	-	-	-	2,511,165	1/08	(100)%	1,562,745	48,130,314	-	-	-
Diarrhea Treatment Kit	-	16,320	464,760	-	418,265		11%	426,665	2,746,946	-	25,030	25,030
Orasel Zinc DTK	-	16,320	464,760	-	418,265	9/12	11%	426,665	2,746,946	-	25,030	25,030
Free Condom	3,530,592	2,243,135	15,092,396	42,136,556	-		0%	864,000	15,956,396	10,553	41,656	52,209
Condom Combo	61,064	6,371	146,176	1,086,696	-	11/16	-%	-	146,176	102	403	506
Generic Condom	3,469,528	2,236,764	14,946,220	41,049,860	-	11/16	-%	864,000	15,810,220	10,451	41,252	51,703
Free Female Condom	75,963	19,899	168,660	435,985	-		0%	-	168,660	118	358	476
Condom Feminin	75,963	19,899	168,660	435,985	-	5/16	-%	-	168,660	118	358	476
HIV Testing Services	857	181	1,401	-	-		0%	-	326,563	12	-	12
VCT Individual (HIV-Negative)	831	163	1,319	-	-	12/09	-%	-	311,336	11	-	11
VCT Individual (HIV-Positive)	26	19	82	-	-	12/09	-%	-	15,227	1	-	1
Injectable 3	-	-	-	-	60,259		(100)%	60,259	1,438,474	-	-	-
Equilibre	-	-	-	-	60,259	9/07	(100)%	60,259	1,438,474	-	-	-
Lubricant	1,798,029	533,065	4,549,223	-	-		0%	-	4,549,223	-	-	-
Vanilla Scented Lubricant Sachet	1,798,029	533,065	4,549,223	-	-	10/16	-%	-	4,549,223	-	-	-
OCs	-	-	-	-	218,035		(100)%	218,035	6,447,369	-	-	-
Planyl	-	-	-	-	218,035	12/95	(100)%	218,035	6,447,369	-	-	-
Safe Water Solution	-	2,442	608,310	-	46,248		1215%	46,632	3,994,084	-	3,062	3,062
Sur Eau	-	2,442	608,310	-	46,248	7/06	1,215%	46,632	3,994,084	-	3,062	3,062
STI Screening	41	78	275	-	-		0%	-	275	-	-	-
STI Screening	41	78	275	-	-		-%	-	275	-	-	-
TB Diagnosis	-	-	-	-	6,186		(100)%	10,219	10,219	-	-	-
TB Diagnosis	-	-	-	-	6,186		(100)%	10,219	10,219	-	-	-
TB DOTS	-	-	-	-	3,668		(100)%	5,763	5,763	-	-	-
TB DOTS	-	-	-	-	3,668		(100)%	5,763	5,763	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
TB Screening	-	-	-	-	-		0%	7,139	7,139	-	-	-
TB Screening	-	-	-	-	-		-%	7,139	7,139	-	-	-
<b>Liberia</b>										2,686	1,740	4,426
Condom	133,728	30,752	682,176	1,100,000	640,512		7%	1,014,608	4,992,802	2,609	1,457	4,066
STAR	133,728	30,752	682,176	1,100,000	640,512	7/09	7%	1,014,608	4,992,802	2,609	1,457	4,066
Free Condom	-	6,567	19,700	500,000	-		0%	-	66,908	75	42	117
Free Condom	-	-	-	500,000	-	11/13	-%	-	47,208	-	-	-
Generic Condom	-	6,567	19,700	-	-	5/17	-%	-	19,700	75	42	117
HIV Testing Services	64	55	381	-	-		0%	-	2,186	2	-	2
VCT Individual (HIV-Negative)	61	50	333	-	-	5/14	-%	-	2,120	2	-	2
VCT Individual (HIV-Positive)	3	5	48	-	-	5/14	-%	-	66	-	-	-
Implant 5	-	-	-	-	-		0%	3,030	4,745	-	-	-
Jadelle	-	-	-	-	-	11/13	-%	3,030	4,745	-	-	-
Lubricant	-	3,233	9,700	-	-		0%	-	9,700	-	-	-
Lube Sachet Free	-	3,233	9,700	-	-	5/17	-%	-	9,700	-	-	-
Referral to HIV Testing Services	-	-	-	50,000	-		0%	-	1	-	-	-
Referral to HIV Testing & Counseling	-	-	-	50,000	-	12/13	-%	-	1	-	-	-
Safe Water Solution	4,608	4,696	62,568	50,000	7,680		715%	13,272	715,906	-	241	241
WaterGuard	4,608	4,696	62,568	50,000	7,680	7/09	715%	13,272	715,906	-	241	241
<b>Mali</b>										-	1,808,143	1,808,143
Cervical Cancer-VIA and Cryotherapy	7	20	155	719	333		(53)%	599	884	-	70	70
Cervical Cancer-VIA and Cryotherapy	7	20	155	719	333	12/13	(53)%	599	884	-	70	70
Cervical Cancer-VIA/VILI Screening	2,503	2,681	17,041	-	10,193		67%	23,345	46,911	-	-	-
Cervical Cancer-VIA/VILI Screening	2,503	2,681	17,041	-	10,193		67%	23,345	46,911	-	-	-
Condom Provided	-	-	-	-	13		(100)%	18	88	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI Condom Provided	-	-	-	-	13		(100)%	18	88	-	-	-
Family Planning Counseling	-	-	-	-	337		(100)%	659	688	-	-	-
Family Planning Counseling	-	-	-	-	337		(100)%	659	688	-	-	-
Free Condom	-	-	-	110,000	204,200		(100)%	204,200	916,360	-	-	-
Protector Free	-	-	-	110,000	-	1/08	-%	-	72,000	-	-	-
Protector Plus Free	-	-	-	-	204,200	4/14	(100)%	204,200	844,360	-	-	-
Free Female Condom	-	-	-	-	150		(100)%	150	150	-	-	-
Protectiv Free	-	-	-	-	150	1/08	(100)%	150	150	-	-	-
HIV Testing Services	-	-	-	-	4,351		(100)%	4,351	128,136	-	-	-
VCT Concordant Couple (HIV-Nega	-	-	-	-	6	1/10	(100)%	6	611	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	4,230	1/10	(100)%	4,230	124,942	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	115	1/10	(100)%	115	2,583	-	-	-
Implant 3	-	-	-	-	-		0%	-	(3,198)	-	-	-
PSI Implant 3 Distributed Inserted (	-	-	-	-	(200)		-%	(200)	(3,398)	-	-	-
Implanon NXT	-	-	-	-	200	2/16	(100)%	200	200	-	-	-
Implant 3 Insertion	826	365	2,431	10,000	275		784%	796	6,425	-	5,705	5,705
PSI Implant 3 Inserted	-	-	-	-	200		(100)%	200	3,398	-	-	-
Non-PSI Implant 3 Inserted	826	365	2,431	10,000	75		3,141%	596	3,027	-	5,705	5,705
Implant 5	-	-	-	-	(30)		0%	(30)	(1,060)	-	-	-
PSI Implant 5 Distributed Inserted (	-	-	-	-	(2,340)		-%	(2,340)	(108,214)	-	-	-
Jadelle	-	-	-	-	2,310	7/09	(100)%	2,310	107,154	-	-	-
Implant 5 Insertion	1,945	2,102	14,717	21,000	20,274		(27)%	28,286	159,899	-	50,826	50,826
PSI Implant 5 Inserted	-	-	-	-	2,340		(100)%	2,340	108,214	-	-	-
Non-PSI Implant 5 Inserted	1,945	2,102	14,717	21,000	17,934		(18)%	25,946	51,685	-	50,826	50,826
Injectable 3	-	-	-	-	90,360		(100)%	95,040	4,053,900	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Confiance Injectable	-	-	-	-	90,360	5/03	(100)%	95,040	4,053,900	-	-	-
Injectable 3 Provided	106	48	488	-	570		(14)%	739	2,506	-	82	82
Non-PSI Injectable 3 Provided	106	48	488	-	570		(14)%	739	2,506	-	82	82
IUD 10	-	-	820	6,000	1,500		(45)%	1,783	(48,583)	-	3,154	3,154
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	(2,650)		-%	(2,650)	(67,117)	-	-	-
IUD Copper T 380A	-	-	820	6,000	4,150	12/13	(80)%	4,433	18,534	-	3,154	3,154
IUD 10 Insertion	1,459	1,518	10,606	23,000	15,301		(31)%	21,400	96,596	-	45,322	45,322
PSI IUD 10 Inserted	-	-	-	-	2,650		(100)%	2,650	67,117	-	-	-
Non-PSI IUD 10 Inserted	1,459	1,518	10,606	23,000	12,651		(16)%	18,750	29,479	-	45,322	45,322
LLIN	293,184	166,260	2,157,040	3,210,000	607,722		255%	2,275,809	12,754,910	-	856,309	856,309
MILD - (G)	293,184	-	1,653,684	3,210,000	277,000	10/14	497%	549,100	6,840,503	-	656,485	656,485
MILD - (O)	-	-	-	-	-	9/16	-%	336,140	336,140	-	-	-
MILD - (U)	-	166,260	503,356	-	330,722	12/14	52%	1,390,569	5,578,267	-	199,824	199,824
Lubricant	-	-	-	-	19		(100)%	19	19	-	-	-
Lubricant	-	-	-	-	19		(100)%	19	19	-	-	-
Malaria PPT (ACT)	855,849	133,333	1,575,859	320,000	2,011,813		(22)%	2,256,073	7,318,433	-	835,081	835,081
Coartem 12 tabs	-	-	96,000	96,000	405,755	5/10	(76)%	464,105	1,556,315	-	50,872	50,872
Coartem 24 tabs	855,849	133,333	1,255,849	-	1,005,793	10/14	25%	1,005,793	3,132,108	-	665,501	665,501
Coartem 6 tabs	-	-	224,010	224,000	600,265	5/10	(63)%	786,175	2,630,010	-	118,708	118,708
Manual Vacuum Aspiration for PAC	210	226	1,627	1,555	881		85%	1,384	3,082	-	919	919
MVA for PAC	210	226	1,627	1,555	881	7/15	85%	1,384	3,082	-	919	919
Misoprostol for PAC (Oral)	-	-	-	-	-		0%	2,400	2,400	-	-	-
Misoprostol for PAC (oral)	-	-	-	-	-	9/16	-%	2,400	2,400	-	-	-
Misoprostol for PAC (oral) Provided	1,422	1,693	13,875	8,000	-		0%	933	14,808	-	2,612	2,612
Non-PSI Misoprostol for PAC (oral)	1,422	1,693	13,875	8,000	-		-%	933	14,808	-	2,612	2,612

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
OCs	-	-	173,600	173,600	221,200		(22)%	197,680	14,158,129	-	7,077	7,077
Pilplan	-	-	173,600	173,600	221,200	5/03	(22)%	197,680	14,158,129	-	7,077	7,077
OCs Provided	88	51	396	-	155		155%	262	900	-	18	18
Non-PSI OCs Provided	88	51	396	-	155		155%	262	900	-	18	18
SDM (Cycle Beads) Provided	-	-	2	-	1		100%	1	10	-	3	3
Non-PSI SDM (Cycle Beads) Provid	-	-	2	-	1		100%	1	10	-	3	3
Toilets Constructed	106	432	3,564	-	-		0%	-	3,564	-	-	-
Toilet Type 1	106	432	3,564	-	-	10/16	-%	-	3,564	-	-	-
Toilets Sold	106	432	3,564	3,000	-		0%	2,598	6,162	-	955	955
Toilet Type 1, Direct Sales	106	432	3,564	3,000	-	12/16	-%	2,598	6,162	-	955	955
Water Treatment Tablets	6,400	6,400	67,200	2,324,000	-		0%	176,000	42,212,470	-	11	11
Aquatab	6,400	6,400	67,200	2,324,000	-	2/09	-%	176,000	42,212,470	-	11	11
<b>Niger</b>										299	25,526	25,826
Condom Provided	-	-	-	-	4,571		(100)%	10,223	10,223	-	-	-
Non-PSI Condom Provided	-	-	-	-	4,571		(100)%	10,223	10,223	-	-	-
Free Condom	-	19,200	57,600	280,000	252,000		(77)%	465,120	522,720	250	181	432
Generic Condom	-	19,200	57,600	280,000	252,000	6/16	(77)%	465,120	522,720	250	181	432
HIV Testing Services	278	1,184	6,095	4,400	6,044		1%	9,319	15,414	49	-	49
VCT Concordant Couple (HIV-Nega	-	-	-	-	58		(100)%	127	127	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	6		(100)%	6	6	-	-	-
VCT Individual (HIV-Negative)	275	1,176	6,040	4,385	5,471		10%	8,639	14,679	48	-	48
VCT Individual (HIV-Positive)	3	8	55	15	509		(89)%	547	602	-	-	-
Implant 3 Insertion	996	501	3,288	1,614	326		909%	807	4,095	-	7,584	7,584
Non-PSI Implant 3 Inserted	996	501	3,288	1,614	326		909%	807	4,095	-	7,584	7,584
Implant 5 Insertion	212	187	783	900	218		259%	430	1,213	-	2,653	2,653

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI Implant 5 Inserted	212	187	783	900	218		259%	430	1,213	-	2,653	2,653
Injectable 3 Provided	1,881	3,043	12,417	1,000	222		5493%	821	13,238	-	2,045	2,045
Non-PSI Injectable 3 Provided	1,881	3,043	12,417	1,000	222		5,493%	821	13,238	-	2,045	2,045
IUD 10	-	33	100	-	-		0%	-	100	-	376	376
Generic IUD 10	-	33	100	-	-	6/17	-%	-	100	-	376	376
IUD 10 Insertion	79	74	610	400	39		1464%	198	808	-	2,551	2,551
Non-PSI IUD 10 Inserted	79	74	610	400	39		1,464%	198	808	-	2,551	2,551
Manual Vacuum Aspiration for PAC	-	-	-	40	-		0%	-	-	-	-	-
MVA for PAC	-	-	-	40	-	1/16	-%	-	-	-	-	-
Misoprostol for PAC (Oral)	-	17,012	51,036	1,306	-		0%	-	51,036	-	8,303	8,303
Misoprostol for PAC (oral)	-	17,012	51,036	1,306	-		-%	-	51,036	-	8,303	8,303
OCs Provided	8,223	6,706	41,072	15,000	4,294		856%	11,744	52,816	-	1,832	1,832
Non-PSI OCs Provided	8,223	6,706	41,072	15,000	4,294		856%	11,744	52,816	-	1,832	1,832
Referral to IUD 10 Insertion	-	-	-	-	-		0%	22	22	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	-		-%	22	22	-	-	-
<b>Nigeria</b>										598,604	2,100,044	2,698,648
Cervical Cancer-Pap Smear Screening	-	-	-	-	1,450		(100)%	1,450	1,450	-	-	-
Cervical Cancer-Pap Smear Screeni	-	-	-	-	1,450		(100)%	1,450	1,450	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	333	-	942		(65)%	1,652	2,388	-	74	74
Cervical Cancer-VIA and Cryotherap	-	-	333	-	942	3/16	(65)%	1,652	2,388	-	74	74
Cervical Cancer-VIA/VILI Screening	-	-	6,274	-	14,919		(58)%	26,108	48,911	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	6,274	-	14,919		(58)%	26,108	48,911	-	-	-
Chlorhexidine	4,600	5,000	91,806	200,000	-		0%	46,000	137,806	-	9,237	9,237
Chlorxy-G Gel 25 gm tube	4,600	5,000	91,806	200,000	-	11/16	-%	46,000	137,806	-	9,237	9,237
Clean Delivery Kit	665	2,908	9,390	15,000	3,700		154%	4,400	53,140	-	1,189	1,189

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Clean Delivery Kit	665	2,908	9,390	15,000	3,700	9/10	154%	4,400	53,140	-	1,189	1,189
Condom	6,870,672	7,157,589	62,508,922	125,100,000	89,488,125		(30)%	126,960,705	3,103,154,628	539,050	199,170	738,219
Gold Circle	6,520,320	6,780,309	59,793,568	120,000,000	86,529,996	3/90	(31)%	122,269,932	3,086,469,204	515,634	190,518	706,152
Gold Circle Flex	304,992	332,136	2,410,146	4,500,000	2,568,672	5/14	(6)%	4,119,660	9,585,378	20,784	7,679	28,463
Lifestyle - Flavours	11,016	10,584	79,704	120,000	110,169	10/06	(28)%	160,281	1,678,854	687	254	941
Lifestyle - Original Small Cartons	9,072	7,344	46,656	120,000	62,856	10/06	(26)%	102,384	1,536,276	402	149	551
Lifestyle - Ribbed	12,312	13,608	92,016	180,000	104,976	10/06	(12)%	153,576	1,955,325	794	293	1,087
Lifestyle - Ultra Thin	12,960	13,608	86,832	180,000	111,456	10/06	(22)%	154,872	1,929,591	749	277	1,025
Diarrhea Treatment Kit	15,800	16,867	231,200	450,000	223,900		3%	387,800	1,162,725	-	18,533	18,533
Pediatric Zinc Sulphate Tabs/ORS C15,800	15,800	16,867	231,200	450,000	223,900	2/14	3%	387,800	1,162,725	-	18,533	18,533
Emergency Contraception	154,752	167,296	1,162,374	2,000,000	1,194,968		(3)%	1,790,360	13,179,045	-	13,960	13,960
Postinor II	154,752	167,296	1,162,374	2,000,000	1,194,968	4/99	(3)%	1,790,360	13,179,045	-	13,960	13,960
Female Condom	13,824	8,448	51,550	200,000	440,826		(88)%	455,376	6,512,128	445	126	571
Female Condom	13,824	8,448	51,550	200,000	440,826	7/09	(88)%	455,376	6,512,128	445	126	571
Free Condom	-	1,034,400	6,854,400	18,000,000	13,939,344		(51)%	24,724,944	103,625,033	59,109	21,840	80,949
Condom Sample	-	-	1,152,000	-	6,768,144	12/05	(83)%	10,821,744	84,019,433	9,934	3,671	13,605
GF HIV Condom	-	1,034,400	5,702,400	18,000,000	7,171,200	1/16	(20)%	13,903,200	19,605,600	49,175	18,169	67,344
Free Female Condom	-	-	-	500,000	-		0%	-	-	-	-	-
Free Female Condoms	-	-	-	500,000	-		-%	-	-	-	-	-
HIV Testing Services	-	-	-	-	-		0%	82,009	1,876,117	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	-	12/09	-%	78,516	1,738,272	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	-	12/09	-%	3,493	137,845	-	-	-
Implant 5	310	1,000	6,490	12,000	8,072		(20)%	13,852	94,853	-	20,103	20,103
PSI Implant 5 Distributed Inserted (	-	-	-	-	(548)		-%	(548)	(18,830)	-	-	-
Jadelle	310	1,000	6,490	12,000	8,620	9/07	(25)%	14,400	113,683	-	20,103	20,103

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Implant 5 Insertion</b>	<b>2,237</b>	<b>2,242</b>	<b>17,904</b>	-	<b>14,685</b>		<b>22%</b>	<b>22,903</b>	<b>101,058</b>	-	<b>61,619</b>	<b>61,619</b>
PSI Implant 5 Inserted	-	-	-	-	<b>548</b>		(100)%	<b>548</b>	<b>18,830</b>	-	-	-
Non-PSI Implant 5 Inserted	<b>2,237</b>	<b>2,242</b>	<b>17,904</b>	-	<b>14,137</b>	3/16	27%	<b>22,355</b>	<b>82,228</b>	-	<b>61,619</b>	<b>61,619</b>
<b>Injectable 2</b>	<b>64,500</b>	<b>96,267</b>	<b>659,106</b>	<b>1,000,000</b>	<b>1,000,226</b>		<b>(34)%</b>	<b>1,508,326</b>	<b>15,631,800</b>	-	<b>65,964</b>	<b>65,964</b>
Noristerat	<b>64,500</b>	<b>96,267</b>	<b>659,106</b>	<b>1,000,000</b>	<b>1,000,226</b>	12/95	(34)%	<b>1,508,326</b>	<b>15,631,800</b>	-	<b>65,964</b>	<b>65,964</b>
<b>Injectable 3</b>	<b>109,800</b>	<b>60,967</b>	<b>636,506</b>	<b>1,200,000</b>	<b>920,901</b>		<b>(31)%</b>	<b>1,476,701</b>	<b>15,923,747</b>	-	<b>95,554</b>	<b>95,554</b>
Depo-Provera	<b>109,800</b>	<b>60,967</b>	<b>636,506</b>	<b>1,200,000</b>	<b>920,901</b>	12/95	(31)%	<b>1,476,701</b>	<b>15,923,747</b>	-	<b>95,554</b>	<b>95,554</b>
<b>Iron Folic Acid Tablet</b>	<b>1,540</b>	<b>6,007</b>	<b>23,160</b>	-	-		<b>0%</b>	<b>14,500</b>	<b>37,660</b>	-	-	-
Folic Acid 5 mg	<b>1,540</b>	<b>6,007</b>	<b>23,160</b>	-	-	11/16	-%	<b>14,500</b>	<b>37,660</b>	-	-	-
<b>IUD 10</b>	<b>780</b>	<b>2,580</b>	<b>19,686</b>	<b>50,000</b>	<b>40,277</b>		<b>(51)%</b>	<b>68,597</b>	<b>1,413,483</b>	-	<b>75,421</b>	<b>75,421</b>
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	<b>(1,243)</b>		-%	<b>(1,243)</b>	<b>(95,577)</b>	-	-	-
Copper T 380	-	-	-	<b>50,000</b>	-	9/12	-%	-	<b>21,250</b>	-	-	-
IUD	<b>780</b>	<b>2,580</b>	<b>19,686</b>	-	<b>41,520</b>	5/93	(53)%	<b>69,840</b>	<b>1,487,810</b>	-	<b>75,421</b>	<b>75,421</b>
<b>IUD 10 Insertion</b>	<b>6,592</b>	<b>6,377</b>	<b>48,346</b>	-	<b>40,270</b>		<b>20%</b>	<b>62,607</b>	<b>345,195</b>	-	<b>205,804</b>	<b>205,804</b>
PSI IUD 10 Inserted	-	-	-	-	<b>1,243</b>		(100)%	<b>1,243</b>	<b>95,577</b>	-	-	-
Non-PSI IUD 10 Inserted	<b>6,592</b>	<b>6,377</b>	<b>48,346</b>	-	<b>39,027</b>	3/16	24%	<b>61,364</b>	<b>249,618</b>	-	<b>205,804</b>	<b>205,804</b>
<b>IUS 5 Insertion</b>	<b>44</b>	<b>85</b>	<b>300</b>	-	-		<b>0%</b>	-	<b>300</b>	-	<b>949</b>	<b>949</b>
Non-PSI IUS 5 Inserted	<b>44</b>	<b>85</b>	<b>300</b>	-	-		-%	-	<b>300</b>	-	<b>949</b>	<b>949</b>
<b>LLIN</b>	<b>30</b>	<b>53</b>	<b>15,360</b>	<b>20,000</b>	<b>4,487,334</b>		<b>(100)%</b>	<b>5,218,177</b>	<b>19,013,838</b>	-	<b>2,929</b>	<b>2,929</b>
GF Rectangular Net	-	-	-	-	<b>4,480,344</b>	11/13	(100)%	<b>5,204,770</b>	<b>16,582,137</b>	-	-	-
PermaNet	-	<b>13</b>	<b>2,355</b>	<b>20,000</b>	<b>2,600</b>	11/04	(9)%	<b>3,795</b>	<b>2,157,476</b>	-	<b>449</b>	<b>449</b>
Permanet Rectangular (220 x210x 1	<b>15</b>	<b>20</b>	<b>12,855</b>	-	<b>3,615</b>	1/16	256%	<b>8,662</b>	<b>21,517</b>	-	<b>2,451</b>	<b>2,451</b>
PermaNet Student	<b>15</b>	<b>20</b>	<b>150</b>	-	<b>775</b>	9/06	(81)%	<b>950</b>	<b>252,708</b>	-	<b>29</b>	<b>29</b>
<b>Lubricant</b>	<b>6,615</b>	<b>9,450</b>	<b>44,209</b>	-	<b>176,970</b>		<b>(75)%</b>	<b>202,288</b>	<b>1,728,823</b>	-	-	-
Lubrica	<b>6,615</b>	<b>9,450</b>	<b>43,895</b>	-	<b>93,730</b>	12/03	(53)%	<b>118,895</b>	<b>1,645,116</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant 30 ml Sachet	-	-	314	-	83,240	1/16	(100)%	83,393	83,707	-	-	-
<b>Malaria PPT (ACT)</b>	<b>3,240</b>	<b>704,480</b>	<b>3,169,037</b>	-	<b>5,149,923</b>		<b>(38)%</b>	<b>7,018,483</b>	<b>39,477,568</b>	-	<b>1,126,206</b>	<b>1,126,206</b>
ACT 1 (Lumartem 6's)	720	2,040	43,926	-	3,240	1/16	1,256%	8,280	52,206	-	15,610	15,610
ACT 1 (Yellow)	-	54,500	340,611	-	1,488,000	9/12	(77)%	2,202,000	10,039,498	-	121,046	121,046
ACT 2 (Blue)	-	172,200	723,186	-	1,325,700	9/12	(45)%	1,853,860	10,038,150	-	257,004	257,004
ACT 2 (Lumartem 12's)	2,160	14,400	183,606	-	111,600	1/16	65%	142,920	326,526	-	65,250	65,250
ACT 3 (Lumartem 18's)	360	2,160	45,360	-	2,160	1/16	2,000%	3,600	48,960	-	16,120	16,120
ACT 3 (Orange)	-	197,280	627,126	-	553,500	9/12	13%	556,560	7,189,124	-	222,867	222,867
ACT 4 (Green)	-	252,540	1,024,136	-	1,582,923	9/12	(35)%	2,156,943	11,507,698	-	363,955	363,955
ACT 4 (Lumartem 24's)	-	9,360	181,086	-	82,800	1/16	119%	94,320	275,406	-	64,354	64,354
<b>Malaria RDK</b>	-	<b>77,068</b>	<b>308,106</b>	-	<b>3,885,975</b>		<b>(92)%</b>	<b>5,103,442</b>	<b>6,742,871</b>	-	-	-
GF Malaria Test Kit (Access Bio by :)	-	9,900	37,800	-	3,885,975	1/16	(99)%	4,882,275	4,920,075	-	-	-
Rapid Diagnostic Test (RDT) Kit	-	67,168	270,306	-	-	9/10	-%	221,167	1,822,796	-	-	-
<b>Manual Vacuum Aspiration for PAC</b>	-	-	-	-	-		<b>0%</b>	<b>5,296</b>	<b>5,296</b>	-	-	-
MVA for PAC	-	-	-	-	-	11/16	-%	5,296	5,296	-	-	-
<b>Misoprostol for PAC (Oral)</b>	<b>37,500</b>	<b>40,567</b>	<b>171,300</b>	<b>600,000</b>	<b>341,500</b>		<b>(50)%</b>	<b>403,100</b>	<b>1,169,350</b>	-	<b>40,172</b>	<b>40,172</b>
Misoprostol for PAC (oral)	37,500	40,567	171,300	600,000	341,500	3/15	(50)%	403,100	1,169,350	-	40,172	40,172
<b>Misoprostol for PPH</b>	-	-	-	<b>300,000</b>	-		<b>0%</b>	-	<b>349,630</b>	-	-	-
Misoprostol	-	-	-	300,000	-	7/11	-%	-	349,630	-	-	-
<b>OCs</b>	<b>443,700</b>	<b>458,100</b>	<b>3,427,656</b>	<b>7,500,000</b>	<b>4,626,890</b>		<b>(26)%</b>	<b>7,389,890</b>	<b>37,290,848</b>	-	<b>139,329</b>	<b>139,329</b>
Combination 3	443,700	458,100	3,427,656	7,500,000	4,626,890	10/11	(26)%	7,389,890	37,290,848	-	139,329	139,329
<b>PUR</b>	<b>10,320</b>	<b>11,200</b>	<b>85,926</b>	<b>3,500,000</b>	<b>773,280</b>		<b>(89)%</b>	<b>5,058,720</b>	<b>15,769,611</b>	-	<b>7</b>	<b>7</b>
PuR	10,320	11,200	85,926	3,500,000	773,280	1/08	(89)%	5,058,720	15,769,611	-	7	7
<b>Safe Water Solution</b>	<b>7,992</b>	<b>6,904</b>	<b>59,478</b>	<b>150,000</b>	<b>89,503</b>		<b>(34)%</b>	<b>101,095</b>	<b>8,139,150</b>	-	<b>476</b>	<b>476</b>
WaterGuard	-	-	25,680	-	89,503	11/04	(71)%	101,095	8,105,352	-	198	198

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
WaterGuard Plus (1000L)	7,992	6,904	33,798	150,000	-	4/17	-%	-	33,798	-	278	278
SDM (Cycle Beads)	100	167	906	10,000	9,300		(90)%	12,300	201,047	-	1,290	1,290
CycleBeads	100	167	906	10,000	9,300	7/06	(90)%	12,300	201,047	-	1,290	1,290
STI Screening	-	-	-	-	-		0%	13,407	13,407	-	-	-
STI Screening	-	-	-	-	-		-%	13,407	13,407	-	-	-
Tubal Ligation	-	1	12	-	-		0%	-	12	-	86	86
Tubal Ligation	-	1	12	-	-		-%	-	12	-	86	86
Vasectomy	-	-	1	-	-		0%	-	1	-	7	7
Vasectomy	-	-	1	-	-		-%	-	1	-	7	7
<b>Senegal</b>										11,036	6,937	17,972
Acute Malnutrition Screening_CU5	200	84	676	-	-		0%	-	676	-	-	-
Acute Malnutrition Screening_CU5	200	84	676	-	-		-%	-	676	-	-	-
Condom	316,404	513,029	1,855,492	9,123,403	3,898,348		(52)%	4,252,780	25,068,945	11,035	3,138	14,174
Fagaru	40,176	151,136	493,584	1,876,597	1,270,016	11/12	(61)%	1,443,536	8,396,600	2,936	835	3,770
Protec	-	-	-	3,623,403	-	11/12	-%	-	1,160,433	-	-	-
Protec Fraise	45,848	64,436	239,156	655,380	402,768	1/13	(41)%	524,304	3,057,016	1,422	405	1,827
Protec Naturel	230,380	297,457	1,122,752	2,742,231	2,055,164	1/13	(45)%	2,108,540	11,699,604	6,678	1,899	8,577
Protec Vanille	-	-	-	225,792	170,400	1/13	(100)%	176,400	755,292	-	-	-
Counseling & Tx for Moderate Acute N	-	-	8	-	-		0%	-	8	-	-	-
Counseling & Tx for Moderate Acute	-	-	8	-	-		-%	-	8	-	-	-
HIV Testing Services	79	60	309	-	-		0%	-	309	-	-	-
VCT Individual (HIV-Negative)	79	59	304	-	-		-%	-	304	-	-	-
VCT Individual (HIV-Positive)	-	1	5	-	-		-%	-	5	-	-	-
Implant 3 Insertion	6	6	37	-	-		0%	-	37	-	46	46
Non-PSI Implant 3 Inserted	6	6	37	-	-		-%	-	37	-	46	46

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 4 Insertion	-	2	7	-	-		0%	-	7	-	11	11
Non-PSI Implant 4 Inserted	-	2	7	-	-		-%	-	7	-	11	11
Implant 5 Insertion	8	7	45	-	-		0%	-	45	-	82	82
Non-PSI Implant 5 Inserted	8	7	45	-	-		-%	-	45	-	82	82
Injectable 3	952	-	952	30,000	-		0%	300	43,558	-	76	76
Depo-Provera	-	-	-	-	-	11/12	-%	300	42,606	-	-	-
Securil Press	952	-	952	30,000	-		-%	-	952	-	76	76
Injectable 3 Provided	15	13	64	-	-		0%	-	64	-	6	6
Non-PSI Injectable 3 Provided	15	13	64	-	-		-%	-	64	-	6	6
IPTp2	-	3	54	-	-		0%	-	54	-	3	3
IPTp2	-	3	54	-	-		-%	-	54	-	3	3
IUD 10 Insertion	1	1	3	-	-		0%	-	3	-	7	7
Non-PSI IUD 10 Inserted	1	1	3	-	-		-%	-	3	-	7	7
LLIN	9,744	-	9,744	300,000	154,036		(94)%	155,089	675,475	-	331	331
MILDA	9,744	-	9,744	300,000	154,036	8/13	(94)%	155,089	675,475	-	331	331
OCs	149,448	14	149,489	500,000	345,674		(57)%	509,798	2,453,074	-	3,226	3,226
Securil	149,448	14	149,489	500,000	345,674	11/12	(57)%	509,798	2,453,074	-	3,226	3,226
OCs Provided	1	1	5	-	-		0%	-	5	-	-	-
Non-PSI OCs Provided	1	1	5	-	-		-%	-	5	-	-	-
Treatment for Severe Acute Malnutritic	-	-	4	-	-		0%	-	4	-	-	-
Treatment for Severe Acute Malnutri	-	-	4	-	-		-%	-	4	-	-	-
Water Treatment Tablets	223,850	-	223,850	1,650,000	2,507,060		(91)%	2,678,060	6,915,266	-	11	11
Aquatabs 67 mg (20 L)	223,850	-	223,850	1,650,000	2,507,060	11/12	(91)%	2,678,060	6,915,266	-	11	11

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>West and Central Africa</b>														
<b>Benin</b>							\$58,091		\$49,426	\$44,603	1.11			
<b>Medicines &amp; Supplies</b>														
MVA Kit	08/2017	8	11	0	19	58%	\$253	0%	\$0	NA	NA	481	NA	NA
<b>Other Revenues</b>														
Amour et Vie +	08/2017	3,300	1,400	-100	4,600	30%	\$290	0%	\$0	\$111	NA	119,761	2,717	44.08
<b>Condom</b>														
Kool	08/2017	87,288	3,472	0	90,760	4%	\$4,494	39%	\$1,740	\$6,438	0.27	1,267,748	130,419	9.72
Prudence Plus	08/2017	410,720	7,000	0	417,720	2%	\$8,740	0%	\$1,017	\$6,724	0.15	4,498,374	329,265	13.66
<b>Female Condom</b>														
Cupid	08/2017	0	0	0	0	NA	\$0	NA	\$1	\$0	NA	24	0	NA
Femidom	08/2017	0	12,960	0	12,960	100%	\$0	NA	\$0	\$0	NA	6,480	8,922	0.73
<b>Free Condom</b>														
No Logo	08/2017	0	33,604	0	33,604	100%	\$0	NA	\$0	\$0	NA	36,348	33,716	1.08
<b>Lubricant A</b>														
Gel Lubricant 5 mL	08/2017	0	44,336	0	44,336	100%	\$0	NA	\$0	\$0	NA	42,720	36,411	1.17
<b>LLIN</b>														
Super Moustiquaire Longue Durée	08/2017	922	0	0	922	0%	\$3,983	83%	\$8,866	\$4,126	2.15	4,408	876	5.03
SuperMoustiquaire (blanche 1 plac	08/2017	40	0	0	40	0%	\$158	0%	\$186	\$316	0.59	1,891	85	22.16
SuperMoustiquaire (blanche 3 plac	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$2	NA	36	0	108.00
<b>Retreatment</b>														
Alafia	08/2017	0	0	0	0	NA	\$0	NA	\$2,384	\$0	NA	0	0	NA
<b>Diarrhea Treatment Kit</b>														
Orasel Zinc DTK	08/2017	15,757	0	0	15,757	0%	\$8,187	40%	\$4,574	\$7,653	0.60	65,479	15,050	4.35
<b>Misoprostol for PAC (Oral)</b>														
Misoprostol for PAC (oral)	08/2017	13,840	0	0	13,840	0%	\$2,416	43%	\$1,033	\$2,628	0.39	83,416	15,427	5.41
<b>ORS</b>														
Orasel	08/2017	0	0	0	0	NA	\$0	NA	\$1,312	\$0	NA	0	0	NA
<b>Water Treatment Tablets</b>														
Aquatab	08/2017	782,800	1,700	0	784,500	0%	\$11,443	51%	\$5,957	\$6,592	0.90	3,172,250	453,400	7.00
<b>Implant 5</b>														
Implant 5 (insertion)	08/2017	680	950	0	1,630	58%	\$358	0%	\$11	\$419	0.03	42,239	1,207	35.00
<b>Injectable 2</b>														
Noristerat	08/2017	6,510	30	0	6,540	0%	\$4,764	67%	\$3,856	\$3,797	1.02	54,301	5,502	9.87



Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Benin</b>							\$58,091		\$49,426	\$44,603	1.11				
<u><b>Injectable 3</b></u>															
Equilibre	08/2017	0	0	0	0	NA	\$0	NA	\$2,094	\$0	NA	0	0	NA	
<u><b>IUD 10</b></u>															
IUD (insertion)	08/2017	500	312	0	812	38%	\$88	0%	\$0	\$174	NA	11,359	850	13.36	
IUD Copper-T TCU 380A	08/2017	60	0	0	60	0%	\$11	0%	\$0	\$6	NA	49,660	32	1,535.88	
<u><b>OCs</b></u>															
Harmonie	08/2017	0	0	0	0	NA	\$0	NA	\$1,595	\$0	NA	0	0	NA	
Laafia Pilule	08/2017	58,170	120	0	58,290	0%	\$12,714	79%	\$14,466	\$5,420	2.67	286,537	24,710	11.60	
Microgynon	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	148,551	0	NA	
<u><b>SDM (Cycle Beads)</b></u>															
CycleBeads	08/2017	291	5	0	296	2%	\$191	21%	\$335	\$113	2.96	5,297	182	29.10	
<b>Cameroon</b>							\$45,417		\$67,089	\$49,461	1.36				
<u><b>HIV Test Kit</b></u>															
HIV Determine Test	08/2017	0	2,349	0	2,349	100%	\$0	NA	\$0	\$0	NA	10,511	825	12.74	
HIV ORAQUICK	08/2017	0	234	0	234	100%	\$0	NA	\$0	\$0	NA	1,266	83	15.31	
<u><b>Medicines &amp; Supplies</b></u>															
MEDBAR AMIU KIT	08/2017	19	0	0	19	0%	\$500	0%	-\$68	\$617	-0.11	260	24	10.99	
<u><b>Other Revenues</b></u>															
100% Jeune	08/2017	0	3,000	0	3,000	100%	\$0	NA	-\$22	\$0	NA	35,333	1,000	35.33	
<u><b>Condom</b></u>															
Lovers Plus	08/2017	0	0	0	0	NA	\$0	NA	\$2,549	\$0	NA	181,984	-3,852	-47.24	
Préservatif Masculin Aromatisé UN	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	48,326	643	75.12	
Préservatif Masculin UNFPA	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,211,960	4,771	463.66	
Prudence Plus	08/2017	0	0	0	0	NA	\$0	NA	\$795	\$0	NA	2,160	-720	-3.00	
Prudence Plus Nouveau	08/2017	1,015,200	0	0	1,015,200	0%	\$28,419	10%	\$5,955	\$19,892	0.30	47,261,573	727,092	65.00	
<u><b>Female Condom</b></u>															
Préservatif Féminin CUPID	08/2017	0	0	0	0	NA	\$0	NA	\$2,382	\$51	46.36	511,157	592	863.93	
Préservatif Féminins UNFPA	08/2017	3,360	50	0	3,410	1%	\$146	0%	-\$1,307	\$50	-26.06	649,577	1,374	472.65	
Protectiv Plus	08/2017	0	0	0	0	NA	\$0	NA	\$7	\$0	NA	675,884	0	NA	
Securite Plus Female Condom	08/2017	0	0	0	0	NA	\$0	NA	-\$554	\$714	-0.78	1,432,460	16,667	85.95	
<u><b>Free Condom</b></u>															
Generic MC	08/2017	0	21,201	0	21,201	100%	\$0	NA	\$0	\$0	NA	585,015	7,200	81.25	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Cameroon</b>							\$45,417		\$67,089	\$49,461	1.36				
<b>Free Female Condom</b>															
Generic FC	08/2017	0	1,500	0	1,500	100%	\$0	NA	\$0	\$0	NA	116,000	500	232.00	
<b>Lubricant A</b>															
Water-based Lubricant, 4 mL sach	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	11,125	67	166.88	
<b>Lubricant E</b>															
Lubricant 60 mL bottle	08/2017	105	300	0	405	74%	\$76	0%	-\$9	\$88	-0.10	7,749	219	35.38	
<b>LLIN</b>															
Super Moustiquaire	08/2017	703	0	0	703	0%	\$4,979	73%	\$20,220	\$12,050	1.68	123,041	1,732	71.05	
Super Moustiquaire Interceptor	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	7,530	13	564.75	
<b>Malaria PPT (ACT)</b>															
ACT 2 (ASAQ 50 / 135.5 mg, 3 tab	08/2017	0	2,007	0	2,007	100%	\$0	NA	\$0	\$0	NA	8,443	1,369	6.17	
ACT 3 (ASAQ 100 / 270 mg, 3 tabl	08/2017	0	1,022	0	1,022	100%	\$0	NA	\$0	\$0	NA	3,110	482	6.45	
ACT 4 (ASAQ 100 / 270 mg, 6 tabl	08/2017	0	1,079	0	1,079	100%	\$0	NA	\$0	\$0	NA	2,481	535	4.64	
<b>Malaria RDK</b>															
Malaria Ag Pf/Pan_PA	08/2017	0	6,657	0	6,657	100%	\$0	NA	\$0	\$0	NA	9,143	3,419	2.67	
<b>Diarrhea Treatment Kit</b>															
Orasel Zinc	08/2017	4,960	1,344	0	6,304	21%	\$3,287	0%	\$6,000	\$5,373	1.12	21,521	9,256	2.33	
<b>Micronutrient Powder</b>															
Super Bebe	08/2017	15,840	88,920	-630	104,130	85%	\$417	0%	\$1,198	\$1,754	0.68	890,039	102,150	8.71	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	08/2017	9,840	0	0	9,840	0%	\$2,434	14%	\$14,876	\$2,547	5.84	202,320	10,413	19.43	
<b>ORS</b>															
Orasel	08/2017	0	0	0	0	NA	\$0	NA	\$2,822	\$0	NA	1,515	0	NA	
<b>Safe Water Solution</b>															
Sur'Eau Water Guard	08/2017	0	0	0	0	NA	\$0	NA	\$339	NA	NA	0	NA	NA	
<b>Water Treatment Tablets</b>															
Aquatabs 67 mg (20 L)	08/2017	3,317	20	0	3,337	1%	\$757	0%	\$1,885	\$1,488	1.27	1,021	7,123	0.14	
<b>Zinc</b>															
Zinc	08/2017	850	6,174	0	7,024	88%	\$75	0%	\$10	\$257	0.04	7,930	4,008	1.98	
<b>Emergency Contraception</b>															
Norlevo	08/2017	1,478	3	0	1,481	0%	\$1,223	0%	\$4,419	\$1,886	2.34	96,171	2,009	47.86	
<b>Implant 3</b>															
Implanon NXT	08/2017	2,202	180	-2	2,380	8%	\$1,850	0%	\$3,897	\$1,233	3.16	21,186	1,453	14.58	
<b>Implant 5</b>															
Jadelle UNFPA	08/2017	730	0	0	730	0%	\$741	0%	-\$62	\$671	-0.09	3,111	683	4.55	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Cameroon</b>							\$45,417		\$67,089	\$49,461	1.36				
<b><u>Injectable 3</u></b>															
Depo-Provera UNFPA	08/2017	1,775	0	0	1,775	0%	\$199	0%	-\$408	\$342	-1.19	44,270	3,217	13.76	
Equilibre	08/2017	1,350	43	-20	1,373	3%	\$143	0%	\$1,450	\$129	11.28	439,408	1,193	368.22	
<b><u>IUD 10</u></b>															
DIU UNFPA	08/2017	0	0	0	0	NA	\$0	NA	-\$1	\$7	-0.13	2,077	175	11.87	
IUD	08/2017	2,400	0	0	2,400	0%	\$105	0%	\$57	\$103	0.55	70,172	2,408	29.14	
IUD Copper T 380A	08/2017	150	300	0	450	67%	\$0	NA	\$6	\$21	0.27	15,892	733	21.67	
<b><u>OCs</u></b>															
Microgynon Ed Fe	08/2017	1,440	0	0	1,440	0%	\$51	0%	\$30	\$91	0.33	1,050	2,867	0.37	
Novelle Duo	08/2017	280	55,795	-2	56,073	100%	\$15	0%	\$622	\$97	6.43	372,223	20,312	18.32	
<b><u>Pneumonia PPT</u></b>															
Amoxicillin 500mg x 15's -- Childre	08/2017	0	11,690	0	11,690	100%	\$0	NA	\$0	\$0	NA	19,470	7,830	2.49	
Amoxicillin 500mg x 7's - Children	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,400	0	NA	
<b>Congo-Kinshasa</b>							\$16,496		\$0	\$21,354	NA				
<b><u>Medicines &amp; Supplies</u></b>															
Amoxicillin 250 mg	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	230,244	0	NA	
Artésunate 200mg Suppositoire	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	155	870	0.18	
La Sulfadoxine-Pyriméthamine	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	58,000	5,616	10.33	
Mebendazole 100 mg	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,013,000	0	NA	
NEVIRAPINE Comprimés de 200	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	280	0	NA	
ZIDOVUDINE Comprimés de 300	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	100	0	NA	
<b><u>Other Revenues</u></b>															
100% Jeune	08/2017	0	700	0	700	100%	\$0	NA	\$0	\$0	NA	4,776	233	20.47	
<b><u>Condom</u></b>															
Prudence	08/2017	37,152	50,328	0	87,480	58%	\$1,345	0%	\$0	\$1,398	NA	29,190,951	69,385	420.71	
Prudence Sensuel	08/2017	672	8,129,470	0	8,130,142	100%	\$23	0%	\$0	\$2,232	NA	20,197,772	3,729,139	5.42	
<b><u>Female Condom</u></b>															
Prudence Femme	08/2017	0	21,706	0	21,706	100%	\$0	NA	\$0	\$0	NA	0	35,917	NA	
<b><u>Free Condom</u></b>															
Generic MC	08/2017	0	1,503,000	0	1,503,000	100%	\$0	NA	\$0	\$0	NA	1,801,345	1,321,001	1.36	
<b><u>Free Female Condom</u></b>															
Generic FC	08/2017	0	153,000	0	153,000	100%	\$0	NA	\$0	\$0	NA	358,843	86,652	4.14	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Congo-Kinshasa</b>							\$16,496		\$0	\$21,354	NA				
<b><u>Lubricant A</u></b>															
Personal Lubricant 4.5 g	08/2017	0	6,000	0	6,000	100%	\$0	NA	\$0	\$0	NA	4,600	11,783	0.39	
<b><u>LLIN</u></b>															
Dawa Plus Large Rectangular Mos	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	722,350	0	NA	
Dawa Plus Rectangular Mosquito	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,993,666	0	NA	
PermaNet-Rectangular	08/2017	0	58	0	58	100%	\$0	NA	\$0	\$0	NA	6,262	9,086	0.69	
Yorkool Rectangular Mosquito Net	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2	0	NA	
<b><u>Malaria PPT (ACT)</u></b>															
ACT 1 (2 to 11 months)	08/2017	0	8,391	0	8,391	100%	\$0	NA	\$0	\$0	NA	197,398	5,230	37.74	
ACT 2 (1 to 5 years)	08/2017	0	5,329	0	5,329	100%	\$0	NA	\$0	\$0	NA	728,112	15,587	46.71	
ACT 3 (6 to 13 years)	08/2017	0	900	0	900	100%	\$0	NA	\$0	\$0	NA	760,560	9,831	77.36	
ACT 4 (over 13 years)	08/2017	0	51,277	0	51,277	100%	\$0	NA	\$0	\$0	NA	748,208	37,587	19.91	
<b><u>Malaria RDK</u></b>															
SD Bioline	08/2017	0	32,750	0	32,750	100%	\$0	NA	\$0	\$0	NA	1,546,200	74,533	20.75	
<b><u>Diarrhea Treatment Kit</u></b>															
ORA-ZINC	08/2017	0	38,420	0	38,420	100%	\$0	NA	\$0	\$0	NA	46,201	29,347	1.57	
<b><u>ORS</u></b>															
ORS	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2	0	NA	
<b><u>PUR</u></b>															
P&G Purifiant Water	08/2017	59,280	3,120	0	62,400	5%	\$2,799	0%	\$0	\$5,793	NA	1,205,490	118,640	10.16	
<b><u>Zinc</u></b>															
Zinc Sulfate 20 mg	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	134,600	0	NA	
<b><u>Emergency Contraception</u></b>															
Norlevo	08/2017	2,368	0	0	2,368	0%	\$1,388	0%	\$0	\$2,831	NA	0	4,393	NA	
<b><u>Implant 3</u></b>															
Implanon	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,213	523	2.32	
<b><u>Implant 5</u></b>															
Jadelle	08/2017	0	5,863	0	5,863	100%	\$0	NA	\$0	\$41	NA	6,899	7,721	0.89	
<b><u>Injectable 3</u></b>															
Confiance Depo-Provera	08/2017	28,140	1,846	0	29,986	6%	\$4,030	0%	\$0	\$3,956	NA	163,776	31,901	5.13	
Sayana Press	08/2017	0	56,322	0	56,322	100%	\$0	NA	\$0	\$37	NA	20,605	38,060	0.54	
<b><u>IUD 10</u></b>															
Confiance	08/2017	3	1,125	0	1,128	100%	\$1	0%	\$0	\$2	NA	1,720	855	2.01	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Congo-Kinshasa</b>							\$16,496		\$0	\$21,354	NA				
<u>OCs</u>															
Combination 3	08/2017	116,820	78,189	0	195,009	40%	\$6,908	0%	\$0	\$4,999	NA	653,388	151,085	4.32	
Microgynon	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	63,741	0	NA	
Microlut	08/2017	0	40,247	0	40,247	100%	\$0	NA	\$0	\$8	NA	2,620	32,721	0.08	
<u>SDM (Cycle Beads)</u>															
CycleBeads	08/2017	10	666	0	676	99%	\$2	0%	\$0	\$57	NA	17,795	2,406	7.40	
<b>Cote d'Ivoire</b>							\$0		\$0	\$0	NA				
<u>Free Condom</u>															
Free Distribution	08/2017	0	60,920	0	60,920	100%	\$0	NA	\$0	\$0	NA	217,536	66,869	3.25	
<u>Free Female Condom</u>															
Female Condom Free	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	10,236	1,333	7.68	
<u>Lubricant A</u>															
Gel Lubricant 4.5 g	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	18,918	2,168	8.73	
<u>LifeStraw</u>															
Life Straw - PLWHIV	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	5	0	NA	
<b>Ghana</b>							\$37,420		\$45,315	\$31,938	1.42				
<u>Condom</u>															
Protector	08/2017	0	300	0	300	100%	\$0	NA	\$22,776	\$2	12,436.22	2,936,692	127	23,184.41	
<u>Injectable 3</u>															
Famplan	08/2017	70,600	0	0	70,600	0%	\$3,305	0%	\$0	\$4,152	NA	778,246	75,870	10.26	
<u>OCs</u>															
Secure	08/2017	272,940	0	271,000	543,940	0%	\$34,115	0%	\$22,539	\$27,785	0.81	3,488,037	218,000	16.00	
<b>Guinea</b>							\$0		\$0	\$0	NA				
<u>Free Condom</u>															
Condom Combo	08/2017	0	61,064	0	61,064	100%	\$0	NA	\$0	\$0	NA	100,324	26,725	3.75	
Generic Condom	08/2017	0	3,469,528	0	3,469,528	100%	\$0	NA	\$0	\$0	NA	9,450,500	2,421,273	3.90	
<u>Free Female Condom</u>															
Condom Feminin	08/2017	0	75,963	0	75,963	100%	\$0	NA	\$0	\$0	NA	267,325	45,220	5.91	
<u>Lubricant A</u>															
Vanilla Scented Lubricant Sachet,	08/2017	0	1,798,029	0	1,798,029	100%	\$0	NA	\$0	\$0	NA	5,650,271	1,031,074	5.48	
<u>Diarrhea Treatment Kit</u>															
Orasel Zinc DTK	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
<u>Injectable 3</u>															
Equilibre	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	0	0	NA	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Liberia</b>							\$6,763		\$458	\$5,614	0.08				
<b>Condom</b>															
STAR	08/2017	133,728	0	0	133,728	0%	\$5,622	0%	\$458	\$4,292	0.11	592,330	75,328	7.86	
<b>Free Condom</b>															
Generic Condom	08/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	408,008	NA	NA	
<b>Free Female Condom</b>															
Generic Female Condom	08/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	15,000	NA	NA	
<b>Lubricant A</b>															
Lube Sachet Free	08/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	3,644,900	NA	NA	
<b>Safe Water Solution</b>															
WaterGuard	08/2017	4,608	0	24	4,632	0%	\$1,140	0%	\$0	\$1,322	NA	17,736	5,144	3.45	
<b>Niger</b>							\$0		\$0	\$0	NA				
<b>Free Condom</b>															
Generic Condom	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	217,400	0	NA	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	98,964	17,012	5.82	
<b>IUD 10</b>															
Generic IUD 10	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	7,820	33	234.60	
<b>Nigeria</b>							\$394,211		\$0	\$413,481	NA				
<b>HIV Test Kit</b>															
Determine	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	173,528	22,267	7.79	
Stat Pak	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4,963	127	39.18	
Uni Gold Kit	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,492	0	NA	
<b>Medicines &amp; Supplies</b>															
Fersolate (Iron 200 mg)	08/2017	0	2,860	-5	2,855	100%	\$0	NA	\$0	\$0	NA	42,650	11,135	3.83	
Sulfadoxine 500mg/ Pyrimethamin	08/2017	0	0	1,041,526	1,041,526	NA	\$0	NA	\$0	\$0	NA	102,751	4,500	22.84	
<b>Condom</b>															
Gold Circle	08/2017	6,520,320	0	0	6,520,320	0%	\$134,813	0%	\$0	\$136,409	NA	16,514,768	6,642,453	2.49	
Gold Circle Flex	08/2017	304,992	0	0	304,992	0%	\$20,179	0%	\$0	\$20,675	NA	414,693	312,192	1.33	
Lifestyle - Flavours	08/2017	11,016	0	0	11,016	0%	\$1,431	0%	\$0	\$1,516	NA	53,187	11,664	4.56	
Lifestyle - Original Small Cartons	08/2017	9,072	0	0	9,072	0%	\$1,178	0%	\$0	\$983	NA	17,556	7,560	2.32	
Lifestyle - Ribbed	08/2017	12,312	0	0	12,312	0%	\$1,599	0%	\$0	\$1,741	NA	130,014	13,392	9.71	
Lifestyle - Ultra Thin	08/2017	12,960	0	0	12,960	0%	\$1,683	0%	\$0	\$1,825	NA	128,514	14,040	9.15	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Nigeria</b>							\$394,211		\$0	\$413,481	NA				
<b>Female Condom</b>															
Female Condom	08/2017	13,824	0	0	13,824	0%	\$439	0%	\$0	\$380	NA	1,439,571	11,952	120.45	
<b>Free Condom</b>															
Condom Sample	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15,068	0	NA	
GF HIV Condom	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	6,757,979	1,034,400	6.53	
<b>Lubricant C</b>															
Lubricant 30 ml Sachet	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	94	0	NA	
<b>Lubricant E</b>															
Lubrica	08/2017	6,615	0	0	6,615	0%	\$11,554	0%	\$0	\$15,421	NA	176,757	8,820	20.04	
<b>LLIN</b>															
PermaNet-Conical	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	425	0	NA	
PermaNet-Rectangular	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$89	NA	9,480	13	711.00	
Permanet Rectangular (220 x210x	08/2017	15	0	0	15	0%	\$100	0%	\$0	\$167	NA	769,057	25	30,762.28	
PermaNet Student	08/2017	15	0	0	15	0%	\$95	0%	\$0	\$159	NA	208	25	8.32	
<b>Malaria PPT (ACT)</b>															
ACT 1 (Lumartem 6's)	08/2017	720	0	0	720	0%	\$69	0%	\$0	\$137	NA	39,450	1,440	27.40	
ACT 2 (Lumartem 12's)	08/2017	2,160	0	0	2,160	0%	\$309	0%	\$0	\$1,494	NA	45,006	10,440	4.31	
ACT 3 (Lumartem 18's)	08/2017	360	0	0	360	0%	\$65	0%	\$0	\$261	NA	42,880	1,440	29.78	
ACT 4 (Lumartem 24's)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$989	NA	88,326	4,440	19.89	
<b>Chlorhexidine</b>															
Chlorxy-G Gel 25 gm tube	08/2017	4,600	0	0	4,600	0%	\$2,454	0%	\$0	\$2,564	NA	522,194	4,800	108.79	
<b>Clean Delivery Kit</b>															
Clean Delivery Kit	08/2017	0	665	0	665	100%	\$0	NA	\$0	\$0	NA	9,985	1,595	6.26	
<b>Diarrhea Treatment Kit</b>															
Pediatric Zinc Sulphate Tabs/ORS	08/2017	15,800	0	0	15,800	0%	\$6,272	0%	\$0	\$6,570	NA	49,943	16,533	3.02	
<b>Iron Folic Acid Tablet</b>															
Folic Acid 5 mg	08/2017	0	1,540	42,625	44,165	100%	\$0	NA	\$0	\$0	NA	20,465	6,520	3.14	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	08/2017	37,500	0	0	37,500	0%	\$7,146	0%	\$0	\$8,585	NA	529,780	45,000	11.77	
<b>PUR</b>															
PuR	08/2017	10,320	0	0	10,320	0%	\$492	0%	\$0	\$485	NA	3,718,183	10,160	365.96	
<b>Safe Water Solution</b>															
WaterGuard Plus (1000L)	08/2017	7,992	0	0	7,992	0%	\$6,345	0%	\$0	\$4,451	NA	85,916	5,600	15.34	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Nigeria</b>							\$394,211		\$0	\$413,481	NA				
<u>Emergency Contraception</u>															
Postinor II	08/2017	154,752	0	310	155,062	0%	\$113,037	0%	\$0	\$113,619	NA	1,062,314	155,392	6.84	
<u>Implant 5</u>															
Jadelle	08/2017	310	0	0	310	0%	\$374	0%	\$0	\$1,084	NA	36,093	897	40.25	
<u>Injectable 2</u>															
Noristerat	08/2017	64,500	0	0	64,500	0%	\$18,436	0%	\$0	\$22,240	NA	1,305,665	84,733	15.41	
<u>Injectable 3</u>															
Depo-Provera	08/2017	109,800	0	0	109,800	0%	\$34,870	0%	\$0	\$21,261	NA	2,288,779	70,300	32.56	
<u>IUD 10</u>															
IUD	08/2017	780	0	0	780	0%	\$248	0%	\$0	\$623	NA	157,711	1,960	80.46	
<u>OCs</u>															
Combination 3	08/2017	443,700	0	0	443,700	0%	\$31,000	0%	\$0	\$33,585	NA	4,867,306	480,150	10.14	
<u>SDM (Cycle Beads)</u>															
CycleBeads	08/2017	100	0	0	100	0%	\$22	0%	\$0	\$37	NA	6,824	167	40.94	
<b>Senegal</b>							\$81,586		\$0	\$27,195	NA				
<u>Condom</u>															
Fagaru	08/2017	40,176	0	0	40,176	0%	\$0	NA	\$0	\$0	NA	2,524,499	13,392	188.51	
Protec Fraise	08/2017	45,848	0	0	45,848	0%	\$3,080	0%	\$0	\$1,027	NA	415,835	15,283	27.21	
Protec Naturel	08/2017	230,380	0	0	230,380	0%	\$10,318	0%	\$0	\$3,439	NA	2,024,303	76,793	26.36	
Protec Vanille	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,396	0	NA	
<u>LLIN</u>															
MILDA	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,282	0	NA	
MILDA-Rectangular	08/2017	9,744	0	0	9,744	0%	\$8,772	0%	\$0	NA	NA	-9,744	NA	NA	
<u>Water Treatment Tablets</u>															
Aquatabs 67 mg (20 L)	08/2017	223,850	0	0	223,850	0%	\$3,910	0%	\$0	\$1,303	NA	849,902	74,617	11.39	
<u>Injectable 3</u>															
Depo-Provera	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	-300	0	NA	
Securil Press	08/2017	952	0	0	952	0%	\$1,289	0%	\$0	NA	NA	-952	NA	NA	
<u>OCs</u>															
Securil	08/2017	74,724	0	0	74,724	0%	\$27,108	0%	\$0	\$9,036	NA	755,778	24,908	30.34	
Securil-1 cycle	08/2017	74,724	0	0	74,724	0%	\$27,108	0%	\$0	NA	NA	-74,724	NA	NA	





# East Africa

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 8/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
East Africa	39,035	10	-	-	3,492,951	2,647	923,820	15,673	513	1,583	-	18,620
Burundi	549	2	-	-	33,095	30	6,207	665	-	-	-	670
Ethiopia	1,290	8	-	-	56,708	16	7,983	-	84	-	-	92
Kenya	13,488	-	-	-	646,334	571	157,364	565	74	69	-	914
Malawi	11,775	-	-	-	663,317	745	161,237	151	14	-	-	165
Rwanda	2,347	-	-	-	70,740	20	10,928	-	4	-	-	4
Somaliland	-	-	-	-	1,127	1	298	-	168	81	-	251
South Sudan	-	-	-	-	-	-	-	13,851	134	1,434	-	15,654
Tanzania	6,911	-	-	-	1,071,966	643	275,659	432	6	-	-	693
Uganda	2,675	-	-	-	949,663	622	304,144	9	28	-	-	176

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 8  
 Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>East Africa - All</b>									<b>1,583,545</b>	<b>3,230,634</b>	<b>4,814,179</b>
Antiretroviral Treatment (C	1,752	3,308	25,605	6,986	-	-%	5,564	31,169	5,186	-	5,186
Antiretroviral Treatment (I	214	315	2,202	-	-	-%	901	3,103	-	-	-
Basic Care Package	-	-	400	-	42,574,842	(100)%	52,637,120	172,110,122	-	-	-
CD4 Tests Provided to HIV	-	81	485	-	-	-%	-	485	-	-	-
Cervical Cancer-Pap Sme:	-	-	173	-	-	-%	-	173	-	-	-
Cervical Cancer-VIA and C	110	153	906	2,545	1,889	(52)%	2,707	6,410	-	274	274
Cervical Cancer-VIA and F	-	-	-	102	-	-%	-	19	-	-	-
Cervical Cancer-VIA/VILI §	10,054	11,182	72,313	-	115,545	(37)%	228,181	389,424	-	-	-
Chlorhexidine	320	913	4,069	40,000	-	-%	6,682	10,751	-	254	254
Clean Delivery Kit	576	2,894	25,530	-	29,940	(15)%	53,992	460,473	-	1,785	1,785
Condom	7,348,712	7,456,372	70,711,411	147,400,070	115,390,375	(39)%	168,965,758	2,134,924,172	1,065,797	148,821	1,214,617
Condom Provided	-	-	-	-	2,221,951	(100)%	2,231,548	2,283,254	-	-	-
Counseling & Tx for Mode	-	-	155,147	-	-	-%	-	155,147	-	-	-
Diarrhea Treatment Kit	14,800	14,210	113,978	188,671	122,291	(7)%	176,147	954,355	-	12,217	12,217
Diarrhea Treatment Kit Pri	1,109	1,541	12,442	-	-	-%	17,338	29,780	-	501	501
Emergency Contraception	879	4,474	120,196	154,000	51,280	134%	73,906	396,827	-	993	993
Emergency Contraception	74	182	1,175	2,000	18	6,428%	246	1,423	-	9	9
Expanded Clean Delivery	-	-	-	25,000	-	-%	-	-	-	-	-
Expanded Clean Delivery	-	-	-	14,000	-	-%	-	-	-	-	-
Family Planning Counseli	-	-	-	-	1,285	(100)%	17,574	17,574	-	-	-
Female Condom	4,266	29,433	378,746	140,000	1,019,952	(63)%	1,099,340	11,175,478	3,100	625	3,726

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Region and Product  
Period: 8  
Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Fever Cases Attended	-	-	664	-	-	-%	26,315	26,979	-	-	-
Fever Cases Tested with I	-	-	121	-	-	-%	7,353	7,474	-	-	-
Fever Cases Tested with F	-	-	543	-	-	-%	18,608	19,151	-	-	-
Free Condom	2,724,793	5,246,009	30,769,424	57,032,717	49,082,918	(37)%	85,946,047	527,384,370	390,910	69,496	460,406
Free Female Condom	307,030	149,162	791,522	1,419,000	82,090	864%	107,658	3,075,056	7,126	1,348	8,474
HIV Testing Services	35,059	33,905	283,367	332,377	312,186	(9)%	450,690	2,477,233	8,700	-	8,700
Hypertension Diagnosis	-	-	5,790	-	-	-%	31,404	37,194	-	-	-
Hypertension Screening	-	-	57,107	-	-	-%	129,978	187,085	-	-	-
Hypertension_Controlled	-	-	3,495	-	-	-%	25,842	29,337	-	-	-
Implant 3	(6,743)	5,696	70,084	331,101	149,959	(53)%	143,202	721,350	-	95,754	95,754
Implant 3 Insertion	23,492	19,420	135,837	21,248	46,515	192%	127,841	379,375	-	235,890	235,890
Implant 4 Insertion	-	-	-	-	-	-%	1,460	1,460	-	-	-
Implant 5	(5,118)	4,052	15,893	180,121	65,575	(76)%	63,837	155,761	-	42,914	42,914
Implant 5 Insertion	12,592	10,655	81,735	38,768	42,571	92%	104,800	522,403	-	187,901	187,901
Injectable 3	48,734	309,940	1,891,867	1,894,283	547,087	246%	857,441	9,363,684	-	193,817	193,817
Injectable 3 Provided	17,628	17,299	131,361	155,758	34,200	284%	62,588	212,056	-	13,579	13,579
IPTp2	760	630	4,625	-	10,564	(56)%	19,006	52,625	-	228	228
IUD 10	(10,217)	1,082	19,633	(17,071)	39,584	(50)%	(6,010)	151,902	-	64,974	64,974
IUD 10 Insertion	25,858	23,811	161,691	242,836	67,033	141%	195,352	949,773	-	489,512	489,512
IUD 5	(31)	8	(154)	-	597	(126)%	484	(3,847)	-	(343)	(343)
IUD 5 Insertion	31	72	395	-	469	(16)%	691	28,138	-	979	979
LLIN	117,759	588,078	4,053,960	7,978,360	6,306,523	(36)%	9,344,931	67,763,797	-	479,542	479,542

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant	86,849	71,815	709,528	-	363,760	95%	538,215	2,109,240	-	-	-
Malaria PPT (ACT)	720,066	188,082	2,593,373	3,117,784	2,778,730	(7)%	4,074,406	12,234,108	-	798,691	798,691
Malaria RDK	821,225	123,208	1,234,250	1,881,088	1,580,269	(22)%	1,596,819	5,380,993	-	-	-
Male Circumcision (HIV-Pi	-	-	-	-	220	(100)%	287	607	-	-	-
Manual Vacuum Aspiratio	189	173	1,377	250	862	60%	1,253	2,630	-	268	268
Medical Abortion	(13)	14	28	25,000	-	-%	-	28	-	9	9
Medical Abortion Provider	67	62	252	-	-	-%	-	252	-	86	86
Micronutrient Powder	-	-	-	100,000	3,500	(100)%	3,500	1,238,055	-	-	-
Misoprostol for PAC (Oral	10,436	14,464	382,018	750,300	757,252	(50)%	1,265,369	4,409,811	-	13,595	13,595
Misoprostol for PAC (oral)	372	339	2,832	-	-	-%	129	2,961	-	288	288
Misoprostol for PAC (Subl	4	7	244	2,480,200	88	177%	156	400	-	65	65
Misoprostol for PAC (subl	8	3	56	-	-	-%	-	56	-	17	17
Misoprostol for PPH	277,460	314,033	1,908,760	30,000	1,184,600	61%	1,634,400	6,230,299	-	6,616	6,616
OCs	387,974	611,927	4,720,538	6,170,698	3,908,435	21%	7,878,628	57,461,409	-	120,236	120,236
OCs Provided	5,276	8,524	50,392	39,344	46,278	9%	58,379	121,458	-	1,529	1,529
ORS	23,656	40,625	177,288	1,086,611	637,787	(72)%	752,366	19,966,269	-	5,570	5,570
ORS Provided	306	330	123,250	-	-	-%	5,546	128,796	-	4,452	4,452
Pneumonia PPT	11,660	25,889	53,379	910,330	93,773	(43)%	266,190	1,242,730	-	47,936	47,936
Pneumonia PPT Provided	1,295	1,694	95,764	-	-	-%	19,854	115,618	-	87,358	87,358
Positive RDTs	-	-	110	-	-	-%	3,656	3,766	-	-	-
Positive RDTs Given First	-	-	110	-	-	-%	3,489	3,599	-	-	-
PUR	5,071,376	9,640,422	55,645,568	49,069,647	49,145,464	13%	65,302,222	298,023,277	-	2,043	2,043

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 8  
 Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
QAACTs Provided after C	-	-	110	-	-	-%	3,815	3,925	-	18	18
Referral to CD4/Clinical St	-	-	-	2,043	1,601	(100)%	2,210	3,364	-	-	-
Referral to Clinical Stagin	-	-	-	-	101	(100)%	107	1,893	-	-	-
Referral to Emergency Co	-	-	5	-	25	(80)%	37	133	-	-	-
Referral to HIV Testing Se	1,167	2,095	11,734	113,410	10,716	9%	12,052	117,335	31	-	31
Referral to Implant 3 Inser	-	1	19	8,500	311	(94)%	586	1,603	-	15	15
Referral to Implant 5 Inser	-	-	23	1,500	153	(85)%	1,717	1,997	-	26	26
Referral to Injectable 3	-	2	39	10,000	1,120	(97)%	12,012	13,715	-	2	2
Referral to IUD 10 Insertio	-	-	-	11,200	34	(100)%	343	704	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	9	(100)%	9	49	-	-	-
Referral to Linkage to HIV	369	275	1,360	-	-	-%	-	1,360	691	-	691
Referral to OCs	-	-	7	1,500	287	(98)%	2,049	2,725	-	-	-
Referral to STI Diagnosis	-	-	332	-	-	-%	-	332	-	-	-
Referral to STI Screening	1,135	2,238	12,340	-	-	-%	-	12,340	-	-	-
Referral to STI Treatment	-	-	1	142,281	5	(80)%	5	664	-	-	-
Referral to TB Diagnosis	-	19	414	-	-	-%	-	8,112	-	-	-
Referral to TB DOTS (com	-	-	-	-	26	(100)%	26	1,617	-	-	-
Referral to TB Screening	1,554	1,246	10,662	-	-	-%	-	10,662	-	-	-
Referral to Treatment for I	-	-	28	-	-	-%	-	133	-	-	-
Referral to Treatment for I	-	1	30	-	5	500%	5	103	-	-	-
Referral to Treatment for l	6	7	102	-	-	-%	-	2,517	-	1	1
Referral to Treatment for \	22	22	167	-	136	23%	136	7,205	-	2	2

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 8  
 Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Tubal Ligation	-	-	-	-	3	(100)%	3	3	-	-	-
Referral to Tx for Nonherp	2	2	39	-	22	77%	22	1,001	-	3	3
Referral to Tx for Urethral	-	-	-	-	66	(100)%	66	724	-	-	-
Referral to Voluntary Medi	-	-	-	-	42	(100)%	42	42	-	-	-
Safe Water Solution	318,819	225,027	2,132,752	4,239,239	2,700,117	(21)%	4,616,248	55,196,472	-	7,608	7,608
SDM (Cycle Beads)	-	-	-	-	5	(100)%	5	418	-	-	-
Skilled Birth Attendance	3,730	2,434	18,677	16,237	11,662	60%	28,307	81,260	-	15,656	15,656
STI Kit (Non-Ulcerative)	-	923	3,840	9,070	16,259	(76)%	18,139	823,076	-	243	243
STI Kit (Ulcerative)	-	230	690	1,121	2,788	(75)%	3,373	72,218	-	132	132
STI Screening	7,661	8,877	75,155	3,000	110,179	(32)%	153,790	365,983	-	-	-
TB Screening	5,443	7,747	65,262	-	107,292	(39)%	143,594	342,832	-	-	-
Treatment for Cervicitis	-	1	9	-	-	-%	-	9	-	-	-
Treatment for Genital Herp	19	1	22	300	-	-%	2	24	-	1	1
Treatment for Inguinal Bul	4	1	15	-	-	-%	-	15	-	-	-
Treatment for Lower Abdc	79	51	303	400	-	-%	4	307	-	-	-
Treatment for Nonherpetic	91	104	560	300	-	-%	14	574	-	83	83
Treatment for Pre-Eclamp	6	4	62	39	-	-%	28	90	-	42	42
Treatment for Severe Acu	-	-	16,202	-	-	-%	25,444	41,646	-	20,370	20,370
Treatment for Urethral Dis	145	181	886	700	-	-%	1	887	-	11	11
Treatment for Urethral Dis	175	163	917	900	-	-%	2	919	-	29	29
Treatment for Vaginitis	73	135	748	-	-	-%	67	815	-	15	15
Tubal Ligation	1,830	1,239	8,677	5,500	1,968	341%	4,523	13,739	-	51,014	51,014

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Vasectomy</b>	-	-	7	-	1	600%	2	11	-	43	43
<b>Voluntary Medical Male Ci</b>	12,866	2,364	28,298	68,253	25,821	10%	30,631	117,332	102,004	-	102,004
<b>Water Treatment Tablets</b>	1,120,440	3,774,870	20,666,790	23,405,999	43,868,140	(53)%	47,341,850	211,099,913	-	3,294	3,294
<b>Zinc</b>	15,133	17,723	164,357	312,992	36,692	348%	53,910	1,237,970	-	1,794	1,794
<b>Zinc Provided</b>	-	-	33,075	-	-	-%	-	33,075	-	401	401



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>East Africa - All</b>										<b>1,583,545</b>	<b>3,230,634</b>	<b>4,814,179</b>
<b>Burundi</b>										<b>21,554</b>	<b>66,087</b>	<b>87,640</b>
Antiretroviral Treatment (Currently Enr	619	545	3,980	-	-		0%	-	3,980	748	-	748
Antiretroviral Treatment (Currently E	619	545	3,980	-	-		-%	-	3,980	748	-	748
Antiretroviral Treatment (Newly Enrolle	38	45	311	-	-		0%	-	311	-	-	-
Antiretroviral Treatment (Newly Enrc	38	45	311	-	-		-%	-	311	-	-	-
CD4 Tests Provided to HIV+ Clients	-	81	483	-	-		0%	-	483	-	-	-
CD4 Tests Provided to HIV+ Clients	-	81	483	-	-		-%	-	483	-	-	-
Condom	251,910	377,070	2,077,920	3,500,000	3,214,980		(35)%	4,273,233	22,520,242	15,199	5,836	21,035
PSI Condom Distributed Provided	-	-	-	-	(5,163)		-%	(7,020)	(9,371)	-	-	-
Prudence Class	251,910	377,070	2,077,920	3,500,000	3,220,143	12/09	(35)%	4,280,253	22,529,613	15,199	5,836	21,035
Condom Provided	-	-	-	-	5,163		(100)%	7,020	9,371	-	-	-
PSI Condom Provided	-	-	-	-	5,163		(100)%	7,020	9,371	-	-	-
Family Planning Counseling	-	-	-	-	22		(100)%	1,692	1,692	-	-	-
Family Planning Counseling	-	-	-	-	22		(100)%	1,692	1,692	-	-	-
Free Condom	72,000	74,400	727,200	1,500,000	1,363,360		(47)%	1,591,736	7,499,216	5,319	2,042	7,361
Free Male Condoms	72,000	74,400	727,200	1,500,000	1,363,360	5/11	(47)%	1,591,736	7,499,216	5,319	2,042	7,361
Free Female Condom	4,000	2,333	23,000	8,000	39,000		(41)%	46,000	124,930	168	50	218
Free Female Condoms	4,000	2,333	23,000	8,000	39,000	5/11	(41)%	46,000	124,930	168	50	218
HIV Testing Services	1,962	2,432	18,136	20,300	14,184		28%	20,909	102,615	120	-	120
VCT Concordant Couple (HIV-Nega	-	-	-	-	662	12/09	(100)%	971	3,253	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	11	5/15	(100)%	13	15	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	13	2/12	(100)%	20	26	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	13	2/12	(100)%	20	26	-	-	-
VCT Individual (HIV-Negative)	1,921	2,387	17,806	20,000	13,359	12/09	33%	19,658	98,059	118	-	118

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Positive)	41	46	330	300	127	12/09	160%	227	1,236	2	-	2
Implant 5	43	82	281	600	(91)		0%	(97)	1,006	-	765	765
PSI Implant 5 Distributed Inserted (	(108)	(122)	(731)	(1,400)	(784)		-%	(1,062)	(2,780)	-	(1,989)	(1,989)
Jadelle	151	204	1,012	2,000	693	2/14	46%	965	3,786	-	2,753	2,753
Implant 5 Insertion	108	122	731	1,400	784		(7)%	1,062	2,780	-	2,210	2,210
PSI Implant 5 Inserted	108	122	731	1,400	784		(7)%	1,062	2,780	-	2,210	2,210
Injectable 3	365	739	2,768	5,000	1,844		50%	3,701	9,115	-	366	366
PSI Injectable 3 Distributed Provide	(1,611)	(982)	(9,526)	(12,000)	(7,461)		-%	(11,094)	(27,183)	-	(1,260)	(1,260)
DMPA 3-month Injectable	1,976	1,721	12,294	17,000	9,305	2/14	32%	14,795	36,298	-	1,627	1,627
Injectable 3 Provided	1,611	982	9,526	12,000	7,461		28%	11,094	27,183	-	1,401	1,401
PSI Injectable 3 Provided	1,611	982	9,526	12,000	7,461		28%	11,094	27,183	-	1,401	1,401
IUD 10	(19)	50	209	200	160		31%	240	1,074	-	702	702
PSI IUD 10 Distributed Inserted (1)	(56)	(30)	(230)	(500)	(298)		-%	(409)	(909)	-	(772)	(772)
Copper-T 380-A IUD	37	80	439	700	458	2/14	(4)%	649	1,983	-	1,474	1,474
IUD 10 Insertion	56	30	230	500	298		(23)%	409	909	-	858	858
PSI IUD 10 Inserted	56	30	230	500	298		(23)%	409	909	-	858	858
LLIN	102,150	64,467	563,900	1,063,950	326,132		73%	604,482	6,970,508	-	51,193	51,193
MII Permant Free	-	-	268,350	1,063,950	324,850	4/10	(17)%	603,200	6,624,958	-	24,362	24,362
MIILDA - DAWA PLUS 2.0	102,150	64,467	295,550	-	-	5/17	-%	-	295,550	-	26,831	26,831
Supanet (LLIN)	-	-	-	-	1,282	9/13	(100)%	1,282	50,000	-	-	-
Manual Vacuum Aspiration for PAC	7	7	51	30	8		538%	19	70	-	30	30
MVA for PAC	7	7	51	30	8	6/16	538%	19	70	-	30	30
Misoprostol for PAC (Oral)	(25)	6	205	300	132		55%	234	439	-	37	37
PSI Misoprostol for PAC Oral Dist F	(33)	(37)	(315)	-	-		-%	-	(315)	-	(56)	(56)
Misoprostol for PAC (oral)	8	43	520	300	132	7/16	294%	234	754	-	93	93

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Misoprostol for PAC (oral) Provided	33	37	315	-	-		0%	-	315	-	62	62
PSI Misoprostol for PAC (oral) Prov	33	37	315	-	-		-%	-	315	-	62	62
Misoprostol for PAC (Sublingual)	4	7	244	200	88		177%	156	400	-	65	65
PSI Misoprostol for PAC Sublingual	(8)	(3)	(56)	-	-		-%	-	(56)	-	(15)	(15)
Misoprostol for PAC (Sublingual)	12	11	300	200	88	7/16	241%	156	456	-	80	80
Misoprostol for PAC (sublingual) Provi	8	3	56	-	-		0%	-	56	-	17	17
PSI Misoprostol for PAC (sublingua	8	3	56	-	-		-%	-	56	-	17	17
OCs	357	726	3,564	8,000	3,189		12%	4,992	13,024	-	128	128
PSI OCs Distributed Provided	(993)	(558)	(5,268)	(8,000)	(4,665)		-%	(6,795)	(17,129)	-	(189)	(189)
Confiance OC	1,350	1,284	8,832	16,000	7,854	2/14	12%	11,787	30,153	-	316	316
OCs Provided	993	558	5,268	8,000	4,665		13%	6,795	17,129	-	210	210
PSI OCs Provided	993	558	5,268	8,000	4,665		13%	6,795	17,129	-	210	210
Referral to Implant 5 Insertion	-	-	-	1,500	-		0%	1,100	1,100	-	-	-
Referral to Implant 5 Insertion	-	-	-	1,500	-		-%	1,100	1,100	-	-	-
Referral to Injectable 3	-	-	-	10,000	-		0%	8,547	8,547	-	-	-
Referral to Injectable 3	-	-	-	10,000	-		-%	8,547	8,547	-	-	-
Referral to IUD 10 Insertion	-	-	-	200	-		0%	192	192	-	-	-
Referral to IUD 10 Insertion	-	-	-	200	-		-%	192	192	-	-	-
Referral to OCs	-	-	-	1,500	-		0%	1,381	1,381	-	-	-
Referral to OCs	-	-	-	1,500	-		-%	1,381	1,381	-	-	-
Referral to STI Treatment (unknown)	-	-	-	60	-		0%	-	-	-	-	-
Referral to STI Treatment (unknown	-	-	-	60	-		-%	-	-	-	-	-
STI Screening	507	457	3,105	3,000	1,204		158%	2,374	5,479	-	-	-
STI Screening	507	457	3,105	3,000	1,204		158%	2,374	5,479	-	-	-
Treatment for Cervicitis	-	1	9	-	-		0%	-	9	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Treatment for Cervicitis	-	1	9	-	-		-%	-	9	-	-	-
Treatment for Genital Herpes	19	1	22	300	-		0%	-	22	-	1	1
Treatment for Genital Herpes	19	1	22	300	-		-%	-	22	-	1	1
Treatment for Inguinal Bubo	4	1	15	-	-		0%	-	15	-	-	-
Treatment for Inguinal Bubo	4	1	15	-	-		-%	-	15	-	-	-
Treatment for Lower Abdominal Pain	76	41	258	400	-		0%	-	258	-	-	-
Treatment for Lower Abdominal Pair	76	41	258	400	-		-%	-	258	-	-	-
Treatment for Nonherpetic Genital Ulc	91	99	525	300	-		0%	-	525	-	78	78
Treatment for Nonherpetic Genital U	91	99	525	300	-		-%	-	525	-	78	78
Treatment for Urethral Discharge (Mer	144	156	795	700	-		0%	-	795	-	10	10
Treatment for Urethral Discharge (M	144	156	795	700	-		-%	-	795	-	10	10
Treatment for Urethral Discharge (Wor	173	157	880	900	-		0%	-	880	-	28	28
Treatment for Urethral Discharge (W	173	157	880	900	-		-%	-	880	-	28	28
Treatment for Vaginitis	-	1	5	-	-		0%	-	5	-	-	-
Treatment for Vaginitis	-	1	5	-	-		-%	-	5	-	-	-
<b>Ethiopia</b>										50,575	19,290	69,866
Antiretroviral Treatment (Currently Enr	1,133	780	4,623	900	-		0%	211	4,834	740	-	740
Antiretroviral Treatment (Currently E	1,133	780	4,623	900	-		-%	211	4,834	740	-	740
Antiretroviral Treatment (Newly Enrolle	176	161	891	-	-		0%	76	967	-	-	-
Antiretroviral Treatment (Newly Enrc	176	161	891	-	-		-%	76	967	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	2	-	-		0%	-	2	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	2	-	-		-%	-	2	-	-	-
Free Condom	-	2,054,033	6,231,100	19,678,921	11,069,008		(44)%	31,422,325	124,956,137	44,687	13,193	57,880
Generic Male Condom	-	-	-	-	-	8/16	-%	1,439,620	1,439,620	-	-	-
Protector Plus	-	2,054,033	6,231,100	19,678,921	11,069,008	12/12	(44)%	29,982,705	123,516,517	44,687	13,193	57,880

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Female Condom	285,080	93,360	565,160	1,241,000	24,300		2226%	24,500	623,762	4,053	920	4,974
Free Female Condoms	285,080	93,360	565,160	1,241,000	24,300	10/13	2,226%	24,500	623,762	4,053	920	4,974
HIV Testing Services	6,615	8,076	70,069	129,100	127,852		(45)%	167,787	924,308	373	-	373
VCT Concordant Couple (HIV-Nega	-	-	-	-	182	4/13	(100)%	269	1,373	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	14	4/13	(100)%	26	150	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	11	5/13	(100)%	13	26	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	11	5/13	(100)%	13	26	-	-	-
VCT Individual (HIV-Negative)	6,249	7,717	67,501	129,100	125,328	3/13	(46)%	163,986	902,404	359	-	359
VCT Individual (HIV-Positive)	366	360	2,568	-	2,307	3/13	11%	3,480	20,329	14	-	14
Implant 3	-	-	-	-	3		(100)%	3	1,088	-	-	-
Implanon	-	-	-	-	3	7/14	(100)%	3	1,088	-	-	-
Injectable 3	-	-	-	-	83		(100)%	83	16,400	-	-	-
Depo-Provera	-	-	-	-	83	7/14	(100)%	83	16,400	-	-	-
PUR	92,160	4,279,918	23,996,193	22,469,647	21,515,875		12%	31,608,878	61,183,857	-	922	922
P&G Purifier of Water	92,160	4,279,918	23,996,193	22,469,647	21,515,875	11/15	12%	31,608,878	61,183,857	-	922	922
Referral to CD4/Clinical Staging	-	-	-	2,043	155		(100)%	164	1,205	-	-	-
Referral to CD4/Clinical Staging	-	-	-	2,043	155	12/14	(100)%	164	1,205	-	-	-
Referral to Clinical Staging	-	-	-	-	101		(100)%	107	1,893	-	-	-
Referral to Clinical Staging	-	-	-	-	101	12/14	(100)%	107	1,893	-	-	-
Referral to Emergency Contraception	-	-	5	-	25		(80)%	37	133	-	-	-
Referral to Emergency Contraceptio	-	-	5	-	25	2/15	(80)%	37	133	-	-	-
Referral to HIV Testing Services	1,167	2,095	11,734	113,230	10,598		11%	11,934	117,217	31	-	31
Referral to HIV Testing & Counselin	1,167	2,095	11,734	113,230	10,598	12/13	11%	11,934	117,217	31	-	31
Referral to Implant 3 Insertion	-	1	19	-	244		(92)%	277	1,137	-	15	15
Referral to Implant 3 Insertion	-	1	19	-	244	12/14	(92)%	277	1,137	-	15	15

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Implant 5 Insertion	-	-	23	-	20		15%	24	304	-	26	26
Referral to Implant 5 Insertion	-	-	23	-	20	12/14	15%	24	304	-	26	26
Referral to Injectable 3	-	2	39	-	634		(94)%	711	2,414	-	2	2
Referral to Injectable 3	-	2	39	-	634	1/15	(94)%	711	2,414	-	2	2
Referral to IUD 10 Insertion	-	-	-	-	8		(100)%	9	139	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	8	12/14	(100)%	9	139	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	9		(100)%	9	49	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	9	12/14	(100)%	9	49	-	-	-
Referral to Linkage to HIV Care	369	275	1,360	-	-		0%	-	1,360	691	-	691
Referral to Linkage to HIV Care	369	275	1,360	-	-		-%	-	1,360	691	-	691
Referral to OCs	-	-	7	-	190		(96)%	214	890	-	-	-
Referral to OCs	-	-	7	-	190	1/15	(96)%	214	890	-	-	-
Referral to STI Diagnosis (lab confirmc	-	-	332	-	-		0%	-	332	-	-	-
Referrals to STI Diagnosis (lab confi	-	-	332	-	-		-%	-	332	-	-	-
Referral to STI Screening (syndromic)	1,135	2,238	12,340	-	-		0%	-	12,340	-	-	-
Referrals to STI Screening (syndromic)	1,135	2,238	12,340	-	-		-%	-	12,340	-	-	-
Referral to STI Treatment (unknown)	-	-	1	142,221	5		(80)%	5	664	-	-	-
Referral to STI Treatment (unknown)	-	-	1	142,221	5	12/14	(80)%	5	664	-	-	-
Referral to TB Diagnosis	-	19	414	-	-		0%	-	8,112	-	-	-
Referral to TB Diagnosis	-	19	414	-	-	12/14	-%	-	8,112	-	-	-
Referral to TB DOTS (completion unkr	-	-	-	-	26		(100)%	26	1,617	-	-	-
Referral to TB DOTS (completion un	-	-	-	-	26	12/13	(100)%	26	1,617	-	-	-
Referral to TB Screening	1,554	1,246	10,662	-	-		0%	-	10,662	-	-	-
Referrals to TB Screening	1,554	1,246	10,662	-	-		-%	-	10,662	-	-	-
Referral to Treatment for Inguinal Bubc	-	-	28	-	-		0%	-	133	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Treatment for Inguinal Bt	-	-	28	-	-	12/14	-%	-	133	-	-	-
Referral to Treatment for Lower Abdon	-	1	30	-	5		500%	5	103	-	-	-
Referral to Treatment for Lower Abd	-	1	30	-	5	12/14	500%	5	103	-	-	-
Referral to Treatment for Urethral Disc	6	7	102	-	-		0%	-	2,517	-	1	1
Referral to Treatment for Urethral Di	6	7	102	-	-	12/14	-%	-	2,517	-	1	1
Referral to Treatment for Vaginitis	22	22	167	-	136		23%	136	7,205	-	2	2
Referral to Treatment for Vaginitis	22	22	167	-	136	12/14	23%	136	7,205	-	2	2
Referral to Tubal Ligation	-	-	-	-	3		(100)%	3	3	-	-	-
Referral to Tubal Ligation	-	-	-	-	3		(100)%	3	3	-	-	-
Referral to Tx for Nonherpetic Genital	2	2	39	-	22		77%	22	1,001	-	3	3
Referral to Tx for Nonherpetic Genit:	2	2	39	-	22	12/14	77%	22	1,001	-	3	3
Referral to Tx for Urethral Discharge (\	-	-	-	-	66		(100)%	66	724	-	-	-
Referral to Tx for Urethral Discharge	-	-	-	-	66	12/14	(100)%	66	724	-	-	-
Safe Water Solution	195,500	86,870	991,325	2,267,989	1,600,845		(38)%	2,928,090	23,335,920	-	3,809	3,809
Wuha Agar	195,500	86,870	991,325	2,267,989	1,600,845	2/06	(38)%	2,928,090	23,335,920	-	3,809	3,809
STI Kit (Non-Ulcerative)	-	923	3,840	9,070	16,259		(76)%	18,139	823,076	-	243	243
STI kit for Urethral Discharge	-	507	2,260	4,280	6,043	11/10	(63)%	7,053	445,902	-	124	124
STI Kit for Vaginal Discharge	-	417	1,580	4,790	10,216	11/10	(85)%	11,086	377,174	-	119	119
STI Kit (Ulcerative)	-	230	690	1,121	2,788		(75)%	3,373	72,218	-	132	132
STI Kit for Genital Ulcer	-	230	690	1,121	2,788	11/10	(75)%	3,373	72,218	-	132	132
STI Screening	7,154	8,420	72,050	-	108,975		(34)%	151,416	360,504	-	-	-
STI Screening	7,154	8,420	72,050	-	108,975		(34)%	151,416	360,504	-	-	-
TB Screening	5,443	7,747	65,262	-	107,292		(39)%	143,594	342,832	-	-	-
TB Screening	5,443	7,747	65,262	-	107,292		(39)%	143,594	342,832	-	-	-
Treatment for Genital Herpes	-	-	-	-	-		0%	2	2	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Treatment for Genital Herpes	-	-	-	-	-		-%	2	2	-	-	-
Treatment for Lower Abdominal Pain	3	11	45	-	-		0%	4	49	-	-	-
Treatment for Lower Abdominal Pair	3	11	45	-	-		-%	4	49	-	-	-
Treatment for Nonherpetic Genital Ulc	-	5	35	-	-		0%	14	49	-	5	5
Treatment for Nonherpetic Genital U	-	5	35	-	-		-%	14	49	-	5	5
Treatment for Urethral Discharge (Mer	1	25	91	-	-		0%	1	92	-	1	1
Treatment for Urethral Discharge (M	1	25	91	-	-		-%	1	92	-	1	1
Treatment for Urethral Discharge (Wor	2	6	37	-	-		0%	2	39	-	1	1
Treatment for Urethral Discharge (W	2	6	37	-	-		-%	2	39	-	1	1
Treatment for Vaginitis	73	134	743	-	-		0%	67	810	-	15	15
Treatment for Vaginitis	73	134	743	-	-		-%	67	810	-	15	15
<b>Kenya</b>										<b>586,726</b>	<b>310,769</b>	<b>897,495</b>
Antiretroviral Treatment (Currently Enr	-	1,983	17,002	6,086	-		0%	5,353	22,355	3,699	-	3,699
Antiretroviral Treatment (Currently E	-	1,983	17,002	6,086	-		-%	5,353	22,355	3,699	-	3,699
Antiretroviral Treatment (Newly Enrolle	-	109	1,000	-	-		0%	825	1,825	-	-	-
Antiretroviral Treatment (Newly Encr	-	109	1,000	-	-		-%	825	1,825	-	-	-
Cervical Cancer-VIA and Cryotherapy	26	50	397	384	1,171		(66)%	1,634	3,010	-	84	84
Cervical Cancer-VIA and Cryotherap	26	50	397	384	1,171	7/13	(66)%	1,634	3,010	-	84	84
Cervical Cancer-VIA and Refer to Cryc	-	-	-	102	-		0%	-	19	-	-	-
Cervical Cancer-VIA and Refer to Ci	-	-	-	102	-	12/14	-%	-	19	-	-	-
Cervical Cancer-VIA/VILI Screening	3,145	6,311	43,046	-	73,648		(42)%	161,217	235,456	-	-	-
Cervical Cancer-VIA/VILI Screening	3,145	6,311	43,046	-	73,648		(42)%	161,217	235,456	-	-	-
Condom	2,826,144	1,550,330	19,700,442	31,966,695	21,040,162		(6)%	31,610,311	527,103,803	520,959	36,227	557,185
Mid-tier condom	-	-	-	963,413	-		-%	-	-	-	-	-
Trust	2,488,320	1,064,856	15,167,160	23,500,000	17,066,616	10/93	(11)%	25,384,554	474,566,225	401,080	27,890	428,971

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Trust Ribbed	42,336	66,943	399,670	806,046	453,761	5/14	(12)%	762,510	2,484,341	10,569	735	11,304
Trust Scented	54,432	46,560	657,216	842,747	363,545	5/14	81%	609,834	2,513,071	17,379	1,209	18,588
Trust Studded	241,056	371,971	3,476,396	5,854,489	3,156,240	1/08	10%	4,853,413	47,540,166	91,930	6,393	98,322
Diarrhea Treatment Kit	-	-	-	18,744	6,000		(100)%	6,000	48,678	-	-	-
Diarrhea Treatment Kit	-	-	-	18,744	6,000	12/15	(100)%	6,000	48,678	-	-	-
Diarrhea Treatment Kit Provided	1,109	1,541	12,442	-	-		0%	17,338	29,780	-	501	501
Non-PSI Diarrhea Treatment Kit Pro	1,109	1,541	12,442	-	-		-%	17,338	29,780	-	501	501
Emergency Contraception	(74)	(109)	(924)	-	-		0%	(136)	(1,060)	-	(6)	(6)
PSI Emergency Contraception Distr	(74)	(109)	(924)	-	-		-%	(136)	(1,060)	-	(6)	(6)
Emergency Contraception Provided	74	109	924	2,000	-		0%	136	1,060	-	7	7
PSI Emergency Contraception Prov	74	109	924	-	-		-%	136	1,060	-	7	7
Non-PSI Emergency Contraception I	-	-	-	2,000	-		-%	-	-	-	-	-
Fever Cases Attended	-	-	664	-	-		0%	26,315	26,979	-	-	-
Fever Cases Attended	-	-	664	-	-		-%	26,315	26,979	-	-	-
Fever Cases Tested with Microscopy	-	-	121	-	-		0%	7,353	7,474	-	-	-
Fever Cases Tested with Microscop	-	-	121	-	-		-%	7,353	7,474	-	-	-
Fever Cases Tested with RDTs	-	-	543	-	-		0%	18,608	19,151	-	-	-
Fever Cases Tested with RDTs	-	-	543	-	-		-%	18,608	19,151	-	-	-
Free Condom	1,713,600	146,400	2,152,800	20,070,796	7,064,000		(70)%	8,237,600	208,463,614	56,929	3,959	60,887
Free Male Condom - GOK	-	-	-	-	7,064,000	2/14	(100)%	7,085,600	80,771,600	-	-	-
Free Male Condom - NASCOP	1,713,600	146,400	2,152,800	20,070,796	-	5/11	-%	-	45,107,917	56,929	3,959	60,887
Free Male Condom - UNFPA	-	-	-	-	-	5/11	-%	1,152,000	82,584,097	-	-	-
HIV Testing Services	14,612	14,255	123,040	99,135	116,947		5%	184,245	1,052,133	5,140	-	5,140
VCT Concordant Couple (HIV-Nega	-	-	-	-	20,194	9/11	(100)%	28,529	129,685	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	228	9/11	(100)%	282	3,656	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Discordant Couple (HIV-Negati	-	-	-	-	197	9/11	(100)%	231	1,690	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	197	9/11	(100)%	231	1,690	-	-	-
VCT Individual (HIV-Negative)	14,338	13,985	120,669	96,039	93,815	9/11	29%	151,408	885,257	5,041	-	5,041
VCT Individual (HIV-Positive)	274	270	2,371	3,096	2,316	9/11	2%	3,565	30,155	99	-	99
Hypertension Diagnosis	-	-	5,790	-	-		0%	31,404	37,194	-	-	-
Hypertension Diagnosis	-	-	5,790	-	-		-%	31,404	37,194	-	-	-
Hypertension Screening	-	-	57,107	-	-		0%	129,978	187,085	-	-	-
Hypertension Screening	-	-	57,107	-	-		-%	129,978	187,085	-	-	-
Hypertension_Controlled Condition	-	-	3,495	-	-		0%	25,842	29,337	-	-	-
Hypertension_Controlled Condition	-	-	3,495	-	-		-%	25,842	29,337	-	-	-
Implant 3	-	-	47,848	279,025	137,562		(65)%	140,306	587,356	-	57,934	57,934
Implanon	-	-	47,848	279,025	137,562	3/14	(65)%	140,306	587,356	-	57,934	57,934
Implant 5	(728)	(321)	(4,966)	132,137	50,459		(110)%	51,185	42,156	-	(8,818)	(8,818)
PSI Implant 5 Distributed Inserted (	(828)	(1,017)	(7,192)	(9,180)	(3,770)		-%	(11,324)	(106,586)	-	(12,770)	(12,770)
Jadelle	100	696	2,226	13,317	54,229	1/09	(96)%	62,509	148,742	-	3,952	3,952
Jadelle - GOK	-	-	-	128,000	-		-%	-	-	-	-	-
Implant 5 Insertion	2,989	3,056	23,286	27,000	15,728		48%	32,830	229,070	-	45,941	45,941
PSI Implant 5 Inserted	828	1,017	7,192	9,180	3,770		91%	11,324	106,586	-	14,189	14,189
Non-PSI Implant 5 Inserted	2,161	2,039	16,094	17,820	11,958		35%	21,506	122,484	-	31,752	31,752
Injectable 3	(13,622)	75,677	170,661	325,875	360,936		(53)%	447,968	5,591,633	-	14,786	14,786
PSI Injectable 3 Distributed Provid	(13,622)	(12,523)	(96,228)	-	-		-%	(11,680)	(107,908)	-	(8,337)	(8,337)
Femiplan Injectable	-	88,200	266,889	320,000	360,936	3/00	(26)%	459,648	5,699,541	-	23,123	23,123
GOK Injectable	-	-	-	5,875	-		-%	-	-	-	-	-
Injectable 3 Provided	13,622	12,523	96,228	141,166	-		0%	11,680	107,908	-	9,263	9,263
PSI Injectable 3 Provided	13,622	12,523	96,228	-	-		-%	11,680	107,908	-	9,263	9,263

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI Injectable 3 Provided	-	-	-	141,166	-		-%	-	-	-	-	-
<b>IPTp2</b>	<b>760</b>	<b>630</b>	<b>4,282</b>	-	-		<b>0%</b>	<b>3,595</b>	<b>7,877</b>	-	<b>212</b>	<b>212</b>
IPTp2	760	630	4,282	-	-		-%	3,595	7,877	-	212	212
<b>IUD 10</b>	<b>(88)</b>	<b>(72)</b>	<b>(568)</b>	<b>5,540</b>	<b>(1,147)</b>		<b>0%</b>	<b>(1,578)</b>	<b>2,437</b>	-	<b>(1,241)</b>	<b>(1,241)</b>
PSI IUD 10 Distributed Inserted (1)	(468)	(660)	(4,623)	(4,900)	(2,337)		-%	(6,273)	(77,039)	-	(10,105)	(10,105)
CU 380A (Copper T)	380	588	4,055	10,440	1,190	3/09	241%	4,695	79,476	-	8,863	8,863
<b>IUD 10 Insertion</b>	<b>1,248</b>	<b>1,410</b>	<b>11,098</b>	<b>14,000</b>	<b>8,817</b>		<b>26%</b>	<b>17,920</b>	<b>156,662</b>	-	<b>26,952</b>	<b>26,952</b>
PSI IUD 10 Inserted	468	660	4,623	4,900	2,337		98%	6,273	77,039	-	11,227	11,227
Non-PSI IUD 10 Inserted	780	750	6,475	9,100	6,480		-%	11,647	79,623	-	15,725	15,725
<b>LLIN</b>	<b>2,200</b>	<b>307,746</b>	<b>1,346,224</b>	<b>1,877,333</b>	<b>1,278,327</b>		<b>5%</b>	<b>2,272,960</b>	<b>35,968,619</b>	-	<b>43,194</b>	<b>43,194</b>
ANC LLIN	-	-	-	1,716,333	1,146,571	7/08	(100)%	2,111,533	19,189,925	-	-	-
Mass LLIN	-	-	560	-	488	4/11	15%	28,440	6,481,520	-	18	18
Social Marketed LLIN	-	-	-	-	131,268	8/08	(100)%	131,268	4,692,664	-	-	-
Supanet Conical	2,000	528	4,795	90,500	-	10/16	-%	874	5,669	-	154	154
Supanet Rectangular	200	421	2,641	70,500	-	10/16	-%	845	3,486	-	85	85
Supanet Xtra Power (Olyset)	-	-	129,420	-	-	4/05	-%	-	4,386,547	-	4,153	4,153
Supanet XtraPower BL PNET USAII	-	306,796	1,208,808	-	-	3/14	-%	-	1,208,808	-	38,785	38,785
<b>Malaria PPT (ACT)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>147,378</b>	<b>330</b>		<b>(100)%</b>	<b>330</b>	<b>23,010</b>	-	-	-
Artemether 200mg x 12 (15-24 KG)	-	-	-	113,381	-	3/15	-%	-	9,000	-	-	-
Artemether 200mg x 24 (> 34 KG)	-	-	-	-	330	3/15	(100)%	330	11,010	-	-	-
Artemether 200mg x 6 (5-14 KG)	-	-	-	33,997	-	3/15	-%	-	3,000	-	-	-
<b>Malaria RDK</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>40</b>		<b>(100)%</b>	<b>40</b>	<b>499,905</b>	-	-	-
Malaria Rapid Diagnostic Kit	-	-	-	-	40	11/13	(100)%	40	499,905	-	-	-
<b>OCs</b>	<b>358,132</b>	<b>358,028</b>	<b>2,380,100</b>	<b>3,638,290</b>	<b>2,181,030</b>		<b>9%</b>	<b>5,417,505</b>	<b>34,055,612</b>	-	<b>55,835</b>	<b>55,835</b>
PSI OCs Distributed Provided	(2,624)	(2,342)	(17,314)	-	-		-%	(2,096)	(19,410)	-	(406)	(406)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Femi Girl Oral Pills	24	480	3,432	208,000	-	11/16	-%	4,512	7,944	-	81	81
Femiplan Pill	360,732	359,890	2,393,982	3,430,290	2,181,030	3/00	10%	5,415,089	34,067,078	-	56,161	56,161
OCs Provided	2,624	2,342	17,314	28,752	-		0%	2,096	19,410	-	451	451
PSI OCs Provided	2,624	2,342	17,314	-	-		-%	2,096	19,410	-	451	451
Non-PSI OCs Provided	-	-	-	28,752	-		-%	-	-	-	-	-
ORS Provided	306	330	3,118	-	-		0%	5,546	8,664	-	61	61
Non-PSI ORS Provided	306	330	3,118	-	-		-%	5,546	8,664	-	61	61
Pneumonia PPT	-	-	-	27,065	-		0%	-	-	-	-	-
5 & A Pneumonia Pack-Child	-	-	-	27,065	-		-%	-	-	-	-	-
Pneumonia PPT Provided	1,295	1,694	12,240	-	-		0%	19,854	32,094	-	5,888	5,888
Non-PSI Pneumonia PPT Provided	1,295	1,694	12,240	-	-		-%	19,854	32,094	-	5,888	5,888
Positive RDTs	-	-	110	-	-		0%	3,656	3,766	-	-	-
Positive RDTs	-	-	110	-	-		-%	3,656	3,766	-	-	-
Positive RDTs Given First Line Treatm	-	-	110	-	-		0%	3,489	3,599	-	-	-
Positive RDTs Given First Line Trea	-	-	110	-	-		-%	3,489	3,599	-	-	-
PUR	4,971,120	4,110,024	26,225,640	15,600,000	20,943,233		25%	25,634,046	123,293,116	-	831	831
PuR	4,971,120	4,110,024	26,225,640	15,600,000	20,943,233	2/06	25%	25,634,046	123,293,116	-	831	831
QAACts Provided after Confirmatory I	-	-	110	-	-		0%	3,815	3,925	-	18	18
Non-PSI QAACts Provided after Co	-	-	110	-	-		-%	3,815	3,925	-	18	18
Safe Water Solution	110,640	110,299	940,509	1,601,250	886,125		6%	1,401,214	19,779,730	-	2,981	2,981
WaterGuard	110,640	110,299	940,509	1,601,250	886,125	5/03	6%	1,401,214	19,779,730	-	2,981	2,981
Skilled Birth Attendance	3,730	2,434	18,677	16,237	-		0%	12,016	30,693	-	15,656	15,656
Skilled Birth Attendance	3,730	2,434	18,677	16,237	-		-%	12,016	30,693	-	15,656	15,656
Treatment for Pre-Eclampsia (with Mg'	6	4	62	39	-		0%	28	90	-	42	42
Treatment for Pre-Eclampsia (with Iv	6	4	62	39	-		-%	28	90	-	42	42

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Voluntary Medical Male Circumcision	-	-	-	700	2		(100)%	2	734	-	-	-
Male Circumcision (HIV-Negative)	-	-	-	-	2	3/12	(100)%	2	734	-	-	-
Voluntary Medical Male Circumcision	-	-	-	700	-		-%	-	-	-	-	-
Water Treatment Tablets	2,160	44,710	188,130	239,280	239,280		(21)%	840,790	5,315,130	-	12	12
Aquatab	2,160	44,710	188,130	239,280	239,280	3/09	(21)%	840,790	5,315,130	-	12	12
<b>Malawi</b>										466,854	317,824	784,677
Condom	1,717,130	2,924,680	13,499,930	19,000,000	15,309,160		(12)%	22,203,160	203,443,072	223,247	30,532	253,779
Chishango	1,385,920	2,924,680	13,168,720	19,000,000	15,309,160	10/94	(14)%	22,203,160	203,111,862	217,769	29,783	247,552
Chishango Blue Gold	331,210	-	331,210	-	-	8/17	-%	-	331,210	5,477	749	6,226
Emergency Contraception	547	731	7,250	40,000	23,925		(70)%	34,107	94,242	-	62	62
PSI Emergency Contraception Distr	-	(73)	(241)	-	-		-%	-	(241)	-	(2)	(2)
NORLEVO (Norlevo 1.5mg)	547	804	7,491	40,000	23,925	2/14	(69)%	34,107	94,483	-	64	64
Emergency Contraception Provided	-	73	241	-	-		0%	-	241	-	2	2
PSI Emergency Contraception Prov	-	73	241	-	-		-%	-	241	-	2	2
Female Condom	4,266	1,713	21,586	55,000	37,632		(43)%	55,100	695,412	357	38	395
Care	4,266	1,713	20,406	45,000	37,632	1/08	(46)%	54,148	693,280	337	36	373
Whisper Female Condom	-	-	1,180	10,000	-	11/16	-%	952	2,132	20	2	22
Free Condom	916,153	1,230,269	8,281,413	5,045,000	1,398,164		492%	4,015,632	13,752,528	136,949	18,730	155,678
Free Male Condoms	-	827	7,200	-	322,289	2/14	(98)%	322,289	1,659,772	119	16	135
Key Population Male Condom	916,153	712,274	5,452,779	3,000,000	234,064	7/16	2,230%	2,271,734	7,724,513	90,172	12,332	102,504
One Community Male Condom	-	517,168	2,777,179	2,000,000	628,803	7/16	342%	1,044,215	3,821,394	45,926	6,281	52,207
VMMC Male Condom	-	-	44,255	45,000	213,008	1/15	(79)%	377,394	546,849	732	100	832
Free Female Condom	16,950	12,965	74,362	100,000	17,790		318%	36,158	196,729	1,230	129	1,359
Free Female Condoms	16,950	12,965	74,362	100,000	17,790	2/14	318%	36,158	196,729	1,230	129	1,359
HIV Testing Services	11,870	9,141	72,122	77,000	47,307		52%	69,431	150,877	3,068	-	3,068

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Negative)	11,557	8,890	69,729	73,261	47,307	12/14	47%	69,379	148,391	2,966	-	2,966
VCT Individual (HIV-Positive)	313	251	2,393	3,739	-	12/14	-%	52	2,486	102	-	102
Implant 3	(2,066)	538	(281)	17,000	2,072		(114)%	5,225	20,471	-	(421)	(421)
PSI Implant 3 Distributed Inserted (	(4,235)	(2,791)	(20,808)	-	(6,950)		-%	(13,019)	(42,075)	-	(31,145)	(31,145)
Implanon	2,169	3,329	20,527	17,000	9,022	10/12	128%	18,244	62,546	-	30,725	30,725
Implant 3 Insertion	4,235	2,791	20,808	-	6,950		199%	13,019	42,075	-	34,606	34,606
PSI Implant 3 Inserted	4,235	2,791	20,808	-	6,950		199%	13,019	42,075	-	34,606	34,606
Implant 5	(1,033)	566	122	24,000	4,091		(97)%	9,934	23,155	-	269	269
PSI Implant 5 Distributed Inserted (	(4,997)	(3,213)	(25,314)	-	(9,527)	3/16	-%	(17,447)	(52,204)	-	(55,822)	(55,822)
Jadelle	3,964	3,779	25,436	24,000	13,618	10/12	87%	27,381	75,359	-	56,091	56,091
Implant 5 Insertion	4,997	3,213	25,314	-	9,527		166%	17,447	52,204	-	62,024	62,024
PSI Implant 5 Inserted	4,997	3,213	25,314	-	9,527	3/16	166%	17,447	52,204	-	62,024	62,024
Injectable 3	11,748	9,934	875,511	890,500	74,159		1081%	216,611	1,691,608	-	93,293	93,293
PSI Injectable 3 Distributed Provide	-	(1,412)	(7,340)	-	-		-%	-	(7,340)	-	(782)	(782)
SafePlan Inj3	11,748	11,346	882,851	890,500	74,159	1/08	1,090%	216,611	1,698,948	-	94,075	94,075
Injectable 3 Provided	-	1,412	7,340	-	-		0%	-	7,340	-	869	869
PSI Injectable 3 Provided	-	1,412	7,340	-	-		-%	-	7,340	-	869	869
IUD 10	1,529	111	2,116	1,600	439		382%	532	6,104	-	5,784	5,784
PSI IUD 10 Distributed Inserted (1)	(528)	(207)	(1,742)	-	(714)	3/16	-%	(1,356)	(4,221)	-	(4,761)	(4,761)
IUD Copper T 380A	2,057	318	3,858	1,600	1,153	10/12	235%	1,888	10,325	-	10,545	10,545
IUD 10 Insertion	528	207	1,742	-	714		144%	1,356	4,221	-	5,290	5,290
PSI IUD 10 Inserted	528	207	1,742	-	714	3/16	144%	1,356	4,221	-	5,290	5,290
LLIN	2,169	3,683	114,116	45,000	581,070		(80)%	979,679	8,812,093	-	11,597	11,597
PMI Permanets	-	-	88,852	-	553,585	4/07	(84)%	944,049	8,429,422	-	9,029	9,029
Super Chitetezo Net	2,169	3,683	25,264	45,000	27,485	2/11	(8)%	35,630	382,671	-	2,567	2,567

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant	86,849	71,815	709,528	-	335,260		112%	509,715	1,709,240	-	-	-
Personal Lubricant Water 4.5 g	86,849	71,815	709,528	-	335,260	12/12	112%	509,715	1,709,240	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	220		(100)%	287	607	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	220		(100)%	287	607	-	-	-
OCs	20,023	7,809	100,087	35,000	68,873		45%	104,659	505,903	-	2,888	2,888
PSI OCs Distributed Provided	-	(3,966)	(14,184)	-	-		-%	-	(14,184)	-	(409)	(409)
Microgynon	19,930	11,774	114,178	35,000	68,873	11/11	66%	104,659	519,994	-	3,294	3,294
Microlut	93	-	93	-	-	8/17	-%	-	93	-	3	3
OCs Provided	-	3,966	14,184	-	-		0%	-	14,184	-	455	455
PSI OCs Provided	-	3,966	14,184	-	-		-%	-	14,184	-	455	455
ORS	-	-	-	-	208,492		(100)%	208,492	16,373,449	-	-	-
Thanzi	-	-	-	-	208,492	5/99	(100)%	208,492	16,373,449	-	-	-
PUR	8,095	959,040	3,536,485	6,500,000	3,046,680		16%	3,060,140	52,123,095	-	194	194
PuR WaterGuard Waufa	8,095	959,040	3,536,485	6,500,000	3,046,680	3/06	16%	3,060,140	52,123,095	-	194	194
Referral to CD4/Clinical Staging	-	-	-	-	1,446		(100)%	2,046	2,159	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	1,446		(100)%	2,046	2,159	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	67		(100)%	309	309	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	67		(100)%	309	309	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	133		(100)%	593	593	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	133		(100)%	593	593	-	-	-
Referral to Injectable 3	-	-	-	-	486		(100)%	2,754	2,754	-	-	-
Referral to Injectable 3	-	-	-	-	486		(100)%	2,754	2,754	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	26		(100)%	142	142	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	26		(100)%	142	142	-	-	-
Referral to OCs	-	-	-	-	97		(100)%	454	454	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to OCs	-	-	-	-	97		(100)%	454	454	-	-	-
Safe Water Solution	4,567	20,210	107,975	150,000	121,389		(11)%	153,179	8,307,930	-	592	592
WaterGuard	4,567	20,210	107,975	150,000	121,389	12/02	(11)%	153,179	8,307,930	-	592	592
Tubal Ligation	1,830	1,238	8,654	5,500	1,954		343%	4,500	13,635	-	50,868	50,868
Tubal Ligation	1,830	1,238	8,654	5,500	1,954	1/15	343%	4,500	13,635	-	50,868	50,868
Vasectomy	-	-	4	-	-		0%	-	5	-	24	24
Vasectomy	-	-	4	-	-		-%	-	5	-	24	24
Voluntary Medical Male Circumcision	12,866	2,364	28,298	67,553	25,819		10%	30,629	116,598	102,004	-	102,004
Male Circumcision (HIV-Negative)	-	-	-	-	25,819	3/13	(100)%	30,240	87,911	-	-	-
Voluntary Medical Male Circumcision	12,866	2,364	28,298	67,553	-		-%	389	28,687	102,004	-	102,004
<b>Rwanda</b>										89,754	20,156	109,910
Condom	998,328	837,017	7,076,184	13,567,226	10,641,485		(34)%	14,307,089	182,812,067	86,363	15,405	101,768
Plaisir	52,800	40,987	352,180	1,067,226	1,480,379	1/08	(76)%	1,707,579	14,421,033	4,298	767	5,065
Prudence Plus	945,528	796,031	6,724,004	12,500,000	9,161,106	3/93	(27)%	12,599,510	168,391,034	82,064	14,638	96,703
Condom Provided	-	-	-	-	2,207,978		(100)%	2,207,978	2,208,125	-	-	-
Non-PSI Condom Provided	-	-	-	-	2,207,978		(100)%	2,207,978	2,208,125	-	-	-
Free Condom	-	-	277,881	1,350,000	21,060		1219%	993,900	3,669,986	3,391	605	3,996
Military Condom	-	-	277,881	1,350,000	21,060	11/13	1,219%	993,900	3,669,986	3,391	605	3,996
HIV Testing Services	-	-	-	6,842	5,896		(100)%	8,318	247,300	-	-	-
VCT Concordant Couple (HIV-Negat	-	-	-	-	6	1/10	(100)%	6	22,320	-	-	-
VCT Individual (HIV-Negative)	-	-	-	6,586	5,319	1/10	(100)%	7,511	212,258	-	-	-
VCT Individual (HIV-Positive)	-	-	-	256	571	1/10	(100)%	801	12,722	-	-	-
Injectable 3	1,920	2,720	14,400	22,000	14,928		(4)%	17,328	173,853	-	1,477	1,477
Confiance Depo-Provera	1,920	2,720	14,400	-	14,402	1/08	-%	16,802	31,202	-	1,477	1,477
Depo-Provera (3 Month)	-	-	-	22,000	526	1/06	(100)%	526	142,651	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Injectable 3 Provided	-	-	-	-	11,566		(100)%	11,566	11,728	-	-	-
Non-PSI Injectable 3 Provided	-	-	-	-	11,566	3/16	(100)%	11,566	11,728	-	-	-
OCs	5,760	6,720	87,840	66,000	84,999		3%	95,109	323,288	-	2,440	2,440
Confiance Duofem	-	-	-	-	28,320	1/08	(100)%	28,320	168,656	-	-	-
Microgynon	5,760	6,720	87,840	66,000	56,679		55%	66,789	154,632	-	2,440	2,440
OCs Provided	-	-	-	-	34,593		(100)%	34,593	34,782	-	-	-
Non-PSI OCs Provided	-	-	-	-	34,593		(100)%	34,593	34,782	-	-	-
PUR	-	3,280	64,579	500,000	98,332		(34)%	224,214	11,134,996	-	2	2
PuR	-	3,280	64,579	500,000	98,332	1/11	(34)%	224,214	11,134,996	-	2	2
Referral to HIV Testing Services	-	-	-	180	118		(100)%	118	118	-	-	-
Referral to HIV Testing & Counseling	-	-	-	180	118	12/14	(100)%	118	118	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	42		(100)%	42	42	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	42		(100)%	42	42	-	-	-
Safe Water Solution	8,112	7,648	92,943	220,000	91,758		1%	133,765	3,772,892	-	228	228
Sur Eau	8,112	7,648	92,943	220,000	91,758	8/02	1%	133,765	3,772,892	-	228	228
SDM (Cycle Beads)	-	-	-	-	5		(100)%	5	418	-	-	-
Collier	-	-	-	-	5	1/08	(100)%	5	418	-	-	-
<b>Somaliland</b>										-	21,537	21,537
Diarrhea Treatment Kit	14,800	14,210	113,978	161,500	107,712		6%	161,568	893,168	-	12,217	12,217
SD OFLV-DTK	14,800	14,210	113,978	-	107,712	9/11	6%	161,568	747,647	-	12,217	12,217
Shuban Daweeye_DTK	-	-	-	161,500	-	6/11	-%	-	145,521	-	-	-
Implant 3	(17)	(12)	(43)	-	87		(149)%	197	239	-	(73)	(73)
PSI Implant 3 Distributed Inserted (DALYs)	(17)	(15)	(153)	(360)	(20)		-%	(66)	(219)	-	(259)	(259)
Nasiye Implant (Implanon)	-	3	110	360	107	12/15	3%	263	458	-	186	186
Implant 3 Insertion	17	17	167	360	20		735%	87	254	-	314	314

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Implant 3 Inserted	17	15	153	360	20		665%	66	219	-	288	288
Non-PSI Implant 3 Inserted	-	1	14	-	-		-%	21	35	-	26	26
Injectable 3	-	183	1,120	3,500	3,254		(66)%	4,464	22,609	-	136	136
Nasiye - Inj 3	-	183	1,120	3,500	3,254	6/11	(66)%	4,464	22,609	-	136	136
Micronutrient Powder	-	-	-	100,000	3,500		(100)%	3,500	1,238,055	-	-	-
Super Fariid	-	-	-	100,000	3,500	11/14	(100)%	3,500	1,238,055	-	-	-
Misoprostol for PPH	1,500	2,367	14,600	30,000	7,850		86%	17,750	154,708	-	92	92
Ummul-gargaar	1,500	2,367	14,600	30,000	7,850	3/10	86%	17,750	154,708	-	92	92
OCs	1,125	820	8,055	26,000	18,000		(55)%	27,705	122,271	-	264	264
Nasiye - OC	1,125	820	8,055	26,000	18,000	3/12	(55)%	27,705	122,271	-	264	264
ORS	-	-	-	-	5,750		(100)%	5,750	5,755	-	-	-
Shuban Daweeye_ORs	-	-	-	-	5,750	6/11	(100)%	5,750	5,755	-	-	-
Pneumonia PPT	6,644	-	6,644	11,000	20		33120%	11,050	37,463	-	6,909	6,909
Pneomox 125mg tablet (Amoxicillin)	1,386	-	1,386	2,500	10	11/14	13,760%	2,220	7,566	-	1,441	1,441
Pneomox 250mg tablet (Amoxicillin)	5,258	-	5,258	8,500	10	11/14	52,480%	8,830	29,897	-	5,468	5,468
Water Treatment Tablets	600,000	644,467	4,072,160	4,188,000	2,221,200		83%	3,330,000	68,481,462	-	1,678	1,678
Aquatab	288,000	116,667	638,000	864,000	-	9/10	-%	-	35,574,790	-	263	263
Biyosifeeye	312,000	527,800	3,434,160	3,324,000	2,221,200	7/08	55%	3,330,000	32,906,672	-	1,415	1,415
<b>South Sudan</b>										-	1,292,978	1,292,978
Counseling & Tx for Moderate Acute IV	-	-	155,147	-	-		0%	-	155,147	-	-	-
Counseling & Tx for Moderate Acute	-	-	155,147	-	-		-%	-	155,147	-	-	-
LLIN	-	18,702	1,325,800	1,979,109	1,734,001		(24)%	2,778,617	4,451,637	-	340,320	340,320
Mass LLIN - WES	-	18,702	1,325,800	1,979,109	1,734,001	6/14	(24)%	2,778,617	4,451,637	-	340,320	340,320
Malaria PPT (ACT)	720,066	187,536	2,590,073	2,956,134	2,758,441		(6)%	4,047,867	12,111,807	-	797,965	797,965
ACT Adult - CAIPA	-	-	-	-	758,119	12/15	(100)%	758,119	799,369	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
ACT Child - CAIPA	-	-	-	-	424,500	12/15	(100)%	424,500	424,500	-	-	-
ACT Infant - CAIPA	-	-	-	-	399,000	12/15	(100)%	399,000	423,000	-	-	-
ACTs for Adult (14+ years)	104,400	58,867	570,325	725,465	322,800	2/13	77%	572,600	2,187,980	-	175,709	175,709
ACTs for Child (6-14 years)	63,000	32,808	291,725	458,173	230,675	2/13	26%	247,425	1,171,581	-	89,876	89,876
ACTs for Infant (2-12 months)	233,930	9,536	702,714	736,237	181,148	2/13	288%	685,249	2,751,315	-	216,496	216,496
ACTs for Toddler (1-5 years)	318,736	86,324	1,025,309	1,036,259	442,199	2/13	132%	960,974	4,354,062	-	315,883	315,883
Malaria RDK	821,225	123,208	1,234,250	1,881,088	1,580,144		(22)%	1,596,694	4,666,003	-	-	-
Malaria Rapid Diagnostic Kit	821,225	123,208	1,234,250	1,881,088	1,571,719	9/14	(21)%	1,588,269	4,657,578	-	-	-
mRDT Test Kits - CAIPA	-	-	-	-	8,425	12/15	(100)%	8,425	8,425	-	-	-
ORS	23,656	34,625	159,288	1,068,611	423,545		(62)%	538,124	3,493,884	-	5,240	5,240
PSI ORS Distributed Provided	-	-	(120,132)	-	-		-%	-	(120,132)	-	(3,952)	(3,952)
ORS	23,656	34,625	279,420	1,068,611	423,545	9/08	(34)%	538,124	3,614,016	-	9,192	9,192
ORS Provided	-	-	120,132	-	-		0%	-	120,132	-	4,391	4,391
PSI ORS Provided	-	-	120,132	-	-		-%	-	120,132	-	4,391	4,391
Pneumonia PPT	5,016	25,889	46,735	867,265	90,110		(48)%	251,497	1,178,256	-	41,027	41,027
PSI Pneumonia PPT Distributed Pr	-	-	(83,524)	-	-		-%	-	(83,524)	-	(73,323)	(73,323)
Amoxicillin for Children (1-5 years)	5,016	25,258	118,055	715,056	56,015	10/12	111%	161,804	884,813	-	103,637	103,637
Amoxicillin for Infant (2-12 months)	-	631	12,204	152,209	34,095	10/12	(64)%	89,693	376,967	-	10,714	10,714
Pneumonia PPT Provided	-	-	83,524	-	-		0%	-	83,524	-	81,470	81,470
PSI Pneumonia PPT Provided	-	-	83,524	-	-		-%	-	83,524	-	81,470	81,470
PUR	-	-	-	-	1,099,046		(100)%	1,099,046	13,499,706	-	-	-
PuR	-	-	-	-	1,099,046	1/09	(100)%	1,099,046	13,499,706	-	-	-
Treatment for Severe Acute Malnutritic	-	-	16,202	-	-		0%	25,444	41,646	-	20,370	20,370
Treatment for Severe Acute Malnutri	-	-	16,202	-	-		-%	25,444	41,646	-	20,370	20,370
Zinc	15,133	17,613	164,027	307,202	36,692		347%	53,910	1,208,735	-	1,792	1,792

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Zinc Distributed Provided	-	-	(33,075)	-	-		-%	-	(33,075)	-	(361)	(361)
Zinc	15,133	17,613	197,102	307,202	36,692	1/08	437%	53,910	1,241,810	-	2,153	2,153
Zinc Provided	-	-	33,075	-	-		0%	-	33,075	-	401	401
PSI Zinc Provided	-	-	33,075	-	-		-%	-	33,075	-	401	401
<b>Tanzania</b>										255,666	538,372	794,038
Cervical Cancer-VIA and Cryotherapy	19	24	158	237	327		(52)%	445	1,318	-	60	60
Cervical Cancer-VIA and Cryothera	19	24	158	237	327	12/13	(52)%	445	1,318	-	60	60
Cervical Cancer-VIA/VILI Screening	473	606	4,254	-	8,570		(50)%	12,039	18,926	-	-	-
Cervical Cancer-VIA/VILI Screening	473	606	4,254	-	8,570		(50)%	12,039	18,926	-	-	-
Clean Delivery Kit	-	-	10,415	-	-		0%	19,430	32,892	-	769	769
Clean Delivery Pack-CDP	-	-	10,415	-	-	9/13	-%	19,430	32,892	-	769	769
Condom	1,540,944	1,706,435	27,940,847	76,774,149	64,343,863		(57)%	95,295,423	1,152,664,853	214,628	59,780	274,408
PSI Condom Distributed Provided	-	-	-	-	(3,830)		-%	(6,150)	(29,510)	-	-	-
Dume Condom	-	-	2,019,168	2,019,168	21,795,955	8/11	(91)%	22,103,107	86,748,019	15,510	4,320	19,830
Familia	-	-	-	4,985,280	-	10/07	-%	-	40,194,688	-	-	-
Salama	-	146,388	439,164	-	72	12/93	609,850%	72	448,733,924	3,373	940	4,313
Salama Halisi	753,840	1,004,400	18,766,944	50,286,682	31,419,360	2/11	(40)%	48,705,408	319,143,024	144,158	40,152	184,311
Salama Scented	457,056	327,407	4,312,787	13,053,563	6,412,634	8/06	(33)%	13,642,802	129,849,276	33,129	9,227	42,356
Salama Studded	330,048	228,240	2,402,784	6,429,456	4,719,672	6/04	(49)%	10,850,184	128,025,432	18,457	5,141	23,598
Condom Provided	-	-	-	-	8,810		(100)%	16,550	65,758	-	-	-
PSI Condom Provided	-	-	-	-	3,830		(100)%	6,150	29,510	-	-	-
Non-PSI Condom Provided	-	-	-	-	4,980		(100)%	10,400	36,248	-	-	-
Emergency Contraception	-	-	99,556	99,000	27,299		265%	39,769	289,165	-	803	803
PSI Emergency Contraception Distr	-	-	(6)	-	(12)		-%	(32)	(38)	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Emergency Contraception	-	-	99,562	99,000	27,311	7/12	265%	39,801	289,203	-	803	803
Emergency Contraception Provided	-	-	10	-	18		(44)%	110	122	-	-	-
PSI Emergency Contraception Prov	-	-	6	-	12		(50)%	32	38	-	-	-
Non-PSI Emergency Contraception I	-	-	4	-	6		(33)%	78	84	-	-	-
Female Condom	-	27,720	357,160	85,000	982,320		(64)%	1,044,240	10,480,066	2,744	588	3,331
Care	-	27,720	84,960	85,000	568,470	11/98	(85)%	602,670	6,045,516	653	140	792
Lady Pepeta	-	-	272,200	-	413,850	11/11	(34)%	441,570	4,434,550	2,091	448	2,539
Free Condom	-	240,493	4,985,280	-	27,536,866		(82)%	38,368,944	104,184,186	38,294	10,666	48,961
Free Familia	-	240,493	4,985,280	-	6,623,602	7/10	(25)%	17,455,680	83,270,922	38,294	10,666	48,961
Zana Male Condom	-	-	-	-	20,913,264	5/16	(100)%	20,913,264	20,913,264	-	-	-
Implant 3	(2,442)	(2,515)	(4,409)	35,076	1,231		(458)%	(18,057)	(3,291)	-	(6,210)	(6,210)
PSI Implant 3 Distributed Inserted (	(2,452)	(2,515)	(19,064)	-	(2,481)		-%	(28,041)	(54,298)	-	(26,850)	(26,850)
Implanon	10	-	14,655	35,076	3,712	1/09	295%	9,984	51,007	-	20,640	20,640
Implant 3 Insertion	4,805	4,451	36,095	-	9,339		286%	54,069	120,666	-	56,485	56,485
PSI Implant 3 Inserted	2,452	2,515	19,064	-	2,481		668%	28,041	54,298	-	29,833	29,833
Non-PSI Implant 3 Inserted	2,353	1,937	17,031	-	6,858		148%	26,028	66,368	-	26,652	26,652
Implant 4	-	-	-	-	-		0%	(369)	(369)	-	-	-
PSI Implant 4 Distributed Inserted (	-	-	-	-	-		-%	(369)	(369)	-	-	-
Implant 4 Insertion	-	-	-	-	-		0%	1,460	1,460	-	-	-
PSI Implant 4 Inserted	-	-	-	-	-		-%	369	369	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	-		-%	1,091	1,091	-	-	-
Implant 5	(2,130)	(2,450)	(2,997)	23,384	(2,382)		0%	(27,478)	(12,769)	-	(6,189)	(6,189)
PSI Implant 5 Distributed Inserted (	(2,140)	(2,463)	(17,937)	-	(6,302)		-%	(31,398)	(84,969)	-	(37,038)	(37,038)
Jadelle	10	13	14,940	23,384	3,920	11/09	281%	3,920	72,200	-	30,850	30,850
Implant 5 Insertion	3,210	3,053	23,968	-	10,992		118%	43,975	134,343	-	54,991	54,991

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Implant 5 Inserted	2,140	2,463	17,937	-	6,302		185%	31,398	84,969	-	41,154	41,154
Non-PSI Implant 5 Inserted	1,070	590	6,031	-	4,690		29%	12,577	49,374	-	13,837	13,837
<b>Injectable 3</b>	<b>47,923</b>	<b>220,353</b>	<b>806,737</b>	<b>647,408</b>	<b>46,477</b>		<b>1636%</b>	<b>70,933</b>	<b>1,629,468</b>	-	<b>81,323</b>	<b>81,323</b>
PSI Injectable 3 Distributed Provide (77)	(233)	(233)	(1,663)	(2,592)	(2,323)		-%	(4,367)	(7,403)	-	(168)	(168)
Familia Injectable 3 Kit	48,000	220,587	808,400	650,000	48,800	1/10	1,557%	75,300	1,636,871	-	81,491	81,491
<b>Injectable 3 Provided</b>	<b>2,395</b>	<b>2,382</b>	<b>18,267</b>	<b>2,592</b>	<b>15,173</b>		<b>20%</b>	<b>28,248</b>	<b>57,897</b>	-	<b>2,046</b>	<b>2,046</b>
PSI Injectable 3 Provided	77	233	1,663	2,592	2,323		(28)%	4,367	7,403	-	186	186
Non-PSI Injectable 3 Provided	2,318	2,148	16,604	-	12,850		29%	23,881	50,494	-	1,860	1,860
<b>IUD 10</b>	<b>(7,563)</b>	<b>(7,702)</b>	<b>(13,695)</b>	<b>(33,328)</b>	<b>22,884</b>		<b>(160)%</b>	<b>(51,103)</b>	<b>(50,667)</b>	-	<b>(34,799)</b>	<b>(34,799)</b>
PSI IUD 10 Distributed Inserted (1) (7,773)	(8,282)	(8,282)	(58,605)	(39,828)	(24,877)		-%	(107,414)	(302,227)	-	(148,913)	(148,913)
Familia IUD Kit	200	580	30,826	6,500	47,761	11/09	(35)%	56,311	237,476	-	78,328	78,328
Pregna IUD (no safe load)	10	-	14,084	-	-	3/17	-%	-	14,084	-	35,787	35,787
<b>IUD 10 Insertion</b>	<b>10,376</b>	<b>9,998</b>	<b>75,520</b>	<b>99,828</b>	<b>30,987</b>		<b>144%</b>	<b>124,475</b>	<b>427,721</b>	-	<b>213,216</b>	<b>213,216</b>
PSI IUD 10 Inserted	7,773	8,282	58,605	39,828	24,877		136%	107,414	302,227	-	165,459	165,459
Non-PSI IUD 10 Inserted	2,603	1,716	16,915	60,000	6,110		177%	17,061	125,494	-	47,756	47,756
<b>IUD 5</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(2)</b>		<b>0%</b>	<b>(7)</b>	<b>(7)</b>	-	<b>-</b>	<b>-</b>
PSI IUD 5 Distributed Inserted (1)	-	-	-	-	(2)		-%	(7)	(7)	-	-	-
<b>IUD 5 Insertion</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2</b>		<b>(100)%</b>	<b>8</b>	<b>8</b>	-	<b>-</b>	<b>-</b>
PSI IUD 5 Inserted	-	-	-	-	2		(100)%	7	7	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	-		-%	1	1	-	-	-
<b>LLIN</b>	<b>11,240</b>	<b>193,480</b>	<b>703,920</b>	<b>2,434,025</b>	<b>1,868,402</b>		<b>(62)%</b>	<b>2,075,002</b>	<b>2,778,922</b>	-	<b>33,237</b>	<b>33,237</b>
"New Brand" (School Net Program)	11,240	57,947	185,080	2,434,025	-		-%	-	185,080	-	8,739	8,739
Permanet (180x160x180 CM) SI	-	135,533	518,840	-	1,868,402	2/16	(72)%	2,075,002	2,593,842	-	24,498	24,498
<b>Lubricant</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>28,500</b>		<b>(100)%</b>	<b>28,500</b>	<b>400,000</b>	-	<b>-</b>	<b>-</b>
SHOSTI Lubricant 5mL Sachet	-	-	-	-	28,500	12/14	(100)%	28,500	400,000	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Malaria RDK	-	-	-	-	85		(100)%	85	215,085	-	-	-
Malaria Rapid Diagnostic Kit	-	-	-	-	85	2/14	(100)%	85	215,085	-	-	-
Manual Vacuum Aspiration for PAC	110	122	824	-	-		0%	-	824	-	98	98
MVA for PAC	110	122	824	-	-		-%	-	824	-	98	98
Misoprostol for PAC (Oral)	10,767	14,732	384,135	750,000	757,120		(49)%	1,265,264	4,411,823	-	13,752	13,752
PSI Misoprostol for PAC Oral Dist F	(33)	(28)	(141)	-	-		-%	-	(141)	-	(5)	(5)
Misoprostol for PAC (oral)	10,800	14,760	384,276	750,000	757,120	9/12	(49)%	1,265,264	4,411,964	-	13,757	13,757
Misoprostol for PAC (oral) Provided	33	28	141	-	-		0%	-	141	-	6	6
PSI Misoprostol for PAC (oral) Prov	33	28	141	-	-		-%	-	141	-	6	6
Misoprostol for PPH	1,160	-	1,160	-	-		0%	-	1,160	-	3	3
Misoprostol for PPH	1,160	-	1,160	-	-	9/17	-%	-	1,160	-	3	3
OCs	2,577	227,183	2,087,513	2,397,408	1,544,472		35%	2,184,870	22,057,737	-	56,978	56,978
PSI OCs Distributed Provided	(303)	(481)	(2,967)	(2,592)	(2,088)		-%	(5,226)	(10,955)	-	(81)	(81)
Familia [OC]	2,880	227,664	2,090,048	2,400,000	-	2/08	-%	309,168	9,220,148	-	57,048	57,048
Flexi P	-	-	432	-	1,546,560	11/11	(100)%	1,880,928	12,848,544	-	12	12
OCs Provided	1,659	1,658	13,626	2,592	7,020		94%	14,895	35,953	-	413	413
PSI OCs Provided	303	481	2,967	2,592	2,088		42%	5,226	10,955	-	90	90
Non-PSI OCs Provided	1,356	1,177	10,659	-	4,932		116%	9,669	24,998	-	323	323
Referral to Implant 3 Insertion	-	-	-	8,500	-		0%	-	157	-	-	-
Referral to Implant 3 Insertion	-	-	-	8,500	-	12/12	-%	-	157	-	-	-
Referral to IUD 10 Insertion	-	-	-	11,000	-		0%	-	231	-	-	-
Referral to IUD 10 Insertion	-	-	-	11,000	-	12/12	-%	-	231	-	-	-
Water Treatment Tablets	309,960	422,600	4,430,900	6,700,000	16,346,700		(73)%	18,015,300	43,866,200	-	356	356
Aquatub Tubs 8.68g	60	-	1,500	-	300,000	3/16	(100)%	444,000	445,500	-	14	14
WaterGuard Tablet ENF	309,900	422,600	4,429,400	6,700,000	16,046,700	7/12	(72)%	17,571,300	43,420,700	-	341	341

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Uganda</b>										<b>112,417</b>	<b>643,621</b>	<b>756,038</b>
Basic Care Package	-	-	400	-	42,574,842		(100)%	52,637,120	172,110,122	-	-	-
PLP Condom Resupply	-	-	-	-	19,872,826	10/11	(100)%	22,375,504	92,567,418	-	-	-
PLP Female Condom	-	-	-	-	133,580	2/12	(100)%	133,580	2,188,513	-	-	-
PLP Kit - FB (with WaterGuard Tab)	-	-	-	-	11,132	11/11	(100)%	11,132	60,803	-	-	-
PLP Kit - NFB (with Female Condor	-	-	-	-	4,371	5/12	(100)%	4,371	9,411	-	-	-
PLP Kit - NFB (with WaterGuard Tat	-	-	-	-	78,698	11/11	(100)%	78,698	588,754	-	-	-
PLP LLIN Resupply	-	-	-	-	18,235	10/11	(100)%	18,235	55,623	-	-	-
PLP Waterguard Tablet (67mg) Res	-	-	400	-	22,456,000	10/11	(100)%	30,015,600	76,639,600	-	-	-
Cervical Cancer-Pap Smear Screening	-	-	173	-	-		0%	-	173	-	-	-
Cervical Cancer-Pap Smear Screeni	-	-	173	-	-		-%	-	173	-	-	-
Cervical Cancer-VIA and Cryotherapy	65	80	351	1,924	391		(10)%	628	2,082	-	130	130
Cervical Cancer-VIA and Cryotherap	65	80	351	1,924	391	11/13	(10)%	628	2,082	-	130	130
Cervical Cancer-VIA/VILI Screening	6,436	4,265	25,013	-	33,327		(25)%	54,925	135,042	-	-	-
Cervical Cancer-VIA/VILI Screening	6,436	4,265	25,013	-	33,327		(25)%	54,925	135,042	-	-	-
Chlorhexidine	320	913	4,069	40,000	-		0%	6,682	10,751	-	254	254
Chlorhexidine Gel, 5 g tube	320	913	4,069	40,000	-	11/16	-%	6,682	10,751	-	254	254
Clean Delivery Kit	576	2,894	15,115	-	29,940		(50)%	34,562	427,581	-	1,016	1,016
Maama Kit	3	594	2,082	-	2,223	11/01	(6)%	2,356	254,801	-	140	140
Maama Kit Extra Clean Delivery	573	2,300	13,033	-	27,717	8/10	(53)%	32,206	172,780	-	876	876
Condom	14,256	60,840	416,088	2,592,000	831,732		(50)%	1,263,372	46,341,254	5,402	1,041	6,443
Trust	4,104	14,808	48,528	2,592,000	401,388	6/06	(88)%	417,228	44,860,718	630	121	751
Trust Ribbed	144	15,024	133,128	-	101,808	11/15	31%	227,736	455,976	1,728	333	2,061
Trust Scented	7,416	14,208	89,568	-	218,520	11/15	(59)%	359,280	534,384	1,163	224	1,387

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Trust Studded	2,592	16,800	144,864	-	110,016	11/15	32%	259,128	490,176	1,881	362	2,243
Diarrhea Treatment Kit	-	-	-	8,427	8,579		(100)%	8,579	12,509	-	-	-
A2L Diarrhea Pack	-	-	-	8,427	8,579	7/15	(100)%	8,579	12,509	-	-	-
Emergency Contraception	406	3,851	14,314	15,000	56		25461%	166	14,480	-	135	135
ECP	406	3,851	14,314	15,000	56	6/16	25,461%	166	14,480	-	135	135
Expanded Clean Delivery Kit	-	-	-	25,000	-		0%	-	-	-	-	-
Mama Kit Expanded(Chlorhexidine 4	-	-	-	25,000	-		-%	-	-	-	-	-
Expanded Clean Delivery Kit (+CHX)	-	-	-	14,000	-		0%	-	-	-	-	-
Expanded Clean Delivery Kit (+CHX	-	-	-	14,000	-		-%	-	-	-	-	-
Family Planning Counseling	-	-	-	-	1,263		(100)%	15,882	15,882	-	-	-
Family Planning Counseling	-	-	-	-	1,263		(100)%	15,882	15,882	-	-	-
Free Condom	23,040	1,500,413	8,113,750	9,388,000	630,460		1187%	1,315,910	64,858,703	105,340	20,301	125,642
Generic	23,040	1,500,413	8,113,750	9,388,000	630,460	1/99	1,187%	1,315,910	64,858,703	105,340	20,301	125,642
Free Female Condom	1,000	40,503	129,000	70,000	1,000		12800%	1,000	2,129,635	1,675	248	1,923
Female Condom Free	1,000	40,503	129,000	70,000	1,000	11/09	12,800%	1,000	2,129,635	1,675	248	1,923
Implant 3	(2,218)	7,685	26,969	-	9,004		200%	15,528	115,487	-	44,523	44,523
PSI Implant 3 Distributed Inserted (	(2,218)	(2,142)	(15,700)	(10,368)	(9,881)		-%	(23,353)	(73,511)	-	(25,919)	(25,919)
Implanon	-	9,827	42,669	10,368	18,885	12/08	126%	38,881	188,998	-	70,442	70,442
Implant 3 Insertion	14,435	12,161	78,767	20,888	30,206		161%	60,666	216,380	-	144,485	144,485
PSI Implant 3 Inserted	2,218	2,142	15,700	10,368	9,881		59%	23,353	73,511	-	28,799	28,799
Non-PSI Implant 3 Inserted	12,217	10,019	63,067	10,520	20,325		210%	37,313	142,869	-	115,686	115,686
Implant 5	(1,270)	6,175	23,453	-	13,498		74%	30,293	102,213	-	56,886	56,886
PSI Implant 5 Distributed Inserted (	(1,270)	(1,197)	(8,277)	(10,368)	(5,354)		-%	(9,209)	(75,276)	-	(20,076)	(20,076)
Jadelle	-	7,373	31,730	10,368	18,852	12/08	68%	39,502	177,489	-	76,963	76,963
Implant 5 Insertion	1,288	1,211	8,436	10,368	5,540		52%	9,486	104,006	-	22,735	22,735

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Implant 5 Inserted	1,270	1,197	8,277	10,368	5,354		55%	9,209	75,276	-	22,307	22,307
Non-PSI Implant 5 Inserted	18	14	159	-	186		(15)%	277	28,730	-	429	429
Injectable 3	400	333	20,670	-	45,406		(54)%	96,353	228,998	-	2,437	2,437
Depo-Provera	400	333	20,670	-	45,406	11/11	(54)%	96,353	228,998	-	2,437	2,437
IPTp2	-	-	343	-	10,564		(97)%	15,411	44,748	-	16	16
IPTp2	-	-	343	-	10,564	1/13	(97)%	15,411	44,748	-	16	16
IUD 10	(4,076)	8,695	31,571	8,917	17,248		83%	45,899	192,954	-	94,529	94,529
PSI IUD 10 Distributed Inserted (1)	(4,076)	(4,766)	(31,500)	(53,083)	(18,586)		-%	(36,427)	(201,249)	-	(94,316)	(94,316)
Copper T 380	-	9,468	41,254	62,000	18,718	12/08	120%	44,580	173,651	-	123,521	123,521
IUD PACK CU T380A	-	3,992	21,817	-	17,116	4/11	27%	37,746	220,552	-	65,324	65,324
IUD 10 Insertion	13,650	12,165	73,101	128,508	26,217		179%	51,192	360,260	-	243,196	243,196
PSI IUD 10 Inserted	4,076	4,766	31,500	53,083	18,586		69%	36,427	201,249	-	104,796	104,796
Non-PSI IUD 10 Inserted	9,574	7,399	41,601	75,425	7,631		445%	14,765	159,012	-	138,400	138,400
IUD 5	(31)	8	(154)	-	597		(126)%	484	(3,847)	-	(343)	(343)
PSI IUD 5 Distributed Inserted (1)	(31)	(72)	(394)	-	(413)		-%	(626)	(17,124)	-	(879)	(879)
Multiload CU T375	-	80	240	-	1,010	8/10	(76)%	1,110	13,277	-	535	535
IUD 5 Insertion	31	72	395	-	467		(15)%	683	28,130	-	979	979
PSI IUD 5 Inserted	31	72	394	-	413		(5)%	626	17,124	-	976	976
Non-PSI IUD 5 Inserted	-	-	1	-	54		(98)%	57	11,005	-	2	2
LLIN	-	-	-	578,943	518,591		(100)%	634,191	8,782,018	-	-	-
LLIN - Global Fund (SI)	-	-	-	578,943	518,591	12/10	(100)%	634,191	8,782,018	-	-	-
Malaria PPT (ACT)	-	546	3,300	14,272	19,959		(83)%	26,209	99,291	-	726	726
5 & A Malaria Pack-Child	-	-	-	-	4,995	4/11	(100)%	4,995	33,668	-	-	-
5 & A Malaria Pack-Infant	-	-	-	-	4,999	5/11	(100)%	4,999	33,863	-	-	-
ACT, Lumartem (12 Tabs)	-	546	3,300	14,272	9,521	7/15	(65)%	15,771	22,670	-	726	726

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
ACT, Lumartem (6 Tabs)	-	-	-	-	444	7/15	(100)%	444	9,090	-	-	-
Manual Vacuum Aspiration for PAC	72	44	502	220	854		(41)%	1,234	1,736	-	139	139
MVA for PAC	72	44	502	220	854	3/16	(41)%	1,234	1,736	-	139	139
Medical Abortion	(13)	14	28	25,000	-		0%	-	28	-	9	9
PSI Medical Abortion Distributed Pr	(67)	(62)	(252)	-	-		-%	-	(252)	-	(77)	(77)
Divabo - Combipack (1+4's)	54	75	280	-	-	5/17	-%	-	280	-	86	86
Miso - Mifeprestone pack	-	-	-	25,000	-		-%	-	-	-	-	-
Medical Abortion Provided	67	62	252	-	-		0%	-	252	-	86	86
PSI Medical Abortion Provided	67	62	252	-	-		-%	-	252	-	86	86
Misoprostol for PAC (Oral)	(306)	(274)	(2,322)	-	-		0%	(129)	(2,451)	-	(193)	(193)
PSI Misoprostol for PAC Oral Dist F	(306)	(274)	(2,322)	-	-		-%	(129)	(2,451)	-	(193)	(193)
Misoprostol for PAC (oral) Provided	306	274	2,376	-	-		0%	129	2,505	-	220	220
PSI Misoprostol for PAC (oral) Prov	306	274	2,322	-	-		-%	129	2,451	-	215	215
Non-PSI Misoprostol for PAC (oral) I	-	-	54	-	-		-%	-	54	-	5	5
Misoprostol for PAC (Sublingual)	-	-	-	2,480,000	-		0%	-	-	-	-	-
Misoprostol for PAC (Sublingual)	-	-	-	2,480,000	-		-%	-	-	-	-	-
Misoprostol for PPH	274,800	311,667	1,893,000	-	1,176,750		61%	1,616,650	6,074,431	-	6,522	6,522
Misoprostol Tablet	274,800	311,667	1,893,000	-	1,176,750	7/09	61%	1,616,650	6,074,431	-	6,522	6,522
OCs	-	10,642	53,379	-	7,872		578%	43,788	383,574	-	1,704	1,704
Family Planning Pills	-	9,225	45,945	-	2,448	11/11	1,777%	32,118	352,851	-	1,467	1,467
Microlut - Oral Contraceptive	-	1,417	7,434	-	5,424	6/14	37%	11,670	30,723	-	237	237
ORS	-	6,000	18,000	18,000	-		0%	-	93,181	-	330	330
ORS	-	6,000	18,000	18,000	-	12/10	-%	-	93,181	-	330	330
Pneumonia PPT	-	-	-	5,000	3,643		(100)%	3,643	27,011	-	-	-
5 & A Pneumonia Pack-Child	-	-	-	2,500	-	6/11	-%	-	11,299	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
5 & A Pneumonia Pack-Infant	-	-	-	<b>2,500</b>	-	6/11	-%	-	<b>7,332</b>	-	-	-
A2L Pneumonia Pack, Child	-	-	-	-	<b>2,142</b>	7/15	(100)%	<b>2,142</b>	<b>5,993</b>	-	-	-
A2L Pneumonia Pack, Infant	-	-	-	-	<b>1,501</b>	8/15	(100)%	<b>1,501</b>	<b>2,387</b>	-	-	-
<b>PUR</b>	<b>1</b>	<b>288,160</b>	<b>1,822,671</b>	<b>4,000,000</b>	<b>2,442,298</b>		<b>(25)%</b>	<b>3,675,898</b>	<b>36,788,507</b>	-	<b>95</b>	<b>95</b>
PuR	<b>1</b>	<b>288,160</b>	<b>1,822,671</b>	<b>4,000,000</b>	<b>2,442,298</b>	10/04	(25)%	<b>3,675,898</b>	<b>36,788,507</b>	-	<b>95</b>	<b>95</b>
Skilled Birth Attendance	-	-	-	-	<b>11,662</b>		<b>(100)%</b>	<b>16,291</b>	<b>50,567</b>	-	-	-
Skilled Birth Attendance	-	-	-	-	<b>11,662</b>	1/13	(100)%	<b>16,291</b>	<b>50,567</b>	-	-	-
Tubal Ligation	-	<b>1</b>	<b>23</b>	-	<b>14</b>		<b>64%</b>	<b>23</b>	<b>104</b>	-	<b>146</b>	<b>146</b>
Tubal Ligation	-	<b>1</b>	<b>23</b>	-	<b>14</b>		64%	<b>23</b>	<b>104</b>	-	<b>146</b>	<b>146</b>
Vasectomy	-	-	<b>3</b>	-	<b>1</b>		<b>200%</b>	<b>2</b>	<b>6</b>	-	<b>19</b>	<b>19</b>
Vasectomy	-	-	<b>3</b>	-	<b>1</b>		200%	<b>2</b>	<b>6</b>	-	<b>19</b>	<b>19</b>
Water Treatment Tablets	<b>208,320</b>	<b>2,663,093</b>	<b>11,975,600</b>	<b>12,278,719</b>	<b>25,060,960</b>		<b>(52)%</b>	<b>25,155,760</b>	<b>93,437,121</b>	-	<b>1,248</b>	<b>1,248</b>
WaterGuard Tablets	<b>208,320</b>	<b>2,663,093</b>	<b>11,975,600</b>	<b>12,278,719</b>	<b>25,060,960</b>	12/06	(52)%	<b>25,155,760</b>	<b>93,437,121</b>	-	<b>1,248</b>	<b>1,248</b>
Zinc	-	<b>110</b>	<b>330</b>	<b>5,790</b>	-		<b>0%</b>	-	<b>29,235</b>	-	<b>2</b>	<b>2</b>
Zinc 20 mg	-	<b>110</b>	<b>330</b>	<b>5,790</b>	-	12/10	-%	-	<b>29,235</b>	-	<b>2</b>	<b>2</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>East Africa</b>														
<b>Burundi</b>							\$5,720		\$1,201	\$5,862	0.20			
<b>Condom</b>														
Prudence Class	08/2017	251,910	0	0	251,910	0%	\$4,857	14%	\$1,115	\$5,149	0.22	0	266,580	NA
<b>Free Condom</b>														
Free Male Condoms	08/2017	0	72,000	0	72,000	100%	\$0	NA	\$0	\$0	NA	273,600	62,400	4.38
<b>Free Female Condom</b>														
Free Female Condoms	08/2017	0	4,000	0	4,000	100%	\$0	NA	\$0	\$0	NA	11,000	3,000	3.67
<b>LLIN</b>														
MILDA - DAWA PLUS 2.0	08/2017	0	102,150	0	102,150	100%	\$0	NA	\$0	\$0	NA	1,089,200	54,600	19.95
<b>Misoprostol for PAC (Oral)</b>														
Misoprostol for PAC (oral)	08/2017	0	8	0	8	100%	\$0	NA	\$0	\$0	NA	446	19	23.89
<b>Misoprostol for PAC (Sublingual)</b>														
Misoprostol for PAC (Sublingual)	08/2017	0	12	0	12	100%	\$0	NA	\$0	\$0	NA	344	15	23.45
<b>Implant 5</b>														
Jadelle	08/2017	151	0	0	151	0%	\$131	3%	\$4	\$102	0.04	1,334	161	8.29
<b>Injectable 3</b>														
DMPA 3-month Injectable	08/2017	1,976	0	0	1,976	0%	\$571	14%	\$79	\$491	0.16	3,579	1,803	1.99
<b>IUD 10</b>														
Copper-T 380-A IUD	08/2017	37	0	0	37	0%	\$32	0%	\$0	\$18	NA	4,887	48	101.81
<b>OCs</b>														
Contraception OC	08/2017	1,350	0	0	1,350	0%	\$130	2%	\$3	\$103	0.03	37,572	1,174	32.00
<b>Ethiopia</b>							\$54,171		\$1,446,244	\$258,571	5.59			
<b>HIV Test Kit</b>														
Diagnostic kit for HIV(1+2) Antibod	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,350	0	NA
First Response, HIV-1/2	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	7,410	0	NA
<b>Medicines &amp; Supplies</b>														
Isoniazid 300mg Tablet	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,016	0	NA
Lamivudine150mg+Nevirapine200	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,400	0	NA
Lamivudine300mg+Efravirenz600	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,080	0	NA
<b>Water Vessel</b>														
Water Vessel for PCP Kit	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	197	0	NA
<b>Free Condom</b>														
Blue Denim	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	426	0	NA
Protector Plus	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	14,456,802	1,707,033	8.47

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Ethiopia</b>							\$54,171		\$1,446,244	\$258,571	5.59				
<b>Free Female Condom</b>															
Free Female Condoms	08/2017	0	285,080	0	285,080	100%	\$0	NA	\$0	\$0	NA	677,130	98,360	6.88	
<b>STI Kit (Non-Ulcerative)</b>															
STI Kit for Urethral Discharge	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4,809	383	12.55	
STI Kit for Vaginal Discharge	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4,273	353	12.09	
<b>STI Kit (Ulcerative)</b>															
STI Kit for Genital Ulcer	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	435	167	2.61	
<b>LLIN</b>															
PermaNet NGO Bag-Light Blue	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15	0	NA	
<b>PUR</b>															
P&G Purifier of Water	08/2017	92,160	0	0	92,160	0%	\$4,992	52%	\$1,130,386	\$220,845	5.12	4,657,264	3,973,580	1.17	
<b>Safe Water Solution</b>															
Wuha Agar	08/2017	195,500	0	0	195,500	0%	\$49,178	67%	\$315,858	\$37,726	8.37	102,815	152,037	0.68	
<b>OCs</b>															
Microgynon	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	6	0	NA	
<b>Kenya</b>							\$494,829		\$494,829	\$384,299	1.29				
<b>Condom</b>															
Trust	08/2017	2,488,320	0	0	2,488,320	0%	\$115,423	100%	\$115,423	\$44,596	2.59	22,375,440	1,006,104	22.24	
Trust Ribbed	08/2017	42,336	0	0	42,336	0%	\$3,912	100%	\$3,912	\$5,180	0.76	791,646	55,423	14.28	
Trust Scented	08/2017	54,432	0	0	54,432	0%	\$5,029	100%	\$5,029	\$4,104	1.23	1,126,019	44,256	25.44	
Trust Studded	08/2017	241,056	0	0	241,056	0%	\$22,273	100%	\$22,273	\$34,948	0.64	7,830,460	376,867	20.78	
<b>Free Condom</b>															
Free Male Condom - NASCOP	08/2017	1,713,600	0	0	1,713,600	0%	\$0	NA	\$0	\$0	NA	-72,000	571,200	-0.13	
<b>LLIN</b>															
Supanet Conical	08/2017	2,000	0	0	2,000	0%	\$1,033	100%	\$1,033	\$2,622	0.39	94,331	1,059	89.08	
Supanet Rectangular	08/2017	200	0	0	200	0%	\$1,033	100%	\$1,033	\$2,074	0.50	42,161	370	113.85	
Supanet XtraPower BL PNET USA	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,477,606	54,155	27.28	
<b>Olyset</b>															
Supanet Xtra Power (Olyset)-Coni	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	173,118	0	NA	
<b>PUR</b>															
PuR	08/2017	4,971,120	0	0	4,971,120	0%	\$220,561	100%	\$220,561	\$165,127	1.34	8,129,129	3,605,120	2.25	
<b>Safe Water Solution</b>															
WaterGuard	08/2017	110,640	0	0	110,640	0%	\$15,041	100%	\$15,041	\$11,829	1.27	1,480,644	137,193	10.79	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Kenya</b>							\$494,829		\$494,829	\$384,299	1.29				
<b>Water Treatment Tablets</b>															
Aquatab	08/2017	2,160	0	0	2,160	0%	\$42	100%	\$42	\$511	0.08	63,520	25,980	2.44	
<b>Implant 3</b>															
Implanon	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	231,177	0	NA	
<b>Implant 5</b>															
Jadelle	08/2017	100	0	0	100	0%	\$19	100%	\$19	\$277	0.07	4,600	724	6.35	
<b>Injectable 3</b>															
Femiplan Injectable	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$7,320	NA	1,296	20,256	0.06	
<b>IUD 10</b>															
CU 380A (Copper T)	08/2017	380	0	0	380	0%	\$92	100%	\$92	\$71	1.31	20,470	692	29.60	
<b>OCs</b>															
Femi Girl Oral Pills	08/2017	0	24	0	24	100%	\$0	NA	\$0	\$276	NA	164,592	248	663.68	
Femiplan Pill	08/2017	0	12	0	12	100%	\$0	NA	\$0	\$247	NA	153,060	292	524.18	
Femiplan Pill-1 cycle	08/2017	222,480	0	0	222,480	0%	\$69,847	100%	\$69,847	\$71,677	0.97	1,569,429	237,850	6.60	
Femiplan Pill-3 cycles	08/2017	138,240	0	0	138,240	0%	\$40,522	100%	\$40,522	\$33,440	1.21	-93,682	120,240	-0.78	
<b>Malawi</b>							\$39,412		\$55,392	\$101,577	0.55				
<b>Condom</b>															
Chishango	08/2017	1,237,920	148,000	191,760	1,577,680	11%	\$15,384	18%	\$16,929	\$22,572	0.75	2,551,560	2,162,427	1.18	
Chishango Blue Gold	08/2017	0	331,210	0	331,210	100%	\$0	NA	\$0	NA	NA	1,525,940	NA	NA	
<b>Female Condom</b>															
Care	08/2017	4,240	26	0	4,266	1%	\$117	0%	\$0	\$71	NA	26,960	2,582	10.44	
Whisper Female Condom	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15,597	0	NA	
<b>Free Condom</b>															
Free Male Condoms	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	13,243	0	NA	
Key Population Male Condom	08/2017	0	916,153	0	916,153	100%	\$0	NA	\$0	\$0	NA	1,863,558	866,627	2.15	
One Community Male Condom	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	415,477	339,226	1.22	
<b>Free Female Condom</b>															
Free Female Condoms	08/2017	0	16,950	0	16,950	100%	\$0	NA	\$0	\$0	NA	129,684	16,232	7.99	
<b>Lubricant A</b>															
Personal Lubricant Water 4.5 g	08/2017	0	86,849	0	86,849	100%	\$0	NA	\$0	\$0	NA	600,769	100,024	6.01	
<b>LLIN</b>															
Super Chitetezo Net	08/2017	2,169	0	0	2,169	0%	\$13,460	48%	\$30,640	\$15,677	1.95	117,881	2,528	46.62	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Malawi</b>							\$39,412		\$55,392	\$101,577	0.55				
<b>PUR</b>															
PuR WaterGuard Waufa	08/2017	8,095	0	0	8,095	0%	\$493	0%	\$0	\$51,976	NA	3,444,493	923,658	3.73	
<b>Safe Water Solution</b>															
WaterGuard	08/2017	4,551	16	0	4,567	0%	\$2,041	83%	\$3,378	\$7,581	0.45	2,772	16,936	0.16	
<b>Emergency Contraception</b>															
NORLEVO (Norlevo 1.5mg)	08/2017	297	250	0	547	46%	\$177	23%	\$1,115	\$128	8.68	38,160	914	41.77	
<b>Implant 3</b>															
Implanon	08/2017	210	1,959	0	2,169	90%	\$173	0%	\$0	\$97	NA	1,164	3,143	0.37	
<b>Implant 5</b>															
Jadelle	08/2017	240	3,724	0	3,964	94%	\$166	0%	\$0	\$110	NA	26,866	4,077	6.59	
<b>Injectable 3</b>															
SafePlan Inj3	08/2017	7,420	4,328	0	11,748	37%	\$3,304	38%	\$1,261	\$1,463	0.86	194,083	13,850	14.01	
<b>IUD 10</b>															
IUD Copper T 380A	08/2017	20	2,037	0	2,057	99%	\$7	0%	\$0	\$26	NA	30,861	931	33.16	
<b>OCs</b>															
Microgynon	08/2017	11,390	8,540	0	19,930	43%	\$4,091	51%	\$2,070	\$1,875	1.10	250,727	14,452	17.35	
Microlut	08/2017	0	93	0	93	100%	\$0	NA	\$0	NA	NA	51,177	NA	NA	
<b>SFH Rwanda</b>							\$20,817		\$0	\$51,974	NA				
<b>Condom</b>															
Plaisir	08/2017	52,800	0	0	52,800	0%	\$2,835	0%	\$0	\$2,601	NA	41,106	48,907	0.84	
Prudence Plus	08/2017	930,528	15,000	0	945,528	2%	\$14,991	0%	\$0	\$46,031	NA	8,575,730	910,355	9.42	
<b>Free Condom</b>															
Military Condom	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	36,008	0	NA	
<b>PUR</b>															
PuR	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$5	NA	1,725,633	2,880	599.18	
<b>Safe Water Solution</b>															
Sur Eau	08/2017	8,112	0	0	8,112	0%	\$2,614	0%	\$0	\$2,642	NA	208,634	10,352	20.15	
<b>Injectable 3</b>															
Confiance Depo-Provera	08/2017	1,920	0	0	1,920	0%	\$33	0%	\$0	\$182	NA	76,998	1,600	48.12	
<b>OCs</b>															
Microgynon	08/2017	5,760	0	0	5,760	0%	\$344	0%	\$0	\$514	NA	163,608	8,640	18.94	
<b>SDM (Cycle Beads)</b>															
Collier	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	10	0	NA	



Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Somaliland</b>							\$3,563		\$0	\$5,849	NA				
<b>Diarrhea Treatment Kit</b>															
SD OFLV-DTK	08/2017	14,800	0	0	14,800	0%	\$1,388	0%	\$0	\$1,665	NA	2,038	17,477	0.12	
<b>Misoprostol for PPH</b>															
Ummul-gargaar	08/2017	1,500	0	0	1,500	0%	\$73	0%	\$0	\$101	NA	20,600	2,000	10.30	
<b>ORS</b>															
SD OFLV-ORS	08/2017	0	0	18,000	18,000	NA	\$0	NA	\$0	\$0	NA	241,500	0	NA	
<b>Water Treatment Tablets</b>															
Aquatab	08/2017	0	288,000	-288,000	0	100%	\$0	NA	\$0	\$1,167	NA	7,602	212,667	0.04	
Biyosifeeye	08/2017	312,000	0	0	312,000	0%	\$1,760	0%	\$0	\$2,455	NA	2,640,278	423,800	6.23	
<b>Zinc</b>															
Shuban Daweeye_Zinc	08/2017	0	0	9,000	9,000	NA	\$0	NA	\$0	\$0	NA	134,839	0	NA	
<b>Implant 3</b>															
Nasiye Implant (Implanon)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$26	NA	1,556	3	466.80	
<b>Injectable 3</b>															
Nasiye - Inj 3	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$66	NA	5,038	117	43.18	
<b>OCs</b>															
Nasiye - OC	08/2017	1,125	0	0	1,125	0%	\$343	0%	\$0	\$369	NA	4,696	1,195	3.93	
OC	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	16	0	NA	
<b>Pneumonia PPT</b>															
Pneomox 125mg tablet (Amoxicilli)	08/2017	0	1,386	-1,386	0	100%	\$0	NA	\$0	\$0	NA	1,159	462	2.51	
Pneomox 250mg tablet (Amoxicilli)	08/2017	0	5,258	-5,258	0	100%	\$0	NA	\$0	\$0	NA	4,637	1,753	2.65	
<b>South Sudan</b>							\$0		\$0	\$0	NA				
<b>Medicines &amp; Supplies</b>															
Artesunate 60 mg vial	08/2017	0	167,300	0	167,300	100%	\$0	NA	\$0	\$0	NA	229,590	78,510	2.92	
Falcistat Tablet (SP 500/25 mg)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,000	0	NA	
<b>LLIN</b>															
Mass LLIN - WES-Green Rectang	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,120,599	0	NA	
<b>Malaria PPT (ACT)</b>															
ACTs for Adult (14+ years)	08/2017	0	104,400	0	104,400	100%	\$0	NA	\$0	\$0	NA	312,400	60,267	5.18	
ACTs for Child (6-14 years)	08/2017	0	63,000	0	63,000	100%	\$0	NA	\$0	\$0	NA	234,800	36,208	6.48	
ACTs for Infant (2-12 months)	08/2017	0	233,930	0	233,930	100%	\$0	NA	\$0	\$0	NA	49,062	80,991	0.61	
ACTs for Toddler (1-5 years)	08/2017	0	318,736	0	318,736	100%	\$0	NA	\$0	\$0	NA	189,195	169,993	1.11	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>South Sudan</b>							\$0		\$0	\$0	NA				
<b><u>Malaria RDK</u></b>															
Malaria Rapid Diagnostic Kit	08/2017	0	821,225	0	821,225	100%	\$0	NA	\$0	\$0	NA	646,548	352,250	1.84	
<b><u>ORS</u></b>															
ORS	08/2017	0	23,656	714	24,370	100%	\$0	NA	\$0	\$0	NA	810,382	40,488	20.02	
<b><u>Zinc</u></b>															
Zinc	08/2017	0	15,133	10	15,143	100%	\$0	NA	\$0	\$0	NA	185,327	21,978	8.43	
<b><u>Pneumonia PPT</u></b>															
Amoxicillin for Children (1-5 years)	08/2017	0	5,016	10	5,026	100%	\$0	NA	\$0	\$0	NA	129,211	26,376	4.90	
Amoxicillin for Infant (2-12 months)	08/2017	0	0	10	10	NA	\$0	NA	\$0	\$0	NA	59,691	408	146.30	



# Southern Africa

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 8/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Southern Africa	92,599	16	-	2	1,647,805	706	327,976	9,814	396	1,375	-	12,491
Angola	176	-	-	-	35,705	25	8,999	7,405	33	-	-	8,304
Botswana	325	-	-	-	7,707	1	1,104	-	-	-	-	-
Lesotho	4,825	-	-	2	43,287	22	6,423	-	-	-	-	2
Madagascar	1,060	4	-	-	628,211	340	149,232	2,133	202	1,375	-	3,736
Mozambique	4,676	-	-	-	157,158	102	33,868	276	129	-	-	405
Namibia	80	-	-	-	1,958	1	281	-	-	-	-	-
South Africa	39,474	-	-	-	500,311	73	71,599	-	-	-	-	-
Swaziland	12,327	6	-	-	92,153	38	13,223	-	-	-	-	6
Zambia	15,590	-	-	-	59,355	27	19,092	-	18	-	-	18
Zimbabwe	14,064	5	-	-	121,960	78	24,156	-	13	-	-	19

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 8  
 Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Southern Africa - All</b>									<b>4,207,849</b>	<b>1,414,413</b>	<b>5,622,262</b>
Antiretroviral Treatment (C	9,481	8,816	66,150	76,596	-	-%	5,010	71,160	11,753	-	11,753
Antiretroviral Treatment (I	1,015	935	7,336	-	-	-%	5,283	12,619	-	-	-
CD4 Tests Provided to HIV	1,475	1,375	11,100	-	-	-%	778	11,878	-	-	-
Cervical Cancer-HPV DNA	-	4	11	-	-	-%	-	11	-	3	3
Cervical Cancer-HPV DNA	-	3	9	-	-	-%	-	9	-	2	2
Cervical Cancer-Pap and I	-	-	1	-	1	-%	1	2	-	-	-
Cervical Cancer-Pap and I	-	-	-	-	7	(100)%	7	9	-	-	-
Cervical Cancer-Pap Sme:	-	-	2	-	116	(98)%	116	118	-	-	-
Cervical Cancer-VIA and C	14	14	145	185	-	-%	10	155	-	41	41
Cervical Cancer-VIA and C	36	42	420	278	623	(33)%	1,194	3,491	-	118	118
Cervical Cancer-VIA and F	6	5	26	-	15	73%	17	274	-	4	4
Cervical Cancer-VIA and F	-	3	69	200	361	(81)%	402	1,936	-	10	10
Cervical Cancer-VIA and F	-	-	16	-	33	(52)%	33	449	-	2	2
Cervical Cancer-VIA/VILI §	1,321	1,334	11,849	-	19,564	(39)%	26,740	63,330	-	-	-
Chlorhexidine	4,540	3,390	20,811	53,741	30,370	(31)%	241,094	321,830	-	1,271	1,271
Condom	6,852,210	8,429,697	52,780,973	99,975,773	69,306,282	(24)%	100,683,376	1,351,828,400	999,688	81,064	1,080,752
Condom Provided	-	-	-	-	564,112	(100)%	842,352	1,075,691	-	-	-
Diarrhea Treatment Kit	568	40,968	211,810	318,195	390,524	(46)%	479,996	2,055,810	-	5,348	5,348
Diarrhea Treatment Kit Pri	382	502	4,085	-	-	-%	4,866	8,951	-	115	115
Early Infant Male Circumc	-	-	-	-	2	(100)%	5	5	-	-	-
Emergency Contraception	(67)	3,002	57,471	181,900	133,895	(57)%	208,155	808,206	-	295	295

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 8  
 Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Emergency Contraception	77	101	752	170	1,215	(38)%	1,660	2,803	-	6	6
Family Planning Counseli	-	-	-	-	-	-%	223	223	-	-	-
Female Condom	64,100	67,206	470,854	1,020,724	4,667,446	(90)%	2,709,105	33,670,165	11,386	539	11,925
Female Condom Provided	-	-	-	-	69,647	(100)%	80,452	99,712	-	-	-
Fever Cases Attended	3,136	3,680	297,176	-	-	-%	24,338	321,514	-	-	-
Fever Cases Tested with I	90	764	3,946	-	-	-%	1,885	5,831	-	-	-
Fever Cases Tested with F	2,794	3,361	277,478	-	-	-%	20,935	298,413	-	-	-
Free Condom	19,555,232	3,463,425	54,457,691	78,425,768	72,906,193	(25)%	93,108,576	1,287,342,265	1,222,581	69,640	1,292,221
Free Female Condom	106,200	39,233	288,370	1,000,289	561,458	(49)%	626,979	6,454,992	5,798	207	6,005
HIV Testing Services	137,336	131,708	941,117	1,299,724	649,030	45%	950,683	8,022,445	61,228	-	61,228
Hypertension Diagnosis	699	20	850	-	-	-%	4	854	-	-	-
Hypertension Screening	20,412	16,279	294,273	-	-	-%	12,961	307,234	-	-	-
Hypertension_Controlled	12	6	48	-	-	-%	3	51	-	-	-
Implant 3	80	20	(671)	6,814	(1,574)	-%	(1,712)	832	-	(651)	(651)
Implant 3 Insertion	975	918	7,285	1,151	7,334	(1)%	11,806	42,888	-	7,998	7,998
Implant 4	142	240	1,659	51	2,563	(35)%	3,788	20,701	-	3,890	3,890
Implant 4 Insertion	-	1	20	169	172	(88)%	329	2,649	-	28	28
Implant 5	(167)	(491)	(5,740)	527	(4,590)	-%	(4,046)	(41,815)	-	(13,207)	(13,207)
Implant 5 Insertion	12,117	2,688	27,679	62,375	21,870	27%	32,406	302,457	-	70,929	70,929
Injectable 1 Provided	276	123	770	100	-	-%	135	905	-	28	28
Injectable 2 Provided	4,859	52	5,111	538	381	1,241%	686	5,797	-	434	434
Injectable 3	84,760	147,663	1,106,452	1,138,166	1,472,965	(25)%	2,240,708	19,259,303	-	77,438	77,438

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Injectable 3 Provided</b>	<b>60,467</b>	<b>25,371</b>	<b>215,945</b>	<b>193,875</b>	<b>86,301</b>	<b>150%</b>	<b>210,309</b>	<b>561,178</b>	-	<b>25,024</b>	<b>25,024</b>
<b>IPTp2</b>	<b>11</b>	<b>2</b>	<b>16,528</b>	<b>172,356</b>	<b>-</b>	<b>-%</b>	<b>158,455</b>	<b>174,983</b>	-	<b>979</b>	<b>979</b>
<b>IRS (# of household)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>721,863</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>-</b>	-	<b>-</b>	<b>-</b>
<b>IUD 10</b>	<b>(2,461)</b>	<b>1,699</b>	<b>1,964</b>	<b>14,334</b>	<b>(963)</b>	<b>-%</b>	<b>3,654</b>	<b>23,350</b>	-	<b>6,784</b>	<b>6,784</b>
<b>IUD 10 Insertion</b>	<b>5,024</b>	<b>1,979</b>	<b>18,422</b>	<b>48,331</b>	<b>14,563</b>	<b>26%</b>	<b>25,159</b>	<b>278,867</b>	-	<b>46,484</b>	<b>46,484</b>
<b>IUD 5 Insertion</b>	<b>-</b>	<b>3</b>	<b>8</b>	<b>150</b>	<b>216</b>	<b>(96)%</b>	<b>241</b>	<b>249</b>	-	<b>20</b>	<b>20</b>
<b>IUS 5</b>	<b>89</b>	<b>141</b>	<b>475</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>475</b>	-	<b>880</b>	<b>880</b>
<b>IUS 5 Insertion</b>	<b>11</b>	<b>21</b>	<b>112</b>	<b>500</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>112</b>	-	<b>163</b>	<b>163</b>
<b>LLIN</b>	<b>841,630</b>	<b>1,036,201</b>	<b>4,734,061</b>	<b>4,334,567</b>	<b>1,677,282</b>	<b>182%</b>	<b>2,787,629</b>	<b>35,027,426</b>	-	<b>640,023</b>	<b>640,023</b>
<b>Lubricant</b>	<b>230,280</b>	<b>80,005</b>	<b>830,929</b>	<b>-</b>	<b>428,673</b>	<b>94%</b>	<b>621,962</b>	<b>4,339,119</b>	-	<b>-</b>	<b>-</b>
<b>Malaria PPT (ACT)</b>	<b>8,405</b>	<b>58,008</b>	<b>418,981</b>	<b>1,237,169</b>	<b>825,675</b>	<b>(49)%</b>	<b>991,622</b>	<b>6,134,502</b>	-	<b>133,212</b>	<b>133,212</b>
<b>Malaria RDK</b>	<b>25,375</b>	<b>34,825</b>	<b>2,053,301</b>	<b>1,873,659</b>	<b>1,079,210</b>	<b>90%</b>	<b>1,133,756</b>	<b>10,108,426</b>	-	<b>-</b>	<b>-</b>
<b>Male Circumcision (HIV-Pi</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,461</b>	<b>(100)%</b>	<b>3,239</b>	<b>10,222</b>	-	<b>-</b>	<b>-</b>
<b>Manual Vacuum Aspiratio</b>	<b>70</b>	<b>146</b>	<b>1,273</b>	<b>55</b>	<b>-</b>	<b>-%</b>	<b>1,457</b>	<b>2,730</b>	-	<b>381</b>	<b>381</b>
<b>Micronutrient Powder</b>	<b>793,920</b>	<b>607,240</b>	<b>5,160,430</b>	<b>4,858,780</b>	<b>2,009,480</b>	<b>157%</b>	<b>4,044,450</b>	<b>14,265,400</b>	-	<b>-</b>	<b>-</b>
<b>Misoprostol for PAC (Oral</b>	<b>(537)</b>	<b>(755)</b>	<b>(4,002)</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>(6,537)</b>	<b>(10,539)</b>	-	<b>(359)</b>	<b>(359)</b>
<b>Misoprostol for PAC (oral)</b>	<b>537</b>	<b>755</b>	<b>4,002</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>6,537</b>	<b>10,539</b>	-	<b>399</b>	<b>399</b>
<b>Misoprostol for PAC (Subl</b>	<b>7,068</b>	<b>75,183</b>	<b>232,616</b>	<b>15,000</b>	<b>-</b>	<b>-%</b>	<b>6,000</b>	<b>238,616</b>	-	<b>46,896</b>	<b>46,896</b>
<b>OCs</b>	<b>339,442</b>	<b>323,125</b>	<b>2,382,256</b>	<b>2,721,504</b>	<b>1,574,862</b>	<b>51%</b>	<b>2,583,428</b>	<b>41,364,275</b>	-	<b>45,884</b>	<b>45,884</b>
<b>OCs Provided</b>	<b>46,441</b>	<b>35,055</b>	<b>287,447</b>	<b>379,864</b>	<b>370,633</b>	<b>(22)%</b>	<b>573,214</b>	<b>1,340,052</b>	-	<b>8,467</b>	<b>8,467</b>
<b>Pneumonia PPT</b>	<b>27,800</b>	<b>48,785</b>	<b>320,180</b>	<b>419,927</b>	<b>233,947</b>	<b>37%</b>	<b>376,369</b>	<b>1,152,078</b>	-	<b>117,500</b>	<b>117,500</b>
<b>Positive RDTs</b>	<b>287</b>	<b>489</b>	<b>100,317</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>2,177</b>	<b>102,494</b>	-	<b>-</b>	<b>-</b>

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 8  
 Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>PrEP</b>	<b>198</b>	<b>273</b>	<b>1,870</b>	<b>19,960</b>	<b>-</b>	<b>-%</b>	<b>403</b>	<b>2,273</b>	<b>61</b>	<b>-</b>	<b>61</b>
Referral to Advanced Cer	3	7	42	85	113	(63)%	142	385	-	-	-
Referral to CD4/Clinical St	-	-	-	9,198	6,606	(100)%	8,610	18,607	-	-	-
Referral to Clinical Stagin	-	-	-	-	2,818	(100)%	2,879	5,010	-	-	-
Referral to Diabetes Mana	1	-	1	-	-	-%	-	1	-	-	-
Referral to Early Infant Ma	-	-	-	-	28	(100)%	36	94	-	-	-
Referral to Emergency Co	-	-	-	-	6	(100)%	6	8	-	-	-
Referral to HIV Testing Se	1,688	1,368	9,664	7,200	5,053	91%	7,911	26,561	510	-	510
Referral to Hypertension I	34	137	456	50	-	-%	27	483	-	-	-
Referral to Implant 3 Inser	-	1	3	-	-	-%	1	4	-	2	2
Referral to Implant 5 Inser	-	2	5	20	-	-%	-	979	-	4	4
Referral to Injectable 1	43	30	143	100	16	794%	32	175	-	3	3
Referral to Injectable 2	-	-	-	200	-	-%	-	-	-	-	-
Referral to Injectable 3	91	49	297	370	-	-%	45	342	-	16	16
Referral to IUD 10 Insertio	-	2	33	-	6	450%	7	197	-	30	30
Referral to IUD 5 Insertion	-	-	-	30	-	-%	-	-	-	-	-
Referral to IUD Insertion (i	-	2	5	-	2	150%	2	7	-	3	3
Referral to IUS 3 Insertion	-	9	26	-	-	-%	-	26	-	13	13
Referral to Linkage to HIV	1,251	1,501	12,096	15,609	-	-%	2,624	14,720	7,201	-	7,201
Referral to OCs	125	40	322	330	1	32,100%	79	1,248	-	5	5
Referral to Pre-Exposure I	10	8	122	-	-	-%	-	122	2	-	2
Referral to STI Screening	6	10	70	338	-	-%	8	78	-	-	-



POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 8  
 Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to STI Treatment	3	7	46	-	930	(95)%	952	4,526	-	-	-
Referral to TB Diagnosis	31	22	170	6,750	-	-%	11	3,801	-	-	-
Referral to TB DOTS (com	-	-	1	-	-	-%	2	17	-	1	1
Referral to TB DOTS (com	31	30	179	300	311	(42)%	484	2,632	-	99	99
Referral to TB Screening	335	168	9,052	-	-	-%	434	9,486	-	-	-
Referral to Treatment for (	7	9	34	-	4	750%	4	57	-	2	2
Referral to Treatment for (	3	-	3	5	-	-%	3	6	-	-	-
Referral to Treatment for l	-	1	4	-	8	(50)%	8	27	-	-	-
Referral to Treatment for l	-	-	1	-	26	(96)%	32	57	-	-	-
Referral to Treatment for \	-	-	-	5	3	(100)%	7	12	-	-	-
Referral to Tubal Ligation	-	-	1	-	-	-%	-	1	-	2	2
Referral to Tx for Nonherp	7	6	25	-	10	150%	13	47	-	4	4
Referral to Tx for Urethral	3	12	98	-	132	(26)%	156	497	-	9	9
Referral to Vasectomy	-	-	-	3	-	-%	-	-	-	-	-
Referral to Voluntary Medi	19	34	355	2,249	3,522	(90)%	3,849	20,399	1,627	-	1,627
Safe Water Solution	114,360	380,123	2,722,579	5,699,598	3,082,824	(12)%	4,291,617	68,621,609	-	16,336	16,336
SDM (Cycle Beads)	1,050	5,882	19,879	17,307	9,989	99%	11,341	137,886	-	13,462	13,462
SDM (Cycle Beads) Provic	105	199	1,568	-	10	15,580%	2,176	4,433	-	1,180	1,180
STI Kit (Non-Ulcerative)	91	77	560	241	428	31%	797	4,372	-	100	100
STI Kit (Ulcerative)	21	14	104	184	51	104%	127	576	-	40	40
STI Screening	6,018	8,540	55,920	-	32,626	71%	47,096	117,272	-	-	-
TB Diagnosis	75	43	326	-	205	59%	336	1,061	-	-	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>TB DOTS</b>	<b>5</b>	<b>3</b>	<b>17</b>	<b>-</b>	<b>11</b>	<b>55%</b>	<b>11</b>	<b>59</b>	<b>-</b>	<b>98</b>	<b>98</b>
<b>TB Screening</b>	<b>25,729</b>	<b>24,584</b>	<b>211,849</b>	<b>-</b>	<b>198,943</b>	<b>6%</b>	<b>284,453</b>	<b>744,653</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Treatment for Cervicitis</b>	<b>14</b>	<b>24</b>	<b>256</b>	<b>120</b>	<b>-</b>	<b>-%</b>	<b>20</b>	<b>276</b>	<b>-</b>	<b>24</b>	<b>24</b>
<b>Treatment for Genital Herp</b>	<b>5</b>	<b>1</b>	<b>41</b>	<b>12</b>	<b>-</b>	<b>-%</b>	<b>5</b>	<b>46</b>	<b>-</b>	<b>2</b>	<b>2</b>
<b>Treatment for Inguinal Bul</b>	<b>8</b>	<b>6</b>	<b>70</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>8</b>	<b>78</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Treatment for Lower Abdc</b>	<b>110</b>	<b>111</b>	<b>936</b>	<b>30</b>	<b>-</b>	<b>-%</b>	<b>102</b>	<b>1,038</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Treatment for Nonherpetic</b>	<b>184</b>	<b>197</b>	<b>1,579</b>	<b>150</b>	<b>-</b>	<b>-%</b>	<b>162</b>	<b>1,741</b>	<b>-</b>	<b>271</b>	<b>271</b>
<b>Treatment for Urethral Dis</b>	<b>579</b>	<b>609</b>	<b>5,377</b>	<b>72</b>	<b>-</b>	<b>-%</b>	<b>581</b>	<b>5,958</b>	<b>-</b>	<b>73</b>	<b>73</b>
<b>Treatment for Urethral Dis</b>	<b>53</b>	<b>72</b>	<b>738</b>	<b>340</b>	<b>-</b>	<b>-%</b>	<b>84</b>	<b>822</b>	<b>-</b>	<b>136</b>	<b>136</b>
<b>Treatment for Vaginitis</b>	<b>550</b>	<b>602</b>	<b>5,277</b>	<b>5</b>	<b>-</b>	<b>-%</b>	<b>604</b>	<b>5,881</b>	<b>-</b>	<b>156</b>	<b>156</b>
<b>Tubal Ligation</b>	<b>121</b>	<b>2</b>	<b>160</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>160</b>	<b>-</b>	<b>899</b>	<b>899</b>
<b>Type 2 Diabetes Diagnosi:</b>	<b>43</b>	<b>1</b>	<b>47</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>47</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Type 2 Diabetes Screenin:</b>	<b>937</b>	<b>770</b>	<b>4,518</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>4,518</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Type 2 Diabetes_Controlle</b>	<b>1</b>	<b>1</b>	<b>6</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>6</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Vasectomy</b>	<b>28</b>	<b>-</b>	<b>28</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>28</b>	<b>-</b>	<b>182</b>	<b>182</b>
<b>Voluntary Medical Male Ci</b>	<b>36,501</b>	<b>38,897</b>	<b>264,480</b>	<b>317,426</b>	<b>171,556</b>	<b>54%</b>	<b>249,280</b>	<b>1,748,280</b>	<b>1,885,677</b>	<b>-</b>	<b>1,885,677</b>
<b>Water Treatment Tablets</b>	<b>1,277,920</b>	<b>1,923,580</b>	<b>13,745,312</b>	<b>24,505,402</b>	<b>11,967,470</b>	<b>15%</b>	<b>20,557,660</b>	<b>78,933,302</b>	<b>-</b>	<b>2,940</b>	<b>2,940</b>
<b>Woman Condom</b>	<b>4,656</b>	<b>3,416</b>	<b>20,016</b>	<b>81,624</b>	<b>6,912</b>	<b>190%</b>	<b>9,600</b>	<b>29,616</b>	<b>336</b>	<b>38</b>	<b>374</b>

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Southern Africa - All</b>										<b>4,207,849</b>	<b>1,414,413</b>	<b>5,622,262</b>
<b>Angola</b>										<b>6,364</b>	<b>647,764</b>	<b>654,128</b>
Condom	259,812	156,468	1,536,660	4,700,000	5,695,416		(73)%	6,252,912	100,221,507	6,364	4,309	10,673
Legal	-	-	-	-	1,724,552	6/01	(100)%	1,724,552	85,409,357	-	-	-
Sensual Champagne	38,268	22,512	105,804	700,000	-		-%	-	105,804	438	297	735
Sensual Chocolate	46,296	32,976	352,044	1,000,000	-	12/12	-%	142,380	2,433,480	1,458	987	2,445
Sensual Maracuja	39,060	16,896	302,004	1,000,000	-		-%	-	302,004	1,251	847	2,097
Sensual Menta	85,788	37,188	416,052	1,000,000	578,512	12/12	(28)%	848,476	3,203,524	1,723	1,167	2,890
Sensual Morango	50,400	46,896	360,756	1,000,000	571,392	12/12	(37)%	716,544	3,212,235	1,494	1,012	2,506
Sensual Saliências	-	-	-	-	2,106,980	11/13	(100)%	2,106,980	3,593,643	-	-	-
Sensual Sensitive	-	-	-	-	713,980	11/13	(100)%	713,980	1,961,460	-	-	-
Family Planning Counseling	-	-	-	-	-		0%	223	223	-	-	-
Family Planning Counseling	-	-	-	-	-		-%	223	223	-	-	-
Implant 5 Insertion	-	-	-	-	47		(100)%	47	47	-	-	-
Non-PSI Implant 5 Inserted	-	-	-	-	47		(100)%	47	47	-	-	-
IUD 10	(39)	1,601	4,810	3,000	-		0%	1,272	6,082	-	16,157	16,157
PSI IUD 10 Distributed Inserted (1)	(39)	(15)	(86)	(3,000)	-		-%	(46)	(132)	-	(289)	(289)
Coper T 380 A – ENOVA	-	1,616	4,896	6,000	-		-%	1,318	6,214	-	16,446	16,446
IUD 10 Insertion	39	15	86	3,000	51		69%	105	191	-	321	321
PSI IUD 10 Inserted	39	15	86	3,000	-		-%	46	132	-	321	321
Non-PSI IUD 10 Inserted	-	-	-	-	51		(100)%	59	59	-	-	-
LLIN	610,370	779,311	2,953,508	2,120,000	1,368,230		116%	1,362,451	8,010,996	-	551,114	551,114
Generic LLINs	609,730	778,226	2,944,407	2,100,000	1,322,304	4/11	123%	1,316,525	7,689,304	-	549,416	549,416
Joia	640	1,085	9,101	20,000	45,926	11/04	(80)%	45,926	321,692	-	1,698	1,698
Malaria PPT (ACT)	8,405	11,705	43,520	120,000	-		0%	-	464,864	-	26,461	26,461

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
ALU 20mg/120mg, 12's, 3-8Yrs (15-	4,412	5,335	20,416	-	-	6/17	-%	-	20,416	-	12,413	12,413
ALU 20mg/120mg, 18's, 9-14Yrs (2€	1,021	1,311	4,954	-	-	6/17	-%	-	4,954	-	3,012	3,012
ALU 20mg/120mg, 24's, >14Yrs (>3	780	1,618	5,635	-	-	6/17	-%	-	5,635	-	3,426	3,426
ALU 20mg/120mg, 6's, >3Yrs (5-14†	2,192	3,441	12,515	-	-	6/17	-%	-	12,515	-	7,609	7,609
Coartem B12 (15-25 kg)	-	-	-	30,000	-	7/13	-%	-	147,395	-	-	-
Coartem B18 (25-35 kg)	-	-	-	30,000	-	7/13	-%	-	41,122	-	-	-
Coartem B24 (> 35 kg)	-	-	-	30,000	-	7/13	-%	-	71,658	-	-	-
Coartem B6 (5-15kg)	-	-	-	30,000	-	7/13	-%	-	161,169	-	-	-
<b>Malaria RDK</b>	<b>25,375</b>	<b>34,467</b>	<b>273,375</b>	<b>100,000</b>	<b>73,125</b>		<b>274%</b>	<b>127,550</b>	<b>702,050</b>	-	-	-
Bioline (RDT)	25,375	34,467	273,375	100,000	73,125	2/14	274%	127,550	702,050	-	-	-
<b>Manual Vacuum Aspiration for PAC</b>	-	-	-	<b>55</b>	-		<b>0%</b>	<b>223</b>	<b>223</b>	-	-	-
MVA for PAC	-	-	-	55	-	11/16	-%	223	223	-	-	-
<b>Misoprostol for PAC (Sublingual)</b>	<b>7,068</b>	<b>75,183</b>	<b>232,616</b>	<b>15,000</b>	-		<b>0%</b>	<b>6,000</b>	<b>238,616</b>	-	<b>46,896</b>	<b>46,896</b>
ACE Miso (Misoprostol 200mcg tabl	7,068	75,183	232,616	15,000	-		-%	6,000	238,616	-	46,896	46,896
<b>OCs</b>	<b>4,464</b>	<b>400</b>	<b>5,665</b>	<b>90,000</b>	-		<b>0%</b>	-	<b>5,665</b>	-	<b>203</b>	<b>203</b>
MEURI	4,464	400	5,665	90,000	-		-%	-	5,665	-	203	203
<b>Water Treatment Tablets</b>	<b>65,000</b>	<b>835,967</b>	<b>5,563,912</b>	<b>13,000,000</b>	<b>6,417,800</b>		<b>(13)%</b>	<b>10,098,200</b>	<b>57,178,362</b>	-	<b>2,304</b>	<b>2,304</b>
Certeza Water Tabs	65,000	835,967	5,563,912	13,000,000	6,417,800	4/11	(13)%	10,098,200	57,178,362	-	2,304	2,304
<b>Botswana</b>										<b>12,266</b>	<b>924</b>	<b>13,189</b>
<b>Condom</b>	<b>114,048</b>	<b>123,984</b>	<b>924,840</b>	<b>1,133,856</b>	<b>769,392</b>		<b>20%</b>	<b>1,028,592</b>	<b>66,447,917</b>	<b>12,266</b>	<b>924</b>	<b>13,189</b>
Lovers Plus	10,368	6,912	82,944	141,696	98,496	6/93	(16)%	139,968	52,419,846	1,100	83	1,183
Lovers Plus C&F	10,368	3,456	88,056	145,152	101,952	8/06	(14)%	133,056	7,828,582	1,168	88	1,256
Lovers Plus Extra Play	10,368	3,456	77,760	103,680	62,208	3/16	25%	82,944	419,904	1,031	78	1,109
Lovers Plus R&S	20,736	6,912	88,128	117,504	77,760	10/13	13%	108,864	693,216	1,169	88	1,257

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Trust	31,104	51,408	308,016	331,296	206,064	6/07	49%	268,272	3,403,297	4,085	308	4,393
Trust Studded	31,104	51,840	279,936	294,528	222,912	11/12	26%	295,488	1,683,072	3,713	280	3,992
<b>Lesotho</b>										157,265	10,714	167,978
Antiretroviral Treatment (Currently Enr 1,636	1,636	1,618	12,917	-	-		0%	-	12,917	2,445	-	2,445
Antiretroviral Treatment (Currently E 1,636	1,636	1,618	12,917	-	-		-%	-	12,917	2,445	-	2,445
Antiretroviral Treatment (Newly Enrolle 15	15	7	80	-	-		0%	-	80	-	-	-
Antiretroviral Treatment (Newly Enrc 15	15	7	80	-	-		-%	-	80	-	-	-
Condom	13,824	92,160	905,472	1,303,488	593,300		53%	530,654	30,804,559	23,880	1,788	25,668
PSI Condom Distributed Provided	-	-	-	-	(319,084)	3/16	-%	(461,218)	(520,647)	-	-	-
Lovers Plus	1,728	-	19,008	31,104	6,912	3/99	175%	13,824	2,742,997	501	38	539
Lovers Plus C&F	8,640	-	31,104	50,112	22,464	1/05	38%	32,832	702,520	820	61	882
Lovers Plus Extra Play	1,728	-	22,464	27,648	10,368	3/16	117%	12,096	38,016	592	44	637
Lovers Plus R&S	1,728	-	20,736	41,472	12,096	11/12	71%	20,736	131,400	547	41	588
Trust	-	-	-	46,080	31,104	5/01	(100)%	31,104	12,827,594	-	-	-
Trust Studded	-	92,160	812,160	1,107,072	829,440	1/05	(2)%	881,280	14,882,679	21,419	1,604	23,023
Condom Provided	-	-	-	-	320,375		(100)%	496,850	556,279	-	-	-
PSI Condom Provided	-	-	-	-	319,084	3/16	(100)%	461,218	520,647	-	-	-
Non-PSI Condom Provided	-	-	-	-	1,291		(100)%	35,632	35,632	-	-	-
Emergency Contraception Provided	-	8	24	50	20		20%	21	45	-	-	-
Non-PSI Emergency Contraception I	-	8	24	50	20		20%	21	45	-	-	-
Female Condom	-	11	36	200,000	3,765,959		(100)%	1,505,148	7,647,022	1	-	1
PSI Female Condom Distributed Pr	-	-	-	-	(42,641)	3/16	-%	(49,852)	(52,530)	-	-	-
Female Condom	-	-	-	200,000	1,555,000	7/06	(100)%	1,555,000	5,306,236	-	-	-
Generic	-	11	36	-	2,253,600	1/08	(100)%	-	2,393,316	1	-	1

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Female Condom Provided	-	-	-	-	47,320		(100)%	54,540	57,218	-	-	-
PSI Female Condom Provided	-	-	-	-	42,641	3/16	(100)%	49,852	52,530	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	4,679		(100)%	4,688	4,688	-	-	-
Free Condom	467,167	471,065	4,071,691	12,200,000	6,843,000		(40)%	11,861,420	104,497,927	107,382	8,042	115,424
Blue & Gold Workplace	-	-	-	-	4,413,000	1/08	(100)%	4,413,000	66,291,000	-	-	-
Camouflage Free	-	75,000	849,000	1,000,000	1,029,000	1/16	(17)%	1,113,000	1,962,000	22,391	1,677	24,067
Generic	-	-	-	6,200,000	-	4/05	-%	2,292,480	21,971,296	-	-	-
Vibe Condom	467,167	396,065	3,222,691	5,000,000	1,401,000	9/14	130%	4,042,940	14,273,631	84,992	6,365	91,357
HIV Testing Services	27,936	16,645	157,892	216,510	161,031		(2)%	258,501	830,949	16,541	-	16,541
VCT Concordant Couple (HIV-Nega	-	-	-	-	2,320	12/09	(100)%	3,178	12,206	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	130	12/09	(100)%	164	1,346	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	46	12/09	(100)%	67	666	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	46	12/09	(100)%	67	666	-	-	-
VCT Individual (HIV-Negative)	26,855	16,102	152,364	203,923	150,847	12/09	1%	243,601	759,778	15,962	-	15,962
VCT Individual (HIV-Positive)	1,081	542	5,528	12,587	7,642	12/09	(28)%	11,424	56,287	579	-	579
Hypertension Screening	693	355	7,618	-	-		0%	-	7,618	-	-	-
Hypertension Screening	693	355	7,618	-	-		-%	-	7,618	-	-	-
Implant 3 Insertion	-	-	2	-	613		(100)%	828	830	-	3	3
Non-PSI Implant 3 Inserted	-	-	2	-	613		(100)%	828	830	-	3	3
Implant 4 Insertion	-	-	-	169	-		0%	24	24	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	169	-		-%	24	24	-	-	-
Implant 5 Insertion	-	-	77	338	-		0%	16	93	-	163	163
Non-PSI Implant 5 Inserted	-	-	77	338	-		-%	16	93	-	163	163
Injectable 1 Provided	-	1	8	-	-		0%	-	8	-	-	-
Non-PSI Injectable 1 Provided	-	1	8	-	-		-%	-	8	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Injectable 2 Provided	261	51	510	338	381		34%	686	1,196	-	35	35
Non-PSI Injectable 2 Provided	261	51	510	338	381		34%	686	1,196	-	35	35
Injectable 3 Provided	1,225	314	3,726	7,573	595		526%	3,255	6,981	-	385	385
Non-PSI Injectable 3 Provided	1,225	314	3,726	7,573	595		526%	3,255	6,981	-	385	385
IUD 10 Insertion	-	-	-	1,658	32		(100)%	78	78	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	1,658	32		(100)%	78	78	-	-	-
Lubricant	-	-	-	-	48		(100)%	48	144	-	-	-
Lovers Plus Lube Natural (100mL)	-	-	-	-	48		(100)%	48	144	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	183		(100)%	231	363	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	183	3/16	(100)%	231	363	-	-	-
OCs Provided	2,018	875	7,417	6,774	1,674		343%	8,616	16,033	-	208	208
Non-PSI OCs Provided	2,018	875	7,417	6,774	1,674		343%	8,616	16,033	-	208	208
Referral to CD4/Clinical Staging	-	-	-	-	2,703		(100)%	4,277	6,355	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	2,703	3/16	(100)%	4,277	6,355	-	-	-
Referral to Clinical Staging	-	-	-	-	422		(100)%	422	975	-	-	-
Referral to Clinical Staging	-	-	-	-	422	3/16	(100)%	422	975	-	-	-
Referral to Early Infant Male Circumcis	-	-	-	-	28		(100)%	28	28	-	-	-
Referral to Early Infant Male Circum	-	-	-	-	28		(100)%	28	28	-	-	-
Referral to HIV Testing Services	1,468	1,368	9,444	4,800	420		2149%	1,256	10,721	495	-	495
Referral to HIV Testing & Counselin	1,468	1,368	9,444	4,800	420	3/16	2,149%	1,256	10,721	495	-	495
Referral to Linkage to HIV Care	526	714	4,891	8,811	-		0%	112	5,003	2,941	-	2,941
Referral to Linkage to HIV Care	526	714	4,891	8,811	-		-%	112	5,003	2,941	-	2,941
Referral to STI Treatment (unknown)	-	-	-	-	17		(100)%	17	17	-	-	-
Referral to STI Treatment (unknown	-	-	-	-	17		(100)%	17	17	-	-	-
Referral to Voluntary Medical Male Cir	-	-	-	-	174		(100)%	174	1,711	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Voluntary Medical Male C	-	-	-	-	174	3/16	(100)%	174	1,711	-	-	-
SDM (Cycle Beads) Provided	-	-	-	-	10		(100)%	10	10	-	-	-
Non-PSI SDM (Cycle Beads) Provid	-	-	-	-	10		(100)%	10	10	-	-	-
TB Diagnosis	7	3	28	-	-		0%	-	28	-	-	-
TB Diagnosis	7	3	28	-	-		-%	-	28	-	-	-
TB DOTS	2	2	11	-	-		0%	-	11	-	89	89
TB DOTS	2	2	11	-	-		-%	-	11	-	89	89
TB Screening	595	499	4,586	-	-		0%	-	4,586	-	-	-
TB Screening	595	499	4,586	-	-		-%	-	4,586	-	-	-
Voluntary Medical Male Circumcision	23	63	274	600	4,243		(94)%	4,930	13,068	3,579	-	3,579
Male Circumcision (HIV-Negative)	-	-	-	-	4,226	9/12	(100)%	4,867	12,718	-	-	-
Male Circumcision (HIV-Unknown)	-	-	-	-	17	10/12	(100)%	45	58	-	-	-
Voluntary Medical Male Circumcisio	23	63	274	600	-		-%	18	292	3,579	-	3,579
<b>Madagascar</b>										55,383	497,906	553,288
Cervical Cancer-VIA and Cryotherapy	7	11	73	-	-		0%	13	86	-	21	21
Cervical Cancer-VIA and Cryotherap	7	11	73	-	-		-%	13	86	-	21	21
Cervical Cancer-VIA/VILI Screening	102	132	967	-	-		0%	146	1,113	-	-	-
Cervical Cancer-VIA/VILI Screening	102	132	967	-	-		-%	146	1,113	-	-	-
Chlorhexidine	4,540	3,390	20,811	53,741	30,370		(31)%	241,094	321,830	-	1,271	1,271
Arofoitra	4,540	3,390	20,811	53,741	30,370	9/15	(31)%	241,094	321,830	-	1,271	1,271
Condom	23,610	295,182	1,733,166	3,234,277	4,232,022		(59)%	5,892,786	59,261,054	11,075	2,638	13,713
Protector Plus	1,920	80,832	386,616	1,947,769	3,723,912	1/08	(90)%	4,995,576	56,560,034	2,471	588	3,059
YES	21,690	214,350	1,346,550	1,286,508	508,110	9/14	165%	897,210	2,701,020	8,605	2,050	10,654
Diarrhea Treatment Kit	568	40,968	211,810	318,195	390,524		(46)%	479,996	2,055,810	-	5,348	5,348
PSI Diarrhea Treatment Kit Distribu	(382)	(502)	(4,085)	-	-		-%	(4,866)	(8,951)	-	(103)	(103)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Hydrazinc	750	20,167	69,720	71,592	127,442	1/10	(45)%	166,308	654,304	-	1,760	1,760
ORS-Zinc	200	9,010	27,231	-	180,536	8/14	(85)%	187,651	427,893	-	687	687
Viasur	-	12,293	118,944	246,603	82,546	1/10	44%	130,903	982,564	-	3,003	3,003
Diarrhea Treatment Kit Provided	382	502	4,085	-	-		0%	4,866	8,951	-	115	115
PSI Diarrhea Treatment Kit Provide	382	502	4,085	-	-		-%	4,866	8,951	-	115	115
Emergency Contraception	(62)	54	(121)	61,900	-		0%	11,536	24,225	-	(1)	(1)
PSI Emergency Contraception Distr	(62)	(46)	(421)	-	-		-%	(344)	(933)	-	(2)	(2)
Norlevo	-	100	300	61,900	-	1/14	-%	11,880	25,158	-	2	2
Emergency Contraception Provided	62	46	421	-	-		0%	344	933	-	3	3
PSI Emergency Contraception Prov	62	46	421	-	-		-%	344	933	-	3	3
Female Condom	900	2,008	9,258	20,724	16,986		(45)%	20,721	365,453	59	11	70
Feeling	900	2,008	9,258	20,724	16,986	10/07	(45)%	20,721	365,453	59	11	70
Fever Cases Attended	3,136	3,680	297,176	-	-		0%	24,338	321,514	-	-	-
Fever Cases Attended	3,136	3,680	297,176	-	-		-%	24,338	321,514	-	-	-
Fever Cases Tested with Microscopy	90	764	3,946	-	-		0%	1,885	5,831	-	-	-
Fever Cases Tested with Microscop	90	764	3,946	-	-		-%	1,885	5,831	-	-	-
Fever Cases Tested with RDTs	2,794	3,361	277,478	-	-		0%	20,935	298,413	-	-	-
Fever Cases Tested with RDTs	2,794	3,361	277,478	-	-		-%	20,935	298,413	-	-	-
Free Condom	106,849	534,027	6,813,784	7,780,853	87,500		7687%	344,547	52,541,829	43,541	10,372	53,913
Generic	5,849	4,433	38,100	7,780,853	87,500	1/02	(56)%	152,700	45,574,298	243	58	301
Generic Condom	101,000	529,593	6,775,684	-	-	10/16	-%	191,847	6,967,531	43,297	10,314	53,611
HIV Testing Services	26,785	37,529	209,987	151,639	50,513		316%	55,027	356,583	708	-	708
VCT Individual (HIV-Negative)	26,737	37,448	209,480	150,459	50,513	12/09	315%	54,869	355,809	706	-	706
VCT Individual (HIV-Positive)	48	81	507	1,180	-	12/09	-%	158	774	2	-	2
Implant 3	90	72	(453)	6,814	(1,220)		0%	(1,590)	677	-	(454)	(454)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Implant 3 Distributed Inserted ('	<b>(868)</b>	<b>(778)</b>	<b>(6,254)</b>	-	<b>(4,103)</b>		-%	<b>(7,497)</b>	<b>(33,431)</b>	-	<b>(6,266)</b>	<b>(6,266)</b>
Implanon	<b>158</b>	<b>689</b>	<b>4,518</b>	<b>6,814</b>	<b>2,883</b>	7/06	57%	<b>5,907</b>	<b>32,825</b>	-	<b>4,527</b>	<b>4,527</b>
Implanon NXT	<b>800</b>	<b>161</b>	<b>1,283</b>	-	-	5/17	-%	-	<b>1,283</b>	-	<b>1,286</b>	<b>1,286</b>
Implant 3 Insertion	<b>868</b>	<b>778</b>	<b>6,254</b>	-	<b>4,103</b>		<b>52%</b>	<b>7,497</b>	<b>33,431</b>	-	<b>6,962</b>	<b>6,962</b>
PSI Implant 3 Inserted	<b>868</b>	<b>778</b>	<b>6,254</b>	-	<b>4,103</b>		52%	<b>7,497</b>	<b>33,431</b>	-	<b>6,962</b>	<b>6,962</b>
Implant 4	-	<b>(1)</b>	<b>(3)</b>	<b>51</b>	<b>(66)</b>		<b>0%</b>	<b>(83)</b>	<b>7,553</b>	-	<b>(4)</b>	<b>(4)</b>
PSI Implant 4 Distributed Inserted ('	-	<b>(1)</b>	<b>(20)</b>	-	<b>(172)</b>		-%	<b>(189)</b>	<b>(2,509)</b>	-	<b>(25)</b>	<b>(25)</b>
Implant Zarin	-	-	<b>17</b>	-	<b>106</b>	7/11	(84)%	<b>106</b>	<b>6,336</b>	-	<b>21</b>	<b>21</b>
Zarin	-	-	-	<b>51</b>	-	11/10	-%	-	<b>3,726</b>	-	-	-
Implant 4 Insertion	-	<b>1</b>	<b>20</b>	-	<b>172</b>		<b>(88)%</b>	<b>189</b>	<b>2,509</b>	-	<b>28</b>	<b>28</b>
PSI Implant 4 Inserted	-	<b>1</b>	<b>20</b>	-	<b>172</b>		(88)%	<b>189</b>	<b>2,509</b>	-	<b>28</b>	<b>28</b>
Implant 5	<b>(16)</b>	<b>(4)</b>	<b>(39)</b>	<b>527</b>	<b>451</b>		<b>(109)%</b>	<b>492</b>	<b>1,665</b>	-	<b>(57)</b>	<b>(57)</b>
PSI Implant 5 Distributed Inserted ('	<b>(16)</b>	<b>(25)</b>	<b>(221)</b>	-	<b>(795)</b>		-%	<b>(1,093)</b>	<b>(1,790)</b>	-	<b>(325)</b>	<b>(325)</b>
Jadelle	-	<b>21</b>	<b>182</b>	<b>527</b>	<b>1,246</b>	7/14	(85)%	<b>1,585</b>	<b>3,455</b>	-	<b>267</b>	<b>267</b>
Implant 5 Insertion	<b>16</b>	<b>25</b>	<b>221</b>	-	<b>795</b>		<b>(72)%</b>	<b>1,093</b>	<b>1,790</b>	-	<b>361</b>	<b>361</b>
PSI Implant 5 Inserted	<b>16</b>	<b>25</b>	<b>221</b>	-	<b>795</b>		(72)%	<b>1,093</b>	<b>1,790</b>	-	<b>361</b>	<b>361</b>
Injectable 3	<b>84,510</b>	<b>148,108</b>	<b>1,128,115</b>	<b>1,126,166</b>	<b>1,475,557</b>		<b>(24)%</b>	<b>2,221,330</b>	<b>18,399,168</b>	-	<b>80,905</b>	<b>80,905</b>
PSI Injectable 3 Distributed Provide	<b>(4,892)</b>	<b>(5,447)</b>	<b>(48,052)</b>	-	-		-%	<b>(66,475)</b>	<b>(149,211)</b>	-	<b>(3,446)</b>	<b>(3,446)</b>
Confiance Injectable	<b>9,198</b>	<b>106,264</b>	<b>853,886</b>	<b>804,410</b>	<b>1,261,325</b>	10/98	(32)%	<b>1,966,049</b>	<b>17,862,463</b>	-	<b>61,238</b>	<b>61,238</b>
Sayana Press	<b>80,204</b>	<b>47,291</b>	<b>322,281</b>	<b>321,756</b>	<b>214,232</b>	9/15	50%	<b>321,756</b>	<b>685,916</b>	-	<b>23,113</b>	<b>23,113</b>
Injectable 3 Provided	<b>4,892</b>	<b>5,447</b>	<b>48,052</b>	-	-		<b>0%</b>	<b>66,475</b>	<b>149,211</b>	-	<b>3,829</b>	<b>3,829</b>
PSI Injectable 3 Provided	<b>4,892</b>	<b>5,447</b>	<b>48,052</b>	-	-		-%	<b>66,475</b>	<b>149,211</b>	-	<b>3,829</b>	<b>3,829</b>
IPTp2	<b>11</b>	<b>2</b>	<b>16,528</b>	<b>172,356</b>	-		<b>0%</b>	<b>158,455</b>	<b>174,983</b>	-	<b>979</b>	<b>979</b>
IPTp2	<b>11</b>	<b>2</b>	<b>16,528</b>	<b>172,356</b>	-		-%	<b>158,455</b>	<b>174,983</b>	-	<b>979</b>	<b>979</b>
IRS (# of household)	-	-	-	<b>721,863</b>	-		<b>0%</b>	-	-	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IRS (# of household)	-	-	-	721,863	-		-%	-	-	-	-	-
IUD 10	(302)	84	(279)	11,334	(1,236)		0%	2,663	17,146	-	(504)	(504)
PSI IUD 10 Distributed Inserted (1)	(1,514)	(1,297)	(11,644)	-	(10,945)		-%	(19,846)	(181,994)	-	(21,046)	(21,046)
Copper T	217	946	8,930	9,604	9,369	5/06	(5)%	21,749	193,120	-	16,141	16,141
IUD 1 x 5	200	432	1,630	1,730	340	8/11	379%	760	5,215	-	2,946	2,946
Pregna T Cu 380A	795	3	805	-	-	7/17	-%	-	805	-	1,455	1,455
IUD 10 Insertion	1,514	1,297	11,644	-	10,945		6%	19,858	183,086	-	23,385	23,385
PSI IUD 10 Inserted	1,514	1,297	11,644	-	10,945		6%	19,846	181,994	-	23,385	23,385
Non-PSI IUD 10 Inserted	-	-	-	-	-		-%	12	1,092	-	-	-
LLIN	226,690	253,540	1,711,834	1,848,923	247,844		591%	494,582	21,491,369	-	67,685	67,685
Generic net "PERMANET WHITE"	161,500	113,933	958,752	861,597	16,994	5/15	5,542%	151,204	9,193,506	-	37,908	37,908
Interceptor White	-	-	-	-	1	5/09	(100)%	1	1,099,951	-	-	-
Net Protect	-	-	502	-	16,601	12/13	(97)%	20,851	2,702,750	-	20	20
Olyset Net Blue	-	-	-	-	-	5/12	-%	360	675,553	-	-	-
Olyset Net White	-	-	-	-	480	5/12	(100)%	930	1,387,454	-	-	-
PermaNet	64,500	98,550	521,557	511,034	5,045	3/07	10,238%	7,228	2,346,666	-	20,622	20,622
Permanet Blue	-	1,550	108,205	-	-	2/17	-%	-	108,205	-	4,278	4,278
Super Moustiquaire	690	39,507	122,816	476,292	208,703	9/01	(41)%	313,988	2,911,462	-	4,856	4,856
Yorkkool Blue (Generic Net)	-	-	2	-	20	7/15	(90)%	20	1,065,822	-	-	-
Lubricant	125,200	5,362	256,202	-	-		0%	4,000	460,152	-	-	-
Gel Lubricant 5 mL	125,200	5,362	256,196	-	-	12/16	-%	4,000	260,196	-	-	-
Lubricant	-	-	6	-	-	8/11	-%	-	199,956	-	-	-
Malaria PPT (ACT)	-	46,303	375,461	1,117,169	825,675		(55)%	991,622	5,669,638	-	106,751	106,751
ACT 100 mg (1x3's)	-	-	-	50,813	34,090	7/15	(100)%	34,235	181,157	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
ACT 100 mg (1x6's)	-	-	-	58,630	7,700	7/15	(100)%	7,701	163,575	-	-	-
ACT 25 mg (1x3's)	-	2,525	14,400	156,830	26,426	7/15	(46)%	46,499	79,624	-	4,094	4,094
ACT 50 mg (1x3's)	-	-	-	676,082	17,170	7/15	(100)%	17,218	32,123	-	-	-
AL for Adolescent, 20/120mg, 18's	-	1,742	8,098	5,727	23,182	7/16	(65)%	27,955	36,053	-	2,302	2,302
AL for Adult, 20/120mg, 24's	-	956	8,596	15,434	33,519	7/16	(74)%	46,381	54,977	-	2,444	2,444
AL for Infant, 20/120mg, 6's	-	851	5,070	5,703	14,438	7/16	(65)%	19,191	24,261	-	1,442	1,442
AL for Toddler, 20/120mg, 12's	-	3,611	14,932	6,059	32,619	7/16	(54)%	37,668	52,600	-	4,245	4,245
Artesunate Amodiaquine 25 mg	-	-	-	-	16,425	10/10	(100)%	16,425	1,390,827	-	-	-
Artesunate Amodiaquine combo 50 mg	-	-	-	-	25,975	10/10	(100)%	25,975	2,617,702	-	-	-
ASAQ for Adolescent, 100/270mg, 3's	-	6,253	74,608	22,411	161,605	7/16	(54)%	180,281	254,889	-	21,213	21,213
ASAQ for Adult, 100/270mg, 6's	-	5,814	82,787	59,395	154,035	7/16	(46)%	203,531	286,318	-	23,538	23,538
ASAQ for Infant, 25/67.5mg, 3's	-	10,425	48,447	21,948	75,654	7/16	(36)%	93,944	142,391	-	13,774	13,774
ASAQ for Toddler, 50/135mg, 3's	-	14,127	118,523	38,137	202,837	7/16	(42)%	234,618	353,141	-	33,698	33,698
Malaria RDK	-	358	1,779,900	1,773,659	1,005,963		77%	1,005,988	9,401,438	-	-	-
RDT Malaria	-	358	1,779,900	1,773,659	1,005,963	8/11	77%	1,005,988	9,401,438	-	-	-
Manual Vacuum Aspiration for PAC	70	146	1,273	-	-		0%	1,234	2,507	-	381	381
MVA for PAC	70	146	1,273	-	-	12/16	-%	1,234	2,507	-	381	381
Micronutrient Powder	85,920	302,220	3,068,250	3,558,780	1,302,900		135%	2,466,510	10,594,800	-	-	-
ZAZATOMADY (ZZT)	85,920	302,220	3,068,250	3,558,780	1,302,900	2/13	135%	2,466,510	10,594,800	-	-	-
Misoprostol for PAC (Oral)	(537)	(755)	(4,002)	-	-		0%	(6,537)	(10,539)	-	(359)	(359)
PSI Misoprostol for PAC Oral Dist F	(537)	(755)	(4,002)	-	-		-%	(6,537)	(10,539)	-	(359)	(359)
Misoprostol for PAC (oral) Provided	537	755	4,002	-	-		0%	6,537	10,539	-	399	399
PSI Misoprostol for PAC (oral) Prov	537	755	4,002	-	-		-%	6,537	10,539	-	399	399
<b>OCs</b>	<b>335,536</b>	<b>323,830</b>	<b>2,413,562</b>	<b>2,631,504</b>	<b>1,610,518</b>		<b>50%</b>	<b>2,594,303</b>	<b>37,691,156</b>	<b>-</b>	<b>46,868</b>	<b>46,868</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI OCs Distributed Provided	(2,573)	(3,487)	(27,600)	-	-		-%	(37,201)	(75,035)	-	(536)	(536)
Pilplan	338,109	327,317	2,441,162	2,631,504	1,610,518	10/98	52%	2,631,504	37,766,191	-	47,404	47,404
OCs Provided	2,573	3,487	27,600	-	-		0%	37,201	75,035	-	596	596
PSI OCs Provided	2,573	3,487	27,600	-	-		-%	37,201	75,035	-	596	596
Pneumonia PPT	27,800	48,785	320,180	419,927	233,947		37%	376,369	1,152,078	-	117,500	117,500
PneumoStop Tablet (6 x 480 mg)	1,400	3,260	11,251	-	141,896	8/14	(92)%	141,896	608,676	-	4,129	4,129
Pneumox 250 (10's) for Children un	26,400	45,525	308,929	419,927	92,051	7/16	236%	234,473	543,402	-	113,371	113,371
Positive RDTs	287	489	100,317	-	-		0%	2,177	102,494	-	-	-
Positive RDTs	287	489	100,317	-	-		-%	2,177	102,494	-	-	-
Safe Water Solution	63,372	166,411	1,317,254	3,435,598	1,757,582		(25)%	2,482,324	23,538,033	-	7,263	7,263
Sur Eau 40 mL	580	4,392	13,757	-	271,450	12/11	(95)%	327,383	2,375,222	-	21	21
Sur Eau Vaovao	62,792	162,019	1,303,497	3,435,598	1,486,132	9/04	(12)%	2,154,941	21,162,811	-	7,241	7,241
SDM (Cycle Beads)	1,050	5,882	19,879	17,307	9,989		99%	11,341	137,886	-	13,462	13,462
PSI SDM (Cycle Beads) Distributed	(105)	(199)	(1,568)	-	-		-%	(2,166)	(4,423)	-	(1,062)	(1,062)
Rojo	1,155	6,081	21,447	17,307	9,989	3/12	115%	13,507	142,309	-	14,523	14,523
SDM (Cycle Beads) Provided	105	199	1,568	-	-		0%	2,166	4,423	-	1,180	1,180
PSI SDM (Cycle Beads) Provided	105	199	1,568	-	-		-%	2,166	4,423	-	1,180	1,180
STI Screening	1,257	1,494	12,478	-	28,174		(56)%	33,852	58,820	-	-	-
STI Screening	1,257	1,494	12,478	-	28,174		(56)%	33,852	58,820	-	-	-
Treatment for Inguinal Bubo	7	6	66	-	-		0%	3	69	-	-	-
Treatment for Inguinal Bubo	7	6	66	-	-		-%	3	69	-	-	-
Treatment for Lower Abdominal Pain	85	107	895	-	-		0%	99	994	-	-	-
Treatment for Lower Abdominal Pair	85	107	895	-	-		-%	99	994	-	-	-
Treatment for Nonherpetic Genital UIc	130	160	1,209	-	-		0%	111	1,320	-	135	135
Treatment for Nonherpetic Genital U	130	160	1,209	-	-		-%	111	1,320	-	135	135

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Treatment for Urethral Discharge (Mer	549	575	5,050	-	-		0%	531	5,581	-	29	29
Treatment for Urethral Discharge (M	549	575	5,050	-	-		-%	531	5,581	-	29	29
Treatment for Vaginitis	475	543	4,851	-	-		0%	581	5,432	-	43	43
Treatment for Vaginitis	475	543	4,851	-	-		-%	581	5,432	-	43	43
Tubal Ligation	2	2	41	-	-		0%	-	41	-	140	140
Tubal Ligation	2	2	41	-	-		-%	-	41	-	140	140
Water Treatment Tablets	1,212,920	1,068,573	8,124,280	11,505,402	5,418,460		50%	10,315,940	20,237,450	-	627	627
SUR'EAU PILINA (67mg tablet)	1,212,920	1,068,573	8,124,280	11,505,402	5,418,460	10/14	50%	10,315,940	20,237,450	-	627	627
<b>Mozambique</b>										178,997	108,851	287,847
Condom	2,029,752	1,693,032	11,481,972	17,339,724	5,037,575		128%	9,175,026	82,408,457	178,673	32,663	211,336
PSI Condom Distributed Provided	-	-	-	-	(64,925)	3/16	-%	(96,814)	(203,159)	-	-	-
J1	259,128	645,408	4,000,416	17,339,724	1,547,640	10/12	158%	4,469,256	39,496,512	62,251	11,380	73,631
J14	-	-	-	-	2,232	4/14	(100)%	2,232	135,288	-	-	-
J2	8,784	570,240	2,646,432	-	1,044,432	10/12	153%	1,365,120	16,039,800	41,182	7,528	48,710
J3	1,745,712	388,080	4,091,040	-	1,404,432	10/12	191%	2,065,680	17,656,272	63,661	11,638	75,299
Jeito 4	16,128	88,776	673,920	-	436,392	11/13	54%	649,440	3,442,896	10,487	1,917	12,404
Jeito 5	-	528	70,164	-	261,612	1/14	(73)%	314,352	1,339,488	1,092	200	1,291
Jzero	-	-	-	-	405,760	6/13	(100)%	405,760	4,501,360	-	-	-
Condom Provided	-	-	-	-	117,111		(100)%	149,000	255,345	-	-	-
PSI Condom Provided	-	-	-	-	64,925	3/16	(100)%	96,814	203,159	-	-	-
Non-PSI Condom Provided	-	-	-	-	52,186		(100)%	52,186	52,186	-	-	-
Emergency Contraception	-	-	(106)	-	(962)		0%	(978)	(1,084)	-	(1)	(1)
PSI Emergency Contraception Distr	-	-	(106)	-	(962)		-%	(978)	(1,084)	-	(1)	(1)
Emergency Contraception Provided	2	40	227	-	962		(76)%	978	1,205	-	3	3
PSI Emergency Contraception Prov	-	-	106	-	962		(89)%	978	1,084	-	1	1

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI Emergency Contraception I	2	40	121	-	-		-%	-	121	-	1	1
Female Condom	-	-	-	-	(3,171)		0%	(3,436)	(11,660)	-	-	-
PSI Female Condom Distributed Pr	-	-	-	-	(3,171)	3/16	-%	(3,436)	(11,660)	-	-	-
Female Condom Provided	-	-	-	-	3,917		(100)%	4,182	12,406	-	-	-
PSI Female Condom Provided	-	-	-	-	3,171	3/16	(100)%	3,436	11,660	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	746		(100)%	746	746	-	-	-
Free Condom	9,216	-	9,216	-	141,915		(94)%	167,691	27,362,144	143	26	170
Generic	-	-	-	-	141,051	1/03	(100)%	141,051	26,733,008	-	-	-
No Logo Condom Lubricant Combo	9,216	-	9,216	-	864	5/15	967%	26,640	629,136	143	26	170
Free Female Condom	-	-	3,270	-	4,217		(22)%	4,868	670,026	51	7	58
Female Condom Free	-	-	3,270	-	4,217	8/09	(22)%	4,868	670,026	51	7	58
HIV Testing Services	-	330	1,853	-	3,773		(51)%	5,588	907,807	129	-	129
VCT Concordant Couple (HIV-Negat	-	-	-	-	17	12/09	(100)%	62	91,187	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	1	12/09	(100)%	2	5,455	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	6	12/09	(100)%	12	2,168	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	6	12/09	(100)%	12	2,168	-	-	-
VCT Individual (HIV-Negative)	-	304	1,688	-	3,515	12/09	(52)%	5,154	758,021	118	-	118
VCT Individual (HIV-Positive)	-	26	165	-	229	12/09	(28)%	347	48,809	12	-	12
Implant 4	142	241	1,662	-	2,629		(37)%	3,871	13,148	-	3,894	3,894
Zarin	142	241	1,662	-	2,629	2/15	(37)%	3,871	13,148	-	3,894	3,894
Implant 5	(142)	(241)	(3,921)	-	(4,602)		0%	(3,871)	(14,706)	-	(10,782)	(10,782)
PSI Implant 5 Distributed Inserted (	(142)	(241)	(3,921)	(5,148)	(4,602)		-%	(3,871)	(14,706)	-	(10,782)	(10,782)
Jadelle	-	-	-	5,148	-		-%	-	-	-	-	-
Implant 5 Insertion	2,264	1,776	10,649	24,750	6,263		70%	11,106	28,669	-	32,538	32,538
PSI Implant 5 Inserted	142	241	3,921	5,148	4,602		(15)%	3,871	14,706	-	11,980	11,980

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI Implant 5 Inserted	2,122	1,535	6,728	19,602	1,661		305%	7,235	13,963	-	20,557	20,557
Injectable 3	(1,553)	(1,422)	(29,741)	-	(18,099)		0%	-	(18,398)	-	(3,986)	(3,986)
PSI Injectable 3 Distributed Provide	(1,792)	(1,744)	(33,920)	(26,829)	(29,518)		-%	(16,469)	(92,481)	-	(4,546)	(4,546)
Enaf Injectable	239	321	4,179	26,829	11,419	6/13	(63)%	16,469	74,083	-	560	560
Injectable 3 Provided	17,585	14,230	87,172	137,070	39,332		122%	70,022	199,286	-	12,982	12,982
PSI Injectable 3 Provided	1,792	1,744	33,920	26,829	29,518		15%	16,469	92,481	-	5,052	5,052
Non-PSI Injectable 3 Provided	15,793	12,486	53,252	110,241	9,814		443%	53,553	106,805	-	7,931	7,931
IUD 10	(2,000)	-	(2,666)	-	649		(511)%	-	(2,211)	-	(9,032)	(9,032)
PSI IUD 10 Distributed Inserted (1)	(2,000)	-	(2,666)	(19,000)	(787)		-%	(1,436)	(5,101)	-	(9,032)	(9,032)
DIU Copper T 380A	-	-	-	19,000	1,436	1/15	(100)%	1,436	2,890	-	-	-
IUD 10 Insertion	2,621	518	4,840	30,421	1,983		144%	2,950	9,291	-	18,219	18,219
PSI IUD 10 Inserted	2,000	-	2,666	19,000	787		239%	1,436	5,101	-	10,035	10,035
Non-PSI IUD 10 Inserted	621	518	2,174	11,421	1,196	3/16	82%	1,514	4,190	-	8,183	8,183
LLIN	4,570	3,350	68,719	43,000	17,641		290%	66,603	192,879	-	21,224	21,224
Serena	4,570	3,350	68,719	43,000	17,641	4/14	290%	66,603	192,879	-	21,224	21,224
Lubricant	-	516	6,988	-	1,365		412%	2,742	12,861	-	-	-
J8 (60 ml tube)	-	516	6,988	-	1,365	9/14	412%	2,742	12,861	-	-	-
Malaria RDK	-	-	26	-	122		(79)%	218	4,938	-	-	-
Teste Malaria Rapido	-	-	26	-	122	9/14	(79)%	218	4,938	-	-	-
Micronutrient Powder	708,000	305,020	2,092,180	1,300,000	687,120		204%	1,558,480	5,353,720	-	-	-
Super Bebe	-	-	-	-	(19,460)	9/13	-%	(19,460)	1,683,120	-	-	-
VITA MAIS	708,000	305,020	2,092,180	1,300,000	706,580	11/15	196%	1,577,940	3,670,600	-	-	-
OCs	-	-	(28,794)	-	(25,612)		0%	(1,361)	(352)	-	(1,045)	(1,045)
PSI OCs Distributed Provided	(4,273)	(4,737)	(61,616)	(73,524)	(70,736)		-%	(71,863)	(228,944)	-	(2,236)	(2,236)
Microginon Mobiz	-	40	2,055	-	3	5/15	68,400%	2,163	5,748	-	75	75

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Microlenyn 30 Combined OC	3,186	3,465	23,146	73,524	31,774	6/13	(27)%	47,700	148,467	-	840	840
Progestyn OC	1,087	1,232	7,621	-	13,347	6/13	(43)%	20,639	74,377	-	277	277
<b>OCs Provided</b>	<b>21,050</b>	<b>18,811</b>	<b>120,616</b>	<b>257,718</b>	<b>78,699</b>		<b>53%</b>	<b>135,973</b>	<b>352,054</b>	-	<b>4,864</b>	<b>4,864</b>
PSI OCs Provided	4,273	4,737	61,616	73,524	70,736		(13)%	71,863	228,944	-	2,485	2,485
Non-PSI OCs Provided	16,777	14,074	59,000	184,194	7,963		641%	64,110	123,110	-	2,379	2,379
<b>Safe Water Solution</b>	<b>4,464</b>	<b>154,297</b>	<b>1,015,699</b>	<b>1,250,000</b>	<b>643,749</b>		<b>58%</b>	<b>934,564</b>	<b>9,018,858</b>	-	<b>7,270</b>	<b>7,270</b>
Certeza	-	-	-	690,000	-	10/04	-%	-	3,931,349	-	-	-
Certeza Commercial ISM	4,464	66,614	421,772	-	328,138	9/12	29%	428,338	2,658,556	-	3,019	3,019
Certeza Free ISM	-	87,682	593,927	560,000	315,611	9/12	88%	506,226	2,428,953	-	4,251	4,251
<b>Water Treatment Tablets</b>	<b>-</b>	<b>19,040</b>	<b>57,120</b>	<b>-</b>	<b>131,210</b>		<b>(56)%</b>	<b>143,520</b>	<b>1,517,490</b>	-	<b>8</b>	<b>8</b>
Certeza Comprimido 20L	-	19,040	57,120	-	85,680	2/14	(33)%	90,960	978,480	-	8	8
Certeza Comprimido 5L	-	-	-	-	11,520	2/14	(100)%	11,550	303,360	-	-	-
Certeza Free Comprimido 20L	-	-	-	-	34,010	2/14	(100)%	41,010	235,650	-	-	-
<b>Namibia</b>										<b>3,055</b>	<b>266</b>	<b>3,320</b>
<b>Condom</b>	<b>-</b>	<b>73,728</b>	<b>235,008</b>	<b>-</b>	<b>21,600</b>		<b>988%</b>	<b>69,984</b>	<b>304,992</b>	<b>3,055</b>	<b>266</b>	<b>3,320</b>
Lovers Plus	-	-	-	-	3,600		(100)%	10,512	10,512	-	-	-
Lovers Plus C&F	-	-	3,456	-	3,600		(4)%	12,240	15,696	45	4	49
Lovers Plus R&S	-	-	-	-	3,600		(100)%	12,240	12,240	-	-	-
Trust	-	36,864	115,776	-	5,400		2,044%	17,496	133,272	1,505	131	1,636
Trust Studded	-	36,864	115,776	-	5,400		2,044%	17,496	133,272	1,505	131	1,636
<b>Free Condom</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,586,778</b>		<b>(100)%</b>	<b>1,753,718</b>	<b>16,546,045</b>	-	-	-
Smile	-	-	-	-	1,586,778	1/08	(100)%	1,753,718	16,546,045	-	-	-
<b>Free Female Condom</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>48,341</b>		<b>(100)%</b>	<b>52,311</b>	<b>510,066</b>	-	-	-
Femidom Free	-	-	-	-	48,341	2/07	(100)%	52,311	510,066	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant	-	-	-	-	246,488		(100)%	306,588	1,964,530	-	-	-
Condom Lubricant (Water Based)	-	-	-	-	246,488	8/11	(100)%	306,588	1,964,530	-	-	-
Referral to HIV Testing Services	-	-	-	-	201		(100)%	201	4,492	-	-	-
Referral to HIV Testing & Counseling	-	-	-	-	201	12/14	(100)%	201	4,492	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	11		(100)%	11	363	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	11	12/14	(100)%	11	363	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	17		(100)%	17	67	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	17		(100)%	17	67	-	-	-
<b>South Africa</b>										1,495,949	54,747	1,550,696
CD4 Tests Provided to HIV+ Clients	783	606	4,908	-	-		0%	59	4,967	-	-	-
CD4 Tests Provided to HIV+ Clients	783	606	4,908	-	-		-%	59	4,967	-	-	-
Condom	3,179,124	4,129,031	25,747,055	52,739,076	32,532,660		(21)%	48,943,658	680,261,526	518,988	23,504	542,492
Lovers Plus	329,580	349,870	2,705,876	5,474,844	3,514,526	10/92	(23)%	5,140,551	164,740,256	54,543	2,470	57,013
Lovers Plus C&F	261,360	226,457	1,842,087	4,796,064	2,829,582	1/08	(35)%	4,117,957	54,686,098	37,131	1,682	38,813
Lovers Plus Extra Play	44,352	21,437	217,141	679,752	248,437	9/13	(13)%	458,103	2,448,403	4,377	198	4,575
Lovers Plus R&S	214,056	149,081	1,353,234	3,036,168	1,952,069	4/07	(31)%	2,915,143	36,859,758	27,277	1,235	28,513
Trust	1,355,544	1,468,655	8,412,137	19,931,304	13,068,898	5/01	(36)%	19,643,191	215,315,457	169,565	7,679	177,244
Trust Studded	974,232	1,913,530	11,216,580	18,820,944	10,919,148	4/04	3%	16,668,713	206,211,554	226,095	10,239	236,334
Female Condom	-	-	(2,880)	-	(27,900)		0%	(35,316)	974,999	(58)	(2)	(60)
LP Condom - Inner Condom	-	-	(2,880)	-	(27,900)	9/13	-%	(35,316)	974,999	(58)	(2)	(60)
Free Condom	17,370,000	1,339,333	34,008,000	45,000,000	56,078,000		(39)%	67,505,600	1,037,509,776	685,505	31,045	716,550
Military Condom	-	-	5,000,000	-	5,000,000	3/13	-%	5,000,000	20,800,016	100,786	4,564	105,350
Public Distribution	17,370,000	1,339,333	29,008,000	45,000,000	51,078,000	1/04	(43)%	62,505,600	1,016,709,760	584,720	26,480	611,200
Free Female Condom	106,200	39,233	285,100	1,000,000	508,900		(44)%	555,800	4,750,200	5,747	200	5,947
FC2 Female Condom	-	-	-	1,000,000	-	5/12	-%	-	1,112,000	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Female Condom GOSA	106,200	39,233	285,100	-	508,900	10/13	(44)%	555,800	3,638,200	5,747	200	5,947
HIV Testing Services	66,623	49,674	336,156	515,489	181,558		85%	262,513	1,675,718	23,823	-	23,823
VCT Concordant Couple (HIV-Negati	-	-	-	-	18,628	12/09	(100)%	20,004	89,520	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	680	12/09	(100)%	895	3,545	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	540	12/09	(100)%	1,306	2,989	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	540	12/09	(100)%	1,306	2,989	-	-	-
VCT Individual (HIV-Negative)	59,067	44,479	298,727	444,746	148,689	12/09	101%	217,903	1,442,760	21,170	-	21,170
VCT Individual (HIV-Positive)	7,556	5,195	37,429	70,743	12,481	12/09	200%	21,100	133,916	2,653	-	2,653
Lubricant	280	(123)	4,439	-	122,772		(96)%	118,584	536,575	-	-	-
Lovers Plus Lube Natural (100mL)	280	(123)	5,675	-	2,736	1/13	107%	4,512	83,039	-	-	-
Lovers Plus Lube Natural (50mL)	-	-	(1,236)	-	(26,964)	1/13	-%	(32,928)	46,536	-	-	-
Lovers Plus Lube Natural (5mL)	-	-	-	-	147,000	3/13	(100)%	147,000	407,000	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	1,188		(100)%	1,521	6,118	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	1,188	3/16	(100)%	1,521	6,118	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	1,960		(100)%	1,960	3,364	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	1,960	12/14	(100)%	1,960	3,364	-	-	-
Referral to Clinical Staging	-	-	-	-	1,960		(100)%	1,960	3,364	-	-	-
Referral to Clinical Staging	-	-	-	-	1,960	12/14	(100)%	1,960	3,364	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	890		(100)%	890	1,690	-	-	-
Referral to STI Treatment (unknown	-	-	-	-	890	12/14	(100)%	890	1,690	-	-	-
Referral to Voluntary Medical Male Cir	-	-	-	-	1,153		(100)%	1,153	3,382	-	-	-
Referral to Voluntary Medical Male C	-	-	-	-	1,153		(100)%	1,153	3,382	-	-	-
Voluntary Medical Male Circumcision	5,144	8,876	37,188	49,922	15,941		133%	19,672	194,612	261,944	-	261,944
Bepelopele (MC HIV-Negative)	-	-	-	-	13,945	3/09	(100)%	14,726	146,696	-	-	-
Bepelopele (MC HIV-Unknown)	-	-	-	-	1,996	3/09	(100)%	2,227	8,009	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Voluntary Medical Male Circumcision	5,144	8,876	37,188	49,922	-		-%	2,719	39,907	261,944	-	261,944
<b>Swaziland</b>										500,304	23,677	523,981
Antiretroviral Treatment (Currently Enrolled)	272	180	995	-	-		0%	-	995	205	-	205
Antiretroviral Treatment (Currently Enrolled)	272	180	995	-	-		-%	-	995	205	-	205
Antiretroviral Treatment (Newly Enrolled)	52	78	438	-	-		0%	-	438	-	-	-
Antiretroviral Treatment (Newly Enrolled)	52	78	438	-	-		-%	-	438	-	-	-
CD4 Tests Provided to HIV+ Clients	99	158	910	-	-		0%	80	990	-	-	-
CD4 Tests Provided to HIV+ Clients	99	158	910	-	-		-%	80	990	-	-	-
Cervical Cancer-Pap and Refer to any	-	-	1	-	-		0%	-	1	-	-	-
Cervical Cancer-Pap and Refer to any	-	-	1	-	-		-%	-	1	-	-	-
Cervical Cancer-Pap Smear Screening	-	-	2	-	-		0%	-	2	-	-	-
Cervical Cancer-Pap Smear Screening	-	-	2	-	-		-%	-	2	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	1	-	-		0%	-	1	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	1	-	-		-%	-	1	-	-	-
Condom	25,920	167,632	1,383,840	871,752	1,760,836		(21)%	2,173,060	27,179,292	55,905	2,919	58,824
Lovers Plus	5,184	2,880	23,760	32,832	19,008	2/01	25%	31,104	1,638,466	960	50	1,010
Lovers Plus C&F	8,640	4,032	27,648	42,048	24,192	1/05	14%	43,200	430,096	1,117	58	1,175
Lovers Plus Extra Play	-	1,152	3,456	-	1,728		100%	1,728	6,912	140	7	147
Lovers Plus R&S	8,640	3,456	25,920	31,104	13,824	5/10	88%	31,680	300,744	1,047	55	1,102
Trust	3,456	19,008	94,608	130,032	77,328	5/01	22%	118,800	6,784,057	3,822	200	4,022
Trust Studded	-	103,104	416,448	635,736	392,256	1/05	6%	546,048	9,227,236	16,824	878	17,702
Trust Workplace	-	34,000	792,000	-	1,232,500	2/06	(36)%	1,400,500	8,791,781	31,996	1,671	33,666
Condom Provided	-	-	-	-	-		0%	28,574	28,574	-	-	-
Non-PSI Condom Provided	-	-	-	-	-		-%	28,574	28,574	-	-	-
Emergency Contraception Provided	-	-	1	120	-		0%	4	5	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI Emergency Contraception I	-	-	1	120	-		-%	4	5	-	-	-
Female Condom	21,000	17,333	75,000	200,000	94,000		(20)%	140,000	878,227	3,030	122	3,152
Female Condom	21,000	17,333	75,000	200,000	94,000	7/06	(20)%	140,000	878,227	3,030	122	3,152
Free Condom	1,602,000	1,119,000	9,555,000	13,444,915	8,169,000		17%	11,475,600	48,884,544	386,009	20,155	406,165
Generic	1,602,000	1,119,000	9,555,000	13,444,915	8,169,000	4/05	17%	11,475,600	48,884,544	386,009	20,155	406,165
HIV Testing Services	7,582	9,875	63,646	62,844	32,427		96%	52,093	573,760	8,653	-	8,653
VCT Concordant Couple (HIV-Nega	-	-	-	-	656	12/09	(100)%	898	9,516	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	110	12/09	(100)%	126	1,050	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	73	12/09	(100)%	97	768	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	73	12/09	(100)%	97	768	-	-	-
VCT Individual (HIV-Negative)	7,201	9,348	59,744	56,046	26,697	12/09	124%	44,213	515,874	8,123	-	8,123
VCT Individual (HIV-Positive)	381	526	3,902	6,798	4,818	12/09	(19)%	6,662	45,784	531	-	531
Hypertension Diagnosis	675	-	684	-	-		0%	-	684	-	-	-
Hypertension Diagnosis	675	-	684	-	-		-%	-	684	-	-	-
Hypertension Screening	675	498	3,874	-	-		0%	-	3,874	-	-	-
Hypertension Screening	675	498	3,874	-	-		-%	-	3,874	-	-	-
Implant 5 Insertion	-	-	-	50	-		0%	-	-	-	-	-
Non-PSI Implant 5 Inserted	-	-	-	50	-		-%	-	-	-	-	-
Injectable 1 Provided	276	123	762	100	-		0%	135	897	-	28	28
Non-PSI Injectable 1 Provided	276	123	762	100	-		-%	135	897	-	28	28
Injectable 2 Provided	1	1	4	200	-		0%	-	4	-	-	-
Non-PSI Injectable 2 Provided	1	1	4	200	-		-%	-	4	-	-	-
Injectable 3 Provided	76	157	853	370	-		0%	460	1,313	-	94	94
Non-PSI Injectable 3 Provided	76	157	853	370	-		-%	460	1,313	-	94	94
Lubricant	48,000	25,000	287,000	-	58,000		395%	190,000	1,088,557	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Assegai Branded (5 mL)	-	-	-	-	<b>58,000</b>	8/11	(100)%	<b>58,000</b>	<b>668,557</b>	-	-	-
Lifestyles Liquid Personal Lubricant	<b>48,000</b>	<b>25,000</b>	<b>287,000</b>	-	-	8/11	-%	<b>132,000</b>	<b>420,000</b>	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	<b>110</b>		<b>(100)%</b>	<b>117</b>	<b>230</b>	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	<b>110</b>	3/16	(100)%	<b>117</b>	<b>230</b>	-	-	-
OCs Provided	<b>48</b>	<b>108</b>	<b>683</b>	<b>330</b>	-		<b>0%</b>	<b>632</b>	<b>1,315</b>	-	<b>20</b>	<b>20</b>
Non-PSI OCs Provided	<b>48</b>	<b>108</b>	<b>683</b>	<b>330</b>	-		-%	<b>632</b>	<b>1,315</b>	-	<b>20</b>	<b>20</b>
Referral to CD4/Clinical Staging	-	-	-	<b>6,798</b>	-		<b>0%</b>	-	<b>4,429</b>	-	-	-
Referral to CD4/Clinical Staging	-	-	-	<b>6,798</b>	-	12/14	-%	-	<b>4,429</b>	-	-	-
Referral to HIV Testing Services	<b>220</b>	-	<b>220</b>	<b>2,400</b>	<b>3,960</b>		<b>(94)%</b>	<b>5,736</b>	<b>10,168</b>	<b>15</b>	-	<b>15</b>
Referral to HIV Testing & Counseling	<b>220</b>	-	<b>220</b>	<b>2,400</b>	<b>3,960</b>	12/14	(94)%	<b>5,736</b>	<b>10,168</b>	<b>15</b>	-	<b>15</b>
Referral to Hypertension Management	<b>17</b>	<b>2</b>	<b>30</b>	<b>50</b>	-		<b>0%</b>	<b>3</b>	<b>33</b>	-	-	-
Referral to Hypertension Management	<b>17</b>	<b>2</b>	<b>30</b>	<b>50</b>	-		-%	<b>3</b>	<b>33</b>	-	-	-
Referral to Implant 5 Insertion	-	-	-	<b>20</b>	-		<b>0%</b>	-	-	-	-	-
Referral to Implant 5 Insertion	-	-	-	<b>20</b>	-		-%	-	-	-	-	-
Referral to Injectable 1	<b>43</b>	<b>30</b>	<b>143</b>	<b>100</b>	-		<b>0%</b>	<b>16</b>	<b>159</b>	-	<b>3</b>	<b>3</b>
Referral to Injectable 1	<b>43</b>	<b>30</b>	<b>143</b>	<b>100</b>	-		-%	<b>16</b>	<b>159</b>	-	<b>3</b>	<b>3</b>
Referral to Injectable 2	-	-	-	<b>200</b>	-		<b>0%</b>	-	-	-	-	-
Referral to Injectable 2	-	-	-	<b>200</b>	-		-%	-	-	-	-	-
Referral to Injectable 3	<b>91</b>	<b>49</b>	<b>297</b>	<b>370</b>	-		<b>0%</b>	<b>45</b>	<b>342</b>	-	<b>16</b>	<b>16</b>
Referral to Injectable 3	<b>91</b>	<b>49</b>	<b>297</b>	<b>370</b>	-		-%	<b>45</b>	<b>342</b>	-	<b>16</b>	<b>16</b>
Referral to IUD 5 Insertion	-	-	-	<b>30</b>	-		<b>0%</b>	-	-	-	-	-
Referral to IUD 5 Insertion	-	-	-	<b>30</b>	-		-%	-	-	-	-	-
Referral to Linkage to HIV Care	<b>326</b>	<b>273</b>	<b>2,730</b>	<b>6,798</b>	-		<b>0%</b>	<b>430</b>	<b>3,160</b>	<b>1,783</b>	-	<b>1,783</b>
Referral to Linkage to HIV Care	<b>326</b>	<b>273</b>	<b>2,730</b>	<b>6,798</b>	-		-%	<b>430</b>	<b>3,160</b>	<b>1,783</b>	-	<b>1,783</b>
Referral to OCs	<b>125</b>	<b>40</b>	<b>322</b>	<b>330</b>	-		<b>0%</b>	<b>75</b>	<b>397</b>	-	<b>5</b>	<b>5</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to OCs	125	40	322	330	-		-%	75	397	-	5	5
Referral to STI Screening (syndromic)	-	-	-	338	-		0%	3	3	-	-	-
Referrals to STI Screening (syndromic)	-	-	-	338	-		-%	3	3	-	-	-
Referral to STI Treatment (unknown)	3	6	39	-	7		457%	22	212	-	-	-
Referral to STI Treatment (unknown)	3	6	39	-	7	12/14	457%	22	212	-	-	-
Referral to TB Diagnosis	-	3	18	6,750	-		0%	-	3,638	-	-	-
Referral to TB Diagnosis	-	3	18	6,750	-	12/14	-%	-	3,638	-	-	-
Referral to TB Screening	326	161	2,394	-	-		0%	433	2,827	-	-	-
Referrals to TB Screening	326	161	2,394	-	-		-%	433	2,827	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	5	-		0%	3	3	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	5	-		-%	3	3	-	-	-
Referral to Treatment for Vaginitis	-	-	-	5	-		0%	4	4	-	-	-
Referral to Treatment for Vaginitis	-	-	-	5	-		-%	4	4	-	-	-
Referral to Vasectomy	-	-	-	3	-		0%	-	-	-	-	-
Referral to Vasectomy	-	-	-	3	-		-%	-	-	-	-	-
Referral to Voluntary Medical Male Circumcision	3	4	118	449	163		(28)%	171	4,714	824	-	824
Referral to Voluntary Medical Male Circumcision	3	4	118	449	163	12/14	(28)%	171	4,714	824	-	824
STI Kit (Non-Ulcerative)	91	77	560	241	428		31%	797	4,372	-	100	100
Inguinal Bubo	1	-	2	5	-	4/10	-%	2	4	-	-	-
Urethral Discharge	15	20	140	12	170	3/10	(18)%	298	1,717	-	20	20
Vaginal Discharge	75	56	418	224	258	3/10	62%	497	2,651	-	80	80
STI Kit (Ulcerative)	21	14	104	184	51		104%	127	576	-	40	40
Genital Herpes	-	-	-	12	-	3/10	-%	-	20	-	-	-
Genital Ulcer Syndrome	21	14	104	172	51	3/10	104%	127	556	-	40	40
<b>STI Screening</b>	<b>4,139</b>	<b>6,729</b>	<b>40,659</b>	<b>-</b>	<b>1,952</b>		<b>1983%</b>	<b>9,589</b>	<b>50,248</b>	<b>-</b>	<b>-</b>	<b>-</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
STI Screening	4,139	6,729	40,659	-	1,952		1,983%	9,589	50,248	-	-	-
TB Screening	4,118	6,712	40,675	-	-		0%	484	41,159	-	-	-
TB Screening	4,118	6,712	40,675	-	-		-%	484	41,159	-	-	-
Treatment for Genital Herpes	5	-	21	12	-		0%	2	23	-	1	1
Treatment for Genital Herpes	5	-	21	12	-		-%	2	23	-	1	1
Treatment for Inguinal Bubo	1	-	2	-	-		0%	-	2	-	-	-
Treatment for Inguinal Bubo	1	-	2	-	-		-%	-	2	-	-	-
Treatment for Lower Abdominal Pain	22	4	33	30	-		0%	1	34	-	-	-
Treatment for Lower Abdominal Pair	22	4	33	30	-		-%	1	34	-	-	-
Treatment for Nonherpetic Genital Ulc	21	14	102	80	-		0%	6	108	-	40	40
Treatment for Nonherpetic Genital U	21	14	102	80	-		-%	6	108	-	40	40
Treatment for Urethral Discharge (Mer	15	21	138	2	-		0%	25	163	-	20	20
Treatment for Urethral Discharge (M	15	21	138	2	-		-%	25	163	-	20	20
Treatment for Urethral Discharge (Wor	-	-	1	10	-		0%	1	2	-	-	-
Treatment for Urethral Discharge (W	-	-	1	10	-		-%	1	2	-	-	-
Treatment for Vaginitis	75	58	425	5	-		0%	23	448	-	113	113
Treatment for Vaginitis	75	58	425	5	-		-%	23	448	-	113	113
Type 2 Diabetes Diagnosis	42	-	42	-	-		0%	-	42	-	-	-
Type 2 Diabetes Diagnosis	42	-	42	-	-		-%	-	42	-	-	-
Type 2 Diabetes Screening	42	21	199	-	-		0%	-	199	-	-	-
Type 2 Diabetes Screening	42	21	199	-	-		-%	-	199	-	-	-
Voluntary Medical Male Circumcision	809	226	3,142	4,500	3,324		(5)%	4,240	61,656	43,879	-	43,879
Male Circumcision (HIV-Negative)	-	-	-	-	3,324	6/09	(100)%	4,062	58,336	-	-	-
Voluntary Medical Male Circumcisioi	809	226	3,142	4,500	-		-%	178	3,320	43,879	-	43,879
<b>Zambia</b>										<b>647,541</b>	<b>40,622</b>	<b>688,163</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Condom	-	-	-	<b>453,600</b>	<b>317,952</b>		<b>(100)%</b>	<b>836,352</b>	<b>1,739,520</b>	-	-	-
Trust	-	-	-	<b>211,680</b>	<b>158,976</b>	8/16	(100)%	<b>418,176</b>	<b>418,176</b>	-	-	-
Trust Studded	-	-	-	<b>241,920</b>	<b>158,976</b>	1/08	(100)%	<b>418,176</b>	<b>1,321,344</b>	-	-	-
Early Infant Male Circumcision	-	-	-	-	<b>2</b>		<b>(100)%</b>	<b>5</b>	<b>5</b>	-	-	-
Early Infant MC (HIV-Negative)	-	-	-	-	<b>1</b>		(100)%	<b>3</b>	<b>3</b>	-	-	-
Early Infant MC (HIV-Positive)	-	-	-	-	<b>1</b>		(100)%	<b>1</b>	<b>1</b>	-	-	-
Early Infant MC (HIV-Unknown)	-	-	-	-	-		-%	<b>1</b>	<b>1</b>	-	-	-
Free Female Condom	-	-	-	<b>289</b>	-		<b>0%</b>	-	<b>186,700</b>	-	-	-
Free Female Condoms	-	-	-	<b>289</b>	-	1/12	-%	-	<b>186,700</b>	-	-	-
HIV Testing Services	-	-	-	<b>133,242</b>	-		<b>0%</b>	-	<b>836,505</b>	-	-	-
VCT Individual (HIV-Negative)	-	-	-	<b>133,242</b>	-	12/09	-%	-	<b>836,505</b>	-	-	-
Implant 3 Insertion	-	-	-	-	-		<b>0%</b>	<b>1</b>	<b>1</b>	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	-		-%	<b>1</b>	<b>1</b>	-	-	-
Implant 4 Insertion	-	-	-	-	-		<b>0%</b>	<b>116</b>	<b>116</b>	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	-		-%	<b>116</b>	<b>116</b>	-	-	-
Implant 5	-	-	-	-	<b>(310)</b>		<b>0%</b>	<b>(310)</b>	<b>(178,192)</b>	-	-	-
PSI Implant 5 Distributed Inserted (	-	-	-	-	<b>(310)</b>		-%	<b>(310)</b>	<b>(178,192)</b>	-	-	-
Implant 5 Insertion	<b>9,335</b>	<b>251</b>	<b>10,912</b>	<b>27,997</b>	<b>1,706</b>		<b>540%</b>	<b>2,731</b>	<b>191,525</b>	-	<b>29,268</b>	<b>29,268</b>
PSI Implant 5 Inserted	-	-	-	-	<b>310</b>		(100)%	<b>310</b>	<b>178,192</b>	-	-	-
Non-PSI Implant 5 Inserted	<b>9,335</b>	<b>251</b>	<b>10,912</b>	<b>27,997</b>	<b>1,396</b>		682%	<b>2,421</b>	<b>13,333</b>	-	<b>29,268</b>	<b>29,268</b>
Injectable 2 Provided	<b>4,597</b>	-	<b>4,597</b>	-	-		<b>0%</b>	-	<b>4,597</b>	-	<b>398</b>	<b>398</b>
Non-PSI Injectable 2 Provided	<b>4,597</b>	-	<b>4,597</b>	-	-		-%	-	<b>4,597</b>	-	<b>398</b>	<b>398</b>
Injectable 3 Provided	<b>33,137</b>	<b>802</b>	<b>39,187</b>	<b>9,712</b>	-		<b>0%</b>	<b>1,592</b>	<b>40,779</b>	-	<b>5,093</b>	<b>5,093</b>
Non-PSI Injectable 3 Provided	<b>33,137</b>	<b>802</b>	<b>39,187</b>	<b>9,712</b>	-		-%	<b>1,592</b>	<b>40,779</b>	-	<b>5,093</b>	<b>5,093</b>
IUD 10	-	-	-	-	<b>(49)</b>		<b>0%</b>	<b>(49)</b>	<b>(78,096)</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	(49)		-%	(49)	(78,096)	-	-	-
IUD 10 Insertion	730	11	786	11,999	124		534%	135	78,968	-	2,608	2,608
PSI IUD 10 Inserted	-	-	-	-	49		(100)%	49	78,096	-	-	-
Non-PSI IUD 10 Inserted	730	11	786	11,999	75		948%	86	872	-	2,608	2,608
IUD 5 Insertion	-	3	8	150	216		(96)%	241	249	-	20	20
Non-PSI IUD 5 Inserted	-	3	8	150	216		(96)%	241	249	-	20	20
IUS 5	100	67	300	-	-		0%	-	300	-	666	666
LNG-IUS	100	67	300	-	-		-%	-	300	-	666	666
IUS 5 Insertion	-	3	10	-	-		0%	-	10	-	25	25
Non-PSI IUS 5 Inserted	-	3	10	-	-		-%	-	10	-	25	25
Male Circumcision (HIV-Positive)	-	-	-	-	118		(100)%	143	297	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	118		(100)%	143	297	-	-	-
OCs Provided	14,094	190	15,372	2,242	-		0%	90	15,462	-	541	541
Non-PSI OCs Provided	14,094	190	15,372	2,242	-		-%	90	15,462	-	541	541
Safe Water Solution	46,524	15,060	256,560	864,000	561,372		(54)%	754,608	34,367,063	-	1,025	1,025
Clorin	46,524	15,060	256,560	864,000	561,372	11/98	(54)%	754,608	34,367,063	-	1,025	1,025
Tubal Ligation	119	-	119	-	-		0%	-	119	-	759	759
Tubal Ligation	119	-	119	-	-		-%	-	119	-	759	759
Vasectomy	28	-	28	-	-		0%	-	28	-	182	182
Vasectomy	28	-	28	-	-		-%	-	28	-	182	182
Voluntary Medical Male Circumcision	5,342	12,988	86,762	82,404	60,339		44%	80,719	653,217	647,206	-	647,206
Male Circumcision (HIV-Negative)	-	-	-	-	53,765	4/07	(100)%	67,572	353,786	-	-	-
Male Circumcision (HIV-Unknown)	-	-	-	-	6,574	4/07	(100)%	8,989	208,511	-	-	-
Voluntary Medical Male Circumcision	5,342	12,988	86,762	82,404	-		-%	4,158	90,920	647,206	-	647,206
Woman Condom	4,656	3,416	20,016	81,624	6,912		190%	9,600	29,616	336	38	374

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
MAXIMUM DIVA	4,656	3,416	20,016	81,624	6,912	4/16	190%	9,600	29,616	336	38	374
<b>Zimbabwe</b>										1,150,726	28,944	1,179,670
Antiretroviral Treatment (Currently Enr	7,573	7,018	52,238	76,596	-		0%	5,010	57,248	9,103	-	9,103
Antiretroviral Treatment (Currently E	7,573	7,018	52,238	76,596	-		-%	5,010	57,248	9,103	-	9,103
Antiretroviral Treatment (Newly Enrolle	948	850	6,818	-	-		0%	5,283	12,101	-	-	-
Antiretroviral Treatment (Newly Enrc	948	850	6,818	-	-		-%	5,283	12,101	-	-	-
CD4 Tests Provided to HIV+ Clients	593	612	5,282	-	-		0%	639	5,921	-	-	-
CD4 Tests Provided to HIV+ Clients	593	612	5,282	-	-		-%	639	5,921	-	-	-
Cervical Cancer-HPV DNA and Refer l	-	4	11	-	-		0%	-	11	-	3	3
Cervical Cancer-HPV DNA and Refe	-	4	11	-	-		-%	-	11	-	3	3
Cervical Cancer-HPV DNA and Refer l	-	3	9	-	-		0%	-	9	-	2	2
Cervical Cancer-HPV DNA and Refe	-	3	9	-	-		-%	-	9	-	2	2
Cervical Cancer-Pap and Refer to any	-	-	-	-	1		(100)%	1	1	-	-	-
Cervical Cancer-Pap and Refer to ai	-	-	-	-	1		(100)%	1	1	-	-	-
Cervical Cancer-Pap and Refer to Con	-	-	-	-	7		(100)%	7	9	-	-	-
Cervical Cancer-Pap and Refer to C	-	-	-	-	7		(100)%	7	9	-	-	-
Cervical Cancer-Pap Smear Screeningç	-	-	-	-	116		(100)%	116	116	-	-	-
Cervical Cancer-Pap Smear Screeni	-	-	-	-	116		(100)%	116	116	-	-	-
Cervical Cancer-VIA and Conization	14	14	145	185	-		0%	10	155	-	41	41
Cervical Cancer-VIA and Conization	14	14	145	185	-		-%	10	155	-	41	41
Cervical Cancer-VIA and Cryotherapy	29	31	347	278	623		(44)%	1,181	3,405	-	97	97
Cervical Cancer-VIA and Cryotheraç	29	31	347	278	623	11/13	(44)%	1,181	3,405	-	97	97
Cervical Cancer-VIA and Refer to any	6	5	26	-	15		73%	17	274	-	4	4
Cervical Cancer-VIA and Refer to ar	6	5	26	-	15	1/15	73%	17	274	-	4	4
Cervical Cancer-VIA and Refer to Con	-	3	69	200	361		(81)%	402	1,936	-	10	10

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Cervical Cancer-VIA and Refer to Cr	-	3	69	200	361	12/14	(81)%	402	1,936	-	10	10
Cervical Cancer-VIA and Refer to Cryc	-	-	16	-	33		(52)%	33	449	-	2	2
Cervical Cancer-VIA and Refer to Cr	-	-	16	-	33	12/14	(52)%	33	449	-	2	2
Cervical Cancer-VIA/VILI Screening	1,219	1,202	10,881	-	19,564		(44)%	26,594	62,216	-	-	-
Cervical Cancer-VIA/VILI Screening	1,219	1,202	10,881	-	19,564		(44)%	26,594	62,216	-	-	-
Condom	1,206,120	1,698,480	8,832,960	18,200,000	17,926,354		(51)%	25,178,622	302,414,305	189,483	12,053	201,536
PSI Condom Distributed Provided	-	-	-	-	(35,166)		-%	(43,698)	(61,465)	-	-	-
Protector Plus	280,440	429,040	3,654,960	7,280,000	7,100,840	1/08	(49)%	11,649,920	271,010,650	78,405	4,987	83,393
Protector Plus Flavors	925,680	1,269,440	5,178,000	10,920,000	10,860,680	3/14	(52)%	13,572,400	31,465,120	111,077	7,066	118,143
Condom Provided	-	-	-	-	126,626		(100)%	167,928	235,493	-	-	-
PSI Condom Provided	-	-	-	-	35,166		(100)%	43,698	61,465	-	-	-
Non-PSI Condom Provided	-	-	-	-	91,460		(100)%	124,230	174,028	-	-	-
Emergency Contraception	(5)	2,948	57,698	120,000	134,857		(57)%	197,597	785,065	-	297	297
PSI Emergency Contraception Distr	(5)	(6)	(47)	-	(184)		-%	(219)	(430)	-	-	-
Pregnon	-	2,953	57,745	120,000	61,262	9/10	(6)%	124,037	702,195	-	297	297
Revoke-72	-	-	-	-	73,779	12/15	(100)%	73,779	83,300	-	-	-
Emergency Contraception Provided	13	8	79	-	233		(66)%	313	615	-	-	-
PSI Emergency Contraception Prov	5	6	47	-	184		(74)%	219	430	-	-	-
Non-PSI Emergency Contraception I	8	2	32	-	49		(35)%	94	185	-	-	-
Female Condom	42,200	47,853	389,440	600,000	765,272		(49)%	1,017,642	23,735,568	8,354	409	8,763
PSI Female Condom Distributed Pr	-	-	-	-	(10,488)		-%	(11,058)	(16,366)	-	-	-
Care	42,200	47,853	389,440	600,000	775,760	6/97	(50)%	1,028,700	23,751,934	8,354	409	8,763
Female Condom Provided	-	-	-	-	18,410		(100)%	21,730	30,088	-	-	-
PSI Female Condom Provided	-	-	-	-	10,488		(100)%	11,058	16,366	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	7,922		(100)%	10,672	13,722	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Female Condom	-	-	-	-	-		0%	14,000	338,000	-	-	-
Care (Free Distribution)	-	-	-	-	-	12/11	-%	14,000	338,000	-	-	-
HIV Testing Services	8,410	17,655	171,583	220,000	219,728		(22)%	316,961	2,841,123	11,374	-	11,374
VCT Concordant Couple (HIV-Nega	-	-	-	-	27,294	12/09	(100)%	34,800	334,640	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	1,094	12/09	(100)%	1,364	24,938	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	1,206	12/09	(100)%	1,549	14,482	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	1,206	12/09	(100)%	1,549	14,482	-	-	-
VCT Individual (HIV-Negative)	6,728	16,050	158,055	203,500	170,034	12/09	(7)%	251,984	2,186,662	10,477	-	10,477
VCT Individual (HIV-Positive)	1,682	1,605	13,528	16,500	18,894	12/09	(28)%	25,715	265,919	897	-	897
Hypertension Diagnosis	24	20	166	-	-		0%	4	170	-	-	-
Hypertension Diagnosis	24	20	166	-	-		-%	4	170	-	-	-
Hypertension Screening	19,044	15,426	282,781	-	-		0%	12,961	295,742	-	-	-
Hypertension Screening	19,044	15,426	282,781	-	-		-%	12,961	295,742	-	-	-
Hypertension_Controlled Condition	12	6	48	-	-		0%	3	51	-	-	-
Hypertension_Controlled Condition	12	6	48	-	-		-%	3	51	-	-	-
Implant 3	(10)	(51)	(218)	-	(354)		0%	(122)	155	-	(197)	(197)
PSI Implant 3 Distributed Inserted (	(10)	(51)	(318)	-	(554)		-%	(622)	(2,249)	-	(287)	(287)
Implanon	-	-	100	-	200	9/15	(50)%	500	2,404	-	90	90
Implant 3 Insertion	107	140	1,029	1,151	2,618		(61)%	3,480	8,626	-	1,032	1,032
PSI Implant 3 Inserted	10	51	318	-	554		(43)%	622	2,249	-	319	319
Non-PSI Implant 3 Inserted	97	89	711	1,151	2,064	3/16	(66)%	2,858	6,377	-	713	713
Implant 5	(9)	(246)	(1,780)	-	(439)		0%	(667)	(28,774)	-	(2,367)	(2,367)
PSI Implant 5 Distributed Inserted (	(9)	(246)	(1,780)	-	(439)		-%	(667)	(28,774)	-	(2,367)	(2,367)
Implant 5 Insertion	502	636	5,820	9,240	13,059		(55)%	17,413	80,333	-	8,600	8,600
PSI Implant 5 Inserted	9	246	1,780	-	439		305%	667	28,774	-	2,630	2,630

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI Implant 5 Inserted	493	389	4,040	9,240	12,620	1/14	(68)%	16,746	51,559	-	5,970	5,970
Injectable 3	1,803	977	8,078	12,000	15,507		(48)%	19,378	878,533	-	519	519
PSI Injectable 3 Distributed Provide	(312)	(928)	(6,707)	-	(512)		-%	(1,158)	(37,163)	-	(431)	(431)
Depo-Provera	2,115	1,905	14,785	-	-	9/00	-%	2,575	685,561	-	951	951
Petogen	-	-	-	12,000	16,019	9/09	(100)%	17,961	230,135	-	-	-
Injectable 3 Provided	3,552	4,421	36,955	39,150	46,374		(20)%	68,505	163,608	-	2,640	2,640
PSI Injectable 3 Provided	312	928	6,707	-	512		1,210%	1,158	37,163	-	479	479
Non-PSI Injectable 3 Provided	3,240	3,492	30,248	39,150	45,862		(34)%	67,347	126,445	-	2,161	2,161
IUD 10	(120)	14	99	-	(376)		0%	(281)	2,333	-	163	163
PSI IUD 10 Distributed Inserted (1)	(120)	(136)	(1,051)	-	(1,426)	3/16	-%	(2,031)	(7,058)	-	(1,732)	(1,732)
TCU 380A IUCD Copper T	-	150	1,150	-	1,050	4/12	10%	1,750	9,391	-	1,895	1,895
IUD 10 Insertion	120	138	1,066	1,253	1,428		(25)%	2,033	7,253	-	1,952	1,952
PSI IUD 10 Inserted	120	136	1,051	-	1,426	3/16	(26)%	2,031	7,058	-	1,924	1,924
Non-PSI IUD 10 Inserted	-	2	15	1,253	2		650%	2	195	-	27	27
IUS 5	(11)	75	175	-	-		0%	-	175	-	214	214
PSI IUS 5 Distributed Inserted (1)	(11)	(12)	(85)	(500)	-		-%	-	(85)	-	(104)	(104)
LNG-IUS	-	87	260	500	-		-%	-	260	-	318	318
IUS 5 Insertion	11	18	102	500	-		0%	-	102	-	139	139
PSI IUS 5 Inserted	11	12	85	500	-		-%	-	85	-	115	115
Non-PSI IUS 5 Inserted	-	6	17	-	-		-%	-	17	-	23	23
LLIN	-	-	-	322,644	43,567		(100)%	863,993	5,332,182	-	-	-
Interceptor	-	-	-	322,644	43,567	10/10	(100)%	863,993	5,332,182	-	-	-
Lubricant	56,800	49,250	276,300	-	-		0%	-	276,300	-	-	-
Personal lubricants water based 4.5	56,800	49,250	276,300	-	-	2/17	-%	-	276,300	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	862		(100)%	1,227	3,214	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Male Circumcision (HIV-Positive)	-	-	-	-	862		(100)%	1,227	3,214	-	-	-
<b>OCs</b>	<b>(558)</b>	<b>(1,106)</b>	<b>(8,177)</b>	-	<b>(10,044)</b>		<b>0%</b>	<b>(9,514)</b>	<b>3,667,806</b>	-	<b>(142)</b>	<b>(142)</b>
PSI OCs Distributed Provided	(558)	(1,106)	(8,177)	-	(15,804)		-%	(17,254)	(228,986)	-	(142)	(142)
Control Combined OC	-	-	-	-	2,880	4/12	(100)%	2,880	561,777	-	-	-
Marvelon	-	-	-	-	2,880	2/99	(100)%	4,860	3,335,015	-	-	-
<b>OCs Provided</b>	<b>6,658</b>	<b>11,583</b>	<b>115,759</b>	<b>112,800</b>	<b>290,260</b>		<b>(60)%</b>	<b>390,702</b>	<b>880,153</b>	-	<b>2,239</b>	<b>2,239</b>
PSI OCs Provided	558	1,106	8,177	-	15,804		(48)%	17,254	228,986	-	158	158
Non-PSI OCs Provided	6,100	10,477	107,582	112,800	274,456		(61)%	373,448	651,167	-	2,081	2,081
<b>PrEP</b>	<b>198</b>	<b>273</b>	<b>1,870</b>	<b>19,960</b>	-		<b>0%</b>	<b>403</b>	<b>2,273</b>	<b>61</b>	-	<b>61</b>
PrEP	198	273	1,870	19,960	-		-%	403	2,273	61	-	61
Referral to Advanced Cervical Cancer	3	7	42	85	113		(63)%	142	385	-	-	-
Referral to Advanced Cervical Canc	3	7	42	85	113	12/14	(63)%	142	385	-	-	-
Referral to CD4/Clinical Staging	-	-	-	2,400	1,943		(100)%	2,373	4,459	-	-	-
Referral to CD4/Clinical Staging	-	-	-	2,400	1,943		(100)%	2,373	4,459	-	-	-
Referral to Clinical Staging	-	-	-	-	436		(100)%	497	671	-	-	-
Referral to Clinical Staging	-	-	-	-	436	3/16	(100)%	497	671	-	-	-
Referral to Diabetes Management (nor	1	-	1	-	-		0%	-	1	-	-	-
Referral to Diabetes Management (r	1	-	1	-	-		-%	-	1	-	-	-
Referral to Early Infant Male Circumcis	-	-	-	-	-		0%	8	66	-	-	-
Referral to Early Infant Male Circum	-	-	-	-	-		-%	8	66	-	-	-
Referral to Emergency Contraception	-	-	-	-	6		(100)%	6	8	-	-	-
Referral to Emergency Contraceptio	-	-	-	-	6		(100)%	6	8	-	-	-
Referral to HIV Testing Services	-	-	-	-	472		(100)%	718	1,180	-	-	-
Referral to HIV Testing & Counselin	-	-	-	-	472		(100)%	718	1,180	-	-	-
Referral to Hypertension Management	17	134	426	-	-		0%	24	450	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Hypertension Manageme	17	134	426	-	-		-%	24	450	-	-	-
Referral to Implant 3 Insertion	-	1	3	-	-		0%	1	4	-	2	2
Referral to Implant 3 Insertion	-	1	3	-	-		-%	1	4	-	2	2
Referral to Implant 5 Insertion	-	2	5	-	-		0%	-	979	-	4	4
Referral to Implant 5 Insertion	-	2	5	-	-	12/13	-%	-	979	-	4	4
Referral to Injectable 1	-	-	-	-	16		(100)%	16	16	-	-	-
Referral to Injectable 1	-	-	-	-	16		(100)%	16	16	-	-	-
Referral to IUD 10 Insertion	-	2	33	-	6		450%	7	197	-	30	30
Referral to IUD 10 Insertion	-	2	33	-	6	12/13	450%	7	197	-	30	30
Referral to IUD Insertion (duration unkn	-	2	5	-	2		150%	2	7	-	3	3
Referral to IUD Insertion (duration un	-	2	5	-	2		150%	2	7	-	3	3
Referral to IUS 3 Insertion	-	9	26	-	-		0%	-	26	-	13	13
Referral to IUS 3 Insertion	-	9	26	-	-		-%	-	26	-	13	13
Referral to Linkage to HIV Care	399	514	4,475	-	-		0%	2,082	6,557	2,477	-	2,477
Referral to Linkage to HIV Care	399	514	4,475	-	-		-%	2,082	6,557	2,477	-	2,477
Referral to OCs	-	-	-	-	1		(100)%	4	851	-	-	-
Referral to OCs	-	-	-	-	1	1/15	(100)%	4	851	-	-	-
Referral to Pre-Exposure Prophylaxis (	10	8	122	-	-		0%	-	122	2	-	2
Referral to Pre-Exposure Prophylaxi	10	8	122	-	-		-%	-	122	2	-	2
Referral to STI Screening (syndromic)	6	10	70	-	-		0%	5	75	-	-	-
Referrals to STI Screening (syndronr	6	10	70	-	-		-%	5	75	-	-	-
Referral to STI Treatment (unknown)	-	1	7	-	5		40%	12	2,244	-	-	-
Referral to STI Treatment (unknown	-	1	7	-	5	1/15	40%	12	2,244	-	-	-
Referral to TB Diagnosis	31	19	152	-	-		0%	11	163	-	-	-
Referral to TB Diagnosis	31	19	152	-	-		-%	11	163	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to TB DOTS (completion confi	-	-	1	-	-		0%	2	17	-	1	1
Referral to TB DOTS (completion co	-	-	1	-	-		-%	2	17	-	1	1
Referral to TB DOTS (completion unkr	31	30	179	300	294		(39)%	467	2,565	-	99	99
Referral to TB DOTS (completion un	31	30	179	300	294	12/13	(39)%	467	2,565	-	99	99
Referral to TB Screening	9	7	6,658	-	-		0%	1	6,659	-	-	-
Referrals to TB Screening	9	7	6,658	-	-		-%	1	6,659	-	-	-
Referral to Treatment for Cervicitis	7	9	34	-	4		750%	4	57	-	2	2
Referral to Treatment for Cervicitis	7	9	34	-	4	1/15	750%	4	57	-	2	2
Referral to Treatment for Genital Herp	3	-	3	-	-		0%	-	3	-	-	-
Referral to Treatment for Genital He	3	-	3	-	-		-%	-	3	-	-	-
Referral to Treatment for Lower Abdon	-	1	4	-	8		(50)%	8	27	-	-	-
Referral to Treatment for Lower Abd	-	1	4	-	8		(50)%	8	27	-	-	-
Referral to Treatment for Urethral Disc	-	-	1	-	26		(96)%	32	57	-	-	-
Referral to Treatment for Urethral Di	-	-	1	-	26		(96)%	32	57	-	-	-
Referral to Treatment for Vaginitis	-	-	-	-	3		(100)%	3	8	-	-	-
Referral to Treatment for Vaginitis	-	-	-	-	3	1/15	(100)%	3	8	-	-	-
Referral to Tubal Ligation	-	-	1	-	-		0%	-	1	-	2	2
Referral to Tubal Ligation	-	-	1	-	-		-%	-	1	-	2	2
Referral to Tx for Nonherpetic Genital I	7	6	25	-	10		150%	13	47	-	4	4
Referral to Tx for Nonherpetic Genit	7	6	25	-	10		150%	13	47	-	4	4
Referral to Tx for Urethral Discharge (\	3	12	98	-	132		(26)%	156	497	-	9	9
Referral to Tx for Urethral Discharge	3	12	98	-	132		(26)%	156	497	-	9	9
Referral to Voluntary Medical Male Cir	16	30	237	1,800	2,032		(88)%	2,351	10,592	803	-	803
Referral to Voluntary Medical Male C	16	30	237	1,800	2,032	12/14	(88)%	2,351	10,592	803	-	803
Safe Water Solution	-	44,355	133,066	150,000	120,121		11%	120,121	1,697,655	-	779	779

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
WaterGuard	-	-	-	150,000	-	9/10	-%	-	1,049,801	-	-	-
WaterGuard Solution 150mL SI	-	44,355	133,066	-	120,121	4/14	11%	120,121	647,854	-	779	779
STI Screening	622	317	2,783	-	2,500		11%	3,655	8,204	-	-	-
STI Screening	622	317	2,783	-	2,500		11%	3,655	8,204	-	-	-
TB Diagnosis	68	39	298	-	205		45%	336	1,033	-	-	-
TB Diagnosis	68	39	298	-	205		45%	336	1,033	-	-	-
TB DOTS	3	1	6	-	11		(45)%	11	48	-	8	8
TB DOTS	3	1	6	-	11	7/14	(45)%	11	48	-	8	8
TB Screening	21,016	17,373	166,588	-	198,943		(16)%	283,969	698,908	-	-	-
TB Screening	21,016	17,373	166,588	-	198,943		(16)%	283,969	698,908	-	-	-
Treatment for Cervicitis	14	24	256	120	-		0%	20	276	-	24	24
Treatment for Cervicitis	14	24	256	120	-		-%	20	276	-	24	24
Treatment for Genital Herpes	-	1	20	-	-		0%	3	23	-	-	-
Treatment for Genital Herpes	-	1	20	-	-		-%	3	23	-	-	-
Treatment for Inguinal Bubo	-	-	2	-	-		0%	5	7	-	-	-
Treatment for Inguinal Bubo	-	-	2	-	-		-%	5	7	-	-	-
Treatment for Lower Abdominal Pain	3	-	8	-	-		0%	2	10	-	-	-
Treatment for Lower Abdominal Pair	3	-	8	-	-		-%	2	10	-	-	-
Treatment for Nonherpetic Genital Ulc	33	23	268	70	-		0%	45	313	-	96	96
Treatment for Nonherpetic Genital U	33	23	268	70	-		-%	45	313	-	96	96
Treatment for Urethral Discharge (Mer	15	13	189	70	-		0%	25	214	-	24	24
Treatment for Urethral Discharge (M	15	13	189	70	-		-%	25	214	-	24	24
Treatment for Urethral Discharge (Wor	53	72	737	330	-		0%	83	820	-	136	136
Treatment for Urethral Discharge (W	53	72	737	330	-		-%	83	820	-	136	136
Treatment for Vaginitis	-	-	1	-	-		0%	-	1	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Treatment for Vaginitis	-	-	1	-	-		-%	-	1	-	-	-
Type 2 Diabetes Diagnosis	1	1	5	-	-		0%	-	5	-	-	-
Type 2 Diabetes Diagnosis	1	1	5	-	-		-%	-	5	-	-	-
Type 2 Diabetes Screening	895	749	4,319	-	-		0%	-	4,319	-	-	-
Type 2 Diabetes Screening	895	749	4,319	-	-		-%	-	4,319	-	-	-
Type 2 Diabetes_Controlled Condition	1	1	6	-	-		0%	-	6	-	-	-
Type 2 Diabetes_Controlled Conditic	1	1	6	-	-		-%	-	6	-	-	-
Voluntary Medical Male Circumcision	25,183	16,745	137,114	180,000	87,709		56%	139,719	825,727	929,069	-	929,069
Male Circumcision (HIV-Negative)	-	-	-	-	87,625	1/09	(100)%	128,675	674,924	-	-	-
Male Circumcision (HIV-Unknown)	-	-	-	-	84	1/09	(100)%	93	2,738	-	-	-
Voluntary Medical Male Circumcisio	25,183	16,745	137,114	180,000	-		-%	10,951	148,065	929,069	-	929,069

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>Southern Africa</b>														
<b>Angola</b>							\$0		\$0	\$0	NA			
<b>Medicines &amp; Supplies</b>														
IUD Insertion Kit	08/2017	0	1	0	1	100%	\$0	NA	\$0	NA	NA	19,999	NA	NA
MVA Kit	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	82	0	NA
<b>Condom</b>														
Sensual Champagne	08/2017	0	38,268	0	38,268	100%	\$0	NA	\$0	\$0	NA	614,232	35,268	17.42
Sensual Chocolate	08/2017	0	46,296	0	46,296	100%	\$0	NA	\$0	\$0	NA	225,576	44,880	5.03
Sensual Maracuja	08/2017	0	39,060	0	39,060	100%	\$0	NA	\$0	\$0	NA	417,996	27,564	15.16
Sensual Menta	08/2017	0	85,788	0	85,788	100%	\$0	NA	\$0	\$0	NA	895,544	60,852	14.72
Sensual Morango	08/2017	0	50,400	0	50,400	100%	\$0	NA	\$0	\$0	NA	362,700	48,156	7.53
<b>LLIN</b>														
Generic LLINs	08/2017	0	609,730	0	609,730	100%	\$0	NA	\$0	\$0	NA	78,158	981,469	0.08
Joia	08/2017	0	640	0	640	100%	\$0	NA	\$0	\$0	NA	899	585	1.54
<b>Malaria PPT (ACT)</b>														
ALU 20mg/120mg, 12's, 3-8Yrs (1	08/2017	0	4,412	0	4,412	100%	\$0	NA	\$0	\$0	NA	9,584	6,805	1.41
ALU 20mg/120mg, 18's, 9-14Yrs (	08/2017	0	1,021	0	1,021	100%	\$0	NA	\$0	\$0	NA	25,046	1,651	15.17
ALU 20mg/120mg, 24's, >14Yrs (>	08/2017	0	780	0	780	100%	\$0	NA	\$0	\$0	NA	24,365	1,878	12.97
ALU 20mg/120mg, 6's, >3Yrs (5-1	08/2017	0	2,192	0	2,192	100%	\$0	NA	\$0	\$0	NA	17,485	4,172	4.19
<b>Malaria RDK</b>														
Bioline (RDT)	08/2017	0	25,375	0	25,375	100%	\$0	NA	\$0	\$0	NA	15,550	29,658	0.52
<b>Misoprostol for PAC (Sublingual)</b>														
ACE Miso (Misoprostol 200mcg ta	08/2017	0	7,068	0	7,068	100%	\$0	NA	\$0	\$0	NA	9,384	77,539	0.12
<b>Water Treatment Tablets</b>														
Certeza Water Tabs	08/2017	0	65,000	0	65,000	100%	\$0	NA	\$0	\$0	NA	2,253,888	549,167	4.10
<b>IUD 10</b>														
Coper T 380 A – ENOVA	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,786	1,616	2.34
<b>OCs</b>														
MEURI	08/2017	0	4,464	0	4,464	100%	\$0	NA	\$0	\$0	NA	81,019	1,888	42.91
<b>Lesotho</b>							\$0		\$451	\$0	NA			
<b>Condom</b>														
Lovers Plus C&F	08/2017	0	0	0	0	NA	\$0	NA	\$104	\$0	NA	0	0	NA
Trust	08/2017	0	0	0	0	NA	\$0	NA	\$81	\$0	NA	0	0	NA

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Lesotho</b>							\$0		\$451	\$0	NA				
<b>Condom</b>															
Trust Studded	08/2017	0	0	0	0	NA	\$0	NA	\$266	\$0	NA	0	0	NA	
<b>Female Condom</b>															
Generic	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	74	11	6.73	
<b>Free Condom</b>															
Camouflage Free	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,068,000	75,000	14.24	
Vibe Condom	08/2017	0	467,167	0	467,167	100%	\$0	NA	\$0	\$0	NA	14,792,651	440,882	33.55	
<b>Madagascar</b>							\$18,208		\$148,543	\$41,687	3.56				
<b>Medicines &amp; Supplies</b>															
Sulfadoxine 500mg/ Pyrimethamin	08/2017	0	4,000	0	4,000	100%	\$0	NA	\$0	\$0	NA	229,000	10,667	21.47	
Syringe IPAS MVA Plus Aspirator	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$16	NA	16	8	2.09	
<b>Condom</b>															
Protector Plus	08/2017	1,920	0	0	1,920	0%	\$7	0%	\$0	\$364	NA	1,556,881	48,832	31.88	
YES	08/2017	21,660	30	30	21,720	0%	\$1,100	0%	\$0	\$5,304	NA	1,950	113,470	0.02	
<b>Female Condom</b>															
Feeling	08/2017	900	0	0	900	0%	\$10	0%	\$0	\$14	NA	7,710	1,281	6.02	
<b>Free Condom</b>															
Generic	08/2017	0	5,849	0	5,849	100%	\$0	NA	\$0	\$0	NA	3,600	3,716	0.97	
Generic Condom	08/2017	0	101,000	0	101,000	100%	\$0	NA	\$0	\$0	NA	278,229	301,200	0.92	
<b>Lubricant A</b>															
Gel Lubricant 5 mL	08/2017	0	125,200	0	125,200	100%	\$0	NA	\$0	\$0	NA	174,604	42,832	4.08	
<b>LLIN</b>															
Generic net "PERMANET WHITE"	08/2017	0	161,500	0	161,500	100%	\$0	NA	\$0	\$0	NA	29,322	154,450	0.19	
Global Fund Free Nets	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	19,378	0	NA	
Net Protect	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,403	0	NA	
Olyset Net Blue	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	90	0	NA	
PermaNet-Blue	08/2017	0	64,500	0	64,500	100%	\$0	NA	\$0	\$0	NA	0	54,167	NA	
PermaNet-White	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	151,977	27,683	5.49	
Permanet Blue	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	62,140	0	NA	
Super Moustiquaire-Blue	08/2017	340	0	0	340	0%	\$184	0%	\$0	\$4,132	NA	4,565	8,360	0.55	
Super Moustiquaire-White	08/2017	250	100	0	350	29%	\$197	0%	\$0	\$12,747	NA	8,313	26,210	0.32	
Yorkool Blue (Generic Net)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	20	0	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Madagascar</b>							\$18,208		\$148,543	\$41,687	3.56				
<b>Malaria PPT (ACT)</b>															
ACT 100 mg (1x3's)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15,493	0	NA	
ACT 100 mg (1x6's)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	99,500	0	NA	
ACT 25 mg (1x3's)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	19,919	8	2,390.28	
ACT 50 mg (1x3's)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	648,802	0	NA	
Artesunate Amodiaquine 25 mg	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	50	0	NA	
Artesunate Amodiaquine combo 5	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	50	0	NA	
<b>Malaria RDK</b>															
RDT Malaria	08/2017	0	0	0	0	NA	\$0	NA	\$28,768	\$0	NA	506,525	0	NA	
<b>Chlorhexidine</b>															
Arofoitra	08/2017	640	3,900	0	4,540	86%	\$116	0%	\$0	\$143	NA	125,315	2,990	41.91	
<b>Diarrhea Treatment Kit</b>															
Hydrazinc	08/2017	0	750	0	750	100%	\$0	NA	\$51,489	\$0	NA	3,517	253	13.88	
ORS-Zinc	08/2017	200	0	0	200	0%	\$9	0%	\$0	\$45	NA	8,990	9,077	0.99	
Viasur	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$249	NA	50,498	8,897	5.68	
<b>Micronutrient Powder</b>															
ZAZATOMADY (ZZT)	08/2017	61,740	24,180	0	85,920	28%	\$342	0%	\$1,725	\$840	2.05	5,931,780	243,710	24.34	
<b>Safe Water Solution</b>															
Sur Eau 40 mL	08/2017	580	0	0	580	0%	\$14	0%	\$0	\$76	NA	19,170	3,859	4.97	
Sur Eau Vaovao	08/2017	60,905	1,887	0	62,792	3%	\$8,265	0%	\$0	\$10,077	NA	1,907,870	101,303	18.83	
<b>Water Treatment Tablets</b>															
SUR EAU PILINA (67mg tablet)	08/2017	892,000	320,920	0	1,212,920	26%	\$676	0%	\$0	\$603	NA	3,329,930	1,218,167	2.73	
<b>Emergency Contraception</b>															
Norlevo	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	300	100	3.00	
<b>Implant 3</b>															
Implanon	08/2017	156	2	0	158	1%	\$26	0%	\$0	\$51	NA	2,312	332	6.97	
Implanon NXT	08/2017	751	49	0	800	6%	\$127	0%	\$0	\$68	NA	4,477	428	10.47	
<b>Implant 4</b>															
Implant Zarin	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	34	0	NA	
<b>Implant 5</b>															
Jadelle	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$3	NA	345	21	16.17	
<b>Injectable 3</b>															
Confiance Injectable	08/2017	9,175	23	0	9,198	0%	\$103	0%	\$25,726	\$618	41.62	100,520	63,483	1.58	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Madagascar</b>							\$18,208		\$148,543	\$41,687	3.56				
<u><b>Injectable 3</b></u>															
Sayana Press	08/2017	74,818	5,386	53,443	133,647	7%	\$1,008	0%	\$0	\$704	NA	205,041	59,952	3.42	
<u><b>IUD 10</b></u>															
Copper T	08/2017	217	0	0	217	0%	\$37	0%	\$0	\$72	NA	674	519	1.30	
IUD 1 x 5	08/2017	140	60	0	200	30%	\$24	0%	\$0	\$58	NA	100	473	0.21	
Pregna T Cu 380A	08/2017	0	795	0	795	100%	\$134	0%	\$0	NA	NA	29,595	NA	NA	
<u><b>OCs</b></u>															
Pilplan	08/2017	331,753	6,356	0	338,109	2%	\$4,368	69%	\$40,835	\$3,500	11.67	1,341,681	337,512	3.98	
<u><b>SDM (Cycle Beads)</b></u>															
Rojo	08/2017	885	270	0	1,155	23%	\$12	0%	\$0	\$24	NA	7,165	5,053	1.42	
<u><b>Pneumonia PPT</b></u>															
PneumoStop Tablet (6 x 480 mg)	08/2017	1,400	0	0	1,400	0%	\$21	0%	\$0	\$47	NA	3,490	3,727	0.94	
Pneumox 250 (10's) for Children u	08/2017	26,400	0	0	26,400	0%	\$1,428	0%	\$0	\$1,889	NA	110,998	43,740	2.54	
<b>Mozambique</b>							\$73,794		\$293,920	\$101,876	2.89				
<u><b>LLIC</b></u>															
Serena Curtina	08/2017	0	3,752	0	3,752	100%	\$0	NA	-\$660	\$0	NA	10,632	1,651	6.44	
<u><b>Medicines &amp; Supplies</b></u>															
JV (Finger Vibes)	08/2017	0	0	0	0	NA	\$0	NA	\$573	\$0	NA	9,287	0	NA	
Teste Glicemia	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,324	0	NA	
<u><b>Condom</b></u>															
J1	08/2017	259,128	0	0	259,128	0%	\$5,731	91%	\$28,074	\$13,671	2.05	255,552	615,480	0.42	
J14	08/2017	0	0	0	0	NA	\$0	NA	-\$391	\$0	NA	6,552	0	NA	
J2	08/2017	8,784	0	0	8,784	0%	\$369	0%	\$61,851	\$19,644	3.15	6,120	538,824	0.01	
J3	08/2017	1,745,712	0	0	1,745,712	0%	\$61,986	99%	\$117,513	\$31,348	3.75	116,568	877,848	0.13	
Jeito 4	08/2017	16,128	0	0	16,128	0%	\$655	0%	\$13,667	\$2,171	6.30	44,856	54,192	0.83	
Jeito 5	08/2017	0	0	0	0	NA	\$0	NA	\$5,108	\$16	322.53	12,492	180	69.40	
Jzero	08/2017	0	0	0	0	NA	\$0	NA	-\$12	\$0	NA	0	0	NA	
<u><b>Free Condom</b></u>															
No Logo Condom Lubricant Comb	08/2017	0	9,216	0	9,216	100%	\$0	NA	\$0	\$0	NA	94,752	3,072	30.84	
<u><b>Free Female Condom</b></u>															
Female Condom Free	08/2017	0	0	0	0	NA	\$0	NA	-\$3,934	\$0	NA	11	0	NA	
<u><b>Lubricant E</b></u>															
J8 (60 ml tube)	08/2017	0	0	0	0	NA	\$0	NA	\$1,130	\$0	NA	7,071	134	52.90	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Mozambique</b>							\$73,794		\$293,920	\$101,876	2.89				
<u>LLIN</u>															
Serena	08/2017	4,570	0	0	4,570	0%	\$3,801	0%	\$13,413	\$2,910	4.61	6,953	3,520	1.98	
<u>Malaria RDK</u>															
Teste Malaria Rapido	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,062	0	NA	
<u>Micronutrient Powder</u>															
Super Bebe	08/2017	0	0	0	0	NA	\$0	NA	\$553	\$0	NA	0	0	NA	
VITA MAIS	08/2017	0	708,000	0	708,000	100%	\$0	NA	\$7,543	\$30	251.02	330,200	506,633	0.65	
<u>Safe Water Solution</u>															
Certeza Commercial ISM	08/2017	4,464	0	0	4,464	0%	\$1,252	0%	\$12,629	\$12,837	0.98	17,400	53,710	0.32	
Certeza Free ISM	08/2017	0	0	0	0	NA	\$0	NA	\$33,621	\$18,619	1.81	158,892	65,879	2.41	
<u>Water Treatment Tablets</u>															
Certeza Comprimido 20L	08/2017	0	0	0	0	NA	\$0	NA	\$2,085	\$632	3.30	33,600	19,040	1.76	
Certeza Comprimido 5L	08/2017	0	0	0	0	NA	\$0	NA	\$923	\$0	NA	1,680	0	NA	
Certeza Free Comprimido 20L	08/2017	0	0	0	0	NA	\$0	NA	-\$135	\$0	NA	246,000	0	NA	
<u>Implant 4</u>															
Zarin	08/2017	0	142	0	142	100%	\$0	NA	\$0	\$0	NA	35,569	216	164.93	
<u>Injectable 3</u>															
Enaf Injectable	08/2017	0	239	0	239	100%	\$0	NA	\$0	\$0	NA	51,185	298	171.95	
<u>IUD 10</u>															
DIU Copper T 380A	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	21,871	0	NA	
<u>OCs</u>															
Microginon Mobiz	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	24,252	0	NA	
Microlyn 30 Combined OC	08/2017	0	3,186	0	3,186	100%	\$0	NA	\$0	\$0	NA	242,502	3,382	71.70	
Progestyn OC	08/2017	0	1,087	0	1,087	100%	\$0	NA	\$0	\$0	NA	41,727	1,132	36.85	
<u>SDM (Cycle Beads)</u>															
Missangas Ciclo	08/2017	0	0	0	0	NA	\$0	NA	\$370	\$0	NA	7,660	0	NA	
<b>Namibia</b>							\$0		\$0	\$0	NA				
<u>Free Condom</u>															
Smile	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	164,035	0	NA	
<u>Free Female Condom</u>															
Femidom Free	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	55,455	0	NA	
<u>Lubricant A</u>															
Condom Lubricant (Water Based)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,809,869	0	NA	



Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Swaziland</b>							\$0		-\$2,061	\$0	NA				
<b>Other Revenues</b>															
VCT Fees	08/2017	0	7,586	0	7,586	100%	\$0	NA	\$0	\$0	NA	0	9,461	NA	
<b>Condom</b>															
Lovers Plus	08/2017	0	0	0	0	NA	\$0	NA	-\$751	\$0	NA	0	0	NA	
Lovers Plus C&F	08/2017	0	0	0	0	NA	\$0	NA	\$1,567	\$0	NA	0	0	NA	
Lovers Plus R&S	08/2017	0	0	0	0	NA	\$0	NA	-\$109	\$0	NA	0	0	NA	
Trust	08/2017	0	0	0	0	NA	\$0	NA	-\$923	\$0	NA	0	0	NA	
Trust Studded	08/2017	0	0	0	0	NA	\$0	NA	-\$1,930	\$0	NA	0	0	NA	
Trust Workplace	08/2017	0	0	0	0	NA	\$0	NA	\$17	\$0	NA	42,000	3,000	14.00	
<b>Female Condom</b>															
Care	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
Female Condom	08/2017	0	21,000	0	21,000	100%	\$0	NA	\$68	\$0	NA	7,000	14,667	0.48	
<b>Free Condom</b>															
Generic	08/2017	0	1,602,000	0	1,602,000	100%	\$0	NA	\$0	\$0	NA	675,000	1,204,000	0.56	
<b>Lubricant A</b>															
Lifestyles Liquid Personal Lubrica	08/2017	0	48,000	0	48,000	100%	\$0	NA	\$0	\$0	NA	80,000	30,333	2.64	
<b>STI Kit (Non-Ulcerative)</b>															
Inguinal Bubo	08/2017	0	1	0	1	100%	\$0	NA	\$0	\$0	NA	0	1	NA	
Urethral Discharge	08/2017	0	15	0	15	100%	\$0	NA	\$0	\$0	NA	0	21	NA	
Vaginal Discharge	08/2017	0	75	0	75	100%	\$0	NA	\$0	\$0	NA	0	60	NA	
<b>STI Kit (Ulcerative)</b>															
Genital Ulcer Syndrome	08/2017	0	21	0	21	100%	\$0	NA	\$0	\$0	NA	0	19	NA	



# Latin America & the Caribbean

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 8/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Americas	1,952	14	-	648	432,835	46	91,895	-	112	-	-	781
Caribbean	1	-	-	-	57	-	8	-	-	-	-	-
Costa Rica	33	-	-	-	9,122	-	1,307	-	-	-	-	-
Dominican Republic	275	-	-	-	67,047	4	9,668	-	-	-	-	-
El Salvador	100	-	-	-	38,690	2	8,844	-	-	-	-	-
Guatemala	235	-	-	-	155,289	15	41,243	-	-	-	-	4
Haiti	604	14	-	648	9,957	5	3,170	-	112	-	-	775
Honduras	269	-	-	-	24,609	2	3,549	-	-	-	-	-
Nicaragua	130	-	-	-	53,646	8	11,321	-	-	-	-	1
Panama	74	-	-	-	16,250	1	2,328	-	-	-	-	-
Paraguay	232	-	-	-	58,168	7	10,455	-	-	-	-	1

\* Using USAID CYP conversion factors

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Caribbean</b>									<b>22</b>	<b>4</b>	<b>26</b>
<b>Free Condom</b>	<b>2,437</b>	<b>40</b>	<b>6,793</b>	<b>-</b>	<b>9,113</b>	<b>(25)%</b>	<b>11,779</b>	<b>400,975</b>	<b>19</b>	<b>4</b>	<b>23</b>
<b>HIV Testing Services</b>	<b>-</b>	<b>57</b>	<b>409</b>	<b>-</b>	<b>591</b>	<b>(31)%</b>	<b>636</b>	<b>7,122</b>	<b>3</b>	<b>-</b>	<b>3</b>
<b>Lubricant</b>	<b>1,421</b>	<b>20</b>	<b>3,589</b>	<b>-</b>	<b>483</b>	<b>643%</b>	<b>939</b>	<b>94,654</b>	<b>-</b>	<b>-</b>	<b>-</b>

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Region and Product  
Period: 8  
Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Central America</b>									<b>34,543</b>	<b>22,488</b>	<b>57,031</b>
Condom	2,530,621	2,659,185	19,965,033	31,715,405	18,035,263	11%	27,549,084	337,260,260	34,516	6,857	41,372
Condom Provided	-	-	-	-	154,684	(100)%	466,816	612,770	-	-	-
Emergency Contraception	-	1	5	-	2	150%	6	11	-	-	-
Family Planning Counseli	-	-	-	-	3,690	(100)%	3,787	3,787	-	-	-
Female Condom Provided	-	-	-	-	1	(100)%	1	1	-	-	-
Free Condom	-	-	-	-	6,135,838	(100)%	6,917,715	6,983,994	-	-	-
Free Female Condom	-	-	-	-	147,578	(100)%	167,978	183,380	-	-	-
HIV Testing Services	2,208	1,552	13,117	12,485	12,222	7%	16,648	131,379	27	-	27
Implant 3	(19)	(9)	(101)	100	166	(161)%	333	575	-	(25)	(25)
Implant 3 Insertion	19	14	186	311	586	(68)%	797	1,162	-	49	49
Implant 5	532	(69)	(651)	558	(42)	-%	(333)	12,781	-	(392)	(392)
Implant 5 Insertion	504	796	4,984	2,372	2,949	69%	4,862	31,369	-	2,389	2,389
Injectable 1	2,622	3,165	22,157	54,269	23,127	(4)%	30,796	218,939	-	160	160
Injectable 1 Provided	2,725	4,282	19,965	42	7,300	173%	11,222	37,242	-	160	160
Injectable 2 Provided	318	750	4,406	-	5,125	(14)%	6,869	19,006	-	71	71
Injectable 3 Provided	1,881	8,706	45,718	58	21,957	108%	37,200	111,230	-	1,100	1,100
IUD 10	1,905	(204)	1,295	2,083	6,903	(81)%	4,537	94,957	-	201	201
IUD 10 Insertion	1,756	1,709	13,156	25,173	9,766	35%	18,956	179,945	-	7,124	7,124
IUD 5	46	29	208	50	351	(41)%	591	799	-	72	72
IUD 5 Insertion	-	-	1	800	40	(98)%	154	155	-	-	-
Lubricant	94,576	98,778	633,515	-	456,674	39%	641,646	4,650,005	-	-	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Manual Vacuum Aspiratio	327	522	4,630	780	3,136	48%	5,421	10,051	-	103	103
Micronutrient Powder	-	-	-	-	20,460	(100)%	395,910	546,420	-	-	-
Misoprostol for PAC (Oral	14,698	640	20,066	118,920	430	4,567%	2,042	37,618	-	151	151
Misoprostol for PAC (oral]	894	1,389	9,048	600	-	-%	36	9,084	-	70	70
Misoprostol for PPH	-	-	880	-	50,700	(98)%	79,680	181,252	-	2	2
OCs	16,950	4,878	95,865	173,120	112,243	(15)%	152,705	721,242	-	453	453
OCs Provided	1,020	4,126	17,930	40	8,036	123%	12,463	45,222	-	117	117
Referral to HIV Testing Se	-	-	-	-	24	(100)%	27	27	-	-	-
Referral to Linkage to HIV	-	-	-	-	-	-%	292	292	-	-	-
Repellant	-	-	-	-	-	-%	1,835	1,835	-	-	-
SDM (Cycle Beads) Provic	-	1	12	-	23	(48)%	39	116	-	3	3
Tubal Ligation	296	411	2,305	-	1,164	98%	1,982	12,915	-	3,611	3,611
Vasectomy	54	22	133	-	12	1,008%	14	404	-	212	212
Zika Prevention Kit	-	14	105	-	-	-%	112,890	112,995	-	2	2

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 8  
 Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Other</b>									<b>56,684</b>	<b>57,612</b>	<b>114,297</b>
Antiretroviral Treatment (C	32,432	31,786	202,191	8,000	-	-%	-	202,191	34,320	-	34,320
Antiretroviral Treatment (I	533	431	3,140	-	-	-%	-	3,140	-	-	-
CD4 Tests Provided to HIV	-	-	113	-	-	-%	118	231	-	-	-
Cervical Cancer-VIA and C	69	-	69	-	-	-%	-	109	-	6	6
Cervical Cancer-VIA/VILI §	337	-	337	-	-	-%	-	759	-	-	-
Condom	916,058	1,004,786	8,287,152	12,981,520	7,262,890	14%	11,295,344	352,101,511	18,792	3,075	21,867
Diarrhea Treatment Kit	-	-	-	40,000	-	-%	-	-	-	-	-
Emergency Contraception	27,952	49,800	200,559	336,500	202,576	(1)%	308,976	2,413,749	-	277	277
Fever Cases Attended	-	1,466	31,104	-	-	-%	1,187	32,291	-	-	-
Fever Cases Tested with H	-	4,692	93,384	-	-	-%	4,934	98,318	-	-	-
Fever Cases Tested with F	-	21,376	417,852	-	-	-%	23,956	441,808	-	-	-
Free Condom	436,000	271,000	1,756,000	7,684,000	1,042,000	69%	1,150,000	9,122,472	2,314	654	2,968
HIV Testing Services	20,579	20,620	167,327	155,000	-	-%	337,775	546,759	1,258	-	1,258
Implant 3	-	672	2,016	350	-	-%	-	2,016	-	1,938	1,938
Implant 3 Insertion	132	14	224	-	-	-%	-	3,853	-	166	166
Injectable 2 Provided	-	12	73	-	-	-%	-	149	-	1	1
Injectable 3	-	-	-	57,500	-	-%	-	-	-	-	-
Injectable 3 Provided	12	18	94	-	-	-%	-	362	-	3	3
IUD 10	17	269	850	100	88	866%	88	2,224	-	1,487	1,487
IUD 10 Insertion	145	1	156	-	-	-%	-	412	-	287	287
LLIN	-	-	-	375,000	-	-%	-	2,987,900	-	-	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant	9,020	17,667	106,020	-	341,000	(69)%	360,000	1,410,992	-	-	-
Malaria PPT (Non-ACT)	-	-	-	11,000	-	-%	-	316,240	-	-	-
Multivitamin	252,780	356,840	1,535,850	2,476,080	1,089,570	41%	1,789,770	34,376,100	-	114	114
OCs	70,840	113,534	467,659	927,500	507,183	(8)%	749,197	7,443,944	-	2,188	2,188
OCs Provided	108	15	165	-	-	-%	-	2,644	-	3	3
ORS	-	-	300,000	330,000	249,840	20%	300,000	10,047,338	-	10,285	10,285
Positive RDTs	-	150	25,283	-	-	-%	1,069	26,352	-	-	-
Referral to Linkage to HIV	-	-	-	-	-	-%	41	41	-	-	-
STI Screening	20,724	20,767	141,460	-	179,161	(21)%	222,184	363,644	-	-	-
TB Diagnosis	3,121	986	9,484	-	-	-%	11,406	20,890	-	-	-
TB DOTS	4,152	1,125	10,637	10,000	-	-%	9,997	20,634	-	36,409	36,409
TB Screening	4,008	1,312	11,507	-	-	-%	12,026	23,533	-	-	-
Treatment for Nonherpetic	563	597	4,323	-	-	-%	1,290	5,613	-	721	721



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Caribbean</b>										<b>22</b>	<b>4</b>	<b>26</b>
<b>Caribbean</b>										<b>22</b>	<b>4</b>	<b>26</b>
Free Condom	<b>2,437</b>	<b>40</b>	<b>6,793</b>	-	<b>9,113</b>		<b>(25)%</b>	<b>11,779</b>	<b>400,975</b>	<b>19</b>	<b>4</b>	<b>23</b>
GIGI (Got it? Get it!) Free Condom	<b>2,437</b>	<b>40</b>	<b>6,793</b>	-	<b>9,113</b>	10/09	<b>(25)%</b>	<b>11,779</b>	<b>400,975</b>	<b>19</b>	<b>4</b>	<b>23</b>
HIV Testing Services	-	<b>57</b>	<b>409</b>	-	<b>591</b>		<b>(31)%</b>	<b>636</b>	<b>7,122</b>	<b>3</b>	-	<b>3</b>
VCT Individual (HIV-Negative)	-	<b>55</b>	<b>395</b>	-	<b>541</b>	12/10	<b>(27)%</b>	<b>584</b>	<b>6,999</b>	<b>3</b>	-	<b>3</b>
VCT Individual (HIV-Positive)	-	<b>2</b>	<b>14</b>	-	<b>50</b>	12/10	<b>(72)%</b>	<b>52</b>	<b>123</b>	-	-	-
Lubricant	<b>1,421</b>	<b>20</b>	<b>3,589</b>	-	<b>483</b>		<b>643%</b>	<b>939</b>	<b>94,654</b>	-	-	-
GIGI (Got it? Get it!) Lube Sachet	<b>1,421</b>	<b>20</b>	<b>3,589</b>	-	<b>483</b>	10/09	<b>643%</b>	<b>939</b>	<b>94,654</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Central America</b>										<b>34,543</b>	<b>22,488</b>	<b>57,031</b>
<b>Belize</b>										-	-	-
Condom	-	-	-	-	2,325		(100)%	2,325	994,749	-	-	-
GIGI (Got it? Get it!) Condom	-	-	-	-	2,325	3/10	(100)%	2,325	994,749	-	-	-
Free Condom	-	-	-	-	2,606		(100)%	2,606	68,885	-	-	-
GIGI (Got it? Get it!) Free Condom	-	-	-	-	2,606	3/10	(100)%	2,606	68,885	-	-	-
Free Female Condom	-	-	-	-	104		(100)%	104	15,506	-	-	-
GIGI (Got it? Get it!) Free Female C	-	-	-	-	104	3/10	(100)%	104	15,506	-	-	-
HIV Testing Services	-	-	-	-	477		(100)%	481	8,061	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	455	12/10	(100)%	455	7,962	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	22	12/10	(100)%	26	99	-	-	-
Lubricant	-	-	-	-	868		(100)%	868	8,715	-	-	-
GIGI (Got it? Get it!) Lube Sachet	-	-	-	-	868	3/10	(100)%	868	8,715	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		0%	8	8	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	8	8	-	-	-
<b>Costa Rica</b>										<b>1,169</b>	<b>83</b>	<b>1,251</b>
Condom	159,141	158,823	1,094,586	1,405,851	957,532		14%	1,518,375	16,921,081	1,169	83	1,251
Combo Pack	-	-	-	2,695	13,354	5/05	(100)%	13,354	53,757	-	-	-
Combo-Mix Lub Fresa	350	64	1,646	2,695	4,054	6/12	(59)%	4,556	16,718	2	-	2
Combo-Mix Lub Natural	-	-	-	2,282	888	6/12	(100)%	1,112	5,342	-	-	-
Combo-Pack Lub Fresa	3,882	921	8,210	-	7,088	10/10	16%	10,212	49,319	9	1	9
Tira Multilinea	13,572	11,001	132,342	-	60,860	8/16	117%	173,439	305,781	141	10	151
Vive	28,060	35,799	185,633	203,664	198,524	12/97	(6)%	257,825	4,585,502	198	14	212
Vive Amor	52,848	68,992	485,760	525,667	378,324	6/04	28%	633,204	7,160,201	519	37	555
Vive Colors/Mas Colors	42,768	25,441	170,718	370,049	163,053	5/03	5%	239,085	3,063,429	182	13	195

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Vive Mas Fuerte /Retardante	3,120	2,168	21,477	134,182	53,349	6/04	(60)%	73,401	609,207	23	2	25
Vive Mas Natural /Sensitivo	13,371	12,027	74,160	131,936	66,527	6/04	11%	94,586	763,549	79	6	85
Vive Mas/Texturizado	1,170	2,409	14,640	32,681	11,511	6/04	27%	17,601	308,276	16	1	17
Lubricant	2,185	2,139	16,207	-	11,595		40%	18,606	125,438	-	-	-
Vive Lub Natural (sachet)	272	425	3,347	-	3,265	5/11	3%	5,235	44,479	-	-	-
Vive Lub Natural (tube)	345	412	3,617	-	2,826	5/11	28%	4,540	15,790	-	-	-
Vive Lub Sachet Fresa 5 mL	322	567	3,097	-	2,714	5/12	14%	3,879	49,547	-	-	-
Vive Lub Tubo Fresa 120 mL	1,246	735	6,146	-	2,790	1/12	120%	4,952	15,622	-	-	-
<b>El Salvador</b>										3,607	1,546	5,153
Condom	144,880	357,461	2,450,872	3,244,205	1,697,704		44%	2,668,520	36,236,427	3,603	506	4,108
Combo-Mix Lub Fresa	-	219	1,840	9,861	1,120	10/10	64%	3,424	26,664	3	-	3
Combo-Mix Lub Natural	800	107	2,752	9,861	144	10/10	1,811%	784	19,352	4	1	5
Combo-Pack Lub Fresa	320	-	320	-	-	5/12	-%	-	5,328	-	-	1
Vive	21,120	121,136	743,280	879,791	503,328	4/98	48%	747,792	14,327,356	1,093	153	1,246
Vive Amor	52,896	151,760	1,033,248	991,402	687,312	7/04	50%	1,086,000	12,557,425	1,519	213	1,732
Vive Colors/Mas Colors	43,872	52,232	414,960	826,840	327,552	10/03	27%	539,424	6,530,394	610	86	696
Vive Mas Fuerte /Retardante	10,536	17,352	134,808	254,193	92,616	7/04	46%	156,312	1,292,324	198	28	226
Vive Mas Natural /Sensitivo	8,424	6,504	54,072	172,952	41,616	7/04	30%	62,784	676,064	79	11	91
Vive Mas/Texturizado	6,912	8,152	65,592	99,305	44,016	7/04	49%	72,000	801,520	96	14	110
Condom Provided	-	-	-	-	1		(100)%	1	1	-	-	-
Non-PSI Condom Provided	-	-	-	-	1		(100)%	1	1	-	-	-
Family Planning Counseling	-	-	-	-	3,690		(100)%	3,787	3,787	-	-	-
Family Planning Counseling	-	-	-	-	3,690		(100)%	3,787	3,787	-	-	-
Free Condom	-	-	-	-	6,133,232		(100)%	6,915,109	6,915,109	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Condom	-	-	-	-	6,133,232	11/15	(100)%	6,915,109	6,915,109	-	-	-
Free Female Condom	-	-	-	-	147,474		(100)%	167,874	167,874	-	-	-
Free Female Condoms	-	-	-	-	147,474	11/15	(100)%	167,874	167,874	-	-	-
HIV Testing Services	502	503	3,410	2,551	522		553%	1,283	40,600	5	-	5
VCT Individual (HIV-Negative)	493	487	3,308	2,412	480	12/09	589%	1,207	40,109	5	-	5
VCT Individual (HIV-Positive)	9	16	102	139	42	12/09	143%	76	491	-	-	-
Implant 3 Insertion	-	-	-	-	169		(100)%	169	169	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	169		(100)%	169	169	-	-	-
Implant 5	30	33	204	550	49		316%	126	3,816	-	41	41
PSI Implant 5 Distributed Inserted (	(7)	(16)	(109)	-	(29)		-%	(74)	(817)	-	(22)	(22)
Jadelle	37	49	313	550	78	12/08	301%	200	4,633	-	63	63
Implant 5 Insertion	7	22	127	-	32		297%	77	838	-	28	28
PSI Implant 5 Inserted	7	16	109	-	29		276%	74	817	-	24	24
Non-PSI Implant 5 Inserted	-	6	18	-	3		500%	3	21	-	4	4
Injectable 1	-	-	(8)	-	(2)		0%	(2)	(10)	-	-	-
PSI Injectable 1 Distributed Provide	-	-	(8)	-	(2)		-%	(2)	(10)	-	-	-
Injectable 1 Provided	2	2	34	-	9		278%	20	54	-	-	-
PSI Injectable 1 Provided	-	-	8	-	2		300%	2	10	-	-	-
Non-PSI Injectable 1 Provided	2	2	26	-	7		271%	18	44	-	-	-
Injectable 3 Provided	-	-	1	-	-		0%	-	1	-	-	-
Non-PSI Injectable 3 Provided	-	-	1	-	-		-%	-	1	-	-	-
IUD 10	103	154	1,150	816	957		20%	902	30,702	-	285	285
PSI IUD 10 Distributed Inserted (1)	(121)	(96)	(851)	(6,932)	(1,083)		-%	(1,850)	(23,621)	-	(211)	(211)
Copper T 380	224	250	2,001	7,748	2,040	12/08	(2)%	2,752	54,323	-	496	496
IUD 10 Insertion	306	300	2,132	6,932	2,096		2%	3,266	34,160	-	588	588

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI IUD 10 Inserted	121	96	851	6,932	1,083		(21)%	1,850	23,621	-	235	235
Non-PSI IUD 10 Inserted	185	204	1,281	-	1,013	11/13	26%	1,416	10,539	-	353	353
Lubricant	53,967	53,558	309,637	-	117,816		163%	173,765	1,193,264	-	-	-
Vive Lub (sachet)	33,400	24,667	149,300	-	56,450	12/06	164%	73,750	687,090	-	-	-
Vive Lub (tube)	746	875	6,363	-	5,016	12/06	27%	7,105	52,112	-	-	-
Vive Lub Natural (sachet)	18,450	27,280	147,390	-	53,655	1/10	175%	88,705	432,452	-	-	-
Vive Lub Natural (tube)	1,371	737	6,584	-	2,695	1/10	144%	4,205	21,610	-	-	-
Manual Vacuum Aspiration for PAC	78	122	975	155	885		10%	1,280	2,255	-	14	14
MVA for PAC	78	122	975	155	885	8/16	10%	1,280	2,255	-	14	14
Micronutrient Powder	-	-	-	-	20,460		(100)%	395,910	546,420	-	-	-
VitalDia Kids	-	-	-	-	20,460	10/14	(100)%	395,910	546,420	-	-	-
Misoprostol for PAC (Oral)	32	(5)	1,243	30,200	430		189%	738	17,491	-	6	6
PSI Misoprostol for PAC Oral Dist F	-	(13)	(39)	-	-		-%	(12)	(51)	-	-	-
Misoprostol for PAC (oral)	32	8	1,282	30,200	430	10/13	198%	750	17,542	-	6	6
Misoprostol for PAC (oral) Provided	3	15	186	-	-		0%	12	198	-	1	1
PSI Misoprostol for PAC (oral) Prov	-	13	39	-	-		-%	12	51	-	-	-
Non-PSI Misoprostol for PAC (oral) I	3	2	147	-	-		-%	-	147	-	1	1
OCs	8,000	38	28,475	42,360	10,479		172%	15,361	139,255	-	75	75
PSI OCs Distributed Provided	-	(1)	(5)	-	(2)		-%	(4)	(9)	-	-	-
Segura Plus	8,000	39	28,480	42,360	10,481	2/12	172%	15,365	139,264	-	75	75
OCs Provided	-	1	5	-	5		0%	7	12	-	-	-
PSI OCs Provided	-	1	5	-	2		150%	4	9	-	-	-
Non-PSI OCs Provided	-	-	-	-	3		(100)%	3	3	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		0%	42	42	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	42	42	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Tubal Ligation	-	-	1	-	-		0%	-	1	-	1	1
Tubal Ligation	-	-	1	-	-		-%	-	1	-	1	1
Zika Prevention Kit	-	14	105	-	-		0%	930	1,035	-	2	2
Zika Prevention Kit	-	14	105	-	-	7/16	-%	930	1,035	-	2	2
<b>Guatemala</b>										9,738	15,973	25,711
Condom	850,430	1,114,299	7,493,982	12,755,737	6,911,561		8%	10,980,589	129,434,335	9,726	3,444	13,170
PSI Condom Distributed Provided	-	-	-	-	(391)		-%	(11,755)	(11,804)	-	-	-
Bodyguard	-	-	-	-	59,616	10/15	(100)%	77,328	259,488	-	-	-
Combo Pack	1,190	5,019	31,446	34,548	21,072	4/05	49%	32,960	397,022	41	14	55
Vive	391,152	372,000	2,424,048	3,628,203	2,491,296	4/98	(3)%	3,856,224	52,475,517	3,146	1,114	4,260
Vive Amor	327,168	543,536	3,861,600	3,839,268	3,567,984	7/04	8%	5,796,576	58,642,623	5,012	1,775	6,786
Vive Colors/Mas Colors	66,576	143,000	800,760	3,472,854	492,480	4/02	63%	778,296	13,217,662	1,039	368	1,407
Vive Mas Fuerte /Retardante	47,232	33,192	168,816	1,382,019	200,064	7/04	(16)%	312,576	2,562,488	219	78	297
Vive Mas Natural /Sensitivo	16,704	10,384	56,496	368,803	44,112	7/04	28%	76,080	948,373	73	26	99
Vive Mas/Texturizado	408	7,168	150,816	30,042	35,328	7/04	327%	62,304	942,966	196	69	265
Condom Provided	-	-	-	-	154,683		(100)%	466,815	612,769	-	-	-
PSI Condom Provided	-	-	-	-	391		(100)%	11,755	11,804	-	-	-
Non-PSI Condom Provided	-	-	-	-	154,292		(100)%	455,060	600,965	-	-	-
Emergency Contraception Provided	-	1	5	-	2		150%	6	11	-	-	-
Non-PSI Emergency Contraception I	-	1	5	-	2		150%	6	11	-	-	-
Female Condom Provided	-	-	-	-	1		(100)%	1	1	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	1		(100)%	1	1	-	-	-
HIV Testing Services	751	474	4,664	4,672	7,143		(35)%	8,883	47,924	12	-	12
VCT Individual (HIV-Negative)	728	455	4,499	4,433	6,987	12/09	(36)%	8,640	47,286	12	-	12

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Positive)	23	19	165	239	156	12/09	6%	243	638	-	-	-
Implant 3 Insertion	-	-	-	-	5		(100)%	11	33	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	5		(100)%	11	33	-	-	-
Implant 5	411	(197)	(1,453)	108	(275)		0%	(723)	7,331	-	(647)	(647)
PSI Implant 5 Distributed Inserted (	(111)	(231)	(2,400)	(972)	(1,538)		-%	(2,859)	(11,114)	-	(1,069)	(1,069)
Jadelle	522	34	947	1,080	1,263	12/08	(25)%	2,136	18,445	-	422	422
Implant 5 Insertion	378	708	4,417	972	2,803		58%	4,553	28,050	-	2,186	2,186
PSI Implant 5 Inserted	111	231	2,400	972	1,538		56%	2,859	11,114	-	1,188	1,188
Non-PSI Implant 5 Inserted	267	476	2,017	-	1,265		59%	1,694	16,936	-	998	998
Injectable 1	2,622	3,166	22,165	54,269	23,129		(4)%	30,798	218,949	-	160	160
PSI Injectable 1 Distributed Provide	(167)	(268)	(1,708)	-	(1,330)		-%	(1,826)	(4,131)	-	(12)	(12)
Cyclofem	2,789	3,433	23,873	54,269	24,459	5/11	(2)%	32,624	223,080	-	172	172
Injectable 1 Provided	2,688	4,253	19,783	-	7,266		172%	11,103	36,941	-	159	159
PSI Injectable 1 Provided	167	268	1,708	-	1,330		28%	1,826	4,131	-	14	14
Non-PSI Injectable 1 Provided	2,521	3,986	18,075	-	5,936		204%	9,277	32,810	-	145	145
Injectable 2	-	-	-	-	(7)		0%	(7)	(7)	-	-	-
PSI Injectable 2 Distributed Provide	-	-	-	-	(7)		-%	(7)	(7)	-	-	-
Injectable 2 Provided	318	750	4,406	-	5,125		(14)%	6,869	19,006	-	71	71
PSI Injectable 2 Provided	-	-	-	-	7		(100)%	7	7	-	-	-
Non-PSI Injectable 2 Provided	318	750	4,406	-	5,118		(14)%	6,862	18,999	-	71	71
Injectable 3	-	-	-	-	(407)		0%	(407)	(593)	-	-	-
PSI Injectable 3 Distributed Provide	-	-	-	-	(407)		-%	(407)	(593)	-	-	-
Injectable 3 Provided	1,875	8,701	45,676	-	21,951		108%	37,157	111,145	-	1,099	1,099
PSI Injectable 3 Provided	-	-	-	-	407		(100)%	407	593	-	-	-
Non-PSI Injectable 3 Provided	1,875	8,701	45,676	-	21,544		112%	36,750	110,552	-	1,099	1,099

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 10	1,687	(646)	(1,367)	517	2,281		(160)%	(618)	27,403	-	(751)	(751)
PSI IUD 10 Distributed Inserted (1)	(999)	(851)	(7,909)	(12,226)	(4,783)		-%	(11,625)	(83,287)	-	(4,347)	(4,347)
Copper T 380	2,634	204	6,437	12,743	7,064	12/08	(9)%	11,007	110,585	-	3,538	3,538
Copper T 380 Postpartum	52	1	105	-	-	1/17	-%	-	105	-	58	58
IUD 10 Insertion	1,193	1,203	9,405	12,226	6,160		53%	13,400	104,233	-	5,744	5,744
PSI IUD 10 Inserted	999	851	7,909	12,226	4,783		65%	11,625	83,287	-	4,830	4,830
Non-PSI IUD 10 Inserted	194	352	1,496	-	1,377		9%	1,775	20,946	-	914	914
IUD 5	-	-	43	-	301		(86)%	530	573	-	18	18
IUD Sleek	-	-	43	-	301	5/16	(86)%	530	573	-	18	18
IUD 5 Insertion	-	-	-	-	40		(100)%	147	147	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	40		(100)%	147	147	-	-	-
Lubricant	7,134	7,906	49,949	-	149,446		(67)%	192,313	1,311,854	-	-	-
Vive Lub (sachet)	740	1,827	8,875	-	90,362	4/05	(90)%	107,228	883,354	-	-	-
Vive Lub (tube)	2,119	1,070	9,663	-	12,655	4/05	(24)%	19,302	123,501	-	-	-
Vive Lub Natural (sachet)	1,800	3,958	20,469	-	34,231	1/10	(40)%	46,983	231,103	-	-	-
Vive Lub Natural (tube)	2,475	1,051	10,942	-	12,198	1/10	(10)%	18,800	73,896	-	-	-
Manual Vacuum Aspiration for PAC	124	364	3,283	300	2,105		56%	3,716	6,999	-	76	76
MVA for PAC	124	364	3,283	300	2,105	5/16	56%	3,716	6,999	-	76	76
Misoprostol for PAC (Oral)	12,618	665	14,196	59,720	-		0%	(24)	14,172	-	99	99
PSI Misoprostol for PAC Oral Dist F	(342)	(42)	(4,284)	(600)	-		-%	(24)	(4,308)	-	(30)	(30)
Misoprostol for PAC (oral)	12,960	707	18,480	60,320	-	7/13	-%	-	18,480	-	129	129
Misoprostol for PAC (oral) Provided	867	1,354	8,745	600	-		0%	24	8,769	-	68	68
PSI Misoprostol for PAC (oral) Prov	342	42	4,284	600	-		-%	24	4,308	-	33	33
Non-PSI Misoprostol for PAC (oral) I	525	1,312	4,461	-	-		-%	-	4,461	-	35	35
Misoprostol for PPH	-	-	880	-	50,700		(98)%	79,680	181,252	-	2	2

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Misoprostol for PPH	-	-	880	-	50,700	7/13	(98)%	79,680	181,252	-	2	2
<b>OCs</b>	<b>8,947</b>	<b>4,840</b>	<b>52,956</b>	<b>39,760</b>	<b>49,299</b>		<b>7%</b>	<b>60,581</b>	<b>477,005</b>	-	<b>310</b>	<b>310</b>
PSI OCs Distributed Provided	(53)	(349)	(1,900)	-	(499)		-%	(906)	(2,950)	-	(11)	(11)
Oralcon-F (28 tablets Blister)	-	-	-	-	40,143	8/10	(100)%	40,212	366,801	-	-	-
Segura Plus	9,000	5,190	54,856	39,760	9,655	5/14	468%	21,275	113,154	-	322	322
<b>OCs Provided</b>	<b>1,005</b>	<b>4,113</b>	<b>17,859</b>	-	<b>8,023</b>		<b>123%</b>	<b>12,390</b>	<b>45,078</b>	-	<b>116</b>	<b>116</b>
PSI OCs Provided	53	349	1,900	-	499		281%	906	2,950	-	12	12
Non-PSI OCs Provided	952	3,764	15,959	-	7,524		112%	11,484	42,128	-	104	104
Referral to Linkage to HIV Care	-	-	-	-	-		0%	90	90	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	90	90	-	-	-
Repellant	-	-	-	-	-		0%	1,835	1,835	-	-	-
Repellant	-	-	-	-	-	12/16	-%	1,835	1,835	-	-	-
SDM (Cycle Beads)	-	-	-	-	(2)		0%	(2)	(2)	-	-	-
PSI SDM (Cycle Beads) Distributed	-	-	-	-	(2)		-%	(2)	(2)	-	-	-
<b>SDM (Cycle Beads) Provided</b>	-	<b>1</b>	<b>12</b>	-	<b>23</b>		<b>(48)%</b>	<b>39</b>	<b>116</b>	-	<b>3</b>	<b>3</b>
PSI SDM (Cycle Beads) Provided	-	-	-	-	2		(100)%	2	2	-	-	-
Non-PSI SDM (Cycle Beads) Provid	-	1	12	-	21		(43)%	37	114	-	3	3
<b>Tubal Ligation</b>	<b>296</b>	<b>410</b>	<b>2,301</b>	-	<b>1,164</b>		<b>98%</b>	<b>1,982</b>	<b>12,911</b>	-	<b>3,606</b>	<b>3,606</b>
Tubal Ligation	296	410	2,301	-	1,164	7/12	98%	1,982	12,911	-	3,606	3,606
<b>Vasectomy</b>	<b>54</b>	<b>22</b>	<b>133</b>	-	<b>12</b>		<b>1008%</b>	<b>14</b>	<b>404</b>	-	<b>212</b>	<b>212</b>
Vasectomy	54	22	133	-	12	7/12	1,008%	14	404	-	212	212
<b>Honduras</b>										<b>11,341</b>	<b>898</b>	<b>12,239</b>
<b>Condom</b>	<b>458,074</b>	<b>304,143</b>	<b>2,938,576</b>	<b>4,290,217</b>	<b>2,702,112</b>		<b>9%</b>	<b>4,121,656</b>	<b>45,578,792</b>	<b>11,334</b>	<b>888</b>	<b>12,222</b>
Bodyguard	-	-	2,208	-	-	7/16	-%	98,592	100,800	9	1	9
Combo Pack	-	-	-	-	(256)	4/05	-%	(256)	153,800	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Combo-Mix Lub Fresa	-	-	-	1,259	816	10/10	(100)%	848	10,864	-	-	-
Combo-Mix Lub Natural	-	-	-	1,111	944	10/10	(100)%	1,216	9,984	-	-	-
Combo-Pack Lub Fresa	1,296	1,760	6,576	4,852	-	2/16	-%	-	6,576	25	2	27
Combo-Pack Lub Natural	240	155	784	6,219	3,584	10/10	(78)%	4,160	26,480	3	-	3
Vive	75,360	132,912	832,944	720,013	476,208	9/00	75%	657,168	14,189,251	3,213	252	3,464
Vive Amor	264,432	72,000	1,328,208	2,760,149	1,789,632	8/04	(26)%	2,619,312	21,206,264	5,123	401	5,524
Vive Colors/Mas Colors	80,266	75,037	568,608	589,161	308,664	4/02	84%	537,168	8,025,142	2,193	172	2,365
Vive Mas Fuerte /Retardante	20,832	9,248	103,416	117,089	73,752	8/04	40%	131,064	938,784	399	31	430
Vive Mas Natural /Sensitivo	6,888	4,168	30,600	35,859	23,232	8/04	32%	38,448	435,098	118	9	127
Vive Mas/Texturizado	8,760	8,864	65,232	54,505	25,536	8/04	155%	33,936	475,749	252	20	271
HIV Testing Services	448	416	3,157	2,725	2,238		41%	3,717	10,721	7	-	7
VCT Individual (HIV-Negative)	443	402	3,073	2,589	2,200	4/12	40%	3,659	10,575	7	-	7
VCT Individual (HIV-Positive)	5	14	84	136	38	4/14	121%	58	146	-	-	-
Implant 3	-	1	4	-	-		0%	-	4	-	1	1
PSI Implant 3 Distributed Inserted ('	-	1	4	-	-		-%	-	4	-	1	1
Implant 3 Insertion	-	4	17	11	-		0%	5	22	-	4	4
PSI Implant 3 Inserted	-	(1)	(4)	-	-		-%	-	(4)	-	(1)	(1)
Non-PSI Implant 3 Inserted	-	5	21	11	-		-%	5	26	-	5	5
Injectable 1	-	-	-	-	(1)		0%	(5)	(5)	-	-	-
PSI Injectable 1 Distributed Provide	-	-	-	-	(1)		-%	(5)	(5)	-	-	-
Injectable 1 Provided	1	3	22	42	5		340%	24	46	-	-	-
PSI Injectable 1 Provided	-	-	-	-	1		(100)%	5	5	-	-	-
Non-PSI Injectable 1 Provided	1	4	22	42	4		450%	19	41	-	-	-
Injectable 3	-	1	-	-	(3)		0%	(7)	(7)	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Injectable 3 Distributed Provide	-	1	-	-	(3)		-%	(7)	(7)	-	-	-
Injectable 3 Provided	4	3	27	58	3		800%	26	53	-	-	-
PSI Injectable 3 Provided	-	(1)	-	-	3		(100)%	7	7	-	-	-
Non-PSI Injectable 3 Provided	4	4	27	58	-		-%	19	46	-	-	-
IUD 10	-	-	1	-	(1)		0%	(1)	-	-	-	-
PSI IUD 10 Distributed Inserted (1)	-	-	1	-	(1)		-%	(1)	-	-	-	-
IUD 10 Insertion	3	2	12	15	5		140%	7	19	-	5	5
PSI IUD 10 Inserted	-	-	(1)	-	1		(200)%	1	-	-	-	-
Non-PSI IUD 10 Inserted	3	2	13	15	4		225%	6	19	-	5	5
IUD 5	-	-	-	-	-		0%	(4)	(4)	-	-	-
PSI IUD 5 Distributed Inserted (1)	-	-	-	-	-		-%	(4)	(4)	-	-	-
IUD 5 Insertion	-	-	-	-	-		0%	7	7	-	-	-
PSI IUD 5 Inserted	-	-	-	-	-		-%	4	4	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	-		-%	3	3	-	-	-
Lubricant	15,026	13,724	100,043	-	42,919		133%	67,107	752,984	-	-	-
Vive Lub (sachet)	6,310	9,003	72,570	-	16,620	3/05	337%	27,717	509,877	-	-	-
Vive Lub (tube)	1,401	642	4,316	-	8,187	3/05	(47)%	14,698	78,045	-	-	-
Vive Lub Natural (sachet)	6,280	2,597	14,670	-	12,951	1/10	13%	16,191	124,446	-	-	-
Vive Lub Natural (tube)	1,035	1,482	8,487	-	5,161	1/10	64%	8,501	40,616	-	-	-
OCs	-	-	-	-	(1)		0%	(20)	(20)	-	-	-
PSI OCs Distributed Provided	-	-	-	-	(1)		-%	(20)	(20)	-	-	-
OCs Provided	-	1	7	40	2		250%	26	33	-	-	-
PSI OCs Provided	-	-	-	-	1		(100)%	20	20	-	-	-
Non-PSI OCs Provided	-	2	7	40	1		600%	6	13	-	-	-
Referral to HIV Testing Services	-	-	-	-	24		(100)%	27	27	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to HIV Testing & Counseling	-	-	-	-	24		(100)%	27	27	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		0%	24	24	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	24	24	-	-	-
<b>Nicaragua</b>										<b>5,763</b>	<b>3,540</b>	<b>9,303</b>
Condom	<b>748,344</b>	<b>532,896</b>	<b>4,037,032</b>	<b>5,632,395</b>	<b>3,301,462</b>		22%	<b>4,590,438</b>	<b>70,139,694</b>	<b>5,763</b>	<b>1,488</b>	<b>7,251</b>
Bodyguard	-	160	84,768	30,000	77,920	2/04	9%	111,568	11,102,320	121	31	152
Combo-Pack Lub Fresa	-	1,125	7,104	14,041	5,904	5/11	20%	9,152	49,368	10	3	13
Combo-Pack Lub Natural	-	971	3,856	6,797	3,120	10/10	24%	5,904	25,696	6	1	7
Vive	576,000	362,560	2,835,552	4,182,330	2,282,256	4/98	24%	2,984,352	45,058,064	4,048	1,045	5,093
Vive Colors/Mas Colors	121,824	103,408	696,120	916,570	594,900	4/02	17%	998,172	10,526,060	994	257	1,250
Vive Mas Fuerte /Retardante	43,296	39,456	259,848	308,902	225,456	6/04	15%	333,384	1,770,230	371	96	467
Vive Mas Natural /Sensitivo	3,744	13,568	85,440	126,853	65,484	6/04	30%	95,868	875,339	122	32	153
Vive Mas/Texturizado	3,480	11,648	64,344	46,902	46,422	6/04	39%	52,038	732,617	92	24	116
HIV Testing Services	-	-	47	-	539		(91)%	616	6,985	-	-	-
VCT Individual (HIV-Negative)	-	-	43	-	502	12/09	(91)%	567	6,896	-	-	-
VCT Individual (HIV-Positive)	-	-	4	-	37	12/09	(89)%	49	89	-	-	-
Implant 3	(19)	(10)	(105)	100	166		(163)%	333	571	-	(26)	(26)
PSI Implant 3 Distributed Inserted (	(19)	(10)	(169)	(300)	(412)	3/16	-%	(612)	(938)	-	(41)	(41)
Implanon	-	-	64	400	578	7/15	(89)%	945	1,509	-	16	16
Implant 3 Insertion	19	10	169	300	412		(59)%	612	938	-	46	46
PSI Implant 3 Inserted	19	10	169	300	412	3/16	(59)%	612	938	-	46	46
Implant 5	91	96	598	(100)	184		225%	264	1,634	-	214	214
PSI Implant 5 Distributed Inserted (	(119)	(66)	(440)	(1,400)	(114)		-%	(232)	(2,481)	-	(157)	(157)
Jadelle	210	162	1,038	1,300	298	12/08	248%	496	4,115	-	371	371

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 5 Insertion	119	66	440	1,400	114		286%	232	2,481	-	175	175
PSI Implant 5 Inserted	119	66	440	1,400	114		286%	232	2,481	-	175	175
Injectable 1 Provided	34	24	126	-	20		530%	75	201	-	1	1
Non-PSI Injectable 1 Provided	34	24	126	-	20		530%	75	201	-	1	1
Injectable 3 Provided	2	1	14	-	3		367%	17	31	-	-	-
Non-PSI Injectable 3 Provided	2	1	14	-	3		367%	17	31	-	-	-
IUD 10	115	288	1,511	750	3,666		(59)%	4,254	36,852	-	667	667
PSI IUD 10 Distributed Inserted (1)	(254)	(204)	(1,607)	(6,000)	(1,505)		-%	(2,283)	(41,533)	-	(709)	(709)
Copper T 380	359	492	3,108	6,750	5,119	12/08	(39)%	6,485	78,323	-	1,371	1,371
Copper-T 380-A IUD	10	-	10	-	52	3/16	(81)%	52	62	-	4	4
IUD 10 Insertion	254	204	1,607	6,000	1,505		7%	2,283	41,533	-	788	788
PSI IUD 10 Inserted	254	204	1,607	6,000	1,505		7%	2,283	41,533	-	788	788
IUD 5	46	29	165	50	50		230%	61	226	-	54	54
PSI IUD 5 Distributed Inserted (1)	-	-	(1)	(800)	-		-%	-	(1)	-	-	-
Copper T375 Sleek	46	29	166	850	50	3/16	232%	61	227	-	55	55
IUD 5 Insertion	-	-	1	800	-		0%	-	1	-	-	-
PSI IUD 5 Inserted	-	-	1	800	-		-%	-	1	-	-	-
Lubricant	6,460	17,251	118,885	-	99,612		19%	141,496	837,752	-	-	-
Vive Lub (sachet)	-	7,753	43,138	-	44,913	3/05	(4)%	60,504	387,677	-	-	-
Vive Lub (tube)	3,105	2,186	16,909	-	11,402	3/05	48%	16,332	102,993	-	-	-
Vive Lub Natural (sachet)	-	5,326	43,954	-	34,757	1/10	26%	52,175	282,739	-	-	-
Vive Lub Natural (tube)	3,355	1,986	14,884	-	8,540	1/10	74%	12,485	64,343	-	-	-
Manual Vacuum Aspiration for PAC	125	36	372	325	146		155%	425	797	-	13	13
MVA for PAC	125	36	372	325	146	5/16	155%	425	797	-	13	13
Misoprostol for PAC (Oral)	2,048	(20)	4,627	29,000	-		0%	1,328	5,955	-	47	47

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Misoprostol for PAC Oral Dist F	-	(20)	(93)	-	-		-%	-	(93)	-	(1)	(1)
Misoprostol for PAC (oral)	2,048	-	4,720	29,000	-	10/16	-%	1,328	6,048	-	48	48
Misoprostol for PAC (oral) Provided	24	20	117	-	-		0%	-	117	-	1	1
PSI Misoprostol for PAC (oral) Prov	-	20	93	-	-		-%	-	93	-	1	1
Non-PSI Misoprostol for PAC (oral) I	24	-	24	-	-		-%	-	24	-	-	-
OCs	3	-	14,434	91,000	52,459		(72)%	76,754	104,973	-	68	68
PSI OCs Distributed Provided	-	-	-	-	(6)		-%	(9)	(9)	-	-	-
Segura Plus	3	-	14,434	91,000	52,465	7/15	(72)%	76,763	104,982	-	68	68
OCs Provided	15	10	59	-	6		883%	40	99	-	-	-
PSI OCs Provided	-	-	-	-	6		(100)%	9	9	-	-	-
Non-PSI OCs Provided	15	10	59	-	-		-%	31	90	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		0%	35	35	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	35	35	-	-	-
Tubal Ligation	-	1	3	-	-		0%	-	3	-	4	4
Tubal Ligation	-	1	3	-	-		-%	-	3	-	4	4
<b>Panama</b>										2,925	448	3,373
Condom	169,752	191,563	1,949,985	4,387,000	2,461,920		(21)%	3,655,170	38,097,178	2,922	448	3,370
Bodyguard	-	-	-	-	3,456	12/14	(100)%	3,700	27,460	-	-	-
Vive	56,544	128,608	1,383,792	3,552,285	2,042,208	7/00	(32)%	3,056,256	31,492,289	2,074	318	2,391
Vive Colors/Mas Colors	77,760	37,344	304,467	470,962	194,640	3/05	56%	270,696	3,746,748	456	70	526
Vive Mas Fuerte /Retardante	19,416	10,736	144,024	207,076	139,152	3/05	4%	201,110	1,456,999	216	33	249
Vive Mas Natural /Sensitivo	8,616	8,547	71,865	94,353	50,832	3/05	41%	73,632	746,417	108	17	124
Vive Mas/Texturizado	7,416	6,328	45,837	62,324	31,632	3/05	45%	49,776	627,265	69	11	79
HIV Testing Services	507	160	1,839	2,537	1,303		41%	1,668	17,088	3	-	3

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 8**

**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Negative)	481	152	1,759	2,417	1,170	12/11	50%	1,502	16,575	3	-	3
VCT Individual (HIV-Positive)	26	7	80	120	133	12/11	(40)%	166	513	-	-	-
<b>Lubricant</b>	<b>9,804</b>	<b>4,200</b>	<b>38,794</b>	-	<b>34,418</b>		<b>13%</b>	<b>47,491</b>	<b>419,998</b>	-	-	-
Vive Lub (sachet)	150	(517)	3,600	-	20,000	2/09	(82)%	22,573	246,376	-	-	-
Vive Lub (tube)	902	1,933	10,652	-	6,065	2/09	76%	8,965	63,594	-	-	-
Vive Lub Natural (sachet)	7,700	483	9,850	-	1,850	5/11	432%	5,400	52,455	-	-	-
Vive Lub Natural (tube)	1,052	2,300	14,692	-	6,503	5/11	126%	10,553	57,573	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		0%	93	93	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	93	93	-	-	-
Zika Prevention Kit	-	-	-	-	-		0%	111,960	111,960	-	-	-
Zika Prevention Kit	-	-	-	-	-	7/16	-%	111,960	111,960	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Other</b>										<b>56,684</b>	<b>57,612</b>	<b>114,297</b>
<b>Dominican Republic</b>										<b>10,592</b>	<b>3,015</b>	<b>13,607</b>
CD4 Tests Provided to HIV+ Clients	-	-	113	-	-		0%	118	231	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	113	-	-		-%	118	231	-	-	-
Condom	639,600	488,761	6,251,636	8,669,760	5,344,254		17%	8,230,724	178,305,953	8,239	2,328	10,567
Pante	639,600	488,761	6,251,636	8,669,760	5,344,254	9/03	17%	8,230,724	178,305,953	8,239	2,328	10,567
Free Condom	436,000	271,000	1,756,000	684,000	1,042,000		69%	1,150,000	9,122,472	2,314	654	2,968
No Logo	436,000	271,000	1,756,000	684,000	1,042,000	4/10	69%	1,150,000	9,122,472	2,314	654	2,968
HIV Testing Services	-	-	16,136	-	-		0%	24,360	54,919	39	-	39
VCT Individual (HIV-Negative)	-	-	15,804	-	-	9/13	-%	23,751	53,734	38	-	38
VCT Individual (HIV-Positive)	-	-	332	-	-	9/13	-%	609	1,185	1	-	1
Implant 3 Insertion	-	14	92	-	-		0%	-	3,721	-	25	25
Non-PSI Implant 3 Inserted	-	14	92	-	-	11/13	-%	-	3,721	-	25	25
Injectable 2 Provided	-	12	73	-	-		0%	-	149	-	1	1
Non-PSI Injectable 2 Provided	-	12	73	-	-		-%	-	149	-	1	1
Injectable 3 Provided	-	18	82	-	-		0%	-	350	-	2	2
Non-PSI Injectable 3 Provided	-	18	82	-	-	3/16	-%	-	350	-	2	2
IUD 10 Insertion	-	1	11	-	-		0%	-	267	-	6	6
Non-PSI IUD 10 Inserted	-	1	11	-	-	11/13	-%	-	267	-	6	6
Lubricant	9,020	17,667	106,020	-	341,000		(69)%	360,000	1,410,992	-	-	-
No Logo Lubricant (4.5 gram sachet	9,020	17,667	106,020	-	341,000	3/13	(69)%	360,000	1,410,992	-	-	-
OCs Provided	-	15	57	-	-		0%	-	2,536	-	-	-
Non-PSI OCs Provided	-	15	57	-	-	3/16	-%	-	2,536	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		0%	41	41	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	41	41	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Haiti</b>										<b>35,539</b>	<b>51,272</b>	<b>86,810</b>
Antiretroviral Treatment (Currently Enr	<b>32,432</b>	<b>31,786</b>	<b>202,191</b>	<b>8,000</b>	-		<b>0%</b>	-	<b>202,191</b>	<b>34,320</b>	-	<b>34,320</b>
Antiretroviral Treatment (Currently E	<b>32,432</b>	<b>31,786</b>	<b>202,191</b>	<b>8,000</b>	-		<b>-%</b>	-	<b>202,191</b>	<b>34,320</b>	-	<b>34,320</b>
Antiretroviral Treatment (Newly Enrolle	<b>533</b>	<b>431</b>	<b>3,140</b>	-	-		<b>0%</b>	-	<b>3,140</b>	-	-	-
Antiretroviral Treatment (Newly Enrc	<b>533</b>	<b>431</b>	<b>3,140</b>	-	-		<b>-%</b>	-	<b>3,140</b>	-	-	-
Cervical Cancer-VIA and Cryotherapy	<b>69</b>	-	<b>69</b>	-	-		<b>0%</b>	-	<b>109</b>	-	<b>6</b>	<b>6</b>
Cervical Cancer-VIA and Cryotherap	<b>69</b>	-	<b>69</b>	-	-		<b>-%</b>	-	<b>109</b>	-	<b>6</b>	<b>6</b>
Cervical Cancer-VIA/VILI Screening	<b>337</b>	-	<b>337</b>	-	-		<b>0%</b>	-	<b>759</b>	-	-	-
Cervical Cancer-VIA/VILI Screening	<b>337</b>	-	<b>337</b>	-	-		<b>-%</b>	-	<b>759</b>	-	-	-
Condom	-	-	-	<b>250,000</b>	-		<b>0%</b>	-	<b>135,350,664</b>	-	-	-
Pante	-	-	-	<b>250,000</b>	-	11/90	<b>-%</b>	-	<b>135,350,664</b>	-	-	-
Diarrhea Treatment Kit	-	-	-	<b>40,000</b>	-		<b>0%</b>	-	-	-	-	-
Salusel & Saluzinc	-	-	-	<b>40,000</b>	-	3/17	<b>-%</b>	-	-	-	-	-
Emergency Contraception	-	-	-	<b>17,500</b>	-		<b>0%</b>	-	-	-	-	-
Pronta1	-	-	-	<b>17,500</b>	-	3/17	<b>-%</b>	-	-	-	-	-
Fever Cases Attended	-	<b>1,466</b>	<b>31,104</b>	-	-		<b>0%</b>	<b>1,187</b>	<b>32,291</b>	-	-	-
Fever Cases Attended	-	<b>1,466</b>	<b>31,104</b>	-	-		<b>-%</b>	<b>1,187</b>	<b>32,291</b>	-	-	-
Fever Cases Tested with Microscopy	-	<b>4,692</b>	<b>93,384</b>	-	-		<b>0%</b>	<b>4,934</b>	<b>98,318</b>	-	-	-
Fever Cases Tested with Microscop	-	<b>4,692</b>	<b>93,384</b>	-	-		<b>-%</b>	<b>4,934</b>	<b>98,318</b>	-	-	-
Fever Cases Tested with RDTs	-	<b>21,376</b>	<b>417,852</b>	-	-		<b>0%</b>	<b>23,956</b>	<b>441,808</b>	-	-	-
Fever Cases Tested with RDTs	-	<b>21,376</b>	<b>417,852</b>	-	-		<b>-%</b>	<b>23,956</b>	<b>441,808</b>	-	-	-
Free Condom	-	-	-	<b>7,000,000</b>	-		<b>0%</b>	-	-	-	-	-
Generic Condom	-	-	-	<b>7,000,000</b>	-	3/17	<b>-%</b>	-	-	-	-	-
HIV Testing Services	<b>20,579</b>	<b>20,620</b>	<b>151,191</b>	<b>155,000</b>	-		<b>0%</b>	<b>313,415</b>	<b>491,840</b>	<b>1,219</b>	-	<b>1,219</b>
VCT Individual (HIV-Negative)	<b>3,164</b>	<b>20,037</b>	<b>129,922</b>	<b>150,000</b>	-	4/10	<b>-%</b>	<b>306,390</b>	<b>462,938</b>	<b>1,048</b>	-	<b>1,048</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Positive)	17,415	583	21,269	5,000	-	4/10	-%	7,025	28,902	171	-	171
Implant 3	-	672	2,016	350	-		0%	-	2,016	-	1,938	1,938
Implanon	-	-	-	350	-	3/17	-%	-	-	-	-	-
Implanon NXT	-	672	2,016	-	-	7/17	-%	-	2,016	-	1,938	1,938
Implant 3 Insertion	132	-	132	-	-		0%	-	132	-	141	141
Non-PSI Implant 3 Inserted	132	-	132	-	-		-%	-	132	-	141	141
Injectable 3	-	-	-	57,500	-		0%	-	-	-	-	-
Saluplan Piki	-	-	-	50,000	-	3/17	-%	-	-	-	-	-
Sayana Press	-	-	-	7,500	-	3/17	-%	-	-	-	-	-
Injectable 3 Provided	12	-	12	-	-		0%	-	12	-	1	1
Non-PSI Injectable 3 Provided	12	-	12	-	-		-%	-	12	-	1	1
IUD 10	17	269	850	100	88		866%	88	2,224	-	1,487	1,487
Confiance Plus IUD	17	269	850	100	88	12/13	866%	88	2,224	-	1,487	1,487
IUD 10 Insertion	145	-	145	-	-		0%	-	145	-	282	282
Non-PSI IUD 10 Inserted	145	-	145	-	-		-%	-	145	-	282	282
LLIN	-	-	-	375,000	-		0%	-	2,987,900	-	-	-
LLIN Free	-	-	-	375,000	-	1/08	-%	-	2,987,900	-	-	-
Malaria PPT (Non-ACT)	-	-	-	11,000	-		0%	-	316,240	-	-	-
Chloroquine	-	-	-	11,000	-	3/12	-%	-	316,240	-	-	-
OCs	-	-	-	117,500	-		0%	-	-	-	-	-
MEURI	-	-	-	17,500	-	3/17	-%	-	-	-	-	-
Saluplan Grenn	-	-	-	100,000	-	3/17	-%	-	-	-	-	-
OCs Provided	108	-	108	-	-		0%	-	108	-	2	2
Non-PSI OCs Provided	108	-	108	-	-		-%	-	108	-	2	2
ORS	-	-	300,000	330,000	249,840		20%	300,000	10,047,338	-	10,285	10,285

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Salusel	-	-	-	80,000	-	3/17	-%	-	-	-	-	-
Sel Lavi	-	-	300,000	250,000	249,840	10/99	20%	300,000	10,047,338	-	10,285	10,285
Positive RDTs	-	150	25,283	-	-		0%	1,069	26,352	-	-	-
Positive RDTs	-	150	25,283	-	-		-%	1,069	26,352	-	-	-
STI Screening	20,724	20,767	141,460	-	179,161		(21)%	222,184	363,644	-	-	-
STI Screening	20,724	20,767	141,460	-	179,161		(21)%	222,184	363,644	-	-	-
TB Diagnosis	3,121	986	9,484	-	-		0%	11,406	20,890	-	-	-
TB Diagnosis	3,121	986	9,484	-	-		-%	11,406	20,890	-	-	-
TB DOTS	4,152	1,125	10,637	10,000	-		0%	9,997	20,634	-	36,409	36,409
TB DOTS	4,152	1,125	10,637	10,000	-		-%	9,997	20,634	-	36,409	36,409
TB Screening	4,008	1,312	11,507	-	-		0%	12,026	23,533	-	-	-
TB Screening	4,008	1,312	11,507	-	-		-%	12,026	23,533	-	-	-
Treatment for Nonherpetic Genital Ulc	563	597	4,323	-	-		0%	1,290	5,613	-	721	721
Treatment for Nonherpetic Genital U	563	597	4,323	-	-		-%	1,290	5,613	-	721	721
<b>Paraguay</b>										10,553	3,326	13,879
Condom	276,458	516,025	2,035,516	4,061,760	1,918,636		6%	3,064,620	38,444,894	10,553	747	11,300
Pantera	159,433	266,847	1,081,403	1,982,400	1,119,386	8/98	(3)%	1,649,108	34,457,288	5,607	397	6,003
Pantera Banana	13,127	20,986	85,938	240,000	-	9/16	-%	69,557	155,495	446	32	477
Pantera Chocolate	18,553	33,196	129,621	278,400	159,692	2/14	(19)%	234,083	686,599	672	48	720
Pantera Frutilla	-	-	-	326,400	-		-%	-	-	-	-	-
Pantera Retardant	20,631	82,261	289,393	598,560	339,402	2/14	(15)%	528,012	1,436,190	1,500	106	1,607
Pantera Ribbed	12,086	26,105	99,445	180,000	113,842	2/14	(13)%	169,989	557,748	516	36	552
Pantera Strawberry	22,291	41,913	164,670	-	186,314	2/14	(12)%	280,297	832,954	854	60	914
Pantera Tachas	10,402	19,660	79,242	216,000	-	9/16	-%	61,081	140,323	411	29	440

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 8**

**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Pantera Tutti Frutti	19,935	25,057	105,804	240,000	-	9/16	-%	72,493	178,297	549	39	587
Emergency Contraception	27,952	49,800	200,559	319,000	202,576		(1)%	308,976	2,413,749	-	277	277
Pronta	27,952	49,800	200,559	319,000	202,576	2/04	(1)%	308,976	2,413,749	-	277	277
Multivitamin	252,780	356,840	1,535,850	2,476,080	1,089,570		41%	1,789,770	34,376,100	-	114	114
VitalDia	252,780	356,840	1,535,850	2,476,080	1,089,570	11/00	41%	1,789,770	34,376,100	-	114	114
OCs	70,840	113,534	467,659	810,000	507,183		(8)%	749,197	7,443,944	-	2,188	2,188
Segura	67,475	107,576	444,534	750,000	473,963	4/01	(6)%	706,380	7,250,972	-	2,080	2,080
Segura Plus	3,365	5,958	23,125	60,000	33,220	3/11	(30)%	42,817	192,972	-	108	108

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Americas - Caribbean</b>															
<b>Caribbean</b>							\$0		\$0	\$0	NA				
<u>Free Condom</u>															
GI GI (Got it? Get it!) Free Condom	08/2017	0	2,437	0	2,437	100%	\$0	NA	\$0	\$0	NA	0	852	NA	
<u>Lubricant A</u>															
GI GI (Got it? Get it!) Lube Sachet	08/2017	0	1,421	0	1,421	100%	\$0	NA	\$0	\$0	NA	0	494	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Americas - Central America</b>															
<b>Belize</b>							\$0		\$109	\$0	NA				
<u>Condom</u>															
GIGI (Got it? Get it!) Condom	08/2017	0	0	0	0	NA	\$0	NA	\$109	\$0	NA	0	0	NA	
<u>Free Female Condom</u>															
GIGI (Got it? Get it!) Free Female	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4	0	NA	
<u>Lubricant A</u>															
GIGI (Got it? Get it!) Lube Sachet	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	70	0	NA	
<b>Costa Rica</b>							\$0		\$34,611	\$0	NA				
<u>Condom</u>															
Combo Pack	08/2017	0	0	0	0	NA	\$0	NA	\$42	\$0	NA	0	0	NA	
Combo-Mix Lub Fresa	08/2017	320	30	0	350	9%	\$0	NA	\$177	\$0	NA	0	122	NA	
Combo-Pack Lub Fresa	08/2017	3,882	0	0	3,882	0%	\$0	NA	\$83	\$0	NA	12,958	2,050	6.32	
Tira Multilinea	08/2017	13,572	0	0	13,572	0%	\$0	NA	\$9,652	\$0	NA	0	7,075	NA	
Vive	08/2017	27,196	864	0	28,060	3%	\$0	NA	\$4,273	\$0	NA	135,155	37,089	3.64	
Vive Amor	08/2017	52,560	288	0	52,848	1%	\$0	NA	\$0	\$0	NA	249,120	61,792	4.03	
Vive Colors/Mas Colors	08/2017	42,162	606	0	42,768	1%	\$0	NA	\$6,756	\$0	NA	249,027	34,787	7.16	
Vive Mas Fuerte /Retardante	08/2017	3,000	120	0	3,120	4%	\$0	NA	\$2,170	\$0	NA	85,680	1,904	45.00	
Vive Mas Natural /Sensitivo	08/2017	13,227	144	0	13,371	1%	\$0	NA	\$5,731	\$0	NA	86,928	13,809	6.30	
Vive Mas/Texturizado	08/2017	1,131	39	0	1,170	3%	\$0	NA	\$518	\$0	NA	0	2,084	NA	
<u>Lubricant A</u>															
Vive Lub Natural (sachet)	08/2017	150	122	0	272	45%	\$0	NA	\$73	\$0	NA	13,635	416	32.80	
Vive Lub Sachet Fresa 5 mL	08/2017	200	122	0	322	38%	\$0	NA	\$107	\$0	NA	9,382	474	19.79	
<u>Lubricant E</u>															
Vive Lub Natural (tube)	08/2017	345	0	0	345	0%	\$0	NA	\$1,431	\$0	NA	12,792	383	33.40	
Vive Lub Tubo Fresa 120 mL	08/2017	1,246	0	0	1,246	0%	\$0	NA	\$3,598	\$0	NA	9,478	912	10.40	
<b>El Salvador</b>							\$52,820		\$146,893	\$87,678	1.68				
<u>Medicines &amp; Supplies</u>															
Intrauterine Vacuum cleaner for p	08/2017	8	0	0	8	0%	\$496	0%	\$0	\$3,283	NA	12	54	0.22	
Accessories for the vacuum cleane	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	11	12	0.94	
<u>Other Revenues</u>															
IUD Insertion Kits	08/2017	3	0	0	3	0%	\$66	0%	\$0	\$44	NA	26	2	13.00	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>El Salvador</b>							\$52,820		\$146,893	\$87,678	1.68				
<b>Condom</b>															
Combo-Mix Lub Fresa	08/2017	0	0	0	0	NA	\$0	NA	\$94	\$31	3.00	0	85	NA	
Combo-Mix Lub Natural	08/2017	800	0	0	800	0%	\$325	100%	\$443	\$148	3.00	80	373	0.21	
Combo-Pack Lub Fresa	08/2017	320	0	0	320	0%	\$130	100%	\$130	\$43	3.00	24,640	107	231.00	
Vive	08/2017	20,976	144	0	21,120	1%	\$4,016	94%	\$27,994	\$17,952	1.56	298,176	95,392	3.13	
Vive Amor	08/2017	52,176	720	0	52,896	1%	\$7,083	75%	\$22,609	\$19,092	1.18	800,928	147,664	5.42	
Vive Colors/Mas Colors	08/2017	43,608	264	0	43,872	1%	\$11,746	91%	\$42,209	\$19,414	2.17	764,784	51,832	14.76	
Vive Mas Fuerte /Retardante	08/2017	10,416	120	0	10,536	1%	\$2,824	81%	\$6,398	\$4,164	1.54	152,568	16,536	9.23	
Vive Mas Natural /Sensitivo	08/2017	8,424	0	0	8,424	0%	\$2,284	91%	\$17,152	\$6,445	2.66	111,248	8,664	12.84	
Vive Mas/Texturizado	08/2017	6,912	0	0	6,912	0%	\$1,867	87%	\$2,214	\$1,950	1.14	48,552	7,640	6.35	
<b>Lubricant A</b>															
Vive Lub (sachet)	08/2017	33,400	0	0	33,400	0%	\$5,022	96%	\$6,120	\$4,193	1.46	1,300	30,100	0.04	
Vive Lub Natural (sachet)	08/2017	18,450	0	0	18,450	0%	\$2,777	95%	\$4,935	\$2,524	1.96	950	18,183	0.05	
<b>Lubricant E</b>															
Vive Lub (tube)	08/2017	746	0	0	746	0%	\$1,809	96%	\$4,363	\$2,440	1.79	644	1,121	0.57	
Vive Lub Natural (tube)	08/2017	1,371	0	0	1,371	0%	\$3,306	98%	\$3,763	\$2,323	1.62	5,976	1,026	5.82	
<b>Micronutrient Powder</b>															
VitalDia Kids	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	30	0	NA	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	08/2017	32	0	0	32	0%	\$23	0%	\$164	\$9	17.34	2,368	13	177.60	
<b>Zika Prevention Kit</b>															
Zika Prevention Kit	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	133	12	11.40	
<b>Implant 5</b>															
Jadelle	08/2017	28	9	0	37	24%	\$532	0%	\$226	\$498	0.45	987	42	23.31	
<b>IUD 10</b>															
Copper T 380	08/2017	216	8	0	224	4%	\$435	0%	\$0	\$399	NA	17,663	209	84.38	
<b>OCs</b>															
Segura Plus	08/2017	8,000	0	0	8,000	0%	\$8,080	100%	\$8,080	\$2,725	2.96	2,080	2,686	0.77	
<b>Guatemala</b>							\$0		\$0	\$0	NA				
<b>HIV Test Kit</b>															
Determine	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	400	0	NA	
<b>Condom</b>															
Bodyguard	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	88,272	0	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Guatemala</b>							\$0		\$0	\$0	NA				
<b>Condom</b>															
Combo Pack	08/2017	1,190	0	0	1,190	0%	\$0	NA	\$0	\$0	NA	45,514	3,591	12.67	
Vive	08/2017	385,200	1,200	0	386,400	0%	\$0	NA	\$0	\$0	NA	1,457,277	343,456	4.24	
Vive Amor	08/2017	284,544	2,592	0	287,136	1%	\$0	NA	\$0	\$0	NA	3,540,240	445,632	7.94	
Vive Colors/Mas Colors	08/2017	63,648	2,928	0	66,576	4%	\$0	NA	\$0	\$0	NA	2,401,440	65,736	36.53	
Vive Mas Fuerte /Retardante	08/2017	46,944	288	0	47,232	1%	\$0	NA	\$0	\$0	NA	776,160	38,448	20.19	
Vive Mas Natural /Sensitivo	08/2017	16,440	264	0	16,704	2%	\$0	NA	\$0	\$0	NA	243,720	12,792	19.05	
Vive Mas/Texturizado	08/2017	288	120	0	408	29%	\$0	NA	\$0	\$0	NA	29,520	3,896	7.58	
<b>Lubricant A</b>															
Vive Lub (sachet)	08/2017	740	0	0	740	0%	\$0	NA	\$0	\$0	NA	149,304	1,613	92.54	
Vive Lub Natural (sachet)	08/2017	1,800	0	0	1,800	0%	\$0	NA	\$0	\$0	NA	36,774	3,808	9.66	
<b>Lubricant E</b>															
Vive Lub (tube)	08/2017	2,113	0	0	2,113	0%	\$0	NA	\$0	\$0	NA	10,533	1,437	7.33	
Vive Lub Natural (tube)	08/2017	2,469	0	0	2,469	0%	\$0	NA	\$0	\$0	NA	5,152	1,586	3.25	
<b>Repellant</b>															
Repellant	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	9,325	0	NA	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	08/2017	0	0	55,000	55,000	NA	\$0	NA	\$0	\$0	NA	2,616	560	4.67	
<b>Implant 5</b>															
Jadelle	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,210	12	267.50	
<b>Injectable 1</b>															
Cyclofem	08/2017	2,150	0	0	2,150	0%	\$0	NA	\$0	\$0	NA	82,778	3,134	26.42	
<b>IUD 10</b>															
Copper T 380	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	207	101	2.05	
Copper T 380 Postpartum	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	62	0	NA	
<b>IUD 5</b>															
IUD Sleek	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	57	0	NA	
<b>OCs</b>															
Oralcon-F (28 tablets Blister)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	5	0	NA	
Segura Plus	08/2017	9,000	0	0	9,000	0%	\$0	NA	\$0	\$0	NA	1,087	5,069	0.21	
<b>Guatemala SA</b>							\$0		\$0	\$0	NA				
<b>Condom</b>															
Vive	08/2017	4,752	0	0	4,752	0%	\$0	NA	\$0	NA	NA	67,248	NA	NA	



Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Guatemala SA</b>							\$0		\$0	\$0	NA				
<b>Condom</b>															
Vive Amor	08/2017	40,032	0	0	40,032	0%	\$0	NA	\$0	NA	NA	31,968	NA	NA	
<b>Lubricant E</b>															
Vive Lub (tube)	08/2017	6	0	0	6	0%	\$0	NA	\$0	NA	NA	114	NA	NA	
Vive Lub Natural (tube)	08/2017	6	0	0	6	0%	\$0	NA	\$0	NA	NA	114	NA	NA	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	08/2017	12,960	0	0	12,960	0%	\$0	NA	\$0	NA	NA	44,040	NA	NA	
<b>Implant 5</b>															
Jadelle	08/2017	522	0	0	522	0%	\$0	NA	\$0	NA	NA	1,095	NA	NA	
<b>Injectable 1</b>															
Cyclofem	08/2017	639	0	0	639	0%	\$0	NA	\$0	NA	NA	2,361	NA	NA	
<b>IUD 10</b>															
Copper T 380	08/2017	2,634	0	0	2,634	0%	\$0	NA	\$0	NA	NA	32,663	NA	NA	
Copper T 380 Postpartum	08/2017	52	0	0	52	0%	\$0	NA	\$0	NA	NA	2,694	NA	NA	
<b>IUD 5</b>															
IUD Sleek	08/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	1,370	NA	NA	
<b>Honduras</b>							\$0		\$0	\$0	NA				
<b>Condom</b>															
Combo-Mix Lub Fresa	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	288	0	NA	
Combo-Mix Lub Natural	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	320	0	NA	
Combo-Pack Lub Fresa	08/2017	1,296	0	0	1,296	0%	\$0	NA	\$0	\$0	NA	7,280	1,616	4.50	
Combo-Pack Lub Natural	08/2017	240	0	0	240	0%	\$0	NA	\$0	\$0	NA	4,160	181	22.94	
Vive	08/2017	75,024	336	0	75,360	0%	\$0	NA	\$0	\$0	NA	730,608	130,528	5.60	
Vive Amor	08/2017	264,144	288	0	264,432	0%	\$0	NA	\$0	\$0	NA	1,224,048	136,432	8.97	
Vive Colors/Mas Colors	08/2017	76,128	4,138	0	80,266	5%	\$0	NA	\$0	\$0	NA	295,632	80,000	3.70	
Vive Mas Fuerte /Retardante	08/2017	20,832	0	0	20,832	0%	\$0	NA	\$0	\$0	NA	57,720	13,512	4.27	
Vive Mas Natural /Sensitivo	08/2017	6,888	0	0	6,888	0%	\$0	NA	\$0	\$0	NA	20,208	4,936	4.09	
Vive Mas/Texturizado	08/2017	8,760	0	0	8,760	0%	\$0	NA	\$0	\$0	NA	41,952	10,608	3.95	
<b>Lubricant A</b>															
Vive Lub (sachet)	08/2017	6,310	0	0	6,310	0%	\$0	NA	\$0	\$0	NA	10,352	7,203	1.44	
Vive Lub Natural (sachet)	08/2017	6,280	0	0	6,280	0%	\$0	NA	\$0	\$0	NA	12,832	2,640	4.86	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Honduras</b>							\$0		\$0	\$0	NA				
<b><u>Lubricant E</u></b>															
Vive Lub (tube)	08/2017	1,401	0	0	1,401	0%	\$0	NA	\$0	\$0	NA	2,259	1,103	2.05	
Vive Lub Natural (tube)	08/2017	1,035	0	0	1,035	0%	\$0	NA	\$0	\$0	NA	89	1,173	0.08	
<b>Nicaragua</b>							\$0		\$0	\$81,380	NA				
<b><u>Condom</u></b>															
Bodyguard	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$11	NA	90,536	160	565.85	
Combo-Pack Lub Fresa	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$365	NA	10,304	971	10.62	
Combo-Pack Lub Natural	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$365	NA	3,088	971	3.18	
Vive	08/2017	572,736	3,264	0	576,000	1%	\$0	NA	\$0	\$49,184	NA	1,843,827	418,144	4.41	
Vive Colors/Mas Colors	08/2017	90,504	31,320	0	121,824	26%	\$0	NA	\$0	\$8,849	NA	649,188	110,016	5.90	
Vive Mas Fuerte /Retardante	08/2017	40,368	2,928	0	43,296	7%	\$0	NA	\$0	\$8,360	NA	118,464	45,064	2.63	
Vive Mas Natural /Sensitivo	08/2017	2,808	936	0	3,744	25%	\$0	NA	\$0	\$2,399	NA	126,433	10,144	12.46	
Vive Mas/Texturizado	08/2017	3,480	0	0	3,480	0%	\$0	NA	\$0	\$1,308	NA	18,703	6,624	2.82	
<b><u>Lubricant A</u></b>															
Vive Lub (sachet)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$1,163	NA	54	6,525	0.01	
Vive Lub Natural (sachet)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$828	NA	157	4,176	0.04	
<b><u>Lubricant E</u></b>															
Vive Lub (tube)	08/2017	3,031	74	0	3,105	2%	\$0	NA	\$0	\$3,413	NA	1,937	2,834	0.68	
Vive Lub Natural (tube)	08/2017	3,306	49	0	3,355	1%	\$0	NA	\$0	\$2,980	NA	687	2,611	0.26	
<b><u>Misoprostol for PAC (Oral)</u></b>															
Misoprostol for PAC (oral)	08/2017	2,048	0	0	2,048	0%	\$0	NA	\$0	\$0	NA	27,952	683	40.95	
<b><u>Implant 5</u></b>															
Jadelle	08/2017	210	0	0	210	0%	\$0	NA	\$0	\$1,875	NA	1,965	210	9.37	
<b><u>IUD 10</u></b>															
Copper T 380	08/2017	344	15	0	359	4%	\$0	NA	\$0	\$251	NA	1,236	601	2.06	
Copper-T 380-A IUD	08/2017	10	0	0	10	0%	\$0	NA	\$0	\$0	NA	4,938	3	1,481.40	
<b><u>IUD 5</u></b>															
Copper T375 Sleek	08/2017	46	0	0	46	0%	\$0	NA	\$0	\$32	NA	4,773	42	112.75	
<b><u>OCs</u></b>															
Segura Plus	08/2017	3	0	0	3	0%	\$0	NA	\$0	\$0	NA	17	1	17.00	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Panama</b>							\$0		\$0	\$0	NA				
<b><u>HIV Test Kit</u></b>															
Uni Gold Kit	08/2017	0	220	0	220	100%	\$0	NA	\$0	\$0	NA	1,444	210	6.89	
<b><u>Condom</u></b>															
Bodyguard	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	44,640	0	NA	
Vive	08/2017	56,448	96	0	56,544	0%	\$0	NA	\$0	\$0	NA	3,282,000	55,584	59.05	
Vive Colors/Mas Colors	08/2017	75,648	2,112	0	77,760	3%	\$0	NA	\$0	\$0	NA	895,464	47,496	18.85	
Vive Mas Fuerte /Retardante	08/2017	19,200	216	0	19,416	1%	\$0	NA	\$0	\$0	NA	159,624	10,248	15.58	
Vive Mas Natural /Sensitivo	08/2017	8,400	216	0	8,616	3%	\$0	NA	\$0	\$0	NA	250,776	7,819	32.07	
Vive Mas/Texturizado	08/2017	7,200	216	0	7,416	3%	\$0	NA	\$0	\$0	NA	83,592	6,800	12.29	
<b><u>Lubricant A</u></b>															
Vive Lub (sachet)	08/2017	0	150	0	150	100%	\$0	NA	\$0	\$0	NA	36,850	-1,300	-28.35	
Vive Lub Natural (sachet)	08/2017	7,550	150	0	7,700	2%	\$0	NA	\$0	\$0	NA	39,550	3,050	12.97	
<b><u>Lubricant E</u></b>															
Vive Lub (tube)	08/2017	900	2	0	902	0%	\$0	NA	\$0	\$0	NA	17,230	1,867	9.23	
Vive Lub Natural (tube)	08/2017	1,050	2	0	1,052	0%	\$0	NA	\$0	\$0	NA	12,526	2,151	5.82	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>Americas - Other</b>														
<b>Haiti</b>							\$25		\$10,920	\$7,333	1.49			
<b><u>Malaria PPT (Non-ACT) P</u></b>														
Primaquine Tablet	08/2017	0	0	1,883	1,883	NA	\$0	NA	\$0	\$0	NA	26,051	0	NA
<b><u>Malaria PPT (Non-ACT)</u></b>														
Chloroquine	08/2017	0	0	1,000	1,000	NA	\$0	NA	\$0	\$0	NA	1,100	0	NA
<b><u>Implant 3</u></b>														
Implanon NXT	08/2017	0	0	120	120	NA	\$0	NA	\$10,664	NA	NA	0	NA	NA
<b><u>IUD 10</u></b>														
Confiance Plus IUD	08/2017	17	0	-17	0	0%	\$25	0%	\$256	\$202	1.27	553	275	2.01
Copper-T 380-A IUD	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	993	0	NA
<b>Paraguay</b>							\$193,775		\$0	\$339,379	NA			
<b><u>Condom</u></b>														
Pantera	08/2017	158,073	1,360	-7	159,426	1%	\$31,927	65%	\$0	\$21,363	NA	759,966	319,992	2.37
Pantera Banana	08/2017	12,117	1,010	-1	13,126	8%	\$0	NA	\$0	\$0	NA	160,689	25,362	6.34
Pantera Chocolate	08/2017	17,403	1,150	-3	18,550	6%	\$0	NA	\$0	\$0	NA	206,203	39,380	5.24
Pantera Retardant	08/2017	20,061	570	0	20,631	3%	\$0	NA	\$0	\$0	NA	32,331	89,138	0.36
Pantera Ribbed	08/2017	11,136	950	4	12,090	8%	\$0	NA	\$0	\$0	NA	47,052	30,134	1.56
Pantera Strawberry	08/2017	21,186	1,105	2	22,293	5%	\$0	NA	\$0	\$0	NA	203,794	49,343	4.13
Pantera Tachas	08/2017	9,522	880	22	10,424	8%	\$0	NA	\$0	\$0	NA	175,861	23,127	7.60
Pantera Tutti Frutti	08/2017	18,915	1,020	-4	19,931	5%	\$0	NA	\$0	\$0	NA	138,443	31,702	4.37
<b><u>Multivitamin</u></b>														
VitalDia	08/2017	245,040	7,740	0	252,780	3%	\$18,927	95%	\$0	\$33,272	NA	98,430	441,100	0.22
<b><u>Emergency Contraception</u></b>														
Pronta	08/2017	27,951	1	-7	27,945	0%	\$63,416	87%	\$0	\$132,839	NA	1,626	59,118	0.03
<b><u>OCs</u></b>														
Segura	08/2017	67,475	0	55	67,530	0%	\$76,745	82%	\$0	\$146,445	NA	214,258	130,068	1.65
Segura Plus	08/2017	2,785	580	0	3,365	17%	\$2,759	95%	\$0	\$5,459	NA	52,734	7,080	7.45
<b>SFH Dominican Republic</b>							\$0		\$9,144	\$8,067	1.13			
<b><u>Condom</u></b>														
Pante	08/2017	472,320	167,280	0	639,600	26%	\$0	NA	\$9,144	\$8,067	1.13	29,990,276	503,415	59.57
<b><u>Free Condom</u></b>														
No Logo	08/2017	0	436,000	0	436,000	100%	\$0	NA	\$0	\$0	NA	6,289,528	414,333	15.18

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>SFH Dominican Republic</b>							\$0		\$9,144	\$8,067	1.13				
<u>Lubricant A</u>															
No Logo Lubricant (4.5 gram sach	08/2017	0	9,020	0	9,020	100%	\$0	NA	\$0	\$0	NA	2,292,173	20,673	110.88	



# Asia & Eastern Europe

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 8/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Asia and Eastern Eur	5,932	-	50	2,825	4,348,810	982	1,143,258	309	538	-	-	4,569
Cambodia	1,138	-	-	-	467,328	74	114,458	25	8	-	-	279
India	-	-	-	755	331,353	91	139,662	-	398	-	-	1,151
India LLC	2,768	-	-	-	844,457	161	169,528	-	58	-	-	523
Kazakhstan	6	-	-	-	83	-	11	-	-	-	-	-
Kyrgyzstan	9	-	-	-	-	-	-	-	-	-	-	-
Laos	33	-	-	2	67,547	12	21,566	-	-	-	-	26
Myanmar	1,542	-	-	1,117	420,360	71	90,138	284	72	-	-	1,475
Nepal	30	-	-	-	82,631	29	27,513	-	-	-	-	98
Pakistan	343	-	-	950	2,127,029	543	579,022	-	-	-	-	965
Papua New Guinea	38	-	-	-	5,115	1	725	-	1	-	-	1
Tajikistan	23	-	50	-	1,668	-	239	-	-	-	-	50
Viet Nam	-	-	-	-	1,239	-	396	-	1	-	-	1
<b>Total</b>	<b>157,111</b>	<b>40</b>	<b>50</b>	<b>3,475</b>	<b>13,336,209</b>	<b>7,893</b>	<b>3,294,983</b>	<b>69,963</b>	<b>2,961</b>	<b>3,265</b>	<b>-</b>	<b>83,723</b>

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Region and Product  
Period: 8  
Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Asia and Eastern Europe - Asia</b>									<b>283,972</b>	<b>1,086,060</b>	<b>1,370,033</b>
Antiretroviral Treatment (C	4,231	3,757	27,149	36,450	-	-%	1,661	28,810	4,743	-	4,743
Antiretroviral Treatment (I	292	272	2,002	2,100	-	-%	1,042	3,044	-	-	-
Cervical Cancer-Pap Sme:	-	-	304	-	2,807	(89)%	4,743	5,047	-	-	-
Cervical Cancer-VIA and C	-	-	420	-	1,419	(70)%	2,718	4,013	-	115	115
Cervical Cancer-VIA and F	-	-	79	-	-	-%	48	127	-	11	11
Cervical Cancer-VIA and F	-	-	419	-	-	-%	446	865	-	57	57
Cervical Cancer-VIA/VILI §	7	11	5,604	-	53,276	(89)%	98,040	107,329	-	-	-
Clean Delivery Kit	-	-	-	-	400	(100)%	400	260,026	-	-	-
Condom	19,100,806	18,052,846	136,316,919	293,359,477	115,759,756	18%	232,147,502	6,296,991,740	240,129	120,657	360,786
Condom Provided	-	-	-	-	31,187	(100)%	63,111	85,090	-	-	-
Diarrhea Treatment Kit	3,283	6,809	55,923	92,360	261,343	(79)%	443,466	5,916,660	-	1,718	1,718
Emergency Contraception	117,898	144,174	1,201,048	1,784,252	1,616,441	(26)%	2,360,728	17,900,848	-	4,881	4,881
Emergency Contraception	624	940	6,834	-	6,043	13%	9,101	27,450	-	30	30
Fecal Sludge Managemen	191	34	524	670	-	-%	921	1,445	-	-	-
Fecal Sludge Managemen	927,200	147,333	2,425,200	1,571,000	-	-%	3,021,000	5,446,200	-	134	134
Female Condom	5,340	10,567	74,285	152,960	78,225	(5)%	108,934	1,669,255	284	47	331
Fever Cases Attended	189,418	87,897	682,259	-	-	-%	657,831	1,340,090	-	-	-
Fever Cases Tested with F	189,399	87,897	682,240	-	-	-%	657,831	1,340,071	-	-	-
Free Condom	-	47,372	736,346	5,034,034	41,690	1,666%	681,034	6,912,969	1,955	489	2,444
Free Female Condom	-	-	4,000	34,000	-	-%	20,000	24,000	4	1	5
HIV Testing Services	10,383	10,379	71,923	113,553	44,298	62%	70,109	361,937	106	-	106



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Hypertension Diagnosis	4,840	410	6,221	-	-	-%	-	6,221	-	-	-
Hypertension Screening	7,448	963	10,508	-	-	-%	-	10,508	-	-	-
Hypertension_Controlled	3,687	406	5,034	-	-	-%	-	5,034	-	-	-
Implant 3	218	115	6,774	11,000	1,368	395%	2,657	9,431	-	2,028	2,028
Implant 3 Insertion	963	1,054	7,512	6,730	2,404	212%	4,155	11,943	-	3,486	3,486
Implant 5	371	395	2,993	3,250	2,222	35%	21,275	44,722	-	2,283	2,283
Implant 5 Insertion	237	362	2,515	2,525	2,182	15%	3,146	30,560	-	1,755	1,755
Injectable 1	3,350	7,868	56,148	79,473	54,789	2%	85,224	1,574,805	-	968	968
Injectable 1 Provided	2,158	2,894	25,044	-	19,511	28%	30,476	80,200	-	479	479
Injectable 2	14,842	23,555	215,372	225,406	202,453	6%	299,852	6,888,625	-	7,429	7,429
Injectable 2 Provided	1,958	1,799	16,208	-	14,187	14%	22,868	62,339	-	621	621
Injectable 3	134,181	159,596	1,129,429	1,857,118	1,088,263	4%	1,598,677	17,383,677	-	42,004	42,004
Injectable 3 Provided	27,812	34,388	254,700	9,500	23,340	991%	39,569	315,340	-	14,350	14,350
IUD 10	10,592	11,057	105,692	154,558	105,417	-%	161,290	356,518	-	133,743	133,743
IUD 10 Insertion	9,714	13,569	107,772	38,056	26,051	314%	47,793	402,518	-	133,319	133,319
IUD 5	6,969	9,242	120,736	399,227	20,312	494%	34,252	4,227,136	-	103,331	103,331
IUD 5 Insertion	16,856	11,790	121,462	-	136,127	(11)%	202,186	949,520	-	123,566	123,566
IUS 5	-	-	-	3,500	-	-%	-	-	-	-	-
LLIN	5,762	3,203	15,371	15,800	-	-%	22,280	37,651	-	1,192	1,192
LLIN (Hammock net)	-	-	-	550	-	-%	-	-	-	-	-
Lubricant	67,026	72,763	575,927	-	502,282	15%	712,089	9,184,897	-	-	-
Malaria PPT (ACT)	18,695	14,887	181,450	1,230,330	312,556	(42)%	466,511	3,337,485	-	25,122	25,122

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 8  
 Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Malaria PPT (Non-ACT)	103	187	1,180	344	5,036	(77)%	3,078	106,145	-	165	165
Malaria RDK	156,470	137,031	932,704	1,386,516	708,166	32%	1,231,291	8,872,168	-	-	-
Manual Vacuum Aspiratio	2,433	1,509	17,391	-	-	-%	31,135	48,526	-	892	892
Medical Abortion	66,524	68,697	506,641	954,436	293,956	72%	390,924	3,294,102	-	45,723	45,723
Medical Abortion Provider	527	732	5,105	-	-	-%	-	5,105	-	436	436
Micronutrient Powder	408,825	1,245,107	4,648,507	-	-	-%	97,980	4,746,487	-	-	-
Misoprostol for PAC (Oral	19,000	12,333	76,000	156,000	40,500	88%	124,500	345,900	-	1,320	1,320
Multivitamin	122,280	29,057	209,450	-	-	-%	-	209,450	-	50	50
Naloxone	-	669	2,066	5,892	-	-%	-	12,698	2,819	-	2,819
Needle & Syringe	310,900	478,533	4,041,411	6,082,749	2,455,605	65%	4,903,605	18,790,828	32,608	-	32,608
OCs	1,301,483	1,032,633	9,053,313	17,157,537	4,859,895	86%	9,152,550	126,711,968	-	76,620	76,620
OCs Provided	50,835	72,762	521,167	23,434	55,616	837%	91,978	671,527	-	7,979	7,979
ORS	95,856	98,081	484,123	2,370,620	737,885	(34)%	568,984	26,169,258	-	10,750	10,750
Pneumonia PPT	-	-	-	-	112,026	(100)%	127,866	1,057,411	-	-	-
Positive RDTs	11,432	950	17,163	-	-	-%	13,201	30,364	-	-	-
Positive RDTs Given First	10,699	923	15,616	-	-	-%	10,870	26,486	-	-	-
PUR	680,067	15,522	800,798	1,110,000	1,279,663	(37)%	2,080,716	16,414,360	-	19	19
QAACTs Provided after C	9,862	483	12,979	10,513	-	-%	7,361	20,340	-	1,874	1,874
Referral to HIV Testing Se	9	60	5,200	2,935	4,746	10%	10,424	34,935	8	-	8
Referral to Implant 3 Inse	-	-	-	-	-	-%	636	636	-	-	-
Referral to Implant 5 Inse	16	16	137	-	64	114%	114	724	-	48	48
Referral to Injectable 3	3	7	77	5,478	173	(55)%	1,248	2,155	-	1	1

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to IUD 10 Insertio	22	24	326	55,834	661	(51)%	2,010	10,541	-	140	140
Referral to Linkage to HIV	106	146	1,456	1,172	-	-%	834	2,290	1,318	-	1,318
Referral to Manual Vacuur	-	-	-	-	-	-%	46	46	-	-	-
Referral to Medication Abi	-	-	-	-	-	-%	24	24	-	-	-
Referral to OCs	2	6	65	-	67	(3)%	1,280	1,698	-	-	-
Referral to Opioid Treatme	49	14	154	-	-	-%	136	290	-	-	-
Referral to PAC Service (u	-	-	-	-	-	-%	488	488	-	-	-
Referral to TB Diagnosis	580	117	2,295	13,044	-	-%	1,435	14,444	-	-	-
Referral to TB DOTS (com	262	9	718	9,502	293	145%	771	1,489	-	1,204	1,204
Referral to TB DOTS (com	553	78	1,848	6,796	-	-%	1,268	3,297	-	2,789	2,789
Referral to TB Screening	10,781	1,206	43,581	12,177	-	-%	35,261	78,842	-	-	-
Safe Water Solution	-	-	-	-	6,973	(100)%	6,973	655,267	-	-	-
STI Kit (Non-Ulcerative)	-	-	-	-	42,436	(100)%	43,388	548,483	-	-	-
STI Kit (Ulcerative)	-	-	-	-	2,964	(100)%	3,679	60,473	-	-	-
STI Screening	2,825	2,739	22,338	-	139	15,971%	221	23,142	-	-	-
TB Diagnosis	9,862	4,283	43,609	-	21,564	102%	40,546	107,757	-	-	-
TB DOTS	4,329	2,803	22,981	22,517	15,531	48%	23,790	284,913	-	116,030	116,030
TB Screening	27,004	12,358	140,576	-	36,550	285%	109,755	315,059	-	-	-
Toilets Constructed	-	-	12,802	-	-	-%	-	12,802	-	-	-
Toilets Sold	15,462	7,339	123,566	105,137	-	-%	73,282	196,848	-	16,088	16,088
Tubal Ligation	2,478	901	20,475	67,302	10,816	89%	18,281	253,555	-	74,146	74,146
Vasectomy	251	58	1,514	2,112	995	52%	1,870	3,384	-	5,678	5,678

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Vivax Treatment after Con</b>	<b>207</b>	<b>192</b>	<b>1,399</b>	<b>3,443</b>	<b>-</b>	<b>-%</b>	<b>3,796</b>	<b>5,195</b>	<b>-</b>	<b>230</b>	<b>230</b>
<b>Water Treatment Tablets</b>	<b>4,300</b>	<b>1,733</b>	<b>15,000</b>	<b>50,000</b>	<b>242,930</b>	<b>(94)%</b>	<b>268,130</b>	<b>3,640,623</b>	<b>-</b>	<b>1</b>	<b>1</b>
<b>Zinc</b>	<b>-</b>	<b>-</b>	<b>8,490</b>	<b>8,490</b>	<b>250</b>	<b>3,296%</b>	<b>5,050</b>	<b>32,844</b>	<b>-</b>	<b>58</b>	<b>58</b>

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Asia and Eastern Europe - Asia</b>										<b>283,972</b>	<b>1,086,060</b>	<b>1,370,033</b>
<b>Cambodia</b>										<b>45,352</b>	<b>78,559</b>	<b>123,911</b>
Condom	894,696	937,140	7,128,354	12,238,560	7,238,130		(2)%	10,681,429	370,952,380	45,352	4,620	49,972
PSI Condom Distributed Provided	-	-	-	-	(1,098)		-%	(2,117)	(3,043)	-	-	-
Number One	307,656	314,880	2,451,024	4,829,760	2,328,048	12/94	5%	3,632,976	262,804,381	15,594	1,589	17,182
OK Condom	587,040	622,260	4,677,330	7,408,800	4,911,180	2/04	(5)%	7,050,570	108,151,042	29,758	3,032	32,790
Condom Provided	-	-	-	-	1,098		(100)%	2,117	3,043	-	-	-
PSI Condom Provided	-	-	-	-	1,098		(100)%	2,117	3,043	-	-	-
Diarrhea Treatment Kit	3,250	6,213	36,270	72,360	84,190		(57)%	115,160	852,030	-	715	715
Orasel Kit	3,250	6,213	36,270	72,360	84,190	3/09	(57)%	115,160	852,030	-	715	715
Emergency Contraception	5,008	6,186	40,392	58,800	34,175		18%	51,970	203,260	-	99	99
PSI Emergency Contraception Distr	(2)	(1)	(8)	-	(5)		-%	(10)	(30)	-	-	-
NEXT 72 EC	5,010	6,187	40,400	58,800	34,180	8/13	18%	51,980	203,290	-	99	99
Emergency Contraception Provided	2	1	8	-	5		60%	10	30	-	-	-
PSI Emergency Contraception Prov	2	1	8	-	5		60%	10	30	-	-	-
Fever Cases Attended	70,888	-	70,888	-	-		0%	-	70,888	-	-	-
Fever Cases Attended	70,888	-	70,888	-	-		-%	-	70,888	-	-	-
Fever Cases Tested with RDTs	70,872	-	70,872	-	-		0%	-	70,872	-	-	-
Fever Cases Tested with RDTs	70,872	-	70,872	-	-		-%	-	70,872	-	-	-
Implant 5	371	263	2,074	3,250	1,877		10%	2,801	12,261	-	1,300	1,300
PSI Implant 5 Distributed Inserted (	(224)	(356)	(2,427)	(2,500)	(2,129)		-%	(3,061)	(27,837)	-	(1,522)	(1,522)
Implant 5	595	619	4,501	5,750	4,006	5/09	12%	5,862	40,098	-	2,822	2,822
Implant 5 Insertion	224	356	2,427	2,525	2,132		14%	3,064	27,864	-	1,691	1,691
PSI Implant 5 Inserted	224	356	2,427	2,500	2,129		14%	3,061	27,837	-	1,691	1,691
Non-PSI Implant 5 Inserted	-	-	-	25	3		(100)%	3	27	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Injectable 3</b>	<b>33,395</b>	<b>35,410</b>	<b>228,354</b>	<b>376,000</b>	<b>267,828</b>		<b>(15)%</b>	<b>349,694</b>	<b>5,118,806</b>	-	<b>6,974</b>	<b>6,974</b>
PSI Injectable 3 Distributed Provide	(305)	(315)	(2,721)	-	(2,212)		-%	(3,446)	(9,453)	-	(83)	(83)
OK Injection-3	33,700	35,725	231,075	376,000	270,040	2/02	(14)%	353,140	5,128,259	-	7,057	7,057
<b>Injectable 3 Provided</b>	<b>305</b>	<b>315</b>	<b>2,721</b>	<b>-</b>	<b>2,214</b>		<b>23%</b>	<b>3,448</b>	<b>9,455</b>	-	<b>92</b>	<b>92</b>
PSI Injectable 3 Provided	305	315	2,721	-	2,212		23%	3,446	9,453	-	92	92
Non-PSI Injectable 3 Provided	-	-	-	-	2		(100)%	2	2	-	-	-
<b>IUD 10</b>	<b>1,113</b>	<b>1,146</b>	<b>8,866</b>	<b>10,000</b>	<b>9,275</b>		<b>(4)%</b>	<b>12,935</b>	<b>68,877</b>	-	<b>6,852</b>	<b>6,852</b>
PSI IUD 10 Distributed Inserted (1)	(1,672)	(2,021)	(14,434)	(19,000)	(10,165)		-%	(15,805)	(117,388)	-	(11,155)	(11,155)
IUD Copper T	2,785	3,167	23,300	29,000	19,440	1/10	20%	28,740	186,265	-	18,007	18,007
<b>IUD 10 Insertion</b>	<b>1,672</b>	<b>2,021</b>	<b>14,434</b>	<b>19,190</b>	<b>10,179</b>		<b>42%</b>	<b>15,819</b>	<b>117,752</b>	-	<b>12,395</b>	<b>12,395</b>
PSI IUD 10 Inserted	1,672	2,021	14,434	19,000	10,165		42%	15,805	117,388	-	12,395	12,395
Non-PSI IUD 10 Inserted	-	-	-	190	14		(100)%	14	364	-	-	-
<b>Lubricant</b>	<b>63,780</b>	<b>71,520</b>	<b>566,400</b>	<b>-</b>	<b>476,160</b>		<b>19%</b>	<b>676,860</b>	<b>8,405,780</b>	-	-	-
OK Plus Lubricant	63,780	71,520	566,400	-	476,160	6/09	19%	676,860	8,405,780	-	-	-
<b>Malaria PPT (ACT)</b>	<b>(2,692)</b>	<b>1,212</b>	<b>10,069</b>	<b>50,000</b>	<b>36,042</b>		<b>(72)%</b>	<b>70,406</b>	<b>409,308</b>	-	<b>1,154</b>	<b>1,154</b>
PSI QAACTs Distributed Provided ε	(8,814)	-	(8,814)	-	-		-%	-	(8,814)	-	(1,010)	(1,010)
ASMQ for Adolescent	749	-	749	1,156	-		-%	-	749	-	86	86
ASMQ for Adult	5,373	760	11,260	23,802	5,520	5/16	104%	17,673	28,933	-	1,291	1,291
ASMQ for Children	-	-	201	1,042	-	10/16	-%	357	558	-	23	23
DHA-PIP For Adolescent	-	42	541	1,067	2,465	8/12	(78)%	6,049	40,822	-	62	62
DHA-PIP For Adult	-	391	5,671	21,971	25,862	8/12	(78)%	41,229	312,087	-	650	650
DHA-PIP For Children	-	19	461	962	2,195	8/12	(79)%	5,098	34,973	-	53	53
<b>Malaria RDK</b>	<b>23,175</b>	<b>26,350</b>	<b>193,925</b>	<b>500,000</b>	<b>247,050</b>		<b>(22)%</b>	<b>401,875</b>	<b>5,265,120</b>	-	-	-
MalaCheck	-	-	-	500,000	-	2/03	-%	-	3,772,420	-	-	-
Malaria RDT (Diagnosis)	23,175	26,350	193,925	-	247,050	6/15	(22)%	401,875	1,492,700	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Medical Abortion	19,394	23,097	171,753	255,000	169,779		1%	250,187	1,299,383	-	13,210	13,210
PSI Medical Abortion Distributed Pr	(527)	(732)	(5,105)	-	-		-%	-	(5,105)	-	(393)	(393)
Medabon	19,921	23,830	176,858	255,000	169,779	11/09	4%	250,187	1,304,488	-	13,603	13,603
Medical Abortion Provided	527	732	5,105	-	-		0%	-	5,105	-	436	436
PSI Medical Abortion Provided	527	732	5,105	-	-		-%	-	5,105	-	436	436
OCs	520,192	436,170	3,339,784	5,168,040	3,188,021		5%	4,871,331	52,787,750	-	27,617	27,617
PSI OCs Distributed Provided	(241)	(380)	(2,672)	-	(1,655)		-%	(2,648)	(7,277)	-	(22)	(22)
Marvelon	121,685	44,842	414,780	488,040	269,560	12/12	54%	419,255	1,225,115	-	3,430	3,430
OK Pills	398,748	391,708	2,927,676	4,680,000	2,920,116	9/97	-%	4,454,724	51,569,912	-	24,209	24,209
OCs Provided	241	380	2,672	-	1,656		61%	2,649	7,278	-	25	25
PSI OCs Provided	241	380	2,672	-	1,655		61%	2,648	7,277	-	25	25
Non-PSI OCs Provided	-	-	-	-	1		(100)%	1	1	-	-	-
Positive RDTs	9,453	-	9,453	-	-		0%	-	9,453	-	-	-
Positive RDTs	9,453	-	9,453	-	-		-%	-	9,453	-	-	-
Positive RDTs Given First Line Treatm	8,814	-	8,814	-	-		0%	-	8,814	-	-	-
Positive RDTs Given First Line Trea	8,814	-	8,814	-	-		-%	-	8,814	-	-	-
QAACTs Provided after Confirmatory I	8,829	-	8,829	-	-		0%	-	8,829	-	1,191	1,191
PSI QAACTs Provided after Confirm	8,814	-	8,814	-	-		-%	-	8,814	-	1,189	1,189
Non-PSI QAACTs Provided after Co	15	-	15	-	-		-%	-	15	-	2	2
Referral to Implant 5 Insertion	16	16	137	-	64		114%	114	724	-	48	48
Referral to Implant 5 Insertion	16	16	137	-	64		114%	114	724	-	48	48
Referral to Injectable 3	3	7	77	-	173		(55)%	250	1,157	-	1	1
Referral to Injectable 3	3	7	77	-	173		(55)%	250	1,157	-	1	1
Referral to IUD 10 Insertion	22	24	326	-	661		(51)%	825	8,611	-	140	140
Referral to IUD 10 Insertion	22	24	326	-	661	12/11	(51)%	825	8,611	-	140	140

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to OCs	2	6	65	-	67		(3)%	105	523	-	-	-
Referral to OCs	2	6	65	-	67		(3)%	105	523	-	-	-
<b>India</b>										(2)	118,987	118,985
Cervical Cancer-Pap Smear Screening	-	-	304	-	2,807		(89)%	4,743	5,047	-	-	-
Cervical Cancer-Pap Smear Screeni	-	-	304	-	2,807		(89)%	4,743	5,047	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	419	-	1,397		(70)%	2,696	3,115	-	114	114
Cervical Cancer-VIA and Cryotherap	-	-	419	-	1,397		(70)%	2,696	3,115	-	114	114
Cervical Cancer-VIA and Refer to any	-	-	79	-	-		0%	48	127	-	11	11
Cervical Cancer-VIA and Refer to ar	-	-	79	-	-		-%	48	127	-	11	11
Cervical Cancer-VIA and Refer to Cryc	-	-	419	-	-		0%	446	865	-	57	57
Cervical Cancer-VIA and Refer to Cl	-	-	419	-	-		-%	446	865	-	57	57
Cervical Cancer-VIA/VILI Screening	-	-	5,504	-	52,692		(90)%	97,406	102,910	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	5,504	-	52,692		(90)%	97,406	102,910	-	-	-
Clean Delivery Kit	-	-	-	-	400		(100)%	400	260,026	-	-	-
NewBorn	-	-	-	-	400	7/02	(100)%	400	260,026	-	-	-
Condom	-	-	(900)	-	17,923,685		(100)%	17,665,520	2,907,664,828	(2)	(1)	(2)
Masti	-	-	(900)	-	17,889,185	9/88	(100)%	17,655,020	1,966,656,606	(2)	(1)	(2)
Nirodh	-	-	-	-	34,500	5/88	(100)%	10,500	941,008,222	-	-	-
Condom Provided	-	-	-	-	27,047		(100)%	50,644	50,644	-	-	-
Non-PSI Condom Provided	-	-	-	-	27,047		(100)%	50,644	50,644	-	-	-
Diarrhea Treatment Kit	-	-	-	-	-		0%	(4,574)	546,681	-	-	-
Neotral Zinc Kit	-	-	-	-	-	7/13	-%	(3,611)	267,989	-	-	-
ORS + Zinc (Generic)	-	-	-	-	-	9/12	-%	(963)	278,692	-	-	-
Fecal Sludge Management (Househok	191	34	524	670	-		0%	921	1,445	-	-	-
Fecal Sludge Management (Househ	191	34	524	670	-		-%	921	1,445	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Fecal Sludge Management (Liters)	<b>927,200</b>	<b>147,333</b>	<b>2,425,200</b>	<b>1,571,000</b>	-		<b>0%</b>	<b>3,021,000</b>	<b>5,446,200</b>	-	<b>134</b>	<b>134</b>
Fecal Sludge Management (Liters)	<b>927,200</b>	<b>147,333</b>	<b>2,425,200</b>	<b>1,571,000</b>	-		<b>-%</b>	<b>3,021,000</b>	<b>5,446,200</b>	-	<b>134</b>	<b>134</b>
Injectable 3	-	-	<b>(414)</b>	-	<b>34,825</b>		<b>(101)%</b>	<b>37,194</b>	<b>266,201</b>	-	<b>(16)</b>	<b>(16)</b>
Freedom Inject (3-month)	-	-	<b>(414)</b>	-	<b>34,825</b>	7/13	<b>(101)%</b>	<b>37,478</b>	<b>152,577</b>	-	<b>(16)</b>	<b>(16)</b>
Procostron 150	-	-	-	-	-	6/10	<b>-%</b>	<b>(284)</b>	<b>113,624</b>	-	-	-
Injectable 3 Provided	<b>2,797</b>	<b>974</b>	<b>11,426</b>	-	<b>9,509</b>		<b>20%</b>	<b>16,188</b>	<b>27,614</b>	-	<b>479</b>	<b>479</b>
Non-PSI Injactable 3 Provided	<b>2,797</b>	<b>974</b>	<b>11,426</b>	-	<b>9,509</b>		<b>20%</b>	<b>16,188</b>	<b>27,614</b>	-	<b>479</b>	<b>479</b>
Iron Folic Acid Tablet	-	-	-	-	-		<b>0%</b>	<b>(5,412)</b>	<b>48,228,558</b>	-	-	-
Vitalet-Preg	-	-	-	-	-	8/02	<b>-%</b>	<b>(5,412)</b>	<b>48,228,558</b>	-	-	-
IUD 10	-	<b>(58)</b>	<b>(174)</b>	-	-		<b>0%</b>	<b>4,370</b>	<b>4,196</b>	-	<b>(166)</b>	<b>(166)</b>
PSI IUD 10 Distributed Inserted (1)	-	<b>(58)</b>	<b>(174)</b>	-	-		<b>-%</b>	-	<b>(174)</b>	-	<b>(166)</b>	<b>(166)</b>
Freedom 10	-	-	-	-	-	7/16	<b>-%</b>	<b>4,370</b>	<b>4,370</b>	-	-	-
IUD 10 Insertion	<b>165</b>	<b>106</b>	<b>881</b>	-	<b>1,173</b>		<b>(25)%</b>	<b>1,608</b>	<b>2,489</b>	-	<b>934</b>	<b>934</b>
PSI IUD 10 Inserted	-	<b>58</b>	<b>174</b>	-	-		<b>-%</b>	-	<b>174</b>	-	<b>184</b>	<b>184</b>
Non-PSI IUD 10 Inserted	<b>165</b>	<b>48</b>	<b>707</b>	-	<b>1,173</b>		<b>(40)%</b>	<b>1,608</b>	<b>2,315</b>	-	<b>750</b>	<b>750</b>
IUD 5	-	<b>(1,135)</b>	<b>(4,537)</b>	-	<b>21,630</b>		<b>(121)%</b>	<b>20,146</b>	<b>995,119</b>	-	<b>(3,231)</b>	<b>(3,231)</b>
PSI IUD 5 Distributed Inserted (1)	-	<b>(1,135)</b>	<b>(3,406)</b>	-	-		<b>-%</b>	-	<b>(3,406)</b>	-	<b>(2,425)</b>	<b>(2,425)</b>
Freedom 5	-	-	<b>(1,131)</b>	-	<b>21,630</b>	7/08	<b>(105)%</b>	<b>20,146</b>	<b>998,525</b>	-	<b>(805)</b>	<b>(805)</b>
IUD 5 Insertion	<b>7,444</b>	<b>2,296</b>	<b>27,060</b>	-	<b>14,513</b>		<b>86%</b>	<b>26,529</b>	<b>53,589</b>	-	<b>21,410</b>	<b>21,410</b>
PSI IUD 5 Inserted	-	<b>1,135</b>	<b>3,406</b>	-	-		<b>-%</b>	-	<b>3,406</b>	-	<b>2,695</b>	<b>2,695</b>
Non-PSI IUD 5 Inserted	<b>7,444</b>	<b>1,160</b>	<b>23,654</b>	-	<b>14,513</b>		<b>63%</b>	<b>26,529</b>	<b>50,183</b>	-	<b>18,715</b>	<b>18,715</b>
Medical Abortion	-	-	<b>(1,258)</b>	-	<b>73,002</b>		<b>(102)%</b>	<b>72,708</b>	<b>1,482,093</b>	-	<b>(117)</b>	<b>(117)</b>
Safe Abort kit	-	-	<b>(1,258)</b>	-	<b>73,002</b>	11/09	<b>(102)%</b>	<b>72,708</b>	<b>1,482,093</b>	-	<b>(117)</b>	<b>(117)</b>
OCs	-	-	<b>(11,250)</b>	-	<b>(284,284)</b>		<b>0%</b>	<b>(642,408)</b>	<b>115,515,319</b>	-	<b>(115)</b>	<b>(115)</b>
Mala-D	-	-	-	-	<b>900</b>	5/97	<b>(100)%</b>	<b>(33,833)</b>	<b>67,283,904</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Pearl 3	-	-	(11,250)	-	(285,184)	1/02	-%	(608,575)	48,231,415	-	(115)	(115)
OCs Provided	7,253	1,860	23,914	9,434	16,421		46%	28,714	52,628	-	271	271
Non-PSI OCs Provided	7,253	1,860	23,914	9,434	16,421		46%	28,714	52,628	-	271	271
ORS	-	-	(12,625)	-	481,400		(103)%	306,053	25,409,579	-	(237)	(237)
Neutral Orange 1000ml	-	-	(12,625)	-	481,400	7/98	(103)%	306,053	25,409,579	-	(237)	(237)
Referral to Injectable 3	-	-	-	5,478	-		0%	-	-	-	-	-
Referral to Injectable 3	-	-	-	5,478	-		-%	-	-	-	-	-
Referral to IUD 10 Insertion	-	-	-	35,834	-		0%	-	-	-	-	-
Referral to IUD 10 Insertion	-	-	-	35,834	-		-%	-	-	-	-	-
Referral to TB Diagnosis	580	89	2,069	13,044	-		0%	1,393	3,462	-	-	-
Referral to TB Diagnosis	580	89	2,069	13,044	-		-%	1,393	3,462	-	-	-
Referral to TB DOTS (completion confi	262	9	718	7,328	-		0%	437	1,155	-	1,204	1,204
Referral to TB DOTS (completion co	262	9	718	7,328	-		-%	437	1,155	-	1,204	1,204
Referral to TB DOTS (completion unkr	553	78	1,848	5,716	-		0%	1,268	3,116	-	2,789	2,789
Referral to TB DOTS (completion un	553	78	1,848	5,716	-		-%	1,268	3,116	-	2,789	2,789
Referral to TB Screening	10,776	1,206	43,576	12,177	-		0%	35,095	78,671	-	-	-
Referrals to TB Screening	10,776	1,206	43,576	12,177	-		-%	35,095	78,671	-	-	-
TB Diagnosis	5,945	573	16,465	-	-		0%	6,769	23,234	-	-	-
TB Diagnosis	5,945	573	16,465	-	-		-%	6,769	23,234	-	-	-
TB DOTS	1,331	22	2,432	8,533	-		0%	880	3,312	-	8,156	8,156
TB DOTS	1,331	22	2,432	8,533	-		-%	880	3,312	-	8,156	8,156
TB Screening	15,890	1,597	54,934	-	-		0%	44,185	99,119	-	-	-
TB Screening	15,890	1,597	54,934	-	-		-%	44,185	99,119	-	-	-
Toilets Constructed	-	-	12,802	-	-		0%	-	12,802	-	-	-
Toilet Type 1	-	-	3,067	-	-	10/16	-%	-	3,067	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Toilet Type 2	-	-	7,308	-	-	10/16	-%	-	7,308	-	-	-
Toilet Type 3	-	-	2,427	-	-	10/16	-%	-	2,427	-	-	-
Toilets Sold	15,324	7,187	122,599	99,647	-		0%	73,282	195,881	-	16,061	16,061
Toilet Type 1, Direct Sales	4,881	2,230	36,613	27,800	-		-%	17,812	54,425	-	8,007	8,007
Toilet Type 2, Direct Sales	6,483	3,138	62,456	50,387	-		-%	30,789	93,245	-	7,683	7,683
Toilet Type 3, Direct Sales	1,084	214	6,020	8,687	-		-%	7,307	13,327	-	370	370
Toilet Type 3, Microfinance	2,876	1,605	17,510	12,773	-		-%	17,374	34,884	-	-	-
Tubal Ligation	2,374	680	17,731	67,302	9,650		84%	16,209	33,940	-	65,569	65,569
Tubal Ligation	2,374	680	17,731	67,302	9,650		84%	16,209	33,940	-	65,569	65,569
Vasectomy	251	58	1,514	2,112	995		52%	1,870	3,384	-	5,678	5,678
Vasectomy	251	58	1,514	2,112	995		52%	1,870	3,384	-	5,678	5,678
Zinc	-	-	-	-	-		0%	(3,758)	478,970	-	-	-
BIBZinC	-	-	-	-	-	11/09	-%	(1,000)	420,928	-	-	-
NeoZinc (50ml zinc acetate syrup)	-	-	-	-	-	7/13	-%	(2,758)	58,042	-	-	-
<b>India LLC</b>										114,717	145,456	260,173
Condom	7,640,400	7,515,213	59,206,565	185,784,321	-		0%	48,873,945	108,080,510	114,717	47,407	162,124
Masti Classic 10's (Flavoured)	1,535,520	843,440	4,065,840	47,902,315	-		-%	-	4,065,840	7,878	3,256	11,133
Masti Classic 3's	2,692,800	3,888,013	28,332,565	57,434,459	-	12/16	-%	29,023,320	57,355,885	54,896	22,686	77,582
Masti Classic 3's (Flavoured)	1,629,120	1,082,880	4,877,760	24,194,683	-		-%	-	4,877,760	9,451	3,906	13,357
Masti Classic 6's	18,000	217,240	9,644,520	7,210,944	-	12/16	-%	17,442,120	27,086,640	18,687	7,722	26,409
Masti Premium 10's (Flavoured)	670,320	621,520	2,534,880	12,006,720	-		-%	-	2,534,880	4,911	2,030	6,941
Masti Premium 3's	7,200	158,440	6,552,520	9,459,504	-	12/16	-%	2,408,505	8,961,025	12,696	5,247	17,943
Masti Premium 3's (Flavoured)	1,087,440	703,680	3,198,480	25,575,696	-		-%	-	3,198,480	6,197	2,561	8,758
Vive 10's (X Dotted + Flavour)	-	-	-	500,000	-		-%	-	-	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Vive 10's (X Time + Flavour)	-	-	-	200,000	-		-%	-	-	-	-	-
Vive 3's (X Dotted + Flavour)	-	-	-	1,000,000	-		-%	-	-	-	-	-
Vive 3's (X Time + Flavour)	-	-	-	300,000	-		-%	-	-	-	-	-
Emergency Contraception	-	-	-	250,000	-		0%	-	-	-	-	-
Pronta	-	-	-	250,000	-		-%	-	-	-	-	-
Injectable 3	7,923	6,421	31,365	298,848	-		0%	-	31,365	-	1,183	1,183
Freedom Inject (3-month)	7,923	6,421	31,365	298,848	-	12/16	-%	-	31,365	-	1,183	1,183
IUD 5	9,430	175	59,040	150,000	-		0%	-	59,040	-	42,041	42,041
Freedom 5	9,430	175	59,040	150,000	-	12/16	-%	-	59,040	-	42,041	42,041
IUS 5	-	-	-	3,500	-		0%	-	-	-	-	-
Freedom LNG-IUS	-	-	-	3,500	-		-%	-	-	-	-	-
Medical Abortion	40,330	39,357	290,450	606,936	-		0%	-	290,450	-	26,958	26,958
Safe Abort kit	40,330	39,357	290,450	606,936	-	12/16	-%	-	290,450	-	26,958	26,958
OCs	211,120	157,667	2,225,940	6,069,120	-		0%	431,100	2,657,040	-	22,738	22,738
MEURI	-	-	-	96,000	-		-%	-	-	-	-	-
Pearl	211,120	157,667	2,225,940	5,973,120	-	12/16	-%	431,100	2,657,040	-	22,738	22,738
ORS	22,203	48,300	273,753	2,001,120	-		0%	-	273,753	-	5,129	5,129
Neotral Orange 1000ml	22,203	48,300	273,753	2,001,120	-	12/16	-%	-	273,753	-	5,129	5,129
<b>Kazakhstan</b>										342	3	345
Free Condom	-	-	6,000	178,420	-		0%	619,800	625,800	5	2	7
Generic Male Condom	-	-	6,000	178,420	-	8/16	-%	619,800	625,800	5	2	7
Free Female Condom	-	-	4,000	34,000	-		0%	20,000	24,000	4	1	5
Generic Female Condom	-	-	4,000	34,000	-	8/16	-%	20,000	24,000	4	1	5
HIV Testing Services	346	294	1,322	2,200	-		0%	367	2,400	2	-	2
VCT Individual (HIV-Negative)	342	288	1,296	2,200	-		-%	367	2,374	2	-	2

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Positive)	4	6	26	-	-		-%	-	26	-	-	-
Referral to HIV Testing Services	5	15	867	635	522		66%	1,273	5,122	1	-	1
Referral to HIV Testing & Counseling	5	15	867	635	522	12/13	66%	1,273	5,122	1	-	1
Referral to Linkage to HIV Care	25	39	365	450	-		0%	281	646	330	-	330
Referral to Linkage to HIV Care	25	39	365	450	-		-%	281	646	330	-	330
Referral to Opioid Treatment	35	3	53	-	-		0%	-	53	-	-	-
Referral to Opioid Treatment	35	3	53	-	-		-%	-	53	-	-	-
Referral to TB Diagnosis	-	4	62	-	-		0%	-	1,324	-	-	-
Referral to TB Diagnosis	-	4	62	-	-	12/14	-%	-	1,324	-	-	-
Referral to TB Screening	4	-	4	-	-		0%	-	4	-	-	-
Referrals to TB Screening	4	-	4	-	-		-%	-	4	-	-	-
TB Screening	143	142	1,138	-	49		2222%	447	2,103	-	-	-
TB Screening	143	142	1,138	-	49		2,222%	447	2,103	-	-	-
<b>Kyrgyzstan</b>										505	-	505
HIV Testing Services	745	771	5,835	13,700	-		0%	1,502	8,232	11	-	11
VCT Individual (HIV-Negative)	721	751	5,691	13,700	-		-%	1,502	8,088	11	-	11
VCT Individual (HIV-Positive)	24	20	144	-	-		-%	-	144	-	-	-
Referral to HIV Testing Services	-	1	7	-	4,224		(100)%	7,517	14,518	-	-	-
Referral to HIV Testing & Counseling	-	1	7	-	4,224	12/13	(100)%	7,517	14,518	-	-	-
Referral to Linkage to HIV Care	24	40	471	568	-		0%	473	944	494	-	494
Referral to Linkage to HIV Care	24	40	471	568	-		-%	473	944	494	-	494
Referral to Opioid Treatment	-	3	12	-	-		0%	131	143	-	-	-
Referral to Opioid Treatment	-	3	12	-	-		-%	131	143	-	-	-
Referral to TB Diagnosis	-	17	109	-	-		0%	-	4,409	-	-	-
Referral to TB Diagnosis	-	17	109	-	-	12/14	-%	-	4,409	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
TB Screening	153	146	1,041	-	95		996%	1,868	4,643	-	-	-
TB Screening	153	146	1,041	-	95		996%	1,868	4,643	-	-	-
<b>Laos</b>										1,172	13,796	14,968
Condom	264,384	225,216	1,150,428	3,200,000	-		0%	2,935,872	26,464,875	1,170	802	1,972
No 1 Condom Grp	13,824	42,624	186,441	600,000	-	11/10	-%	452,736	4,113,343	190	130	320
No 1 Condom Strw	69,120	112,896	571,941	1,800,000	-	8/08	-%	1,410,048	13,693,602	582	399	980
Number One Rose	181,440	69,696	392,046	800,000	-	4/08	-%	1,073,088	8,657,930	399	273	672
Fever Cases Attended	5,518	-	5,518	-	-		0%	-	5,518	-	-	-
Fever Cases Attended	5,518	-	5,518	-	-		-%	-	5,518	-	-	-
Fever Cases Tested with RDTs	5,515	-	5,515	-	-		0%	-	5,515	-	-	-
Fever Cases Tested with RDTs	5,515	-	5,515	-	-		-%	-	5,515	-	-	-
HIV Testing Services	227	259	3,085	2,740	-		0%	195	12,107	2	-	2
VCT Individual (HIV-Negative)	224	257	3,065	2,728	-	2/10	-%	192	11,979	2	-	2
VCT Individual (HIV-Positive)	3	2	20	12	-	4/10	-%	3	128	-	-	-
Implant 3 Insertion	720	725	5,314	6,700	2,404		121%	4,152	9,742	-	2,700	2,700
Non-PSI Implant 3 Inserted	720	725	5,314	6,700	2,404	3/16	121%	4,152	9,742	-	2,700	2,700
Injectable 3 Provided	1,309	-	1,309	9,500	-		0%	-	4,042	-	48	48
Non-PSI Injectable 3 Provided	1,309	-	1,309	9,500	-	3/16	-%	-	4,042	-	48	48
IUD 10 Insertion	1,478	1,223	9,617	-	6,488		48%	10,848	29,986	-	8,743	8,743
Non-PSI IUD 10 Inserted	1,478	1,223	9,617	-	6,488		48%	10,848	29,986	-	8,743	8,743
Lubricant	-	-	-	-	-		0%	6,024	38,836	-	-	-
Number One Lubricant (20 cc)	-	-	-	-	-	7/12	-%	6,024	38,836	-	-	-
Misoprostol for PAC (Oral)	19,000	12,333	76,000	156,000	40,500		88%	124,500	345,900	-	1,320	1,320
Misoprostol for PAC (oral)	19,000	12,333	76,000	156,000	40,500	8/13	88%	124,500	345,900	-	1,320	1,320
OCs Provided	1,646	-	1,646	14,000	-		0%	-	5,748	-	16	16

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI OCs Provided	1,646	-	1,646	14,000	-	3/16	-%	-	5,748	-	16	16
Positive RDTs	301	-	301	-	-		0%	-	301	-	-	-
Positive RDTs	301	-	301	-	-		-%	-	301	-	-	-
Positive RDTs Given First Line Treatm	301	-	301	-	-		0%	-	301	-	-	-
Positive RDTs Given First Line Trea	301	-	301	-	-		-%	-	301	-	-	-
Referral to HIV Testing Services	-	-	-	-	-		0%	195	195	-	-	-
Referral to HIV Testing & Counselin	-	-	-	-	-		-%	195	195	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	-		0%	636	636	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	-		-%	636	636	-	-	-
Referral to Injectable 3	-	-	-	-	-		0%	998	998	-	-	-
Referral to Injectable 3	-	-	-	-	-		-%	998	998	-	-	-
Referral to IUD 10 Insertion	-	-	-	20,000	-		0%	1,185	1,930	-	-	-
Referral to IUD 10 Insertion	-	-	-	20,000	-	12/11	-%	1,185	1,930	-	-	-
Referral to Manual Vacuum Aspiration	-	-	-	-	-		0%	46	46	-	-	-
Referral to Manual Vacuum Aspiratic	-	-	-	-	-		-%	46	46	-	-	-
Referral to Medication Abortion	-	-	-	-	-		0%	24	24	-	-	-
Referral to Medication Abortion	-	-	-	-	-		-%	24	24	-	-	-
Referral to OCs	-	-	-	-	-		0%	1,175	1,175	-	-	-
Referral to OCs	-	-	-	-	-		-%	1,175	1,175	-	-	-
Referral to PAC Service (unknown)	-	-	-	-	-		0%	488	488	-	-	-
Referral to PAC Service (unknown)	-	-	-	-	-		-%	488	488	-	-	-
Referral to TB Diagnosis	-	-	-	-	-		0%	42	42	-	-	-
Referral to TB Diagnosis	-	-	-	-	-		-%	42	42	-	-	-
Referral to TB DOTS (completion confi	-	-	-	120	-		0%	41	41	-	-	-
Referral to TB DOTS (completion co	-	-	-	120	-	3/16	-%	41	41	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to TB DOTS (completion unkr	-	-	-	80	-		0%	-	181	-	-	-
Referral to TB DOTS (completion un	-	-	-	80	-	12/13	-%	-	181	-	-	-
Referral to TB Screening	-	-	-	-	-		0%	166	166	-	-	-
Referrals to TB Screening	-	-	-	-	-		-%	166	166	-	-	-
TB Diagnosis	55	-	178	-	176		1%	218	558	-	-	-
TB Diagnosis	55	-	178	-	176		1%	218	558	-	-	-
TB DOTS	66	-	243	-	80		204%	121	474	-	168	168
TB DOTS	66	-	243	-	80	11/11	204%	121	474	-	168	168
TB Screening	160	-	538	-	616		(13)%	782	2,069	-	-	-
TB Screening	160	-	538	-	616		(13)%	782	2,069	-	-	-
<b>Myanmar</b>										71,616	124,857	196,473
Antiretroviral Treatment (Currently Enr	4,231	3,757	27,149	36,450	-		0%	1,661	28,810	4,743	-	4,743
Antiretroviral Treatment (Currently E	4,231	3,757	27,149	36,450	-		-%	1,661	28,810	4,743	-	4,743
Antiretroviral Treatment (Newly Enrolle	292	272	2,002	2,100	-		0%	1,042	3,044	-	-	-
Antiretroviral Treatment (Newly Enrc	292	272	2,002	2,100	-		-%	1,042	3,044	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	1	-	22		(95)%	22	898	-	-	-
Cervical Cancer-VIA and Cryothera	-	-	1	-	22	11/12	(95)%	22	898	-	-	-
Cervical Cancer-VIA/VILI Screening	7	11	100	-	584		(83)%	634	4,419	-	-	-
Cervical Cancer-VIA/VILI Screening	7	11	100	-	584		(83)%	634	4,419	-	-	-
Condom	1,347,378	1,812,865	12,575,066	16,200,001	11,509,480		9%	21,386,624	395,770,351	59,509	5,900	65,410
Aphaw	376,500	253,900	1,828,520	5,755,658	2,909,293	7/96	(37)%	6,364,593	187,816,611	8,653	858	9,511
Aphaw - Natural Touch	206,100	385,420	2,527,740	2,423,695	1,530,060	8/12	65%	2,680,116	13,467,993	11,962	1,186	13,148
Aphaw Flavors	677,940	695,911	5,183,602	4,504,599	2,317,083	10/01	124%	4,981,175	168,319,561	24,531	2,432	26,963
Aphaw Studded	61,830	464,580	2,934,660	3,316,049	1,800,270	7/12	63%	3,666,879	17,291,697	13,888	1,377	15,265
Generic Male Condom	15,000	167	15,500	-	2,859,174	1/08	(99)%	3,551,661	3,770,029	73	7	81

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
OK Condom	10,008	12,888	85,044	200,000	93,600	5/03	(9)%	142,200	5,104,460	402	40	442
Diarrhea Treatment Kit	33	596	17,410	5,000	175,127		(90)%	322,860	5,046,394	-	936	936
Orasel DTK	33	596	17,410	5,000	175,127	2/09	(90)%	322,860	5,046,394	-	936	936
Emergency Contraception	11	3	41	-	1,010		(96)%	1,084	177,863	-	-	-
OK EC	11	3	41	-	1,010	8/07	(96)%	1,084	177,863	-	-	-
Female Condom	5,240	5,407	44,485	90,000	59,785		(26)%	89,174	1,364,076	211	16	227
Generic Female Condom	5,240	5,407	44,485	90,000	59,785	5/08	(26)%	89,174	1,364,076	211	16	227
Fever Cases Attended	113,012	87,897	605,853	-	-		0%	657,831	1,263,684	-	-	-
Fever Cases Attended	113,012	87,897	605,853	-	-		-%	657,831	1,263,684	-	-	-
Fever Cases Tested with RDTs	113,012	87,897	605,853	-	-		0%	657,831	1,263,684	-	-	-
Fever Cases Tested with RDTs	113,012	87,897	605,853	-	-		-%	657,831	1,263,684	-	-	-
Free Condom	-	-	-	4,000,000	-		0%	-	4,285,491	-	-	-
Generic	-	-	-	4,000,000	-	8/01	-%	-	4,285,491	-	-	-
HIV Testing Services	7,053	6,816	51,036	63,000	44,298		15%	68,045	327,712	61	-	61
VCT Concordant Couple (HIV-Nega	-	-	-	-	32	12/09	(100)%	42	2,090	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	74	12/09	(100)%	94	1,800	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	17	12/09	(100)%	27	752	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	17	12/09	(100)%	27	752	-	-	-
VCT Individual (HIV-Negative)	6,583	6,414	47,833	60,000	42,006	12/09	14%	64,256	299,112	57	-	57
VCT Individual (HIV-Positive)	470	402	3,203	3,000	2,152	12/09	49%	3,599	23,206	4	-	4
Hypertension Diagnosis	998	-	998	-	-		0%	-	998	-	-	-
Hypertension Diagnosis	998	-	998	-	-		-%	-	998	-	-	-
Hypertension Screening	1,582	-	1,582	-	-		0%	-	1,582	-	-	-
Hypertension Screening	1,582	-	1,582	-	-		-%	-	1,582	-	-	-
Hypertension_Controlled Condition	909	-	909	-	-		0%	-	909	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Hypertension_Controlled Condition	909	-	909	-	-		-%	-	909	-	-	-
Implant 3	106	114	6,731	6,000	1,368		392%	2,660	9,391	-	2,082	2,082
PSI Implant 3 Distributed Inserted (	(240)	(322)	(2,077)	-	-		-%	-	(2,077)	-	(643)	(643)
Implanon NXT	346	436	8,808	6,000	1,368	12/15	544%	2,660	11,468	-	2,725	2,725
Implant 3 Insertion	240	322	2,077	-	-		0%	-	2,077	-	714	714
PSI Implant 3 Inserted	240	322	2,077	-	-		-%	-	2,077	-	714	714
Implant 5	-	-	(2)	-	102		(102)%	107	(998)	-	(1)	(1)
PSI Implant 5 Distributed Inserted (	-	-	(2)	-	-		-%	-	(1,105)	-	(1)	(1)
Jadelle	-	-	-	-	102	5/16	(100)%	107	107	-	-	-
Implant 5 Insertion	-	-	2	-	-		0%	-	1,105	-	1	1
PSI Implant 5 Inserted	-	-	2	-	-		-%	-	1,105	-	1	1
Injectable 3	57,091	46,806	376,237	650,000	397,400		(5)%	584,852	9,177,685	-	8,318	8,318
OK-3 Injection	57,091	46,806	376,237	650,000	397,400	9/01	(5)%	584,852	9,177,685	-	8,318	8,318
IUD 10	36	(13)	1,503	-	30		4910%	50	3,150	-	842	842
PSI IUD 10 Distributed Inserted (1)	(7)	(13)	(90)	-	-		-%	-	(90)	-	(50)	(50)
OK IUD (Copper T Cu 380A)	43	-	1,593	-	30	10/14	5,210%	50	3,240	-	892	892
IUD 10 Insertion	7	13	90	-	-		0%	-	90	-	56	56
PSI IUD 10 Inserted	7	13	90	-	-		-%	-	90	-	56	56
IUD 5	23	119	676	4,000	4,312		(84)%	6,528	140,711	-	282	282
PSI IUD 5 Distributed Inserted (1)	(124)	(120)	(1,001)	-	-		-%	-	(56,228)	-	(418)	(418)
OK IUD	147	239	1,677	4,000	4,312	5/03	(61)%	6,528	196,939	-	700	700
IUD 5 Insertion	124	120	1,001	-	-		0%	-	56,228	-	465	465
PSI IUD 5 Inserted	124	120	1,001	-	-		-%	-	56,228	-	465	465
LLIN	5,762	3,203	15,371	15,800	-		0%	22,280	37,651	-	1,192	1,192
LLIN	5,762	3,203	15,371	15,800	-	11/16	-%	22,280	37,651	-	1,192	1,192

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant	3,246	1,243	9,527	-	26,122		(64)%	29,205	740,281	-	-	-
Aphaw Gel - Tube 20 cc	3,246	1,243	8,897	-	-	10/06	-%	-	617,583	-	-	-
Aphaw Gel - Tube 20 cc - Flavors	-	-	630	-	26,122	10/14	(98)%	29,205	122,698	-	-	-
Malaria PPT (ACT)	21,387	13,675	171,381	244,409	273,148		(37)%	392,739	2,912,590	-	23,967	23,967
PSI QAACts Distributed Provided e(1,027)		(481)	(4,135)	(10,088)	-		-%	(7,361)	(11,496)	-	(578)	(578)
AL 1	92	174	937	-	1,261	7/12	(26)%	1,386	13,320	-	131	131
AL 2	136	164	952	-	1,126	7/12	(15)%	1,285	13,984	-	133	133
AL 3	156	208	1,115	-	2,090	1/11	(47)%	2,304	48,177	-	156	156
AL 4	847	576	4,547	4,497	7,461	1/11	(39)%	11,892	259,094	-	636	636
Arte+1	720	15	2,241	3,375	2,762	8/14	(19)%	2,762	22,254	-	313	313
Arte+2	720	15	2,241	3,375	3,660	8/14	(39)%	3,660	23,153	-	313	313
Arte+3	720	15	3,141	4,500	3,630	8/14	(13)%	3,630	25,822	-	439	439
Arte+4	1,440	6,023	62,611	101,250	104,237	8/14	(40)%	143,957	452,263	-	8,756	8,756
Supa Arte 1	340	51	2,471	4,125	12,331	9/12	(80)%	14,120	119,725	-	346	346
Supa Arte 2	371	65	1,354	4,125	11,445	9/12	(88)%	16,436	115,566	-	189	189
Supa Arte 3	281	87	4,720	5,500	13,329	9/12	(65)%	15,611	195,380	-	660	660
Supa Arte 4	16,591	6,764	89,186	123,750	109,816	9/12	(19)%	183,057	1,635,348	-	12,473	12,473
Malaria PPT (Non-ACT)	103	187	1,180	344	5,036		(77)%	3,078	106,145	-	165	165
PSI Vivax Tx Distributed Provided a (207)		(192)	(1,399)	(3,443)	-		-%	(3,796)	(5,195)	-	(196)	(196)
Vivax Treatment Kit	310	380	2,579	3,787	5,036	6/11	(49)%	6,874	111,340	-	361	361
Malaria RDK	133,295	110,681	738,779	886,516	461,116		60%	829,416	3,607,048	-	-	-
Malaria RDT (Diagnosis)	133,295	110,681	738,779	886,516	461,116	3/11	60%	829,416	3,607,048	-	-	-
Micronutrient Powder	408,825	1,245,107	4,648,507	-	-		0%	97,980	4,746,487	-	-	-
Happy Kid (Micronutrient powder)	408,825	1,245,107	4,648,507	-	-	9/16	-%	97,980	4,746,487	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Multivitamin	122,280	29,057	209,450	-	-		0%	-	209,450	-	50	50
May May Vita Plus	122,280	29,057	209,450	-	-	6/17	-%	-	209,450	-	50	50
Needle & Syringe	75,500	138,533	863,900	500,000	146,605		489%	303,605	1,244,505	7,092	-	7,092
Needle & Syringe (LDS)	75,500	138,533	863,900	500,000	146,605	10/15	489%	303,605	1,244,505	7,092	-	7,092
OCs	498,152	339,266	2,793,811	5,070,000	1,311,363		113%	3,337,534	19,471,752	-	16,724	16,724
OK Pills	497,842	339,266	2,793,501	5,070,000	1,311,363	9/01	113%	3,337,534	19,471,442	-	16,722	16,722
OK Pills (Zinnia F)	310	-	310	-	-	11/16	-%	-	310	-	2	2
ORS	73,653	49,781	222,995	369,500	256,485		(13)%	262,931	485,926	-	5,858	5,858
ORS	73,653	49,781	222,995	369,500	256,485	1/08	(13)%	262,931	485,926	-	5,858	5,858
Pneumonia PPT	-	-	-	-	112,026		(100)%	127,866	1,057,411	-	-	-
Pneumox 125 mg (15 tabs)	-	-	-	-	60,186	2/11	(100)%	75,684	431,561	-	-	-
Pneumox 250 mg (15 tabs)	-	-	-	-	51,840	2/11	(100)%	52,182	625,850	-	-	-
Positive RDTs	1,666	944	7,372	-	-		0%	13,201	20,573	-	-	-
Positive RDTs	1,666	944	7,372	-	-		-%	13,201	20,573	-	-	-
Positive RDTs Given First Line Treatm	1,576	920	6,483	-	-		0%	10,870	17,353	-	-	-
Positive RDTs Given First Line Trea	1,576	920	6,483	-	-		-%	10,870	17,353	-	-	-
PUR	680,067	15,522	800,798	1,110,000	917,983		(13)%	1,502,076	15,178,548	-	19	19
Purifier of Water	680,067	15,522	800,798	1,110,000	917,983	4/14	(13)%	1,502,076	15,178,548	-	19	19
QAACts Provided after Confirmatory I	1,027	481	4,135	10,088	-		0%	7,361	11,496	-	680	680
PSI QAACts Provided after Confirm	1,027	481	4,135	10,088	-		-%	7,361	11,496	-	680	680
Referral to TB DOTS (completion confi	-	-	-	2,054	293		(100)%	293	293	-	-	-
Referral to TB DOTS (completion co	-	-	-	2,054	293		(100)%	293	293	-	-	-
STI Kit (Non-Ulcerative)	-	-	-	-	42,436		(100)%	43,388	548,483	-	-	-
Cure U for Urethritis & Cervicitis	-	-	-	-	37,936	8/09	(100)%	38,888	514,283	-	-	-
Cure U Vaginitis	-	-	-	-	4,500	5/11	(100)%	4,500	34,200	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
STI Kit (Ulcerative)	-	-	-	-	2,964		(100)%	3,679	60,473	-	-	-
Cure U for Non-Herpetic Ulcer	-	-	-	-	2,964	8/09	(100)%	3,679	60,473	-	-	-
STI Screening	2,784	2,715	22,146	-	-		0%	-	22,146	-	-	-
STI Screening	2,784	2,715	22,146	-	-		-%	-	22,146	-	-	-
TB Diagnosis	1,176	1,253	8,370	-	9,193		(9)%	15,499	38,862	-	-	-
TB Diagnosis	1,176	1,253	8,370	-	9,193		(9)%	15,499	38,862	-	-	-
TB DOTS	1,383	1,172	9,086	13,984	10,002		(9)%	15,133	199,411	-	56,359	56,359
TB DOTS	1,383	1,172	9,086	13,984	10,002	12/04	(9)%	15,133	199,411	-	56,359	56,359
TB Screening	6,473	6,198	43,883	-	35,790		23%	60,830	165,301	-	-	-
TB Screening	6,473	6,198	43,883	-	35,790		23%	60,830	165,301	-	-	-
Vivax Treatment after Confirmatory Di	207	192	1,399	3,443	-		0%	3,796	5,195	-	230	230
PSI Vivax Treatment after Confirme	207	192	1,399	3,443	-		-%	3,796	5,195	-	230	230
<b>Nepal</b>										1,183	21,088	22,271
Emergency Contraception	-	-	14,464	14,700	-		0%	15	14,479	-	38	38
Emergency Contraception	-	-	14,464	14,700	-	9/16	-%	15	14,479	-	38	38
Free Condom	-	-	530,200	568,070	41,690		1172%	41,934	572,134	1,183	367	1,550
Generic Condom	-	-	530,200	568,070	41,690	1/16	1,172%	41,934	572,134	1,183	367	1,550
Implant 5	-	(1)	(4)	-	99		(104)%	18,088	19,373	-	(3)	(3)
PSI Implant 5 Distributed Inserted (	-	(1)	(4)	-	(3)		-%	(7)	(1,341)	-	(3)	(3)
Jadelle	-	-	-	-	102	8/09	(100)%	18,095	20,714	-	-	-
Implant 5 Insertion	13	7	86	-	50		72%	82	1,591	-	63	63
PSI Implant 5 Inserted	-	1	4	-	3		33%	7	1,341	-	3	3
Non-PSI Implant 5 Inserted	13	6	82	-	47		74%	75	250	-	60	60
Injectable 3	-	-	-	-	2		(100)%	61,975	62,000	-	-	-
Depo-Provera	-	-	-	-	2	6/16	(100)%	61,975	62,000	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 10	2,012	(1,163)	(948)	-	(862)		0%	1,190	12,665	-	(765)	(765)
PSI IUD 10 Distributed Inserted (1)	(2,988)	(2,030)	(16,291)	(18,596)	(8,087)		-%	(18,982)	(176,612)	-	(13,146)	(13,146)
IUD	-	867	10,343	18,596	7,225	8/03	43%	20,172	180,377	-	8,346	8,346
OK IUD	5,000	-	5,000	-	-	5/04	-%	-	8,900	-	4,035	4,035
IUD 10 Insertion	3,057	2,144	17,108	18,596	8,211		108%	19,489	186,530	-	15,340	15,340
PSI IUD 10 Inserted	2,988	2,030	16,291	18,596	8,087		101%	18,982	176,612	-	14,607	14,607
Non-PSI IUD 10 Inserted	69	114	817	-	124		559%	507	9,917	-	733	733
Medical Abortion	6,800	6,243	45,696	92,500	51,175		(11)%	68,029	222,176	-	5,672	5,672
Medabon	6,800	6,243	45,696	92,500	51,175	12/08	(11)%	68,029	222,176	-	5,672	5,672
OCs	-	-	42,624	43,083	2		2131100%	8	143,172	-	376	376
Zinnia	-	-	42,624	43,083	2	8/15	2,131,100%	8	143,172	-	376	376
PUR	-	-	-	-	361,680		(100)%	578,640	1,235,812	-	-	-
PuR	-	-	-	-	361,680	6/15	(100)%	578,640	1,235,812	-	-	-
STI Screening	41	23	192	-	139		38%	221	996	-	-	-
STI Screening	41	23	192	-	139		38%	221	996	-	-	-
<b>Pakistan</b>										17,942	582,187	600,130
Condom	8,949,808	7,399,665	55,673,379	75,326,595	78,507,351		(29)%	129,964,527	2,480,071,538	17,942	61,142	79,084
PSI Condom Distributed Provided	-	-	-	-	(3,042)		-%	(10,350)	(31,403)	-	-	-
Do	981,000	-	981,000	-	-	8/17	-%	-	981,000	316	1,077	1,394
Generic Male Condom	191,044	231,687	1,778,241	1,218,430	1,144,894		55%	1,710,632	3,488,873	573	1,953	2,526
Sathi	6,357,744	6,300,456	45,958,275	62,763,591	68,211,421	1/87	(33)%	113,482,837	2,240,441,816	14,811	50,473	65,284
Sathi Plus	360,000	-	360,000	-	-	8/17	-%	-	360,000	116	395	511
Touch	419,220	867,523	5,955,063	11,344,574	9,154,078	4/96	(35)%	14,781,408	234,190,452	1,919	6,540	8,459
Touch Delay	640,800	-	640,800	-	-	8/17	-%	-	640,800	207	704	910
Condom Provided	-	-	-	-	3,042		(100)%	10,350	31,403	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 8**  
**Year: 2017**

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Condom Provided	-	-	-	-	3,042		(100)%	10,350	31,403	-	-	-
Emergency Contraception	112,879	137,986	1,146,151	1,460,752	1,581,256		(28)%	2,307,659	17,505,246	-	4,744	4,744
PSI Emergency Contraception Distr	(481)	(600)	(5,666)	-	(6,038)		-%	(9,091)	(26,260)	-	(23)	(23)
ECP	-	138,586	1,038,457	1,460,752	1,587,294	9/14	(35)%	2,316,750	5,907,048	-	4,299	4,299
Postinor II	113,360	-	113,360	-	-	6/01	-%	-	11,624,458	-	469	469
Emergency Contraception Provided	481	877	6,496	-	6,038		8%	9,091	27,090	-	30	30
PSI Emergency Contraception Prov	481	600	5,666	-	6,038		(6)%	9,091	26,260	-	26	26
Non-PSI Emergency Contraception I	-	277	830	-	-		-%	-	830	-	4	4
Implant 3	-	-	(87)	-	-		0%	-	(87)	-	(63)	(63)
PSI Implant 3 Distributed Inserted (	-	-	(87)	-	-		-%	-	(87)	-	(63)	(63)
Implant 3 Insertion	-	-	87	-	-		0%	-	87	-	70	70
PSI Implant 3 Inserted	-	-	87	-	-		-%	-	87	-	70	70
Implant 5	-	133	925	-	144		542%	279	14,086	-	986	986
Jadelle	-	133	925	-	144	12/11	542%	279	14,086	-	986	986
Injectable 1	3,350	7,868	56,148	79,473	54,789		2%	85,224	1,574,805	-	968	968
PSI Injectable 1 Distributed Provide	(2,150)	(2,599)	(24,152)	-	(19,511)		-%	(30,476)	(79,308)	-	(417)	(417)
Femi-ject	5,500	10,467	80,300	79,473	74,300	6/03	8%	115,700	1,654,113	-	1,385	1,385
Injectable 1 Provided	2,150	2,886	25,012	-	19,511		28%	30,476	80,168	-	479	479
PSI Injectable 1 Provided	2,150	2,599	24,152	-	19,511		24%	30,476	79,308	-	463	463
Non-PSI Injectable 1 Provided	-	287	860	-	-		-%	-	860	-	16	16
Injectable 2	14,842	23,555	215,372	225,406	202,453		6%	299,852	6,888,625	-	7,429	7,429
PSI Injectable 2 Distributed Provide	(1,958)	(1,405)	(15,028)	-	(14,187)		-%	(22,868)	(61,159)	-	(518)	(518)
Novaject	16,800	24,960	230,400	225,406	216,640	12/96	6%	322,720	6,949,784	-	7,948	7,948
Injectable 2 Provided	1,958	1,799	16,208	-	14,187		14%	22,868	62,339	-	621	621
PSI Injectable 2 Provided	1,958	1,405	15,028	-	14,187		6%	22,868	61,159	-	576	576

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI Injectable 2 Provided	-	393	1,180	-	-		-%	-	1,180	-	45	45
Injectable 3	35,671	70,928	493,668	520,270	388,208		27%	564,683	2,841,030	-	25,544	25,544
PSI Injectable 3 Distributed Provide (1,203)	(1,203)	(1,049)	(11,963)	-	(11,617)		-%	(19,928)	(46,943)	-	(619)	(619)
Depo-Provera	14,800	40,499	280,296	293,030	265,320	7/11	6%	372,600	2,450,627	-	14,503	14,503
Generic 3-month Injectable	22,074	31,478	225,335	227,240	134,505		68%	212,011	437,346	-	11,660	11,660
Injectable 3 Provided	23,277	33,021	238,778	-	11,617		1955%	19,928	273,758	-	13,728	13,728
PSI Injectable 3 Provided	1,203	1,049	11,963	-	11,617		3%	19,928	46,943	-	688	688
Non-PSI Injectable 3 Provided	22,074	31,972	226,815	-	-		-%	-	226,815	-	13,040	13,040
IUD 10	7,431	11,144	96,445	144,558	96,974		(1)%	142,645	267,530	-	126,980	126,980
Generic IUD 10	3,291	8,084	63,505	115,708	53,904		18%	81,552	145,057	-	83,611	83,611
Safeload	4,140	3,060	32,940	28,850	43,070	8/14	(24)%	61,093	122,473	-	43,369	43,369
IUD 10 Insertion	3,291	8,034	65,510	-	-		0%	-	65,510	-	95,834	95,834
Non-PSI IUD 10 Inserted	3,291	8,034	65,510	-	-		-%	-	65,510	-	95,834	95,834
IUD 5	(2,484)	10,084	65,557	245,227	(5,630)		0%	7,578	3,032,266	-	64,238	64,238
PSI IUD 5 Distributed Inserted (1)	(8,886)	(8,928)	(88,081)	-	(121,614)		-%	(175,657)	(834,383)	-	(86,309)	(86,309)
Generic IUD 5	402	445	12,138	15,627	4,584		165%	15,035	27,173	-	11,894	11,894
Multiload	6,000	18,567	141,500	229,600	111,400	12/95	27%	168,200	3,839,476	-	138,654	138,654
IUD 5 Insertion	9,288	9,374	93,401	-	121,614		(23)%	175,657	839,703	-	101,692	101,692
PSI IUD 5 Inserted	8,886	8,928	88,081	-	121,614		(28)%	175,657	834,383	-	95,899	95,899
Non-PSI IUD 5 Inserted	402	445	5,320	-	-		-%	-	5,320	-	5,792	5,792
Manual Vacuum Aspiration for PAC	2,433	1,509	17,391	-	-		0%	31,135	48,526	-	892	892
MVA for PAC	2,433	1,509	17,391	-	-		-%	31,135	48,526	-	892	892
OCs	72,019	99,530	662,404	807,294	645,693		3%	1,121,152	3,420,839	-	9,281	9,281
PSI OCs Distributed Provided	(5,646)	(3,796)	(38,805)	-	(37,539)		-%	(60,615)	(151,743)	-	(544)	(544)
Generic OC	35,905	64,720	447,869	389,165	233,232		92%	364,567	812,436	-	6,275	6,275

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Novadol	41,760	38,607	253,340	418,129	450,000	1/08	(44)%	817,200	2,760,146	-	3,549	3,549
OCs Provided	41,551	70,446	492,464	-	37,539		1212%	60,615	605,402	-	7,666	7,666
PSI OCs Provided	5,646	3,796	38,805	-	37,539		3%	60,615	151,743	-	604	604
Non-PSI OCs Provided	35,905	66,650	453,659	-	-		-%	-	453,659	-	7,062	7,062
TB Diagnosis	2,632	2,394	18,123	-	11,319		60%	15,666	40,440	-	-	-
TB Diagnosis	2,632	2,394	18,123	-	11,319		60%	15,666	40,440	-	-	-
TB DOTS	1,549	1,610	11,220	-	5,449		106%	7,656	81,716	-	51,348	51,348
TB DOTS	1,549	1,610	11,220	-	5,449	4/05	106%	7,656	81,716	-	51,348	51,348
TB Screening	4,033	4,087	37,569	-	-		0%	-	37,569	-	-	-
TB Screening	4,033	4,087	37,569	-	-		-%	-	37,569	-	-	-
Tubal Ligation	104	222	2,744	-	1,166		135%	2,072	219,615	-	8,577	8,577
VSC	104	222	2,744	-	1,166	6/01	135%	2,072	219,615	-	8,577	8,577
Water Treatment Tablets	-	-	-	-	241,500		(100)%	241,500	2,754,300	-	-	-
Aquatabs 33 mg (10 L)	-	-	-	-	167,380	2/12	(100)%	167,380	2,166,780	-	-	-
Aquatabs 67 mg (20 L)	-	-	-	-	74,120	2/12	(100)%	74,120	587,520	-	-	-
<b>Papua New Guinea</b>										1,514	943	2,457
Condom	4,140	162,746	584,027	610,000	576,970		1%	627,118	7,952,812	1,441	785	2,226
Seif Raida	2,640	20,173	89,648	160,000	400,720	1/08	(78)%	427,780	6,885,885	221	121	342
Seif Raida Orange Plus	1,500	142,573	494,379	450,000	176,250	8/13	180%	199,338	1,066,927	1,219	665	1,884
Diarrhea Treatment Kit	-	-	2,243	15,000	2,026		11%	5,446	18,236	-	67	67
DTK	-	-	2,243	15,000	2,026	2/15	11%	5,446	18,236	-	67	67
Female Condom	100	5,160	29,800	62,960	18,440		62%	19,760	305,179	74	31	104
Stap Seif	100	5,160	29,800	62,960	18,440	2/09	62%	19,760	305,179	74	31	104
Malaria PPT (ACT)	-	-	-	935,921	3,366		(100)%	3,366	15,587	-	-	-
Coartem 1x12's for 1-5 years old	-	-	-	305,007	660	8/15	(100)%	660	3,453	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Coartem 1x18's for 6-13 years old	-	-	-	140,358	338	8/15	(100)%	338	1,530	-	-	-
Coartem 1x24's for 14+ years old	-	-	-	290,534	1,590	8/15	(100)%	1,590	5,972	-	-	-
Coartem 1x6's for 2-11 months	-	-	-	200,022	778	8/15	(100)%	778	4,632	-	-	-
<b>Water Treatment Tablets</b>	<b>4,300</b>	<b>1,733</b>	<b>15,000</b>	<b>50,000</b>	<b>1,430</b>		<b>949%</b>	<b>26,630</b>	<b>886,323</b>	-	1	1
Aquatab	4,300	1,733	15,000	50,000	1,430	12/11	949%	26,630	886,323	-	1	1
<b>Zinc</b>	-	-	8,490	8,490	250		<b>3296%</b>	<b>5,050</b>	<b>32,844</b>	-	58	58
Zinc 20 mg	-	-	8,490	8,490	250	12/11	3,296%	5,050	32,844	-	58	58
<b>Tajikistan</b>										11,299	120	11,419
<b>Free Condom</b>	-	47,372	200,146	287,544	-		0%	19,300	1,429,544	766	120	887
Generic Condom	-	-	-	287,544	-	8/10	-%	-	1,210,098	-	-	-
Generic Male Condom	-	47,372	200,146	-	-	8/16	-%	19,300	219,446	766	120	887
<b>HIV Testing Services</b>	1,302	1,744	7,680	21,913	-		0%	-	8,521	25	-	25
VCT Individual (HIV-Negative)	1,263	1,702	7,470	21,913	-		-%	-	8,311	24	-	24
VCT Individual (HIV-Positive)	39	42	210	-	-		-%	-	210	1	-	1
<b>Naloxone</b>	-	669	2,066	5,892	-		0%	-	12,698	2,819	-	2,819
Naloxone	-	669	2,066	5,892	-	1/11	-%	-	12,698	2,819	-	2,819
<b>Needle &amp; Syringe</b>	99,000	90,133	572,761	1,482,749	-		0%	-	1,482,033	7,189	-	7,189
Needle/Syringe	99,000	90,133	572,761	1,482,749	-	1/11	-%	-	1,482,033	7,189	-	7,189
<b>Referral to HIV Testing Services</b>	4	44	4,326	2,300	-		0%	1,439	15,100	7	-	7
Referral to HIV Testing & Counseling	4	44	4,326	2,300	-	12/13	-%	1,439	15,100	7	-	7
<b>Referral to Linkage to HIV Care</b>	57	68	620	154	-		0%	80	700	493	-	493
Referral to Linkage to HIV Care	57	68	620	154	-		-%	80	700	493	-	493
<b>Referral to Opioid Treatment</b>	14	8	89	-	-		0%	5	94	-	-	-
Referral to Opioid Treatment	14	8	89	-	-		-%	5	94	-	-	-
<b>Referral to TB Diagnosis</b>	-	7	55	-	-		0%	-	5,207	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to TB Diagnosis	-	7	55	-	-	12/14	-%	-	5,207	-	-	-
Referral to TB Screening	1	-	1	-	-		0%	-	1	-	-	-
Referrals to TB Screening	1	-	1	-	-		-%	-	1	-	-	-
TB Screening	152	188	1,473	-	-		0%	1,643	4,255	-	-	-
TB Screening	152	188	1,473	-	-		-%	1,643	4,255	-	-	-
<b>Viet Nam</b>										18,332	64	18,396
Emergency Contraception Provided	141	63	330	-	-		0%	-	330	-	-	-
Non-PSI Emergency Contraception I	141	63	330	-	-		-%	-	330	-	-	-
HIV Testing Services	710	494	2,965	10,000	-		0%	-	2,965	5	-	5
VCT Individual (HIV-Negative)	669	454	2,705	10,000	-		-%	-	2,705	4	-	4
VCT Individual (HIV-Positive)	41	40	260	-	-		-%	-	260	-	-	-
Hypertension Diagnosis	3,842	410	5,223	-	-		0%	-	5,223	-	-	-
Hypertension Diagnosis	3,842	410	5,223	-	-		-%	-	5,223	-	-	-
Hypertension Screening	5,866	963	8,926	-	-		0%	-	8,926	-	-	-
Hypertension Screening	5,866	963	8,926	-	-		-%	-	8,926	-	-	-
Hypertension_Controlled Condition	2,778	406	4,125	-	-		0%	-	4,125	-	-	-
Hypertension_Controlled Condition	2,778	406	4,125	-	-		-%	-	4,125	-	-	-
Implant 3	112	1	130	5,000	-		0%	(3)	127	-	9	9
PSI Implant 3 Distributed Inserted (	(2)	(1)	(9)	-	-		-%	(3)	(12)	-	(1)	(1)
Implanon NXT	114	2	139	5,000	-	2/17	-%	-	139	-	9	9
Implant 3 Insertion	3	7	34	30	-		0%	3	37	-	3	3
PSI Implant 3 Inserted	2	1	9	-	-		-%	3	12	-	1	1
Non-PSI Implant 3 Inserted	1	6	25	30	-		-%	-	25	-	2	2
Injectable 1 Provided	8	8	32	-	-		0%	-	32	-	-	-
Non-PSI Injectable 1 Provided	8	8	32	-	-		-%	-	32	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Injectable 3</b>	<b>101</b>	<b>31</b>	<b>219</b>	<b>12,000</b>	-		<b>0%</b>	<b>(5)</b>	<b>214</b>	-	<b>1</b>	<b>1</b>
PSI Injectable 3 Distributed Provide	(19)	(21)	(82)	-	-		-%	(5)	(87)	-	-	-
Depoteron	120	52	301	12,000	-	2/17	-%	-	301	-	1	1
<b>Injectable 3 Provided</b>	<b>124</b>	<b>78</b>	<b>466</b>	-	-		<b>0%</b>	<b>5</b>	<b>471</b>	-	<b>3</b>	<b>3</b>
PSI Injectable 3 Provided	19	21	82	-	-		-%	5	87	-	-	-
Non-PSI Injectable 3 Provided	105	57	384	-	-		-%	-	384	-	2	2
<b>IUD 10</b>	-	-	-	-	-		<b>0%</b>	<b>71</b>	<b>71</b>	-	-	-
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	-		-%	(29)	(29)	-	-	-
Copper-T 380-A IUD	-	-	-	-	-	9/16	-%	100	100	-	-	-
<b>IUD 10 Insertion</b>	<b>44</b>	<b>28</b>	<b>132</b>	<b>270</b>	-		<b>0%</b>	<b>29</b>	<b>161</b>	-	<b>18</b>	<b>18</b>
PSI IUD 10 Inserted	-	-	-	-	-		-%	29	29	-	-	-
Non-PSI IUD 10 Inserted	44	28	132	270	-		-%	-	132	-	18	18
<b>LLIN (Hammock net)</b>	-	-	-	<b>550</b>	-		<b>0%</b>	-	-	-	-	-
LLIN (Hammock net)	-	-	-	550	-		-%	-	-	-	-	-
<b>Needle &amp; Syringe</b>	<b>136,400</b>	<b>249,867</b>	<b>2,604,750</b>	<b>4,100,000</b>	<b>2,309,000</b>		<b>13%</b>	<b>4,600,000</b>	<b>16,064,290</b>	<b>18,327</b>	-	<b>18,327</b>
B-braun Omnican 40 (U-40 Insulin/436,400	249,867	2,604,750	-	2,304,000	9/13	13%	4,584,000	16,041,800	18,327	-	-	18,327
Needle & Syringe (LDS)	-	-	-	4,100,000	5,000	4/13	(100)%	16,000	22,490	-	-	-
<b>OCs Provided</b>	<b>144</b>	<b>77</b>	<b>471</b>	-	-		<b>0%</b>	-	<b>471</b>	-	<b>1</b>	<b>1</b>
Non-PSI OCs Provided	144	77	471	-	-		-%	-	471	-	1	1
<b>Positive RDTs</b>	<b>12</b>	<b>6</b>	<b>37</b>	-	-		<b>0%</b>	-	<b>37</b>	-	-	-
Positive RDTs	12	6	37	-	-		-%	-	37	-	-	-
<b>Positive RDTs Given First Line Treatm</b>	<b>8</b>	<b>2</b>	<b>18</b>	-	-		<b>0%</b>	-	<b>18</b>	-	-	-
Positive RDTs Given First Line Trea	8	2	18	-	-		-%	-	18	-	-	-
<b>QAACTs Provided after Confirmatory I</b>	<b>6</b>	<b>2</b>	<b>15</b>	<b>425</b>	-		<b>0%</b>	-	<b>15</b>	-	<b>3</b>	<b>3</b>
Non-PSI QAACTs Provided after Co	6	2	15	425	-		-%	-	15	-	3	3

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 8

Year: 2017

	DISTRIBUTION 8/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to TB DOTS (completion unkr	-	-	-	<b>1,000</b>	-		<b>0%</b>	-	-	-	-	-
Referral to TB DOTS (completion un	-	-	-	<b>1,000</b>	-		-%	-	-	-	-	-
Safe Water Solution	-	-	-	-	<b>6,973</b>		<b>(100)%</b>	<b>6,973</b>	<b>655,267</b>	-	-	-
SafeWat	-	-	-	-	<b>6,973</b>	11/05	(100)%	<b>6,973</b>	<b>655,267</b>	-	-	-
TB Diagnosis	<b>54</b>	<b>63</b>	<b>473</b>	-	<b>876</b>		<b>(46)%</b>	<b>2,394</b>	<b>4,663</b>	-	-	-
TB Diagnosis	<b>54</b>	<b>63</b>	<b>473</b>	-	<b>876</b>		(46)%	<b>2,394</b>	<b>4,663</b>	-	-	-
Toilets Sold	<b>138</b>	<b>152</b>	<b>967</b>	<b>5,490</b>	-		<b>0%</b>	-	<b>967</b>	-	<b>27</b>	<b>27</b>
Toilet Type 1, Direct Sales	<b>138</b>	<b>152</b>	<b>967</b>	<b>4,740</b>	-		-%	-	<b>967</b>	-	<b>27</b>	<b>27</b>
Toilet Type 2, Direct Sales	-	-	-	<b>750</b>	-		-%	-	-	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Asia and Eastern Europe - Asia</b>															
<b>Cambodia</b>							\$0		\$0	\$0	NA				
<b>Condom</b>															
Number One	08/2017	306,648	1,008	0	307,656	0%	\$0	NA	\$0	\$0	NA	1,071,048	417,432	2.57	
OK Condom	08/2017	586,140	900	0	587,040	0%	\$0	NA	\$0	\$0	NA	7,583,293	817,940	9.27	
<b>Lubricant A</b>															
OK Plus Lubricant	08/2017	63,420	360	0	63,780	1%	\$0	NA	\$0	\$0	NA	256,740	92,780	2.77	
<b>Malaria PPT (ACT)</b>															
ASMQ for Adolescent	08/2017	400	349	0	749	47%	\$0	NA	\$0	\$0	NA	1,893	250	7.58	
ASMQ for Adult	08/2017	4,527	846	0	5,373	16%	\$0	NA	\$0	\$0	NA	12,445	2,551	4.88	
DHA-PIP For Adolescent	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,228	42	77.47	
DHA-PIP For Adult	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	32,014	391	81.95	
DHA-PIP For Children	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,378	19	125.16	
<b>Malaria RDK</b>															
Malaria RDT (Diagnosis)	08/2017	22,775	400	0	23,175	2%	\$0	NA	\$0	\$0	NA	403,600	34,075	11.84	
<b>Diarrhea Treatment Kit</b>															
Orasel Kit	08/2017	2,670	580	0	3,250	18%	\$0	NA	\$0	\$0	NA	16,430	7,297	2.25	
<b>Medical Abortion</b>															
Medabon	08/2017	19,920	1	0	19,921	0%	\$0	NA	\$0	\$0	NA	177,147	30,470	5.81	
<b>Emergency Contraception</b>															
NEXT 72 EC	08/2017	4,800	210	0	5,010	4%	\$0	NA	\$0	\$0	NA	46,568	7,857	5.93	
<b>Implant 5</b>															
Implant 5	08/2017	594	1	0	595	0%	\$0	NA	\$0	\$0	NA	7,282	817	8.91	
<b>Injectable 3</b>															
OK Injection-3	08/2017	33,675	25	0	33,700	0%	\$0	NA	\$0	\$0	NA	203,975	46,958	4.34	
<b>IUD 10</b>															
IUD Copper T	08/2017	2,780	5	0	2,785	0%	\$0	NA	\$0	\$0	NA	22,305	4,095	5.45	
<b>OCs</b>															
Marvelon	08/2017	119,765	1,920	0	121,685	2%	\$0	NA	\$0	\$0	NA	5,905	85,403	0.07	
OK Pills	08/2017	398,736	12	0	398,748	0%	\$0	NA	\$0	\$0	NA	2,144,580	524,624	4.09	
<b>India</b>							\$0		\$0	\$17,622	NA				
<b>Condom</b>															
Masti	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	6,960	0	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>India</b>							\$0		\$0	\$17,622	NA				
<b>Clean Delivery Kit</b>															
NewBorn	08/2017	0	0	60	60	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
<b>ORS</b>															
Neotral Orange 1000ml	08/2017	0	0	14,850	14,850	NA	\$0	NA	\$0	\$0	NA	355	0	NA	
<b>Injectable 3</b>															
Freedom Inject (3-month)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	68	0	NA	
<b>IUD 10</b>															
Freedom 10	08/2017	0	0	-65,560	-65,560	NA	\$0	NA	\$0	\$17,622	NA	65,560	0	NA	
<b>India LLC</b>							\$383,501		\$17,720	\$358,964	0.05				
<b>Condom</b>															
Masti Classic 10's (Flavoured)	08/2017	1,512,000	23,520	0	1,535,520	2%	\$52,836	5%	\$2,390	\$47,012	0.05	3,296,160	1,355,280	2.43	
Masti Classic 3's	08/2017	2,692,800	0	0	2,692,800	0%	\$79,706	1%	\$1,066	\$72,539	0.01	16,486,785	2,450,373	6.73	
Masti Classic 3's (Flavoured)	08/2017	1,611,600	17,520	0	1,629,120	1%	\$57,641	2%	\$1,030	\$57,848	0.02	3,288,960	1,625,920	2.02	
Masti Classic 6's	08/2017	18,000	0	0	18,000	0%	\$533	0%	\$0	\$604	NA	4,200	20,400	0.21	
Masti Premium 10's (Flavoured)	08/2017	663,120	7,200	0	670,320	1%	\$37,090	7%	\$2,618	\$47,004	0.06	3,446,160	844,960	4.08	
Masti Premium 3's	08/2017	7,200	0	0	7,200	0%	\$356	0%	\$0	\$415	NA	12,856	8,400	1.53	
Masti Premium 3's (Flavoured)	08/2017	1,050,000	37,440	0	1,087,440	3%	\$62,591	9%	\$5,365	\$62,641	0.09	6,172,311	1,066,160	5.79	
<b>Medical Abortion</b>															
Safe Abort kit	08/2017	40,220	110	0	40,330	0%	\$32,162	5%	\$1,478	\$31,025	0.05	192,690	37,243	5.17	
<b>ORS</b>															
Neotral Orange 1000ml	08/2017	21,150	1,053	0	22,203	5%	\$2,546	25%	\$626	\$2,582	0.24	1,260,270	22,401	56.26	
<b>Injectable 3</b>															
Freedom Inject (3-month)	08/2017	7,853	70	0	7,923	1%	\$7,791	0%	\$35	\$5,250	0.01	106,551	5,320	20.03	
<b>IUD 5</b>															
Freedom 5	08/2017	9,360	70	0	9,430	1%	\$9,680	0%	\$0	\$3,304	NA	150	3,218	0.05	
<b>OCs</b>															
Pearl	08/2017	211,050	70	0	211,120	0%	\$40,569	8%	\$3,114	\$28,740	0.11	2,244,560	193,113	11.62	
<b>Kazakhstan</b>							\$0		\$0	\$0	NA				
<b>HIV Test Kit</b>															
OraQuick	08/2017	0	150	0	150	100%	\$0	NA	\$0	\$0	NA	4,500	50	90.00	
<b>Free Condom</b>															
Generic Male Condom	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	475,200	0	NA	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Kazakhstan</b>							\$0		\$0	\$0	NA				
<u>Free Female Condom</u>															
Generic Female Condom	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	26,000	0	NA	
<b>Kyrgyzstan</b>							\$0		\$0	\$0	NA				
<u>HIV Test Kit</u>															
Alere Determine	08/2017	0	800	0	800	100%	\$0	NA	\$0	\$0	NA	2,800	948	2.95	
<b>Laos</b>							\$17,530		\$48,429	\$19,430	2.49				
<u>Condom</u>															
No 1 Condom Grp	08/2017	13,824	0	0	13,824	0%	\$698	100%	\$6,193	\$2,398	2.58	445,707	47,232	9.44	
No 1 Condom Strw	08/2017	69,120	0	0	69,120	0%	\$3,489	100%	\$13,084	\$6,899	1.90	1,330,599	135,936	9.79	
Number One Rose	08/2017	181,440	0	0	181,440	0%	\$9,159	100%	\$18,579	\$6,594	2.82	342,639	130,176	2.63	
<u>Misoprostol for PAC (Oral)</u>															
Misoprostol for PAC (oral)	08/2017	19,000	0	0	19,000	0%	\$4,185	100%	\$10,572	\$3,538	2.99	71,570	16,000	4.47	
<u>IUD 5</u>															
IUD Cu375	08/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	8,000	NA	NA	
<b>Myanmar</b>							\$245,265		\$2,627	\$213,323	0.01				
<u>Condom</u>															
Aphaw	08/2017	363,900	12,600	0	376,500	3%	\$13,344	0%	\$0	\$11,441	NA	6,282,974	324,940	19.34	
Aphaw - Natural Touch	08/2017	200,100	6,000	0	206,100	3%	\$7,337	0%	\$0	\$13,202	NA	2,117,350	372,920	5.68	
Aphaw Flavors	08/2017	361,870	316,070	0	677,940	47%	\$13,269	0%	\$0	\$13,989	NA	8,149,737	712,431	11.44	
Aphaw Studded	08/2017	59,940	1,890	0	61,830	3%	\$2,198	0%	\$0	\$11,798	NA	100,890	337,350	0.30	
Generic Male Condom	08/2017	0	15,000	0	15,000	100%	\$0	NA	\$0	\$0	NA	2,705,500	5,000	541.10	
OK Condom	08/2017	10,008	0	0	10,008	0%	\$61	0%	\$0	\$65	NA	130,352	10,680	12.21	
<u>Female Condom</u>															
Generic Female Condom	08/2017	0	5,240	0	5,240	100%	\$0	NA	\$0	\$0	NA	187,493	5,192	36.11	
<u>Lubricant B</u>															
Aphaw Gel - Tube 20 cc	08/2017	0	3,246	0	3,246	100%	\$0	NA	\$0	\$56	NA	84,943	2,112	40.22	
Aphaw Gel - Tube 20 cc - Flavors	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	5,484	0	NA	
<u>Needle &amp; Syringe</u>															
Needle & Syringe (LDS)	08/2017	0	75,500	0	75,500	100%	\$0	NA	\$0	\$0	NA	711,564	123,700	5.75	
<u>LLIN</u>															
LLIN	08/2017	0	5,762	0	5,762	100%	\$0	NA	\$0	\$0	NA	429	5,124	0.08	
<u>Malaria PPT (ACT)</u>															
AL 1	08/2017	0	92	2,160	2,252	100%	\$0	NA	\$0	\$0	NA	13,448	150	89.45	



Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Myanmar</b>							\$245,265		\$2,627	\$213,323	0.01				
<b><u>Malaria PPT (ACT)</u></b>															
AL 2	08/2017	0	136	2,915	3,051	100%	\$0	NA	\$0	\$0	NA	12,797	155	82.38	
AL 3	08/2017	0	156	1,440	1,596	100%	\$0	NA	\$0	\$0	NA	30,208	206	146.40	
AL 4	08/2017	0	847	1,620	2,467	100%	\$0	NA	\$0	\$0	NA	33,816	708	47.74	
Arte+1	08/2017	0	720	149	869	100%	\$0	NA	\$0	\$0	NA	690	250	2.76	
Arte+2	08/2017	0	720	149	869	100%	\$0	NA	\$0	\$0	NA	690	250	2.76	
Arte+3	08/2017	0	720	149	869	100%	\$0	NA	\$0	\$0	NA	690	250	2.76	
Arte+4	08/2017	1,440	0	149	1,589	0%	\$210	100%	\$210	\$946	0.22	180	6,499	0.03	
Supa Arte 1	08/2017	0	340	512	852	100%	\$0	NA	\$0	\$0	NA	1,183	152	7.77	
Supa Arte 2	08/2017	0	371	512	883	100%	\$0	NA	\$0	\$0	NA	1,183	168	7.06	
Supa Arte 3	08/2017	0	281	612	893	100%	\$0	NA	\$0	\$0	NA	2,678	137	19.50	
Supa Arte 4	08/2017	16,560	31	668	17,259	0%	\$2,417	100%	\$2,417	\$1,787	1.35	176	12,277	0.01	
<b><u>Malaria PPT (Non-ACT)</u></b>															
Vivax Treatment Kit	08/2017	0	310	0	310	100%	\$0	NA	\$0	\$0	NA	2,692	346	7.78	
<b><u>Malaria RDK</u></b>															
Malaria RDT (Diagnosis)	08/2017	0	133,295	0	133,295	100%	\$0	NA	\$0	\$0	NA	182,376	123,546	1.48	
<b><u>Diarrhea Treatment Kit</u></b>															
Orasel DTK	08/2017	0	33	0	33	100%	\$0	NA	\$0	\$12	NA	61	113	0.54	
<b><u>Micronutrient Powder</u></b>															
Happy Kid (Micronutrient powder)	08/2017	1,305	407,520	0	408,825	100%	\$38	0%	\$0	\$3,833	NA	2,753,203	946,629	2.91	
<b><u>Multivitamin</u></b>															
May May Vita Plus	08/2017	116,700	5,580	0	122,280	5%	\$7,113	0%	\$0	\$4,089	NA	1,243,360	69,817	17.81	
<b><u>ORS</u></b>															
ORS	08/2017	73,555	98	2,275	75,928	0%	\$6,308	0%	\$0	\$5,460	NA	374,605	74,332	5.04	
<b><u>PUR</u></b>															
Purifier of Water	08/2017	528,571	151,496	0	680,067	22%	\$14,539	0%	\$0	\$5,252	NA	693,025	240,540	2.88	
<b><u>Emergency Contraception</u></b>															
OK EC	08/2017	0	11	0	11	100%	\$0	NA	\$0	\$0	NA	6	5	1.20	
<b><u>Implant 3</u></b>															
Implanon NXT	08/2017	336	10	0	346	3%	\$3,696	0%	\$0	\$4,105	NA	10,532	402	26.22	
<b><u>Implant 5</u></b>															
Jadelle	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	93	0	NA	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Myanmar</b>							\$245,265		\$2,627	\$213,323	0.01				
<u><b>Injectable 3</b></u>															
OK-3 Injection	08/2017	56,975	116	0	57,091	0%	\$16,713	0%	\$0	\$14,822	NA	859,039	50,594	16.98	
<u><b>IUD 10</b></u>															
OK IUD (Copper T Cu 380A)	08/2017	29	14	0	43	33%	\$11	0%	\$0	\$4	NA	259	14	18.07	
<u><b>IUD 5</b></u>															
OK IUD	08/2017	147	0	0	147	0%	\$52	0%	\$0	\$78	NA	14,775	214	69.04	
<u><b>OCs</b></u>															
OK Pills	08/2017	497,631	211	32	497,874	0%	\$157,865	0%	\$0	\$122,354	NA	2,425,205	435,760	5.57	
OK Pills (Zinnia F)	08/2017	310	0	0	310	0%	\$93	0%	\$0	NA	NA	14,690	NA	NA	
<b>Nepal</b>							\$16,969		\$5,333	\$5,656	0.94				
<u><b>Free Condom</b></u>															
Generic Condom	08/2017	0	0	14	14	NA	\$0	NA	\$0	NA	NA	234	NA	NA	
<u><b>Medical Abortion</b></u>															
Medabon	08/2017	6,800	0	2,298	9,098	0%	\$16,969	31%	\$5,333	NA	NA	17,132	NA	NA	
<u><b>PUR</b></u>															
PuR	08/2017	0	0	1,628	1,628	NA	\$0	NA	\$0	NA	NA	0	NA	NA	
<u><b>IUD 10</b></u>															
OK IUD	08/2017	5,000	0	370	5,370	0%	\$0	NA	\$0	NA	NA	14,512	NA	NA	
<b>Pakistan</b>							\$402,658		\$270,105	\$246,896	1.09				
<u><b>Condom</b></u>															
Do	08/2017	981,000	0	0	981,000	0%	\$71,828	100%	\$43,138	NA	NA	2,019,000	NA	NA	
Sathi	08/2017	6,357,744	0	0	6,357,744	0%	\$158,498	100%	\$80,751	\$80,758	1.00	121,768,479	2,525,840	48.21	
Sathi Plus	08/2017	360,000	0	0	360,000	0%	\$29,021	100%	\$24,139	NA	NA	2,640,000	NA	NA	
Touch	08/2017	419,220	0	0	419,220	0%	\$62,663	100%	\$41,023	\$41,959	0.98	16,672,531	360,360	46.27	
Touch Delay	08/2017	640,800	0	0	640,800	0%	\$27,425	100%	\$14,655	NA	NA	2,359,200	NA	NA	
<u><b>Water Treatment Tablets</b></u>															
Aquatabs 33 mg (10 L)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,016	0	NA	
Aquatabs 67 mg (20 L)	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,246	0	NA	
<u><b>Emergency Contraception</b></u>															
ECP	08/2017	0	0	0	0	NA	\$0	NA	\$14,829	\$6,524	2.27	791	60,267	0.01	
Postinor II	08/2017	113,360	0	0	113,360	0%	\$12,200	100%	\$9,913	NA	NA	85,128	NA	NA	
<u><b>Implant 5</b></u>															
Jadelle	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$6	NA	18,461	3	5,538.30	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Pakistan</b>							\$402,658		\$270,105	\$246,896	1.09				
<u><b>Injectable 1</b></u>															
Femi-ject	08/2017	5,500	0	0	5,500	0%	\$2,013	100%	\$241	\$3,370	0.07	348,026	9,167	37.97	
<u><b>Injectable 2</b></u>															
Novaject	08/2017	16,800	0	0	16,800	0%	\$8,198	100%	\$17,506	\$12,431	1.41	181,574	25,360	7.16	
<u><b>Injectable 3</b></u>															
Depo-Provera	08/2017	14,800	0	0	14,800	0%	\$16,263	100%	\$13,832	\$34,903	0.40	358,795	31,613	11.35	
<u><b>IUD 10</b></u>															
Safeload	08/2017	4,140	0	0	4,140	0%	\$3,494	100%	\$517	\$2,999	0.17	122,048	3,540	34.48	
<u><b>IUD 5</b></u>															
Multiload	08/2017	6,000	0	0	6,000	0%	\$5,064	100%	\$3,350	\$11,283	0.30	546,429	13,300	41.08	
<u><b>OCs</b></u>															
Novadol	08/2017	41,760	0	0	41,760	0%	\$5,992	100%	\$6,210	\$5,838	1.06	81,191	40,527	2.00	
<b>Papua New Guinea</b>							\$1,090		\$5,663	\$2,252	2.51				
<u><b>Condom</b></u>															
Seif Raida	08/2017	2,560	80	0	2,640	3%	\$332	100%	\$1,098	\$1,057	1.04	83,168	8,613	9.66	
Seif Raida Orange Plus	08/2017	1,440	60	0	1,500	4%	\$249	100%	\$931	\$614	1.51	14,307	3,900	3.67	
<u><b>Female Condom</b></u>															
Stap Seif	08/2017	60	40	0	100	40%	\$18	100%	-\$65	\$227	-0.29	33,400	993	33.62	
<u><b>Lubricant A</b></u>															
Glide Lubricant	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	256	0	NA	
<u><b>Malaria PPT (ACT)</b></u>															
Coartem 1x12's for 1-5 years old	08/2017	0	0	12,480	12,480	NA	\$0	NA	\$0	\$0	NA	86,850	0	NA	
Coartem 1x18's for 6-13 years old	08/2017	0	0	23,430	23,430	NA	\$0	NA	\$0	\$0	NA	209,670	0	NA	
Coartem 1x24's for 14+ years old	08/2017	0	0	23,430	23,430	NA	\$0	NA	\$0	\$0	NA	192,480	0	NA	
Coartem 1x6's for 2-11 months	08/2017	0	0	15,780	15,780	NA	\$0	NA	\$0	\$0	NA	132,300	0	NA	
<u><b>Diarrhea Treatment Kit</b></u>															
DTK	08/2017	0	0	0	0	NA	\$0	NA	\$1,945	\$0	NA	290	0	NA	
<u><b>Water Treatment Tablets</b></u>															
Aquatab	08/2017	4,300	0	0	4,300	0%	\$492	7%	\$1,754	\$354	4.95	479,070	3,100	154.54	
<b>PSI Pakistan</b>							\$0		\$0	\$0	NA				
<u><b>Condom</b></u>															
Generic Male Condom	08/2017	191,044	0	0	191,044	0%	\$0	NA	\$0	\$0	NA	0	205,912	NA	
<u><b>Injectable 3</b></u>															
Generic 3-month Injectable	08/2017	22,074	0	0	22,074	0%	\$0	NA	\$0	\$0	NA	0	26,304	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>PSI Pakistan</b>							\$0		\$0	\$0	NA				
<u>IUD 10</u>															
Generic IUD 10	08/2017	3,291	0	0	3,291	0%	\$0	NA	\$0	\$0	NA	0	5,496	NA	
<u>IUD 5</u>															
Generic IUD 5	08/2017	402	0	0	402	0%	\$0	NA	\$0	\$0	NA	0	399	NA	
<u>OCs</u>															
Generic OC	08/2017	35,905	0	0	35,905	0%	\$0	NA	\$0	\$0	NA	0	47,437	NA	
<b>Tajikistan</b>							\$0		\$0	\$0	NA				
<u>HIV Test Kit</u>															
HIV Test Kit	08/2017	0	5,000	0	5,000	100%	\$0	NA	\$0	\$0	NA	6,694	1,883	3.55	
<u>Free Condom</u>															
Generic Male Condom	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	784,670	39,667	19.78	
<u>Needle &amp; Syringe</u>															
Needle/Syringe-1 ml (0.3x13mm)	08/2017	0	54,000	0	54,000	100%	\$0	NA	\$0	\$0	NA	0	18,000	NA	
Needle/Syringe-2 ml (0.6x25mm)	08/2017	0	45,000	0	45,000	100%	\$0	NA	\$0	\$0	NA	0	15,000	NA	
<b>Viet Nam</b>							\$0		\$0	\$0	NA				
<u>Needle &amp; Syringe</u>															
B-braun Omnican 40 (U-40 Insulin/	08/2017	0	136,400	-136,400	0	100%	\$0	NA	\$0	\$0	NA	1,150	220,233	0.01	
<u>Implant 3</u>															
Implanon NXT	08/2017	0	114	-34	80	100%	\$0	NA	\$0	\$0	NA	0	39	NA	
<u>Injectable 3</u>															
Depoteron	08/2017	0	120	-120	0	100%	\$0	NA	\$0	\$0	NA	0	75	NA	
<u>IUD 10</u>															
Copper-T 380-A IUD	08/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	544	0	NA	